CA2530416C - Postpartum cells derived from placental tissue, and methods of making and using the same - Google Patents
Postpartum cells derived from placental tissue, and methods of making and using the same Download PDFInfo
- Publication number
- CA2530416C CA2530416C CA2530416A CA2530416A CA2530416C CA 2530416 C CA2530416 C CA 2530416C CA 2530416 A CA2530416 A CA 2530416A CA 2530416 A CA2530416 A CA 2530416A CA 2530416 C CA2530416 C CA 2530416C
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- derived
- growth factor
- placenta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000005059 placental tissue Anatomy 0.000 title claims description 31
- 238000000034 method Methods 0.000 title abstract description 101
- 210000002826 placenta Anatomy 0.000 claims abstract description 149
- 210000004027 cell Anatomy 0.000 claims description 893
- 210000001519 tissue Anatomy 0.000 claims description 113
- 239000001963 growth medium Substances 0.000 claims description 86
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- -1 PDGFr-alpha Proteins 0.000 claims description 72
- 230000012010 growth Effects 0.000 claims description 50
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 43
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 43
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 43
- 210000000130 stem cell Anatomy 0.000 claims description 42
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims description 38
- 108010014423 Chemokine CXCL6 Proteins 0.000 claims description 38
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 38
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 38
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 37
- 235000018102 proteins Nutrition 0.000 claims description 37
- 238000000684 flow cytometry Methods 0.000 claims description 36
- 239000011159 matrix material Substances 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 34
- 108090000790 Enzymes Proteins 0.000 claims description 34
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 34
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 34
- 108010041111 Thrombopoietin Proteins 0.000 claims description 34
- 102000036693 Thrombopoietin Human genes 0.000 claims description 34
- 229940088598 enzyme Drugs 0.000 claims description 34
- 210000002950 fibroblast Anatomy 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 32
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 32
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 31
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 31
- 102000004889 Interleukin-6 Human genes 0.000 claims description 31
- 108090001005 Interleukin-6 Proteins 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 31
- 229940100601 interleukin-6 Drugs 0.000 claims description 31
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 30
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 30
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 30
- 108010082169 Chemokine CCL17 Proteins 0.000 claims description 30
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 30
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 30
- 102000004890 Interleukin-8 Human genes 0.000 claims description 30
- 108090001007 Interleukin-8 Proteins 0.000 claims description 30
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 30
- 229940096397 interleukin-8 Drugs 0.000 claims description 30
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 30
- 108020004999 messenger RNA Proteins 0.000 claims description 30
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 29
- 230000008774 maternal effect Effects 0.000 claims description 29
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 28
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 claims description 28
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 claims description 28
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 28
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 28
- 239000003102 growth factor Substances 0.000 claims description 28
- 229940072041 transforming growth factor beta 2 Drugs 0.000 claims description 28
- 102100036845 C-C motif chemokine 22 Human genes 0.000 claims description 27
- 108010083701 Chemokine CCL22 Proteins 0.000 claims description 27
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 27
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 27
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 24
- 102000029816 Collagenase Human genes 0.000 claims description 24
- 108060005980 Collagenase Proteins 0.000 claims description 24
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 24
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 24
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 24
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 24
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 229960002424 collagenase Drugs 0.000 claims description 24
- 230000028327 secretion Effects 0.000 claims description 24
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 23
- 102100032912 CD44 antigen Human genes 0.000 claims description 23
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 23
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 23
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 23
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 23
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims description 23
- 108090000028 Neprilysin Proteins 0.000 claims description 23
- 102000003729 Neprilysin Human genes 0.000 claims description 23
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 23
- 102100026966 Thrombomodulin Human genes 0.000 claims description 23
- 210000005260 human cell Anatomy 0.000 claims description 23
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 22
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 22
- 210000002798 bone marrow cell Anatomy 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 102100031092 C-C motif chemokine 3 Human genes 0.000 claims description 20
- 101710155856 C-C motif chemokine 3 Proteins 0.000 claims description 20
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 19
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 19
- 238000004113 cell culture Methods 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 108010081589 Becaplermin Proteins 0.000 claims description 17
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 16
- 238000002965 ELISA Methods 0.000 claims description 16
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 16
- 102000001974 Hyaluronidases Human genes 0.000 claims description 16
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 16
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 16
- 229960002773 hyaluronidase Drugs 0.000 claims description 16
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 15
- 102000050083 Class E Scavenger Receptors Human genes 0.000 claims description 15
- 102000005741 Metalloproteases Human genes 0.000 claims description 15
- 108010006035 Metalloproteases Proteins 0.000 claims description 15
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 15
- 108091005418 scavenger receptor class E Proteins 0.000 claims description 15
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 15
- 101710139422 Eotaxin Proteins 0.000 claims description 14
- 102100023688 Eotaxin Human genes 0.000 claims description 14
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 14
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 14
- 102100034980 ICOS ligand Human genes 0.000 claims description 14
- 101710093458 ICOS ligand Proteins 0.000 claims description 14
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims description 14
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims description 14
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 14
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 14
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 14
- 102100021538 Protein kinase C zeta type Human genes 0.000 claims description 14
- 108090000783 Renin Proteins 0.000 claims description 14
- 102100028255 Renin Human genes 0.000 claims description 14
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 14
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 14
- 208000008383 Wilms tumor Diseases 0.000 claims description 14
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 14
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 14
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 14
- 229940116977 epidermal growth factor Drugs 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 13
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 13
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 13
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 13
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 108010050991 protein kinase C zeta Proteins 0.000 claims description 13
- 102100037362 Fibronectin Human genes 0.000 claims description 12
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 12
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000035092 Neutral proteases Human genes 0.000 claims description 11
- 108091005507 Neutral proteases Proteins 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000145 Bacillolysin Proteins 0.000 claims description 10
- 230000000510 mucolytic effect Effects 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims description 8
- 108010014258 Elastin Proteins 0.000 claims description 8
- 102000002452 NPR3 Human genes 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 102100040743 Alpha-crystallin B chain Human genes 0.000 claims description 7
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims description 7
- 102000016942 Elastin Human genes 0.000 claims description 7
- 102100039165 Heat shock protein beta-1 Human genes 0.000 claims description 7
- 101710100504 Heat shock protein beta-1 Proteins 0.000 claims description 7
- 102100029279 Homeobox protein SIX1 Human genes 0.000 claims description 7
- 101000891982 Homo sapiens Alpha-crystallin B chain Proteins 0.000 claims description 7
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 claims description 7
- 101000703741 Homo sapiens Short stature homeobox protein 2 Proteins 0.000 claims description 7
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 7
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 7
- 102100031976 Short stature homeobox protein 2 Human genes 0.000 claims description 7
- 229920002549 elastin Polymers 0.000 claims description 7
- 102100024394 Adipocyte enhancer-binding protein 1 Human genes 0.000 claims description 6
- 101710105604 Adipocyte enhancer-binding protein 1 Proteins 0.000 claims description 6
- 102000004954 Biglycan Human genes 0.000 claims description 6
- 108090001138 Biglycan Proteins 0.000 claims description 6
- 108010010786 Cholesterol 25-hydroxylase Proteins 0.000 claims description 6
- 102100024337 Collagen alpha-1(VIII) chain Human genes 0.000 claims description 6
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 claims description 6
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 6
- 102100038493 Cytokine receptor-like factor 1 Human genes 0.000 claims description 6
- 101710194728 Cytokine receptor-like factor 1 Proteins 0.000 claims description 6
- 102100028556 Disheveled-associated activator of morphogenesis 2 Human genes 0.000 claims description 6
- 102100031814 EGF-containing fibulin-like extracellular matrix protein 1 Human genes 0.000 claims description 6
- 101710176517 EGF-containing fibulin-like extracellular matrix protein 1 Proteins 0.000 claims description 6
- 102100021717 Early growth response protein 3 Human genes 0.000 claims description 6
- 102100036963 Filamin A-interacting protein 1-like Human genes 0.000 claims description 6
- 102000052396 Hephaestin Human genes 0.000 claims description 6
- 108700038053 Hephaestin Proteins 0.000 claims description 6
- 102100022373 Homeobox protein DLX-5 Human genes 0.000 claims description 6
- 102100037102 Homeobox protein MOX-2 Human genes 0.000 claims description 6
- 101710142888 Homeobox protein MOX-2 Proteins 0.000 claims description 6
- 101710189536 Homeobox protein SIX1 Proteins 0.000 claims description 6
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 claims description 6
- 101000915408 Homo sapiens Disheveled-associated activator of morphogenesis 2 Proteins 0.000 claims description 6
- 101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 claims description 6
- 101000878301 Homo sapiens Filamin A-interacting protein 1-like Proteins 0.000 claims description 6
- 101000901627 Homo sapiens Homeobox protein DLX-5 Proteins 0.000 claims description 6
- 101000994363 Homo sapiens Integrin alpha-7 Proteins 0.000 claims description 6
- 101000997670 Homo sapiens Integrin beta-8 Proteins 0.000 claims description 6
- 101001003147 Homo sapiens Interleukin-11 receptor subunit alpha Proteins 0.000 claims description 6
- 101001026236 Homo sapiens Intermediate conductance calcium-activated potassium channel protein 4 Proteins 0.000 claims description 6
- 101000602237 Homo sapiens Neuroblastoma suppressor of tumorigenicity 1 Proteins 0.000 claims description 6
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 claims description 6
- 101000612134 Homo sapiens Procollagen C-endopeptidase enhancer 1 Proteins 0.000 claims description 6
- 101000933601 Homo sapiens Protein BTG1 Proteins 0.000 claims description 6
- 101000890554 Homo sapiens Retinal dehydrogenase 2 Proteins 0.000 claims description 6
- 102100032832 Integrin alpha-7 Human genes 0.000 claims description 6
- 102100033336 Integrin beta-8 Human genes 0.000 claims description 6
- 102100020787 Interleukin-11 receptor subunit alpha Human genes 0.000 claims description 6
- 102100037441 Intermediate conductance calcium-activated potassium channel protein 4 Human genes 0.000 claims description 6
- 102100023529 Iroquois-class homeodomain protein IRX-5 Human genes 0.000 claims description 6
- 101710136127 Iroquois-class homeodomain protein IRX-5 Proteins 0.000 claims description 6
- 102000000853 LDL receptors Human genes 0.000 claims description 6
- 101150066297 NPR3 gene Proteins 0.000 claims description 6
- 102100037142 Neuroblastoma suppressor of tumorigenicity 1 Human genes 0.000 claims description 6
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 claims description 6
- 102100041026 Procollagen C-endopeptidase enhancer 1 Human genes 0.000 claims description 6
- 102100038931 Proenkephalin-A Human genes 0.000 claims description 6
- 102100026036 Protein BTG1 Human genes 0.000 claims description 6
- 102100040070 Retinal dehydrogenase 2 Human genes 0.000 claims description 6
- 102000007000 Tenascin Human genes 0.000 claims description 6
- 108010008125 Tenascin Proteins 0.000 claims description 6
- 102100024554 Tetranectin Human genes 0.000 claims description 6
- 102000033162 Vesicle-associated membrane protein 5 Human genes 0.000 claims description 6
- 108091009550 Vesicle-associated membrane protein 5 Proteins 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims description 6
- 108010041071 proenkephalin Proteins 0.000 claims description 6
- 210000002504 synaptic vesicle Anatomy 0.000 claims description 6
- 108010013645 tetranectin Proteins 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 claims description 5
- 102000003930 C-Type Lectins Human genes 0.000 claims description 5
- 108090000342 C-Type Lectins Proteins 0.000 claims description 5
- 102100027332 Homeobox protein SIX2 Human genes 0.000 claims description 5
- 101710189529 Homeobox protein SIX2 Proteins 0.000 claims description 5
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 5
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 5
- 101000880310 Homo sapiens SH3 and cysteine-rich domain-containing protein Proteins 0.000 claims description 5
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 5
- 108010065942 Prostaglandin-F synthase Proteins 0.000 claims description 5
- 102100037646 SH3 and cysteine-rich domain-containing protein Human genes 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 claims description 3
- 108090000365 Cytochrome-c oxidases Proteins 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102100031102 C-C motif chemokine 4 Human genes 0.000 claims 10
- 102100037140 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Human genes 0.000 claims 2
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 claims 2
- 101000740545 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Proteins 0.000 claims 2
- 101710177419 Cytochrome c oxidase subunit 7A, mitochondrial Proteins 0.000 claims 1
- 239000004017 serum-free culture medium Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 35
- 238000002955 isolation Methods 0.000 abstract description 20
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 238000011160 research Methods 0.000 abstract description 5
- 239000002609 medium Substances 0.000 description 53
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 42
- 210000002744 extracellular matrix Anatomy 0.000 description 39
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 38
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 38
- 108010010803 Gelatin Proteins 0.000 description 37
- 229920000159 gelatin Polymers 0.000 description 37
- 235000019322 gelatine Nutrition 0.000 description 37
- 235000011852 gelatine desserts Nutrition 0.000 description 37
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 37
- 239000008273 gelatin Substances 0.000 description 36
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 34
- 239000012091 fetal bovine serum Substances 0.000 description 34
- 230000004069 differentiation Effects 0.000 description 33
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 31
- 239000002953 phosphate buffered saline Substances 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- 239000008103 glucose Substances 0.000 description 29
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 28
- 238000000338 in vitro Methods 0.000 description 28
- 239000000463 material Substances 0.000 description 28
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 229930182555 Penicillin Natural products 0.000 description 21
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 21
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 21
- 239000013592 cell lysate Substances 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 229940049954 penicillin Drugs 0.000 description 21
- 229960005322 streptomycin Drugs 0.000 description 21
- 230000010261 cell growth Effects 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 17
- 108010007093 dispase Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000003636 conditioned culture medium Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229920003023 plastic Polymers 0.000 description 15
- 239000004033 plastic Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 13
- 102000003951 Erythropoietin Human genes 0.000 description 13
- 108090000394 Erythropoietin Proteins 0.000 description 13
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 13
- 229940105423 erythropoietin Drugs 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 230000009758 senescence Effects 0.000 description 13
- 230000001228 trophic effect Effects 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 238000005138 cryopreservation Methods 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 239000000017 hydrogel Substances 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 108010058597 HLA-DR Antigens Proteins 0.000 description 11
- 102000006354 HLA-DR Antigens Human genes 0.000 description 11
- 239000012595 freezing medium Substances 0.000 description 11
- 238000002513 implantation Methods 0.000 description 11
- 238000010899 nucleation Methods 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 230000000975 bioactive effect Effects 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 238000003501 co-culture Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 210000003954 umbilical cord Anatomy 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 9
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 9
- 108010085895 Laminin Proteins 0.000 description 9
- 102000007547 Laminin Human genes 0.000 description 9
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 9
- 229940121363 anti-inflammatory agent Drugs 0.000 description 9
- 239000002260 anti-inflammatory agent Substances 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 229920000747 poly(lactic acid) Polymers 0.000 description 9
- 229920002627 poly(phosphazenes) Polymers 0.000 description 9
- 239000004626 polylactic acid Substances 0.000 description 9
- 229910052727 yttrium Inorganic materials 0.000 description 9
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 8
- 229960003942 amphotericin b Drugs 0.000 description 8
- 239000012888 bovine serum Substances 0.000 description 8
- 230000002648 chondrogenic effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000002188 osteogenic effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 229920000954 Polyglycolide Polymers 0.000 description 7
- 239000003429 antifungal agent Substances 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 230000003169 placental effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000002293 adipogenic effect Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000002424 anti-apoptotic effect Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000004019 antithrombin Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000031864 metaphase Effects 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 6
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 6
- 239000004633 polyglycolic acid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229930183010 Amphotericin Natural products 0.000 description 5
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 5
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 5
- 229930182831 D-valine Natural products 0.000 description 5
- 101000964749 Homo sapiens Zinc finger protein 710 Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 102000013275 Somatomedins Human genes 0.000 description 5
- 108010000499 Thromboplastin Proteins 0.000 description 5
- 102100030859 Tissue factor Human genes 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 102100035071 Vimentin Human genes 0.000 description 5
- 108010065472 Vimentin Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 102100040663 Zinc finger protein 710 Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940009444 amphotericin Drugs 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000003416 augmentation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000009795 derivation Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 239000012737 fresh medium Substances 0.000 description 5
- 239000006481 glucose medium Substances 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000001272 neurogenic effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 210000005048 vimentin Anatomy 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 108091012583 BCL2 Proteins 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 102100025369 Runt-related transcription factor 3 Human genes 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003589 local anesthetic agent Substances 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 229960000988 nystatin Drugs 0.000 description 4
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 101150036383 rad16 gene Proteins 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 229940116176 remicade Drugs 0.000 description 4
- 238000009256 replacement therapy Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 229960001017 tolmetin Drugs 0.000 description 4
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 4
- 229960005342 tranilast Drugs 0.000 description 4
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 102100032765 Chordin-like protein 1 Human genes 0.000 description 3
- 101710173231 Chordin-like protein 1 Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 102100032883 DNA-binding protein SATB2 Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010055191 EphA3 Receptor Proteins 0.000 description 3
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 101000655236 Homo sapiens DNA-binding protein SATB2 Proteins 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 101000976713 Homo sapiens Integrin beta-like protein 1 Proteins 0.000 description 3
- 101000722006 Homo sapiens Olfactomedin-like protein 2B Proteins 0.000 description 3
- 101000979760 Homo sapiens Protein NDNF Proteins 0.000 description 3
- 101000736906 Homo sapiens Protein prune homolog 2 Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 102100023481 Integrin beta-like protein 1 Human genes 0.000 description 3
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 3
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100025388 Olfactomedin-like protein 2B Human genes 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 102100024983 Protein NDNF Human genes 0.000 description 3
- 102100036040 Protein prune homolog 2 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000781 anti-lymphocytic effect Effects 0.000 description 3
- 230000001857 anti-mycotic effect Effects 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000001494 anti-thymocyte effect Effects 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 229960002170 azathioprine Drugs 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 229960004669 basiliximab Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940046731 calcineurin inhibitors Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 230000010094 cellular senescence Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 229960002806 daclizumab Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 239000002628 heparin derivative Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229940124302 mTOR inhibitor Drugs 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 description 3
- 229960004439 pemirolast Drugs 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 3
- 229960003912 probucol Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002089 prostaglandin antagonist Substances 0.000 description 3
- 229940048914 protamine Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- MDKGKXOCJGEUJW-UHFFFAOYSA-N suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 3
- 229960004492 suprofen Drugs 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 229940123169 Caspase inhibitor Drugs 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108700005087 Homeobox Genes Proteins 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 2
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 2
- 108010066327 Keratin-18 Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100022647 Reticulon-1 Human genes 0.000 description 2
- 101710122684 Reticulon-1 Proteins 0.000 description 2
- 101150040974 Set gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100028748 Transportin-1 Human genes 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001136 chorion Anatomy 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000007878 drug screening assay Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 230000001453 nonthrombogenic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- AAZMHPMNAVEBRE-SDBHATRESA-N 8-(4-chlorophenylthio)-cAMP Chemical compound N=1C=2C(N)=NC=NC=2N([C@H]2[C@@H]([C@@H]3OP(O)(=O)OC[C@H]3O2)O)C=1SC1=CC=C(Cl)C=C1 AAZMHPMNAVEBRE-SDBHATRESA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010017148 CCR8 Receptors Proteins 0.000 description 1
- 102000004426 CCR8 Receptors Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 101710088434 Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 description 1
- 102100025629 Cytochrome c oxidase subunit 7A1, mitochondrial Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 102000017944 Dishevelled Human genes 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- 102100033167 Elastin Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010011593 Healos Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000634171 Homo sapiens Homeobox protein SIX1 Proteins 0.000 description 1
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 description 1
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 1
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 1
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 1
- 101000830570 Homo sapiens Tumor necrosis factor alpha-induced protein 3 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 101000931422 Photobacterium phosphoreum Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101000752546 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Transaminated amino acid decarboxylase Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000002220 Supravalvular aortic stenosis Diseases 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 108010001122 alpha(2)-microglobulin Proteins 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical class [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical class [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical class [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000001625 cardiomyogenic effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000009816 chondrogenic differentiation Effects 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 210000005151 decidua basalis Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920003226 polyurethane urea Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000001590 sorbitan monolaureate Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Abstract
Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.
Description
POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF MAKING AND USING THE SAME
FIELD OF THE INVENTION
This invention relates to the field of mammalian cell biology and cell culture. In particular, the invention relates to cultured cells derived from postpartum placental tissue having the potential to differentiate into multiple lineages, and methods of preparation and use of those placenta-derived cells.
BACKGROUND OF THE INVENTION
Organ and tissue generation from cells provides promising treatments for a number of pathologies, thereby making stem cells a central focus of research in many fields. Human stem cells are capable of generating a variety of mature human cell lineages.
Transplantation of such cells has provided a clinical tool for reconstituting a target tissue, thereby restoring physiologic and anatomic functionality. The application of stem cell technology is wide-ranging, including tissue engineering, gene therapy delivery, and cell therapeutics for disorders including malignancies, inborn errors of metabolism, hemoglobinopathies, and immunodeficiences.
An obstacle to realization of the therapeutic potential of stem cell technology has been difficulty in obtaining sufficient numbers of human stem cells. One source of stem cells is embryonic or fetal tissue. Embryonic stem and progenitor cells have been isolated from a number of mammalian species, including humans. The derivation of stem cells from embryonic or fetal sources, however, has raised many ethical and moral issues.
Stem cells also have been isolated from adult tissues. Methods for isolation of stem cells from adult sources often yield only limited quantities of cells and/or cells having limited ability to differentiate.
Postpartum tissues have generated interest as an alternative source for human stem cells.
For example, methods for recovery of stem cells by perfusion of the placenta or collection from umbilical cord blood have been described. A limitation of stem cell procurement from these methods has been an inadequate volume of cord blood or quantity of cells obtained.
Thus, alternative sources of adequate supplies of cells having the ability to differentiate into an array of cell lineages for cryopreservation and/or use in clinical applications remain in great demand. Such cells may be used in drug screening assays, for cryopreservation and/or banking, and for diagnostic and therapeutic applications.
SUMMARY OF THE INVENTION
The present invention relates to cells derived from postpartum placenta. The cells of the invention may be characterized by any one or more of characteristics including the presence or absence of cell surface markers, methods of extraction from placental tissue, gene expression profiles, protein production profiles, secretion of factors, growth characteristics, or any combination of such characteristics.
The invention encompasses cells derived from human postpartum placental tissue substantially free of blood. In some embodiments, the cell is capable of self-renewal and expansion in culture. In some aspects of the invention, the cell has the potential to differentiate into cells of another phenotype. In some embodiments, the placenta-derived cell requires L-valine for growth. The placenta-derived cells of the invention are capable of growth in about 5%
to about 20% oxygen. In some embodiments of the invention, the placenta-derived cell exhibits at least one of the following characteristics:
(a) production of at least one of tissue factor, vimentin, granulocyte chemotactic protein-2 (GCP-2), and alpha-smooth muscle actin;
FIELD OF THE INVENTION
This invention relates to the field of mammalian cell biology and cell culture. In particular, the invention relates to cultured cells derived from postpartum placental tissue having the potential to differentiate into multiple lineages, and methods of preparation and use of those placenta-derived cells.
BACKGROUND OF THE INVENTION
Organ and tissue generation from cells provides promising treatments for a number of pathologies, thereby making stem cells a central focus of research in many fields. Human stem cells are capable of generating a variety of mature human cell lineages.
Transplantation of such cells has provided a clinical tool for reconstituting a target tissue, thereby restoring physiologic and anatomic functionality. The application of stem cell technology is wide-ranging, including tissue engineering, gene therapy delivery, and cell therapeutics for disorders including malignancies, inborn errors of metabolism, hemoglobinopathies, and immunodeficiences.
An obstacle to realization of the therapeutic potential of stem cell technology has been difficulty in obtaining sufficient numbers of human stem cells. One source of stem cells is embryonic or fetal tissue. Embryonic stem and progenitor cells have been isolated from a number of mammalian species, including humans. The derivation of stem cells from embryonic or fetal sources, however, has raised many ethical and moral issues.
Stem cells also have been isolated from adult tissues. Methods for isolation of stem cells from adult sources often yield only limited quantities of cells and/or cells having limited ability to differentiate.
Postpartum tissues have generated interest as an alternative source for human stem cells.
For example, methods for recovery of stem cells by perfusion of the placenta or collection from umbilical cord blood have been described. A limitation of stem cell procurement from these methods has been an inadequate volume of cord blood or quantity of cells obtained.
Thus, alternative sources of adequate supplies of cells having the ability to differentiate into an array of cell lineages for cryopreservation and/or use in clinical applications remain in great demand. Such cells may be used in drug screening assays, for cryopreservation and/or banking, and for diagnostic and therapeutic applications.
SUMMARY OF THE INVENTION
The present invention relates to cells derived from postpartum placenta. The cells of the invention may be characterized by any one or more of characteristics including the presence or absence of cell surface markers, methods of extraction from placental tissue, gene expression profiles, protein production profiles, secretion of factors, growth characteristics, or any combination of such characteristics.
The invention encompasses cells derived from human postpartum placental tissue substantially free of blood. In some embodiments, the cell is capable of self-renewal and expansion in culture. In some aspects of the invention, the cell has the potential to differentiate into cells of another phenotype. In some embodiments, the placenta-derived cell requires L-valine for growth. The placenta-derived cells of the invention are capable of growth in about 5%
to about 20% oxygen. In some embodiments of the invention, the placenta-derived cell exhibits at least one of the following characteristics:
(a) production of at least one of tissue factor, vimentin, granulocyte chemotactic protein-2 (GCP-2), and alpha-smooth muscle actin;
- 2 -(b) lack of production of at least one of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(c) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(e) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is increased for at least one of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113;
(f) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is reduced for at least one of:
short stature homeobox 2; heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin; cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1;
tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translo cation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; hypothetical protein FLJ23191; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer;
frizzled homolog 7; hypothetical gene BC008967; collagen, type VIII, alpha 1;
tenascin C;
iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2;
cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3;
distal-less homeobox 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; flbronectin 1;
proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA clone EUROIMAGE 1968422; EphA3;
KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide
(c) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(e) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is increased for at least one of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113;
(f) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is reduced for at least one of:
short stature homeobox 2; heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin; cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1;
tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translo cation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; hypothetical protein FLJ23191; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer;
frizzled homolog 7; hypothetical gene BC008967; collagen, type VIII, alpha 1;
tenascin C;
iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2;
cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3;
distal-less homeobox 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; flbronectin 1;
proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA clone EUROIMAGE 1968422; EphA3;
KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide
- 3 -receptor C); hypothetical protein Fu14054; cDNA DKFZp564B222 (froM clone DKFZp564B222); vesicle-associated membrane protein 5; EGF-containing fibulin-like extraceLlular matrix protein 1;'BCL2/adenovirus ElB 19kDa interacting protein 3-like; AE
binding protein 1; cytocbrome c oxidase subunit Vila polypeptide 1 (muscle);
neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 361cDa;
(g) secretion of at least one of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (M-6), stromal-derived factor lalpha (SDF-lalpha), interleukin 8 (1L8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (I1B-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metallpproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha(MIP1a), Rantes (regulated on activation, inormal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(h) lack of secretion of at least one of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MEP 1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA; and = (i) the ability to undergo at least 40 population doublings in culture.
In specific embodiments, the cell has all identifying features of any one of:
cell type PLA 071003 (P8) (ATCC Accession No. PTA-6074); cell type PLA 071003 (P11) (ATCC
Accession No. PTA-6075); and cell type PLA 071Q03 (P16) (ATCC Accession No.
PTA-6079).
The placenta-derived cells of the invention are preferably human cells. The cells of the invention may be of neonatal lineage, maternal lineage, or a combination thereof. -The invention also provides placenta-derived cells isolated from a post-partum placenta or fragment thereof by enzymatic dissociation with a matrix metalloprotease (MMP); a matrix metalloprotease and a neutral protease; a matrix metalloprotease and a mucolytic enzyme that digests hyaluronic acid; or a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid. Preferable matrix metalloproteases include collagenase.=The neutral protease is preferably thermolysin or dispasZand most preferably is dispas ;M.
The mucolytic enzyme that digests hyaluronic -acid preferably is hyaluronidase. The LlBERASE
(Boehringer Mannheim Corp., Indianapolis, IN) Blendzyme (Roche) series-of enzyme combinations are very useful and may be used in the instant methods. Other sources of enzymes are known, and the
binding protein 1; cytocbrome c oxidase subunit Vila polypeptide 1 (muscle);
neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 361cDa;
(g) secretion of at least one of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (M-6), stromal-derived factor lalpha (SDF-lalpha), interleukin 8 (1L8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (I1B-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metallpproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha(MIP1a), Rantes (regulated on activation, inormal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(h) lack of secretion of at least one of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MEP 1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA; and = (i) the ability to undergo at least 40 population doublings in culture.
In specific embodiments, the cell has all identifying features of any one of:
cell type PLA 071003 (P8) (ATCC Accession No. PTA-6074); cell type PLA 071003 (P11) (ATCC
Accession No. PTA-6075); and cell type PLA 071Q03 (P16) (ATCC Accession No.
PTA-6079).
The placenta-derived cells of the invention are preferably human cells. The cells of the invention may be of neonatal lineage, maternal lineage, or a combination thereof. -The invention also provides placenta-derived cells isolated from a post-partum placenta or fragment thereof by enzymatic dissociation with a matrix metalloprotease (MMP); a matrix metalloprotease and a neutral protease; a matrix metalloprotease and a mucolytic enzyme that digests hyaluronic acid; or a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid. Preferable matrix metalloproteases include collagenase.=The neutral protease is preferably thermolysin or dispasZand most preferably is dispas ;M.
The mucolytic enzyme that digests hyaluronic -acid preferably is hyaluronidase. The LlBERASE
(Boehringer Mannheim Corp., Indianapolis, IN) Blendzyme (Roche) series-of enzyme combinations are very useful and may be used in the instant methods. Other sources of enzymes are known, and the
-4--skilled artisan may also obtain such enzymes directly from their natural sources. The skilled artisan is also well-equipped to assess new, or additional enzymes or enzyme combinations for their utility in isolating the cells of the invention. Preferred enzyme treatments are 0.5, 1, 1.5, or 2 hours long or longer. In more preferred embodiments, the tissue is incubated at 37 C during the enzyme treatment of the disintegration step.
In some embodiments of the invention, the placental tissue is separated into fractions prior to cell extraction, such that the cell is predominantly of neonatal or maternal derivation. In some aspects of the invention, placental tissue is mechanically dissociated prior to the step of enzymatic dissociation. In some embodiments, the method of isolation of the cells of the invention further involves growing the cells in culture medium. The culture medium preferably is RPMI1640, Ham's F10 medium, Ham's F12 medium, Mesenchytnal Stem Cell Growth Medium, Iscove's modified Dulbecco's medium, Dulbecco's modified Eagle's Medium DC
(DMEM), advanced DMEM (Gibco), DMEM/MCDB201 (Sigma), CELL-GRO FREE, DMEM/F12, or Eagle's basal medium. In some aspects of the invention, the culture medium is supplemented with about 2% to about 15% (v/v) serum, beta-mercaptoethanol, glucose, and/or an antibiotic agent and an antimycotic agent. The culture medium preferably is Growth medium comprising DMEM, glucose, beta-mercaptoethanol, serum, and an antibiotic agent. The culture medium may contain at least one of fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, epidermal growth factor, and leukemia inhibitory factor. The cells of the invention may be grown on an uncoated or coated surface. Surfaces for growth of the cells may be coated for example with gelatin, collagen (e.g., native or denatured), fibronectin, laminin, omithine, vitronectin, or extracellular membrane protein (e.g., MATR1GEL (BD
Discovery Labware, Bedford, MA)).
The invention includes within its scope placenta-derived cells characterized by growth characteristics, such as but not limited to, cells that yield greater than about 1017 cells in about 60 days upon initial seeding at about 1,000 to about 5,000 cells/cm2. In some embodiments, the placenta-derived cells of the invention have the ability to undergo at least 40 population doublings in about 80 days in culture.
The placenta-derived cells of the invention may be utilized from the first subculture (passage 0) to senescence. The preferable number of passages is that which yields a cell number sufficient for a given application. In certain embodiments, the cells are passaged 2 to 25 times, preferably 4 to 20 times, more preferably 8 to 15 times, more preferably 10 or 11 times, and most preferably 11 times.
In some embodiments of the invention, the placental tissue is separated into fractions prior to cell extraction, such that the cell is predominantly of neonatal or maternal derivation. In some aspects of the invention, placental tissue is mechanically dissociated prior to the step of enzymatic dissociation. In some embodiments, the method of isolation of the cells of the invention further involves growing the cells in culture medium. The culture medium preferably is RPMI1640, Ham's F10 medium, Ham's F12 medium, Mesenchytnal Stem Cell Growth Medium, Iscove's modified Dulbecco's medium, Dulbecco's modified Eagle's Medium DC
(DMEM), advanced DMEM (Gibco), DMEM/MCDB201 (Sigma), CELL-GRO FREE, DMEM/F12, or Eagle's basal medium. In some aspects of the invention, the culture medium is supplemented with about 2% to about 15% (v/v) serum, beta-mercaptoethanol, glucose, and/or an antibiotic agent and an antimycotic agent. The culture medium preferably is Growth medium comprising DMEM, glucose, beta-mercaptoethanol, serum, and an antibiotic agent. The culture medium may contain at least one of fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, epidermal growth factor, and leukemia inhibitory factor. The cells of the invention may be grown on an uncoated or coated surface. Surfaces for growth of the cells may be coated for example with gelatin, collagen (e.g., native or denatured), fibronectin, laminin, omithine, vitronectin, or extracellular membrane protein (e.g., MATR1GEL (BD
Discovery Labware, Bedford, MA)).
The invention includes within its scope placenta-derived cells characterized by growth characteristics, such as but not limited to, cells that yield greater than about 1017 cells in about 60 days upon initial seeding at about 1,000 to about 5,000 cells/cm2. In some embodiments, the placenta-derived cells of the invention have the ability to undergo at least 40 population doublings in about 80 days in culture.
The placenta-derived cells of the invention may be utilized from the first subculture (passage 0) to senescence. The preferable number of passages is that which yields a cell number sufficient for a given application. In certain embodiments, the cells are passaged 2 to 25 times, preferably 4 to 20 times, more preferably 8 to 15 times, more preferably 10 or 11 times, and most preferably 11 times.
- 5 -
6 PCT/US2004/020816 Methods for inducing differentiation of placenta-derived cells of the invention also are contemplated. In some embodiments of the invention, placenta-derived cells are induced to a mesodermal, ectodermal, or endodermal lineage. For example, the cells may be induced to differentiate to an adipogenic, a chondrogenic, an osteogenic, a neurogenic, an oculogenic, a pancreagenic, a cardiomyogenic, or a hepatogenic lineage. Methods of inducing differentiation of the cells of the invention preferably involve contacting or exposing the cells to one or more differentiation-inducing agents. In some embodiments, such contact or exposure occurs in culture. The invention includes the cells so induced.
Cells of the invention may be genetically engineered to express a gene of interest or to produce a protein of interest such as but not limited to a therapeutic protein. For example, PDCs may be genetically engineered to express an antiinflammatory compound or an anti-apoptotic agent.
Methods of the invention further include methods for producing a population of placenta-derived cells by expanding a cell or cells of the invention in culture. The PDCs may be differentiation-induced or undifferentiated. In some embodiments, a population of placenta-derived cells is mixed with another population of cells. In some embodiments, the cell population is heterogeneous. A heterogeneous cell population of the invention may comprise at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% undifferentiated or differentiation-induced PDCs of the invention. The heterogeneous cell populations of the invention may further comprise stem cells or cells of a mesodermal, endodermal, or ectodermal lineage. Cell populations of the invention may be homogeneous. Homogeneous populations of placenta-derived cells may be of neonatal or maternal lineage. Homogeneity of a cell population may be achieved by any method known in the art, for example, by cell sorting (e.g., flow cytometry) or by clonal expansion.
Some embodiments of the invention provide methods of manufacturing a tissue matrix for implantation into a patient by seeding one or more placenta-derived cells of the invention onto or into a tissue matrix for implantation into a patient. The PDCs may be differentiated or undifferentiated. The matrix may contain one or more factors including drugs, anti-apoptotic agents (e.g., erythropoietin (EPO), EPO mimetibody, thrombopoietin, insulin-like growth factor (IGF)-I, IGF-II, hepatocyte growth factor, caspase inhibitors), anti-inflammatory compounds (e.g., p38 MAP kinase inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLIMUS, and non-steroidal anti-inflammatory drugs (NSAIDS) (such as TEPDXALIN, TOLMETIN, and SUPROFEN)) as well as local anesthetics, and growth factors. In some aspects of the invention, the matrix comprises 53471-3, decellularized tissue, such as extracellular matrix or cell lysates of the PDCs. In some embodiments, the matrix is biodegradable. In some aspects of the invention, the matrix comprises natural or synthetic polymers. Matrices of the invention include biocompatible scaffolds, lattices, self-assembling structures and the like, whether biodegradable or not, liquid or solid. Such matrices are known in the arts of cell-based therapy, surgical repair, tissue engineering, and wound healing. Preferably the matrices are pretreated (e.g., seeded, inoculated, contacted with) with the cells, extracellular matrix, conditioned medium, cell lysate, or combination thereof, of the invention. More preferably the matrices are populated with cells in close association to the matrix or its spaces. In some aspects of the invention, the cells adhere to the matrix. In some embodiments, the cells are contained within or bridge interstitial spaces of the matrix. Most preferred are those seeded matrices wherein the cells are in close association with the matrix and which, when used therapeutically, induce or support ingrowth of the patient's cells and/or proper angiogenesis. The seeded matrices can be introduced into a patient's body in any way known in the art, including but not limited to implantation, injection, surgical attachment, transplantation with other tissue, injection, and the like. Examples of scaffolds which may be used in the present invention include nonwoven mats, porous foams, or self-assembling peptides. Nonwoven mats may, for example, be formed using fibers comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA) sold under the tradename VICRYL (Ethicon, Inc. Somerville, NJ). Foams composed of, for example, poly(epsilon-caprolactone)/poly(glycolic aicd) (PCL/PGA) copolymer, formed by the processes such as freeze-drying, or lyophilized, as discussed in U.S. Patent No.
6,355,699, also are possible scaffolds. Hydrogels such as self-assembling peptides (e.g., RAD16) may also be used. These materials are frequently used as supports for growth of tissue. The matrices of the invention may be configured to the shape and/or size of a tissue or organ in vivo. The scaffolds of the invention may be flat or tubular or may comprise sections thereof. The scaffolds of the invention may be multilayered. Organs and tissues comprising PDCs, their extracellular matrix, or cell lysate also are provided.
Also encompassed within the scope of the invention are extracellular matrices of PDCs, cell fractions (e.g., soluble cell fractions) of PDCs, and PDC-conditioned medium.
In some embodiments the invention provides compositions of PDCs and one or more bioactive factors, for example, but not limited to growth factors, anti-apoptotic agents, anti-inflammatory agents, and/or differentiation inducing factors.
Cells of the invention may be genetically engineered to express a gene of interest or to produce a protein of interest such as but not limited to a therapeutic protein. For example, PDCs may be genetically engineered to express an antiinflammatory compound or an anti-apoptotic agent.
Methods of the invention further include methods for producing a population of placenta-derived cells by expanding a cell or cells of the invention in culture. The PDCs may be differentiation-induced or undifferentiated. In some embodiments, a population of placenta-derived cells is mixed with another population of cells. In some embodiments, the cell population is heterogeneous. A heterogeneous cell population of the invention may comprise at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% undifferentiated or differentiation-induced PDCs of the invention. The heterogeneous cell populations of the invention may further comprise stem cells or cells of a mesodermal, endodermal, or ectodermal lineage. Cell populations of the invention may be homogeneous. Homogeneous populations of placenta-derived cells may be of neonatal or maternal lineage. Homogeneity of a cell population may be achieved by any method known in the art, for example, by cell sorting (e.g., flow cytometry) or by clonal expansion.
Some embodiments of the invention provide methods of manufacturing a tissue matrix for implantation into a patient by seeding one or more placenta-derived cells of the invention onto or into a tissue matrix for implantation into a patient. The PDCs may be differentiated or undifferentiated. The matrix may contain one or more factors including drugs, anti-apoptotic agents (e.g., erythropoietin (EPO), EPO mimetibody, thrombopoietin, insulin-like growth factor (IGF)-I, IGF-II, hepatocyte growth factor, caspase inhibitors), anti-inflammatory compounds (e.g., p38 MAP kinase inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLIMUS, and non-steroidal anti-inflammatory drugs (NSAIDS) (such as TEPDXALIN, TOLMETIN, and SUPROFEN)) as well as local anesthetics, and growth factors. In some aspects of the invention, the matrix comprises 53471-3, decellularized tissue, such as extracellular matrix or cell lysates of the PDCs. In some embodiments, the matrix is biodegradable. In some aspects of the invention, the matrix comprises natural or synthetic polymers. Matrices of the invention include biocompatible scaffolds, lattices, self-assembling structures and the like, whether biodegradable or not, liquid or solid. Such matrices are known in the arts of cell-based therapy, surgical repair, tissue engineering, and wound healing. Preferably the matrices are pretreated (e.g., seeded, inoculated, contacted with) with the cells, extracellular matrix, conditioned medium, cell lysate, or combination thereof, of the invention. More preferably the matrices are populated with cells in close association to the matrix or its spaces. In some aspects of the invention, the cells adhere to the matrix. In some embodiments, the cells are contained within or bridge interstitial spaces of the matrix. Most preferred are those seeded matrices wherein the cells are in close association with the matrix and which, when used therapeutically, induce or support ingrowth of the patient's cells and/or proper angiogenesis. The seeded matrices can be introduced into a patient's body in any way known in the art, including but not limited to implantation, injection, surgical attachment, transplantation with other tissue, injection, and the like. Examples of scaffolds which may be used in the present invention include nonwoven mats, porous foams, or self-assembling peptides. Nonwoven mats may, for example, be formed using fibers comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA) sold under the tradename VICRYL (Ethicon, Inc. Somerville, NJ). Foams composed of, for example, poly(epsilon-caprolactone)/poly(glycolic aicd) (PCL/PGA) copolymer, formed by the processes such as freeze-drying, or lyophilized, as discussed in U.S. Patent No.
6,355,699, also are possible scaffolds. Hydrogels such as self-assembling peptides (e.g., RAD16) may also be used. These materials are frequently used as supports for growth of tissue. The matrices of the invention may be configured to the shape and/or size of a tissue or organ in vivo. The scaffolds of the invention may be flat or tubular or may comprise sections thereof. The scaffolds of the invention may be multilayered. Organs and tissues comprising PDCs, their extracellular matrix, or cell lysate also are provided.
Also encompassed within the scope of the invention are extracellular matrices of PDCs, cell fractions (e.g., soluble cell fractions) of PDCs, and PDC-conditioned medium.
In some embodiments the invention provides compositions of PDCs and one or more bioactive factors, for example, but not limited to growth factors, anti-apoptotic agents, anti-inflammatory agents, and/or differentiation inducing factors.
- 7 -õ
=
The cells, matrices, tissues, and compositions of the invention may be cryopreserved.
Cryopreserved cells and compositions of the invention may be banked or stored.
Methods for cryopreserving and/or storing postpartum-derived cells of the invention also are contemplated.
Compositions of PDCs and related products, including for example pharmaceutical compositions, are included within the scope of the invention. Compositions of PDCs may include one or more of a differentiation-inducing factor, a cell survival factor such as caspase inhibitor, an anti-inflammatory agent such as p38 kinase inhibitor, growth factors, such as PDGF-bb, EGF, bFGF, LIF, IGF-1, or VEGF, or an angiogenic factor such as VEGF
or bFGF.
Pharmaceutical compositions of the placenta-derived cells, extracellular matrix produced thereby, cell lysates thereof, and PDC-conditioned medium are included within the scope of the invention. The pharmaceutical compositions preferably include a pharmaceutically acceptable carrier or excipient.
In some embodiments, methods of transplanting placenta-derived cells or matrices and methods of regenerating a tissue or organ in a patient in need thereof by transplanting cells or matrices of the invention into a patient are provided.
Further provided by the invention are methods for treating a disease or injury in a patient by administering one or more placenta-derived cells, PDC populations, matrices, cell lysates, conditioned medium, or compositions of the invention.
The invention also encompasses cell cultures of the placenta-derived cells of the invention. The cultures of the invention preferably are capable of at least 40 population doublings upon initial seeding.
The cell and compositions of the invention may be used, for example, in the treatment of conditions or repair of tissue. In some embodiments of the invention, the condition to be treated is a condition of soft tissue (e.g., skin, muscle, vasculature, tendons, ligaments, bladder, fascia, pelvic floor), bone, pancreas, kidney, liver, nervous system, eye, heart, or cartilage.
Methods of the invention further include methods for producing a population of placenta-derived cells by expanding a cell of the invention in culture.
=
The cells, matrices, tissues, and compositions of the invention may be cryopreserved.
Cryopreserved cells and compositions of the invention may be banked or stored.
Methods for cryopreserving and/or storing postpartum-derived cells of the invention also are contemplated.
Compositions of PDCs and related products, including for example pharmaceutical compositions, are included within the scope of the invention. Compositions of PDCs may include one or more of a differentiation-inducing factor, a cell survival factor such as caspase inhibitor, an anti-inflammatory agent such as p38 kinase inhibitor, growth factors, such as PDGF-bb, EGF, bFGF, LIF, IGF-1, or VEGF, or an angiogenic factor such as VEGF
or bFGF.
Pharmaceutical compositions of the placenta-derived cells, extracellular matrix produced thereby, cell lysates thereof, and PDC-conditioned medium are included within the scope of the invention. The pharmaceutical compositions preferably include a pharmaceutically acceptable carrier or excipient.
In some embodiments, methods of transplanting placenta-derived cells or matrices and methods of regenerating a tissue or organ in a patient in need thereof by transplanting cells or matrices of the invention into a patient are provided.
Further provided by the invention are methods for treating a disease or injury in a patient by administering one or more placenta-derived cells, PDC populations, matrices, cell lysates, conditioned medium, or compositions of the invention.
The invention also encompasses cell cultures of the placenta-derived cells of the invention. The cultures of the invention preferably are capable of at least 40 population doublings upon initial seeding.
The cell and compositions of the invention may be used, for example, in the treatment of conditions or repair of tissue. In some embodiments of the invention, the condition to be treated is a condition of soft tissue (e.g., skin, muscle, vasculature, tendons, ligaments, bladder, fascia, pelvic floor), bone, pancreas, kidney, liver, nervous system, eye, heart, or cartilage.
Methods of the invention further include methods for producing a population of placenta-derived cells by expanding a cell of the invention in culture.
- 8 -, In one aspect, there is provided an isolated substantially homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (M1P1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA.
In another aspect, there is provided an isolated substantially homogenous placenta-derived cell population comprising a cell derived from human postpartum placenta tissue substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; requires L-valine for growth; cell grows in about 5%
to about 20%
oxygen; and further comprises the following characteristics:
(a) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(b) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lacks production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
- 8a -(d) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, downregulated in ovarian cancer 1;
(e) expresses at a reduced level relative to a human cell that is a fibroblast, a mesenchynnal stem cell, or an iliac crest bone marrow cell: short stature homeobox 2; heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1);
elastin; mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; tetranectin; src homology three (SH3) and cysteine rich domain; B cell translocation gene 1, anti-proliferative;
cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7; collagen, type VIII, alpha 1;
tenascin C; iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2; early growth response 3; distal-less homeobox 5;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); vesicle associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1;
BCL2/adenovirus El B
19kDa interacting protein 3-like; AE binding protein 1; cytochrome c oxidase subunit Vila polypeptide 1; neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa;
(f) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor lalpha (SDF-lalpha), interleukin 8 (1L-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(g) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and - 8b -macrophage-derived chemokine (MDC), as detected by ELISA; and (h) has the ability to undergo at least 40 population doublings in culture.
In another aspect, there is provided an isolated homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DO, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein the cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6074.
In another aspect, there is provided an isolated homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, - 8c -CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein the cell population has been deposited with the ATCC under ATCC
Accession No.
PTA-6075.
In another aspect, there is provided an isolated homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (1L-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage - 8d -inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein the cell population has been deposited with the ATCC under ATCC
Accession No.
PTA-6079.
In another aspect, there is provided a composition comprising a cell population as described herein.
In another aspect, there is provided a cell culture comprising an isolated cell population as described herein.
In another aspect, there is provided a method of isolating a placenta-derived cell from a post-partum human placenta or fragment thereof comprising dissociating said cell from said placenta or fragment with a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid.
In another aspect, there is provided a kit comprising an isolated placenta-derived cell population as described herein and at least one additional component of a scaffold, a hydrating agent, a cell culture substrate and cell culture media.
In another aspect, there is provided a pharmaceutical composition comprising a cell population as described herein.
Other features and advantages of the invention will be apparent from the detailed description and examples that follow.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
Definitions Various terms used throughout the specification and claims are defined as set forth below.
- 8e -Stein cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self-renewing progenitors, non-renewing progenitors and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
Stem cells are classified by their developmental potential as: (1) totipotent ¨ able to give rise to all embryonic and extraembryonic cell types; (2) pluripotent ¨ able to give rise to all embryonic cell types; (3) multipotent ¨ able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self-renewal), blood cell-restricted oligopotent progenitors, and all cell types and elements (e.g., platelets) that are normal components of the blood); (4) oligopotent ¨ able to give rise to a more restricted subset of cell lineages than multipotent stem cells; and (5) unipotent ¨ able to give rise to a single cell lineage (e.g., spermatogenic stem cells).
Stem cells are also categorized on the basis of the source from which they may be obtained. An adult stein cell is generally a multipotent undifferentiated cell found in tissue comprising multiple differentiated cell types. The adult stem cell can renew itself and, under normal circumstances, differentiate to yield the specialized cell types of the tissue from which it originated, and possibly other tissue types. An embryonic stem cell is a pluripotent cell from the inner cell mass of a blastocyst-stage embryo. Afetal stein cell is one that originates from fetal tissues or membranes. A postpartum stem cell is a multipotent or pluripotent cell that originates substantially from extraembryonic tissue available after birth, namely, the placenta and the umbilical cord. These cells have been found to possess features characteristic of pluripotent stem cells, including rapid proliferation and the potential for differentiation into many cell lineages. Postpartum stem cells may be blood-derived (e.g., as are those obtained from umbilical cord blood) or non-blood-derived (e.g., as obtained from the non-blood tissues of the umbilical cord and placenta).
Embryonic tissue is typically defined as tissue originating from the embryo (which in humans refers to the period from fertilization to about six weeks of development. Fetal tissue refers to tissue originating from the fetus, which in humans refers to the period from about six weeks of development to parturition. Extraembiyonic tissue is tissue associated with, but not originating from, the embryo or fetus. Extraembryonic tissues include extraembryonic
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (M1P1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA.
In another aspect, there is provided an isolated substantially homogenous placenta-derived cell population comprising a cell derived from human postpartum placenta tissue substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; requires L-valine for growth; cell grows in about 5%
to about 20%
oxygen; and further comprises the following characteristics:
(a) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(b) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lacks production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
- 8a -(d) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, downregulated in ovarian cancer 1;
(e) expresses at a reduced level relative to a human cell that is a fibroblast, a mesenchynnal stem cell, or an iliac crest bone marrow cell: short stature homeobox 2; heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1);
elastin; mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; tetranectin; src homology three (SH3) and cysteine rich domain; B cell translocation gene 1, anti-proliferative;
cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7; collagen, type VIII, alpha 1;
tenascin C; iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2; early growth response 3; distal-less homeobox 5;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); vesicle associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1;
BCL2/adenovirus El B
19kDa interacting protein 3-like; AE binding protein 1; cytochrome c oxidase subunit Vila polypeptide 1; neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa;
(f) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor lalpha (SDF-lalpha), interleukin 8 (1L-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(g) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and - 8b -macrophage-derived chemokine (MDC), as detected by ELISA; and (h) has the ability to undergo at least 40 population doublings in culture.
In another aspect, there is provided an isolated homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DO, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein the cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6074.
In another aspect, there is provided an isolated homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, - 8c -CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein the cell population has been deposited with the ATCC under ATCC
Accession No.
PTA-6075.
In another aspect, there is provided an isolated homogenous placenta-derived cell population, wherein the cell population is obtained from human postpartum placenta substantially free of blood, wherein the cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (1L-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage - 8d -inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T
cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein the cell population has been deposited with the ATCC under ATCC
Accession No.
PTA-6079.
In another aspect, there is provided a composition comprising a cell population as described herein.
In another aspect, there is provided a cell culture comprising an isolated cell population as described herein.
In another aspect, there is provided a method of isolating a placenta-derived cell from a post-partum human placenta or fragment thereof comprising dissociating said cell from said placenta or fragment with a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid.
In another aspect, there is provided a kit comprising an isolated placenta-derived cell population as described herein and at least one additional component of a scaffold, a hydrating agent, a cell culture substrate and cell culture media.
In another aspect, there is provided a pharmaceutical composition comprising a cell population as described herein.
Other features and advantages of the invention will be apparent from the detailed description and examples that follow.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
Definitions Various terms used throughout the specification and claims are defined as set forth below.
- 8e -Stein cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self-renewing progenitors, non-renewing progenitors and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
Stem cells are classified by their developmental potential as: (1) totipotent ¨ able to give rise to all embryonic and extraembryonic cell types; (2) pluripotent ¨ able to give rise to all embryonic cell types; (3) multipotent ¨ able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self-renewal), blood cell-restricted oligopotent progenitors, and all cell types and elements (e.g., platelets) that are normal components of the blood); (4) oligopotent ¨ able to give rise to a more restricted subset of cell lineages than multipotent stem cells; and (5) unipotent ¨ able to give rise to a single cell lineage (e.g., spermatogenic stem cells).
Stem cells are also categorized on the basis of the source from which they may be obtained. An adult stein cell is generally a multipotent undifferentiated cell found in tissue comprising multiple differentiated cell types. The adult stem cell can renew itself and, under normal circumstances, differentiate to yield the specialized cell types of the tissue from which it originated, and possibly other tissue types. An embryonic stem cell is a pluripotent cell from the inner cell mass of a blastocyst-stage embryo. Afetal stein cell is one that originates from fetal tissues or membranes. A postpartum stem cell is a multipotent or pluripotent cell that originates substantially from extraembryonic tissue available after birth, namely, the placenta and the umbilical cord. These cells have been found to possess features characteristic of pluripotent stem cells, including rapid proliferation and the potential for differentiation into many cell lineages. Postpartum stem cells may be blood-derived (e.g., as are those obtained from umbilical cord blood) or non-blood-derived (e.g., as obtained from the non-blood tissues of the umbilical cord and placenta).
Embryonic tissue is typically defined as tissue originating from the embryo (which in humans refers to the period from fertilization to about six weeks of development. Fetal tissue refers to tissue originating from the fetus, which in humans refers to the period from about six weeks of development to parturition. Extraembiyonic tissue is tissue associated with, but not originating from, the embryo or fetus. Extraembryonic tissues include extraembryonic
- 9 -membranes (chorion, amnion, yolk sac and allantois), umbilical cord, and placenta (which itself forms from the chorion and the maternal decidua basalis).
Differentiation is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the features of a specialized cell, such as a nerve cell or a muscle cell, for example. A differentiated or differentiation-induced cell is one that has taken on a more specialized ("committed") position within the lineage of a cell. The term committed, when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type. De-differentiation refers to the process by which a cell reverts to a less specialized (or committed) position within the lineage Of a cell. As used herein, the lineage of a cell defines the heredity of the cell, i.e., which cells it came from and what cells it can give rise to. The lineage of a cell places the cell within a hereditary scheme of development and differentiation. A lineage-specific marker refers to a characteristic specifically associated with the phenotype of cells of a lineage of interest and can be used to assess the differentiation of an uncommitted cell to the lineage of interest.
In a broad sense, a progenitor cell is a cell that has the capacity to create progeny that are more differentiated than itself and yet retains the capacity to replenish the pool of progenitors.
By that definition, stem cells themselves are also progenitor cells, as are the more immediate precursors to terminally differentiated cells. When referring to the cells of the present invention, as described in greater detail below, this broad definition of progenitor cell may be used. In a narrower sense, a progenitor cell is often defined as a cell that is intermediate in the differentiation pathway, i.e., it arises from a stem cell and is intermediate in the production of a mature cell type or subset of cell types. This type of progenitor cell is generally not able to self-renew. Accordingly, if this type of cell is referred to herein, it will be referred to as a non-renewing progenitor cell or as an intermediate progenitor or precursor cell.
As used herein, the phrase differentiates into a mesodermal, ectodermal or endodermal lineage refers to a cell that becomes committed to a specific mesodermal, ectodelinal or endodermal lineage, respectively. Examples of cells that differentiate into a mesodermal lineage or give rise to specific mesodermal cells include, but are not limited to, cells that are adipogenic, chondrogenic, cardiogenic, dermatogenic, hematopoietic, hemangiogenic, myogenic, nephrogenic, urogenitogenic, osteogenic, pericardiogenic, or stromal. Examples of cells that differentiate into ectodermal lineage include, but are not limited to epidermal cells, neurogenic cells, and neurogliagenic cells. Examples of cells that differentiate into endodermal lineage
Differentiation is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the features of a specialized cell, such as a nerve cell or a muscle cell, for example. A differentiated or differentiation-induced cell is one that has taken on a more specialized ("committed") position within the lineage of a cell. The term committed, when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type. De-differentiation refers to the process by which a cell reverts to a less specialized (or committed) position within the lineage Of a cell. As used herein, the lineage of a cell defines the heredity of the cell, i.e., which cells it came from and what cells it can give rise to. The lineage of a cell places the cell within a hereditary scheme of development and differentiation. A lineage-specific marker refers to a characteristic specifically associated with the phenotype of cells of a lineage of interest and can be used to assess the differentiation of an uncommitted cell to the lineage of interest.
In a broad sense, a progenitor cell is a cell that has the capacity to create progeny that are more differentiated than itself and yet retains the capacity to replenish the pool of progenitors.
By that definition, stem cells themselves are also progenitor cells, as are the more immediate precursors to terminally differentiated cells. When referring to the cells of the present invention, as described in greater detail below, this broad definition of progenitor cell may be used. In a narrower sense, a progenitor cell is often defined as a cell that is intermediate in the differentiation pathway, i.e., it arises from a stem cell and is intermediate in the production of a mature cell type or subset of cell types. This type of progenitor cell is generally not able to self-renew. Accordingly, if this type of cell is referred to herein, it will be referred to as a non-renewing progenitor cell or as an intermediate progenitor or precursor cell.
As used herein, the phrase differentiates into a mesodermal, ectodermal or endodermal lineage refers to a cell that becomes committed to a specific mesodermal, ectodelinal or endodermal lineage, respectively. Examples of cells that differentiate into a mesodermal lineage or give rise to specific mesodermal cells include, but are not limited to, cells that are adipogenic, chondrogenic, cardiogenic, dermatogenic, hematopoietic, hemangiogenic, myogenic, nephrogenic, urogenitogenic, osteogenic, pericardiogenic, or stromal. Examples of cells that differentiate into ectodermal lineage include, but are not limited to epidermal cells, neurogenic cells, and neurogliagenic cells. Examples of cells that differentiate into endodermal lineage
-10-include, but are not limited to pleurigenic cells, and hepatogenic cells, cell that give rise to the lining of the intestine, and cells that give rise to pancreogenic and splanchogenic cells.
The cells of the present invention are referred to as placenta-derived cells (PDCs). They also may sometimes be referred to herein as postpartum-derived cells or postpartum cells (PPDCs). In addition, the cells may be described as being stem or progenitor cells, the latter term being used in the broad sense. The term derived is used to indicate that the cells have been obtained from their biological source and grown or otherwise manipulated in vitro (e.g., cultured in a growth medium to expand the population and/or to produce a cell line).
The in vitro manipulations of placenta-derived cells and the unique features of the placenta-derived cells of the present invention are described in detail below.
Various terms are used to describe cells in culture. Cell culture refers generally to cells taken from a living organism and grown under controlled condition ("in culture"). A primary cell culture is a culture of cells, tissues or organs taken directly from organisms and before the first subculture. Cells are expanded in culture when they are placed in a growth medium under conditions that facilitate cell growth and/or division, resulting in a larger population of the cells.
When cells are expanded in culture, the rate of cell proliferation is sometimes measured by the amount of time needed for the cells to double in number. This is referred to as doubling time.
A cell line is a population of cells fowled by one or more subcultivations of a primary cell culture. Each round of subculturing is referred to as a passage. When cells are subcultured, they are referred to as having been passaged. A specific population of cells, or a cell line, is sometimes referred to or characterized by the number of times it has been passaged. For example, a cultured cell population that has been passaged ten times may be referred to as a P10 culture. The primary culture, i.e., the first culture following the isolation of cells from tissue, is designated PO. Following the first subculture, the cells are described as a secondary culture (P1 or passage 1). After the second subculture, the cells become a tertiary culture (P2 or passage 2), and so on. It will be understood by those of skill in the art that there may be many population doublings during the period of passaging; therefore the number of population doublings of a culture is greater than the passage number. The expansion of cells (i.e., the number of population doublings) during the period between passaging depends on many factors, including but not limited to the seeding density, substrate, medium, and time between passaging.
A conditioned medium is a medium in which a specific cell or population of cells has been cultured, and then removed. While the cells are cultured in the medium, they secrete cellular factors that can provide trophic support to other cells. Such trophic factors include, but
The cells of the present invention are referred to as placenta-derived cells (PDCs). They also may sometimes be referred to herein as postpartum-derived cells or postpartum cells (PPDCs). In addition, the cells may be described as being stem or progenitor cells, the latter term being used in the broad sense. The term derived is used to indicate that the cells have been obtained from their biological source and grown or otherwise manipulated in vitro (e.g., cultured in a growth medium to expand the population and/or to produce a cell line).
The in vitro manipulations of placenta-derived cells and the unique features of the placenta-derived cells of the present invention are described in detail below.
Various terms are used to describe cells in culture. Cell culture refers generally to cells taken from a living organism and grown under controlled condition ("in culture"). A primary cell culture is a culture of cells, tissues or organs taken directly from organisms and before the first subculture. Cells are expanded in culture when they are placed in a growth medium under conditions that facilitate cell growth and/or division, resulting in a larger population of the cells.
When cells are expanded in culture, the rate of cell proliferation is sometimes measured by the amount of time needed for the cells to double in number. This is referred to as doubling time.
A cell line is a population of cells fowled by one or more subcultivations of a primary cell culture. Each round of subculturing is referred to as a passage. When cells are subcultured, they are referred to as having been passaged. A specific population of cells, or a cell line, is sometimes referred to or characterized by the number of times it has been passaged. For example, a cultured cell population that has been passaged ten times may be referred to as a P10 culture. The primary culture, i.e., the first culture following the isolation of cells from tissue, is designated PO. Following the first subculture, the cells are described as a secondary culture (P1 or passage 1). After the second subculture, the cells become a tertiary culture (P2 or passage 2), and so on. It will be understood by those of skill in the art that there may be many population doublings during the period of passaging; therefore the number of population doublings of a culture is greater than the passage number. The expansion of cells (i.e., the number of population doublings) during the period between passaging depends on many factors, including but not limited to the seeding density, substrate, medium, and time between passaging.
A conditioned medium is a medium in which a specific cell or population of cells has been cultured, and then removed. While the cells are cultured in the medium, they secrete cellular factors that can provide trophic support to other cells. Such trophic factors include, but
- 11 -are not limited to hormones, cytokines, extracellular matrix (ECM), proteins, vesicles, antibodies, and granules. The medium containing the cellular factors is the conditioned medium.
Generally, a trophic factor is defined as a substance that promotes survival, growth, proliferation, maintenance, differentiation, and /or maturation of a cell, or stimulates increased activity of a cell.
When referring to cultured vertebrate cells, the term senescence (also replicative senescence or cellular senescence) refers to a property attributable to finite cell cultures; namely, their inability to grow beyond a finite number of population doublings (sometimes referred to as Hayflick's limit). Although cellular senescence was first described using fibroblast-like cells, most normal human cell types that can be grown successfully in culture undergo cellular senescence. The in vitro lifespan of different cell types varies, but the maximum lifespan is typically fewer than 100 population doublings (this is the number of doublings for all the cells in the culture to become senescent and thus render the culture unable to divide).
Senescence does not depend on chronological time, but rather is measured by the number of cell divisions, or population doublings, the culture has undergone. Thus, cells made quiescent by removing essential growth factors are able to resume growth and division when the growth factors are re-introduced, and thereafter carry out the same number of doublings as equivalent cells grown continuously. Similarly, when cells are frozen in liquid nitrogen after various numbers of population doublings and then thawed and cultured, they undergo substantially the same number of doublings as cells maintained unfrozen in culture. Senescent cells are not dead or dying cells;
they are actually resistant to programmed cell death (apoptosis), and have been maintained in their nondividing state for as long as three years. These cells are very much alive and metabolically active, but they do not divide. The nondividing state of senescent cells has not yet been found to be reversible by any biological, chemical, or viral agent.
As used herein, the term Growth medium refers to a culture medium sufficient for expansion of placenta-derived cells. The culture medium of Growth medium preferably contains Dulbecco's Modified Essential Media (DMEM). More preferably, Growth medium contains glucose. Growth medium preferably contains DMEM-low glucose (DMEM-LG) (Invitrogen, Carlsbad, CA). Growth medium preferably contains about 15% (v/v) serum (e.g., fetal bovine serum, defined bovine serum). Growth medium preferably contains at least one antibiotic agent and/or antimycotic agent (e.g., penicillin, streptomycin, amphotericin B, gentamicin, nystatin;
preferably 50 units/milliliter penicillin G sodium and 50 micrograms/milliliter streptomycin sulfate). Growth medium preferably contains 2-mercaptoethanol (Sigma, St.
Louis MO). Most
Generally, a trophic factor is defined as a substance that promotes survival, growth, proliferation, maintenance, differentiation, and /or maturation of a cell, or stimulates increased activity of a cell.
When referring to cultured vertebrate cells, the term senescence (also replicative senescence or cellular senescence) refers to a property attributable to finite cell cultures; namely, their inability to grow beyond a finite number of population doublings (sometimes referred to as Hayflick's limit). Although cellular senescence was first described using fibroblast-like cells, most normal human cell types that can be grown successfully in culture undergo cellular senescence. The in vitro lifespan of different cell types varies, but the maximum lifespan is typically fewer than 100 population doublings (this is the number of doublings for all the cells in the culture to become senescent and thus render the culture unable to divide).
Senescence does not depend on chronological time, but rather is measured by the number of cell divisions, or population doublings, the culture has undergone. Thus, cells made quiescent by removing essential growth factors are able to resume growth and division when the growth factors are re-introduced, and thereafter carry out the same number of doublings as equivalent cells grown continuously. Similarly, when cells are frozen in liquid nitrogen after various numbers of population doublings and then thawed and cultured, they undergo substantially the same number of doublings as cells maintained unfrozen in culture. Senescent cells are not dead or dying cells;
they are actually resistant to programmed cell death (apoptosis), and have been maintained in their nondividing state for as long as three years. These cells are very much alive and metabolically active, but they do not divide. The nondividing state of senescent cells has not yet been found to be reversible by any biological, chemical, or viral agent.
As used herein, the term Growth medium refers to a culture medium sufficient for expansion of placenta-derived cells. The culture medium of Growth medium preferably contains Dulbecco's Modified Essential Media (DMEM). More preferably, Growth medium contains glucose. Growth medium preferably contains DMEM-low glucose (DMEM-LG) (Invitrogen, Carlsbad, CA). Growth medium preferably contains about 15% (v/v) serum (e.g., fetal bovine serum, defined bovine serum). Growth medium preferably contains at least one antibiotic agent and/or antimycotic agent (e.g., penicillin, streptomycin, amphotericin B, gentamicin, nystatin;
preferably 50 units/milliliter penicillin G sodium and 50 micrograms/milliliter streptomycin sulfate). Growth medium preferably contains 2-mercaptoethanol (Sigma, St.
Louis MO). Most
- 12 -preferably, Growth medium contains DMEM-low glucose, serum, 2-mercaptoethanol, and an antibiotic agent and antimycotic agent.
As used herein, standard growth conditions refers to standard atmospheric conditions comprising 5% CO2 and a temperature in the range of 35 C to 39 C, more preferably, 37 C, and a relative humidity of about 100%.
The term isolated refers to a cell, cellular component, or a molecule that has been removed from its native environment. PDCs, for example, may be isolated in some embodiments of the invention.
The term about refers to an approximation of a stated value within a range of 10%.
The term treating (or treatment of) a condition refers to ameliorating the effects of, or delaying, halting or reversing the progress of, or delaying or preventing the onset of, a condition such as but not limited to a congenital anomaly, disease, or injury.
The term effective amount refers to a concentration of a reagent or pharmaceutical composition, such as a growth factor, differentiation agent, trophic factor, cell population or other agent, that is effective for producing an intended result, including cell growth and/or differentiation in vitro or in vivo, or treatment of a condition as described herein. With respect to growth factors, an effective amount may range from about 1 nanogram/milliliter to about 1 microgram/milliliter. With respect to PDCs as administered to a patient in vivo, an effective amount may range from as few as several hundred or fewer to as many as several million or more. In specific embodiments, an effective amount may range from 103-1011. It will be appreciated that the number of cells to be administered will vary depending on the specifics of the disorder to be treated, including but not limited to size or total volume/surface area to be treated, as well as proximity of the site of administration to the location of the region to be treated, among other factors familiar to the medicinal biologist.
The terms effective period (or time) and effective conditions refer to a period of time or other controllable conditions (e.g., temperature, humidity for in vitro methods), necessary or preferred for an agent or pharmaceutical composition to achieve its intended result.
The term patient or subject refers to animals, including mammals, preferably humans, who are treated with the pharmaceutical compositions or in accordance with the methods described herein.
The term matrix as used herein refers to a support for the PPDCs of the invention, fOr example, a scaffold (e.g., VICRYL, PCL/PGA, or RAD16) or supporting medium (e.g., hydrogel, extracellular membrane protein (e.g., MATRIGEL (BD Discovery Labware, Bedford, MA)).
As used herein, standard growth conditions refers to standard atmospheric conditions comprising 5% CO2 and a temperature in the range of 35 C to 39 C, more preferably, 37 C, and a relative humidity of about 100%.
The term isolated refers to a cell, cellular component, or a molecule that has been removed from its native environment. PDCs, for example, may be isolated in some embodiments of the invention.
The term about refers to an approximation of a stated value within a range of 10%.
The term treating (or treatment of) a condition refers to ameliorating the effects of, or delaying, halting or reversing the progress of, or delaying or preventing the onset of, a condition such as but not limited to a congenital anomaly, disease, or injury.
The term effective amount refers to a concentration of a reagent or pharmaceutical composition, such as a growth factor, differentiation agent, trophic factor, cell population or other agent, that is effective for producing an intended result, including cell growth and/or differentiation in vitro or in vivo, or treatment of a condition as described herein. With respect to growth factors, an effective amount may range from about 1 nanogram/milliliter to about 1 microgram/milliliter. With respect to PDCs as administered to a patient in vivo, an effective amount may range from as few as several hundred or fewer to as many as several million or more. In specific embodiments, an effective amount may range from 103-1011. It will be appreciated that the number of cells to be administered will vary depending on the specifics of the disorder to be treated, including but not limited to size or total volume/surface area to be treated, as well as proximity of the site of administration to the location of the region to be treated, among other factors familiar to the medicinal biologist.
The terms effective period (or time) and effective conditions refer to a period of time or other controllable conditions (e.g., temperature, humidity for in vitro methods), necessary or preferred for an agent or pharmaceutical composition to achieve its intended result.
The term patient or subject refers to animals, including mammals, preferably humans, who are treated with the pharmaceutical compositions or in accordance with the methods described herein.
The term matrix as used herein refers to a support for the PPDCs of the invention, fOr example, a scaffold (e.g., VICRYL, PCL/PGA, or RAD16) or supporting medium (e.g., hydrogel, extracellular membrane protein (e.g., MATRIGEL (BD Discovery Labware, Bedford, MA)).
- 13 The term pharmaceutically acceptable carrier (or medium), which may be used interchangeably with the term biologically compatible carrier or medium, refers to reagents, cells, compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other complication commensurate with a reasonable benefit/risk ratio. As described in greater detail herein, pharmaceutically acceptable carriers suitable for use in the present invention include liquids, semi-solid (e.g., gels) and solid materials (e.g., cell scaffolds). As used herein, the term biodegradable describes the ability of a material to be broken down (e.g., degraded, eroded, dissolved) in vivo. The term includes degradation in vivo with or without elimination (e.g., by resorption) from the body. The semi-solid and solid materials may be designed to resist degradation within the body (non-biodegradable) or they may be designed to degrade within the body (biodegradable, bioerodable). A biodegradable material may further be bioresorbable or bioabsorbable, i.e., it may be dissolved and absorbed into bodily fluids (water-soluble implants are one example), or degraded and ultimately eliminated from the body, either by conversion into other materials or breakdown and elimination through natural pathways.
Several tenns are used herein with respect to cell replacement therapy. The tams autologous transfer, autologous transplantation, autograft and the like refer to treatments wherein the cell donor is also the recipient of the cell replacement therapy.
The terms allogeneic transfer, allogeneic transplantation, allograft and the like refer to treatments wherein the cell donor is of the same species as the recipient of the cell replacement therapy, but is not the same individual. A cell transfer in which the donor's cells have been histocompatibly matched with a recipient is sometimes referred to as a syngeneic transfer. The terms xenogeneic transfer, xenogeneic transplantation, xeno graft and the like refer to treatments wherein the cell donor is of a different species than the recipient of the cell replacement therapy.
The following abbreviations are used herein:
ANG2 (or Ang2)for angiopoietin 2;
APC for antigen-presenting cells;
BDNF for brain-derived neurotrophic factor;
bFGF for basic fibroblast growth factor;
bid (BID) for "bis in die" (twice per day);
BSP for bone sialoprotein;
CK1 8 for cytokeratin 18;
CXC ligand 3 for chemokine receptor ligand 3;
Several tenns are used herein with respect to cell replacement therapy. The tams autologous transfer, autologous transplantation, autograft and the like refer to treatments wherein the cell donor is also the recipient of the cell replacement therapy.
The terms allogeneic transfer, allogeneic transplantation, allograft and the like refer to treatments wherein the cell donor is of the same species as the recipient of the cell replacement therapy, but is not the same individual. A cell transfer in which the donor's cells have been histocompatibly matched with a recipient is sometimes referred to as a syngeneic transfer. The terms xenogeneic transfer, xenogeneic transplantation, xeno graft and the like refer to treatments wherein the cell donor is of a different species than the recipient of the cell replacement therapy.
The following abbreviations are used herein:
ANG2 (or Ang2)for angiopoietin 2;
APC for antigen-presenting cells;
BDNF for brain-derived neurotrophic factor;
bFGF for basic fibroblast growth factor;
bid (BID) for "bis in die" (twice per day);
BSP for bone sialoprotein;
CK1 8 for cytokeratin 18;
CXC ligand 3 for chemokine receptor ligand 3;
-14-DAPI for 4' - 6-Diamidino-2-phenylindole-2HC1;
DMEM for Dulbecco's Minimal Essential Medium;
DMEM:ig (or DMEM:Lg, DMEM:LG) for DMEM with low glucose;
EDTA for ethylene diamine tetraacetic acid;
EGF (or E) for epidermal growth factor;
EPO for erythropoietin;
FACS for fluorescent activated cell sorting;
FBS for fatal bovine serum;
FGF (or F) for fibroblast growth factor;
GCP-2 for granulocyte chemotactic protein-2;
GDF-5 for growth and differentiation factor 5;
GFAP for glial fibrillary acidic protein;
HB-EGF for heparin-binding epidermal growth factor;
HCAEC for Human coronary artery endothelial cells;
HGF for hepatocyte growth factor;
hMSC for Human mesenchymal stem cells;
HNF-1 alpha for hepatocyte-specific transcription factor;
HUVEC for Human umbilical vein endothelial cells;
1309 for a chemokine and the ligand for the CCR8 receptor and is responsible for chemoattraction of TH2 type T-cells;
IGF for insulin-like growth factor;
IL-6 for interleukin-6;
IL-8 for interleukin 8;
K19 for keratin 19;
K8 for keratin 8;
KGF for keratinocyte growth factor;
MCP-1 for monocyte chemotactic protein 1;
MDC for macrophage-derived chemokine;
MIPlalpha for macrophage inflammatory protein lalpha;
MIP1 beta for macrophage inflammatory protein lbeta;
MMP for matrix metalloprotease (MMP);
MSC for mesenchymal stem cells;
NHDF for Normal Human Dermal Fibroblasts;
NPE for Neural Progenitor Expansion media;
DMEM for Dulbecco's Minimal Essential Medium;
DMEM:ig (or DMEM:Lg, DMEM:LG) for DMEM with low glucose;
EDTA for ethylene diamine tetraacetic acid;
EGF (or E) for epidermal growth factor;
EPO for erythropoietin;
FACS for fluorescent activated cell sorting;
FBS for fatal bovine serum;
FGF (or F) for fibroblast growth factor;
GCP-2 for granulocyte chemotactic protein-2;
GDF-5 for growth and differentiation factor 5;
GFAP for glial fibrillary acidic protein;
HB-EGF for heparin-binding epidermal growth factor;
HCAEC for Human coronary artery endothelial cells;
HGF for hepatocyte growth factor;
hMSC for Human mesenchymal stem cells;
HNF-1 alpha for hepatocyte-specific transcription factor;
HUVEC for Human umbilical vein endothelial cells;
1309 for a chemokine and the ligand for the CCR8 receptor and is responsible for chemoattraction of TH2 type T-cells;
IGF for insulin-like growth factor;
IL-6 for interleukin-6;
IL-8 for interleukin 8;
K19 for keratin 19;
K8 for keratin 8;
KGF for keratinocyte growth factor;
MCP-1 for monocyte chemotactic protein 1;
MDC for macrophage-derived chemokine;
MIPlalpha for macrophage inflammatory protein lalpha;
MIP1 beta for macrophage inflammatory protein lbeta;
MMP for matrix metalloprotease (MMP);
MSC for mesenchymal stem cells;
NHDF for Normal Human Dermal Fibroblasts;
NPE for Neural Progenitor Expansion media;
- 15 -OxLDLR for oxidized low density lipoprotein receptor;
PBMC for peripheral blood mononuclear cell;
PBS for phosphate buffered saline;
PDC for placenta-derived cell;
PDGFbb for platelet derived growth factor;
PDGFr-alpha for platelet derived growth factor receptor alpha;
PD-L2 for programmed - death ligand 2;
PE for phycoerythriii;
PO for "per os" (by mouth);
PPDC for postpartum-derived cell;
Rantes (or RANTES) for regulated on activation, normal T cell expressed and secreted;
rb for rabbit rh for recombinant;
SC for subcutaneously;
SCID for severe combined immunodeficiency;
SDF-1 alpha for stromal-derived factor I alpha;
SHH for sonic hedgehog;
SMA for smooth muscle actin;
SOP for standard operating procedure;
TARC for thymus and activation-regulated chemokine;
TCP for tissue culture plastic;
TGFbeta2 for transforming growth factor beta2;
TGFbeta-3 for transforming growth factor beta-3;
TIMP1 for tissue inhibitor of matrix metalloproteinase 1;
TPO for thrombopoietin;
TuJi for Bill Tubulin;
UDC for umbilical cord-derived cell;
VEGF for vascular endothelial growth factor;
vWF for von Willebrand factor; and alphaFP for alpha-fetoprotein.
Description
PBMC for peripheral blood mononuclear cell;
PBS for phosphate buffered saline;
PDC for placenta-derived cell;
PDGFbb for platelet derived growth factor;
PDGFr-alpha for platelet derived growth factor receptor alpha;
PD-L2 for programmed - death ligand 2;
PE for phycoerythriii;
PO for "per os" (by mouth);
PPDC for postpartum-derived cell;
Rantes (or RANTES) for regulated on activation, normal T cell expressed and secreted;
rb for rabbit rh for recombinant;
SC for subcutaneously;
SCID for severe combined immunodeficiency;
SDF-1 alpha for stromal-derived factor I alpha;
SHH for sonic hedgehog;
SMA for smooth muscle actin;
SOP for standard operating procedure;
TARC for thymus and activation-regulated chemokine;
TCP for tissue culture plastic;
TGFbeta2 for transforming growth factor beta2;
TGFbeta-3 for transforming growth factor beta-3;
TIMP1 for tissue inhibitor of matrix metalloproteinase 1;
TPO for thrombopoietin;
TuJi for Bill Tubulin;
UDC for umbilical cord-derived cell;
VEGF for vascular endothelial growth factor;
vWF for von Willebrand factor; and alphaFP for alpha-fetoprotein.
Description
- 16 -In one aspect, the invention provides placenta-derived cells (PDCs) derived from placental tissue washed substantially free of blood. The PDCs may be derived from placenta of a mammal including but not limited to human. The placentas from which the cells are derived are post-partum placentas. The cells are capable of self-renewal and expansion in culture. The placenta-derived cells have the potential to differentiate into cells of other phenotypes. In preferred embodiments, the cells can differentiate into a cell of ectodermal, mesodermal, or endodermal origin. The invention provides, in one of its several aspects, cells that are isolated from placental tissues, as opposed to placental blood.
The cells have been characterized as to several of their cellular, genetic, immunological, and biochemical properties. For example, the cells have been characterized by their growth, by their cell surface markers, by their gene expression, by their ability to produce certain biochemical trophic factors, and by their immunological properties.
Derivation and expansion of placenta-derived cells (PDCs) According to the methods described herein, a mammalian placenta is recovered upon or shortly after termination of either a fall-term or pre-term pregnancy, for example, after its expulsion after birth. Placental tissue can be obtained from any completed pregnancy, fall-term or less than full-term, whether delivered vaginally, or through other means, for example, Cessarian section. The placenta may be transported from the birth site to a laboratory in a sterile container such as a flask, beaker, culture dish, or bag. The container may have a solution or medium, including but not limited to a salt solution, such as, for example, Dulbecco's Modified Eagle's Medium (DMEM) or phosphate buffered saline (PBS), or any solution used for transportation of organs used for transplantation, such as University of Wisconsin solution or perfluorochemical solution. One or more antibiotic and/or antimycotic agents, such as but not limited to penicillin, streptomycin, amphotericin B, gentamicin, and nystatin, may be added to the medium or buffer. The placenta may be rinsed with an anticoagulant solution such as heparin-containing solution. It is preferable to keep the tissue at about 4-10 C prior to extraction of PDCs. It is even more preferable that the tissue not be frozen prior to extraction of PDCs.
Isolation of PDCs preferably occurs in an aseptic environment. The umbilical cord is removed from the placenta by means known in the art. Placental tissue is washed substantially free of blood and debris prior to derivation of PDCs. For example, the placental tissue may be washed with buffer solution, such as but not limited to phosphate buffered saline. The wash buffer also may comprise one or more antimycotic and/or antibiotic agents, such as but not limited to penicillin, streptomycin, amphotericin B, gentamicin, and nystatin.
The cells have been characterized as to several of their cellular, genetic, immunological, and biochemical properties. For example, the cells have been characterized by their growth, by their cell surface markers, by their gene expression, by their ability to produce certain biochemical trophic factors, and by their immunological properties.
Derivation and expansion of placenta-derived cells (PDCs) According to the methods described herein, a mammalian placenta is recovered upon or shortly after termination of either a fall-term or pre-term pregnancy, for example, after its expulsion after birth. Placental tissue can be obtained from any completed pregnancy, fall-term or less than full-term, whether delivered vaginally, or through other means, for example, Cessarian section. The placenta may be transported from the birth site to a laboratory in a sterile container such as a flask, beaker, culture dish, or bag. The container may have a solution or medium, including but not limited to a salt solution, such as, for example, Dulbecco's Modified Eagle's Medium (DMEM) or phosphate buffered saline (PBS), or any solution used for transportation of organs used for transplantation, such as University of Wisconsin solution or perfluorochemical solution. One or more antibiotic and/or antimycotic agents, such as but not limited to penicillin, streptomycin, amphotericin B, gentamicin, and nystatin, may be added to the medium or buffer. The placenta may be rinsed with an anticoagulant solution such as heparin-containing solution. It is preferable to keep the tissue at about 4-10 C prior to extraction of PDCs. It is even more preferable that the tissue not be frozen prior to extraction of PDCs.
Isolation of PDCs preferably occurs in an aseptic environment. The umbilical cord is removed from the placenta by means known in the art. Placental tissue is washed substantially free of blood and debris prior to derivation of PDCs. For example, the placental tissue may be washed with buffer solution, such as but not limited to phosphate buffered saline. The wash buffer also may comprise one or more antimycotic and/or antibiotic agents, such as but not limited to penicillin, streptomycin, amphotericin B, gentamicin, and nystatin.
- 17-In some aspects of the invention, the different cell types present in postpartum tissue are fractionated into subpopulations from which the PDCs can be isolated. This may be accomplished using techniques for cell separation including, but not limited to, enzymatic treatment to dissociate postpartum tissue into its component cells, followed by cloning and selection of specific cell types, for example but not limited to selection based on morphological and/or biochemical markers; selective growth of desired cells (positive selection), selective destruction of unwanted cells (negative selection); separation based upon differential cell agglutinability in the mixed population as, for example, with soybean agglutinin; freeze-thaw procedures; differential adherence properties of the cells in the mixed population; filtration;
conventional and zonal centrifugation; centrifugal elutriation (counter-streaming centrifugation);
unit gravity separation; countercurrent distribution; electrophoresis; and flow cytometry, for example, fluorescence activated cell sorting (FACS).
In a preferred embodiment, placental tissue comprising a whole placenta or a fragment or section thereof is disaggregated by mechanical force (mincing or shear forces), enzymatic digestion with single or combinatorial proteolytic enzymes, such as a matrix metalloprotease TM
and/or neutral protease, for example, collagenase, trypsin, dispase, LEBERASE
(Boeluinger Mannheim Corp., Indianapolis, EN), hyaluronidase, and/or pepsin, or a combination of mechanical and enzymatic methods. For example, the cellular component of the placental tissue may be disaggregated by methods using collagenase-mediated dissociation.
Collagenase may be type 1, 2, 3, or 4. Enzymatic digestion methods preferably employ a corribination of enzymes, such as a combination of a matrix metalloprotease and a neutral protease, for example, a TM
combination of collagenase and dispase. More preferably, enzymatic digestion of placental tissue uses a combination of a matrix metalloprotease, a neutral protease, and a mucolytic TM
enzyme for digestion of hyaluronic acid, such as a combination of collagenase, dispase, and hyaluronidase or a combination of =ERASE (Boehringer Mannheim Corp., Indianapolis, IN) and hyaluronidase. Other enzymes known in the art for cell isolation include papain, deoxyribonucleases, serine proteases, such as trypsin, chymotrypsin, or elastase, that may be used either on their own or in combination with other enzymes such as matrix metalloproteases, mucolytic enzymes, and neutral proteases. Serine proteases are preferably used consecutively following use of other enzymes. The temperature and period of time tissues or cells are in contact with serine proteases is particularly important. Serine proteases may be inhibited by alpha 2 microglobulin in serum and therefore the medium used for digestion is usually serum-free. EDTA and DNAse are commonly used in enzyme digestion procedures to increase the
conventional and zonal centrifugation; centrifugal elutriation (counter-streaming centrifugation);
unit gravity separation; countercurrent distribution; electrophoresis; and flow cytometry, for example, fluorescence activated cell sorting (FACS).
In a preferred embodiment, placental tissue comprising a whole placenta or a fragment or section thereof is disaggregated by mechanical force (mincing or shear forces), enzymatic digestion with single or combinatorial proteolytic enzymes, such as a matrix metalloprotease TM
and/or neutral protease, for example, collagenase, trypsin, dispase, LEBERASE
(Boeluinger Mannheim Corp., Indianapolis, EN), hyaluronidase, and/or pepsin, or a combination of mechanical and enzymatic methods. For example, the cellular component of the placental tissue may be disaggregated by methods using collagenase-mediated dissociation.
Collagenase may be type 1, 2, 3, or 4. Enzymatic digestion methods preferably employ a corribination of enzymes, such as a combination of a matrix metalloprotease and a neutral protease, for example, a TM
combination of collagenase and dispase. More preferably, enzymatic digestion of placental tissue uses a combination of a matrix metalloprotease, a neutral protease, and a mucolytic TM
enzyme for digestion of hyaluronic acid, such as a combination of collagenase, dispase, and hyaluronidase or a combination of =ERASE (Boehringer Mannheim Corp., Indianapolis, IN) and hyaluronidase. Other enzymes known in the art for cell isolation include papain, deoxyribonucleases, serine proteases, such as trypsin, chymotrypsin, or elastase, that may be used either on their own or in combination with other enzymes such as matrix metalloproteases, mucolytic enzymes, and neutral proteases. Serine proteases are preferably used consecutively following use of other enzymes. The temperature and period of time tissues or cells are in contact with serine proteases is particularly important. Serine proteases may be inhibited by alpha 2 microglobulin in serum and therefore the medium used for digestion is usually serum-free. EDTA and DNAse are commonly used in enzyme digestion procedures to increase the
- 18 -efficiency of cell recovery. The degree of dilution of the digestion may also greatly affect the cell yield as cells may be trapped within the viscous digest.
In some embodiments of the invention, placental tissue is separated into two or more sections, each section consisting of either neonatal, neonatal and maternal, or maternal aspect.
The separated sections then are dissociated by mechanical and/or enzymatic dissociation according to the methods described herein. Cells of neonatal or maternal lineage may be identified by any means known in the art, for example, by karyotype analysis or in situ hybridization for a Y chromosome. Karyotype analysis also may be used to identify cells of normal karyotype.
Isolated cells or placental tisSue from which PDCs grow out may be used to initiate, or seed, cell cultures. Cells are transferred to sterile tissue culture vessels either uncoated or coated with extracellular matrix or ligands such as laminin, collagen (e.g., native or denatured), gelatin, fibronectin, omithine, vitronectin, and extracellular membrane protein (e.g., MATRIGEL (BD
Discovery Labware, Bedford, MA)). PDCs are cultured in any culture medium capable of sustaining growth of the cells such as, but not limited to, DMEM (high or low glucose), Eagle's basal medium, Ham's F10 medium (F10), Ham's F-12 medium (F12), Iscove's modified Dulbecco's medium, Mesenchymal Stem Cell Growth Medium (MSCGM), Liebovitz's L-medium, MCDB, DMEM/F12, RPMI 1640, advanced DMEM (Gibco), DMEM/MCDB201 (Sigma), and CELL-GRO FREE. The culture medium may be supplemented with one or more components including, for example, serum (e.g., fetal bovine serum (FBS), preferably about 2-15% (v/v); equine serum (ES); human serum(HS)); beta-mercaptoethanol (BME), preferably about 0.001% (v/v); one or more growth factors, for example, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1), leukemia inhibitory factor (LIF), vascular endothelial growth factor (VEGF), and erythropoietin (EPO); amino acids, including L-valine; and one or more antibiotic and/or antimycotic agents to control microbial contamination, such as, for example, penicillin G, streptomycin sulfate, amphotericin B, gentamicin, and nystatin, either alone or in combination.
The culture medium preferably comprises Growth medium (DMEM-low glucose), serum, BME, an antimycotic agent, and an antibiotic agent).
The cells are seeded in culture vessels at a density to allow cell growth. For example, the cells may be seeded at low density (for example, about 1,000 to about 5,000 cells/cm2) to high density (for example, about 50,000 or more cells/cm2). In a preferred embodiment, the cells are cultured at about 0 to about 5 percent by volume CO2 in air. In some preferred embodiments, the cells are cultured at about 2 to about 25 percent 02 in air, preferably about 5 to about 20
In some embodiments of the invention, placental tissue is separated into two or more sections, each section consisting of either neonatal, neonatal and maternal, or maternal aspect.
The separated sections then are dissociated by mechanical and/or enzymatic dissociation according to the methods described herein. Cells of neonatal or maternal lineage may be identified by any means known in the art, for example, by karyotype analysis or in situ hybridization for a Y chromosome. Karyotype analysis also may be used to identify cells of normal karyotype.
Isolated cells or placental tisSue from which PDCs grow out may be used to initiate, or seed, cell cultures. Cells are transferred to sterile tissue culture vessels either uncoated or coated with extracellular matrix or ligands such as laminin, collagen (e.g., native or denatured), gelatin, fibronectin, omithine, vitronectin, and extracellular membrane protein (e.g., MATRIGEL (BD
Discovery Labware, Bedford, MA)). PDCs are cultured in any culture medium capable of sustaining growth of the cells such as, but not limited to, DMEM (high or low glucose), Eagle's basal medium, Ham's F10 medium (F10), Ham's F-12 medium (F12), Iscove's modified Dulbecco's medium, Mesenchymal Stem Cell Growth Medium (MSCGM), Liebovitz's L-medium, MCDB, DMEM/F12, RPMI 1640, advanced DMEM (Gibco), DMEM/MCDB201 (Sigma), and CELL-GRO FREE. The culture medium may be supplemented with one or more components including, for example, serum (e.g., fetal bovine serum (FBS), preferably about 2-15% (v/v); equine serum (ES); human serum(HS)); beta-mercaptoethanol (BME), preferably about 0.001% (v/v); one or more growth factors, for example, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1), leukemia inhibitory factor (LIF), vascular endothelial growth factor (VEGF), and erythropoietin (EPO); amino acids, including L-valine; and one or more antibiotic and/or antimycotic agents to control microbial contamination, such as, for example, penicillin G, streptomycin sulfate, amphotericin B, gentamicin, and nystatin, either alone or in combination.
The culture medium preferably comprises Growth medium (DMEM-low glucose), serum, BME, an antimycotic agent, and an antibiotic agent).
The cells are seeded in culture vessels at a density to allow cell growth. For example, the cells may be seeded at low density (for example, about 1,000 to about 5,000 cells/cm2) to high density (for example, about 50,000 or more cells/cm2). In a preferred embodiment, the cells are cultured at about 0 to about 5 percent by volume CO2 in air. In some preferred embodiments, the cells are cultured at about 2 to about 25 percent 02 in air, preferably about 5 to about 20
- 19 -percent 02 in air. The cells preferably are cultured at about 25 to about 40 C, more preferably about 35 C to about 39C, and more preferably are cultured at Tn. The cells are preferably cultured in an incubator. The medium in the culture vessel can be static or agitated, for example, using a bioreactor. PDCs preferably are grown under low oxidative stress (e.g., with addition of glutathione, ascorbic acid, catalase, tocopherol, N-acetylcysteine). "Low oxidative stress", as used herein, refers to conditions of no or minimal free radical damage to the cultured cells.
Methods for the selection of the most appropriate culture medium, medium preparation, and cell culture techniques are well known in the art and are described in a variety of sources, including Doyle et al., (eds.), 1995, CELL & TISSUE CULTURE: LABORATORY
PROCEDURES, John Wiley & Sons, Chichester; and Ho and Wang (eds.), 1991, ANIMAL CELL
BIOREACTORS, Butterworth-Heinemann, Boston.
The culture medium is changed as necessary, for example, by carefully aspirating the medium from the dish, for example, with a pipette, and replenishing with fresh medium.
Incubation is continued until a sufficient number or density of cells accumulate in the dish. The original explanted tissue sections may be removed and the remaining cells trypsinized using standard techniques or using a cell scraper. After trypsinization, the cells are collected, removed to fresh medium and incubated as above. In some embodiments, the medium is changed at least once at approximately 24 hours post-trypsinization to remove any floating cells. The cells remaining in culture are considered to be PDCs.
Afler culturing the cells or tissue fragments for a sufficient period of time, PDCs will have grown out, either as a result of migration from the placental tissue or cell division, or both.
In some embodiments of the invention, PDCs are passaged, or removed to a separate culture vessel containing fresh medium of the same or a different type as that used initially, where the population of cells can be mitotically expanded. PDCs are preferably passaged up to about , 100% confluence, more preferably about 70 to about 85% confluence. The lower limit of confluence for passage is understood by one skilled in the art. The cells of the invention may be used at any point between passage 0 and senescence. The cells preferably are passaged between about 3 and about 25 times, more preferably are passaged about 4 to about 12 times, and preferably are passaged 10 or 11 times. Cloning and/or subcloning may be performed to confirm that a clonal population of cells has been isolated.
Cells of the invention may be cryopreserved. PDCs are preferably cryopreserved in cryopreservation medium, for example, culture medium including but not limited to Growth medium, or cell freezing medium, for example commercially available cell freezing medium, such as but not limited to C2695 (Sigma), C2639 (Sigma), or C6039 (Sigma). The
Methods for the selection of the most appropriate culture medium, medium preparation, and cell culture techniques are well known in the art and are described in a variety of sources, including Doyle et al., (eds.), 1995, CELL & TISSUE CULTURE: LABORATORY
PROCEDURES, John Wiley & Sons, Chichester; and Ho and Wang (eds.), 1991, ANIMAL CELL
BIOREACTORS, Butterworth-Heinemann, Boston.
The culture medium is changed as necessary, for example, by carefully aspirating the medium from the dish, for example, with a pipette, and replenishing with fresh medium.
Incubation is continued until a sufficient number or density of cells accumulate in the dish. The original explanted tissue sections may be removed and the remaining cells trypsinized using standard techniques or using a cell scraper. After trypsinization, the cells are collected, removed to fresh medium and incubated as above. In some embodiments, the medium is changed at least once at approximately 24 hours post-trypsinization to remove any floating cells. The cells remaining in culture are considered to be PDCs.
Afler culturing the cells or tissue fragments for a sufficient period of time, PDCs will have grown out, either as a result of migration from the placental tissue or cell division, or both.
In some embodiments of the invention, PDCs are passaged, or removed to a separate culture vessel containing fresh medium of the same or a different type as that used initially, where the population of cells can be mitotically expanded. PDCs are preferably passaged up to about , 100% confluence, more preferably about 70 to about 85% confluence. The lower limit of confluence for passage is understood by one skilled in the art. The cells of the invention may be used at any point between passage 0 and senescence. The cells preferably are passaged between about 3 and about 25 times, more preferably are passaged about 4 to about 12 times, and preferably are passaged 10 or 11 times. Cloning and/or subcloning may be performed to confirm that a clonal population of cells has been isolated.
Cells of the invention may be cryopreserved. PDCs are preferably cryopreserved in cryopreservation medium, for example, culture medium including but not limited to Growth medium, or cell freezing medium, for example commercially available cell freezing medium, such as but not limited to C2695 (Sigma), C2639 (Sigma), or C6039 (Sigma). The
- 20 -.._ cryopreservation medium preferably comprises dimethylsulfoxide (DMSO), for example about 10% (v/v). The cryopreservation medium may comprise additional cryopreservation agents including but not limited to methylcellulose and/or glycerol. The cells are preferably cooled at about 1 C/min. The preferred cryopreservation temperature is about -80 C to about -180 C, more preferably is about -90 C to about -160 C, and most preferably is about -125 to about -140 C. Cryopreserved cells preferably are transferred to liquid nitrogen prior to thawing for use.
In some embodiments, for example, once the ampoules have reached about ¨90 C, they are transferred to a liquid nitrogen storage area. Cryopreserved cells preferably are thawed at a temperature of about 25 C to about 40 C, more preferably about 35 C to about 39 C, and more preferably about 37 C.
Characterization of PDCs PDCs may be characterized, for example, by growth characteristics (e.g., population doubling capability, doubling time, passages to senescence), karyotype analysis (e.g., maternal or neonatal lineage), flow cytometry (e.g., FAGS analysis), immunohistochemistry and/or immunocytochemistry (e.g., for detection of epitopes including but not limited to vimentin, desmin, alpha-smooth muscle actin, cytokeratin 18, von Willebrand factor, CD34, GROalpha, GCP-2, oxidized low density lipoprotein receptor 1, and NOGO-A), gene expression profiling (e.g., gene chip arrays; polymerase chain reaction (for example, reverse transcriptase PCR, real time PCR, and conventional PCR)), protein arrays, protein secretion (e.g., by plasma clotting assay or analysis of PDC-conditioned medium, for example, by Enzyme Linked ImmunoSorbent Assay (ELISA)), antibody analysis (e.g., ELISA, antibody staining for cell surface markers including but not limited to CD10, CD13, CD31, CD34, CD44, CD45, CD73, CD80, CD86, CD90, CD117, CD141, CD178, platelet-derived growth factor receptor alpha (PDGFr-alpha), HLA class I antigens (HLA-A, HLA-B, HLA-C), HLA class II antigens (HLA-DP, HLA-DQ, HLA-DR), B7-H2, and PD-L2), mixed lymphocyte reaction (e.g., as measure of stimulation of allogeneic peripheral blood mononuclear cells (PBMCs), for example, allogeneic lymphocytes, e.g., naïve CD4+ T cells), or other methods known in the art.
The placenta-derived cells of the invention preferably are derived from human postpartum placenta tissue substantially free of blood. PDCs are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of another phenotype. PDCs require L-valine for growth. PDCs preferably are capable of growth in about 5%
to about 20%
oxygen. PDCs preferably comprise at least one of the following characteristics:
In some embodiments, for example, once the ampoules have reached about ¨90 C, they are transferred to a liquid nitrogen storage area. Cryopreserved cells preferably are thawed at a temperature of about 25 C to about 40 C, more preferably about 35 C to about 39 C, and more preferably about 37 C.
Characterization of PDCs PDCs may be characterized, for example, by growth characteristics (e.g., population doubling capability, doubling time, passages to senescence), karyotype analysis (e.g., maternal or neonatal lineage), flow cytometry (e.g., FAGS analysis), immunohistochemistry and/or immunocytochemistry (e.g., for detection of epitopes including but not limited to vimentin, desmin, alpha-smooth muscle actin, cytokeratin 18, von Willebrand factor, CD34, GROalpha, GCP-2, oxidized low density lipoprotein receptor 1, and NOGO-A), gene expression profiling (e.g., gene chip arrays; polymerase chain reaction (for example, reverse transcriptase PCR, real time PCR, and conventional PCR)), protein arrays, protein secretion (e.g., by plasma clotting assay or analysis of PDC-conditioned medium, for example, by Enzyme Linked ImmunoSorbent Assay (ELISA)), antibody analysis (e.g., ELISA, antibody staining for cell surface markers including but not limited to CD10, CD13, CD31, CD34, CD44, CD45, CD73, CD80, CD86, CD90, CD117, CD141, CD178, platelet-derived growth factor receptor alpha (PDGFr-alpha), HLA class I antigens (HLA-A, HLA-B, HLA-C), HLA class II antigens (HLA-DP, HLA-DQ, HLA-DR), B7-H2, and PD-L2), mixed lymphocyte reaction (e.g., as measure of stimulation of allogeneic peripheral blood mononuclear cells (PBMCs), for example, allogeneic lymphocytes, e.g., naïve CD4+ T cells), or other methods known in the art.
The placenta-derived cells of the invention preferably are derived from human postpartum placenta tissue substantially free of blood. PDCs are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of another phenotype. PDCs require L-valine for growth. PDCs preferably are capable of growth in about 5%
to about 20%
oxygen. PDCs preferably comprise at least one of the following characteristics:
- 21 -(a) production of at least one of tissue factor, vimentin, granulocyte chemotactic protein-2 (GCP-2), and alpha-smooth muscle actin;
(b) lack of production of at least one of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(c) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and BLA-DP, DQ, DR, as detected by flow cytometry;
(e) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is increased for at least one of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113;
(f) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is reduced for at least one of:
short stature homeobox 2; heat shock 27kDa protein 2; chemoldne (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin; cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1;
tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; hypothetical protein FLJ23191; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer;
frizzled homolog 7; hypothetical gene BC008967; collagen, type VIII, alpha 1;
tenascin C;
iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2;
cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3;
distal-less homeobox 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha
(b) lack of production of at least one of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(c) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and BLA-DP, DQ, DR, as detected by flow cytometry;
(e) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is increased for at least one of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113;
(f) expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is reduced for at least one of:
short stature homeobox 2; heat shock 27kDa protein 2; chemoldne (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin; cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1;
tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; hypothetical protein FLJ23191; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer;
frizzled homolog 7; hypothetical gene BC008967; collagen, type VIII, alpha 1;
tenascin C;
iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2;
cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3;
distal-less homeobox 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha
- 22 -hydroxysteroid dehydrogenase, type II); biglycan; fibronectin 1;
proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA clone ELTROIMAGE 1968422; EphA3;
KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; cDNA DKFZp564B222 (from clone DKF'Zp564B222); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus ElB 19kDa interacting protein 3-like; AE
binding protein 1; cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa;
(g) secretion of at least one of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor lalpha (SDF-lalpha), interleukin 8 (IL8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidetmal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha(MIP 1 a), Rantes (regulated on activation, nounal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(h) lack of secretion of at least one of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP lb), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA; and (i) the ability to undergo at least 40 population doublings in culture.
Population doubling may be calculated as [in (cell final/cell initial)/ln 2].
Doubling time may be calculated as (time in culture (h)/population doubling).
In preferred embodiments, the cell comprises two or more of the foregoing characteristics. More preferred are those cells comprising three, four, or five or more of the characteristics. Still more preferred are those postpartum-derived cells comprising six, seven, or eight or more of the characteristics. Still more preferred are those cells comprising all nine of the claimed characteristics.
Also presently preferred are cells that produce at least two of GCP-2, tissue factor, vimentin, and alpha-smooth muscle actin. More preferred are those cells producing three or four of the proteins GCP-2, tissue factor, vimentin, and alpha-smooth muscle actin.
proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA clone ELTROIMAGE 1968422; EphA3;
KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; cDNA DKFZp564B222 (from clone DKF'Zp564B222); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus ElB 19kDa interacting protein 3-like; AE
binding protein 1; cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa;
(g) secretion of at least one of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor lalpha (SDF-lalpha), interleukin 8 (IL8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidetmal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha(MIP 1 a), Rantes (regulated on activation, nounal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(h) lack of secretion of at least one of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP lb), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA; and (i) the ability to undergo at least 40 population doublings in culture.
Population doubling may be calculated as [in (cell final/cell initial)/ln 2].
Doubling time may be calculated as (time in culture (h)/population doubling).
In preferred embodiments, the cell comprises two or more of the foregoing characteristics. More preferred are those cells comprising three, four, or five or more of the characteristics. Still more preferred are those postpartum-derived cells comprising six, seven, or eight or more of the characteristics. Still more preferred are those cells comprising all nine of the claimed characteristics.
Also presently preferred are cells that produce at least two of GCP-2, tissue factor, vimentin, and alpha-smooth muscle actin. More preferred are those cells producing three or four of the proteins GCP-2, tissue factor, vimentin, and alpha-smooth muscle actin.
- 23 -In some embodiments, the cells of the invention do not produce at least one of oxidized low density lipoprotein receptor or GRO-alpha, as detected by FACS analysis.
In some embodiments, the cells produce neither protein as detected by FACS analysis.
The skilled artisan will appreciate that cell markers are subject to vary somewhat under vastly different growth conditions, and that generally herein described are characterizations in Growth Medium, or variations thereof. Postpartum-derived cells that produce of at least one, two, three, or four of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C
are preferred. More preferred are those cells producing five, six, or seven of these cell surface markers. Still more preferred are postpartum-derived cells that can produce all eight of the foregoing cell surface marker proteins.
PPDCs that lack of production of at least one, two, three, four of the proteins CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry are preferred. PPDCs lacking production of at least five, six, seven or eight or more of these markers are preferred. More preferred are cells which lack production of at least nine or ten of the cell surface markers. Most highly preferred are those cells lacking production of eleven, twelve, or thirteen of the foregoing identifying proteins.
Presently preferred cells produce each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C, and do not produce any of CD31, CD34, CD45, CD117, CD141, or HLA-DR,DP,DQ, as detected by flow cytometry.
It is preferred that postpartum-derived cells exhibit increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, for at least one, two, or three of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113. More preferred are those cells which exhibit increased expression for four, five, six, or seven, and still more preferred are cells capable of increased expression of eight, nine, or ten of the foregoing genes.
For some embodiments, preferred are cells, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, have reduced expression for at least one of the genes corresponding to: short stature homeobox 2; heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1);
elastin; cDNA
DKFZp586M2022 (from clone DKFZp586M2022); rnesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B; dishevelled associated activator of morphogenesis 2;
DKFZP586B2420 protein; similar to neuralin 1; tetranectin; src homology three (SH3) and
In some embodiments, the cells produce neither protein as detected by FACS analysis.
The skilled artisan will appreciate that cell markers are subject to vary somewhat under vastly different growth conditions, and that generally herein described are characterizations in Growth Medium, or variations thereof. Postpartum-derived cells that produce of at least one, two, three, or four of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C
are preferred. More preferred are those cells producing five, six, or seven of these cell surface markers. Still more preferred are postpartum-derived cells that can produce all eight of the foregoing cell surface marker proteins.
PPDCs that lack of production of at least one, two, three, four of the proteins CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry are preferred. PPDCs lacking production of at least five, six, seven or eight or more of these markers are preferred. More preferred are cells which lack production of at least nine or ten of the cell surface markers. Most highly preferred are those cells lacking production of eleven, twelve, or thirteen of the foregoing identifying proteins.
Presently preferred cells produce each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C, and do not produce any of CD31, CD34, CD45, CD117, CD141, or HLA-DR,DP,DQ, as detected by flow cytometry.
It is preferred that postpartum-derived cells exhibit increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, for at least one, two, or three of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, clone IMAGE:4179671, hypothetical protein DKFZp564F013, downregulated in ovarian cancer 1, and clone DKFZp547K1113. More preferred are those cells which exhibit increased expression for four, five, six, or seven, and still more preferred are cells capable of increased expression of eight, nine, or ten of the foregoing genes.
For some embodiments, preferred are cells, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, have reduced expression for at least one of the genes corresponding to: short stature homeobox 2; heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1);
elastin; cDNA
DKFZp586M2022 (from clone DKFZp586M2022); rnesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B; dishevelled associated activator of morphogenesis 2;
DKFZP586B2420 protein; similar to neuralin 1; tetranectin; src homology three (SH3) and
-24 -cysteine rich domain; B-cell translocation gene 1, anti-proliferative;
cholesterol 25-hydroxylase;
runt-related transcription factor 3; hypothetical protein FLJ23191;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer; frizzled homolog 7; hypothetical gene BC008967;
collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5;
hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; cDNA FL.T12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein;
transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3; distal-less homeobox 5; hypothetical protein F1120373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan;
fibronectin 1;
= proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA
clone EUROIMAGE
1968422; EphA3; KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; cDNA
DKFZp564B222 (from clone DKFZp564B222); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus ElB 19kDa interacting protein 3-like; AE
binding protein 1; cytochrome c oxidase subunit Vila polypeptide 1 (muscle);
neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa. More preferred are cells that have, relative to human fibroblasts, mesenchymal stem cells, or iliac crest bone marrow cells, reduced expression of at least 5, 10, 15 or 20 genes corresponding to those listed above. Presently more preferred are cells with reduced relative expression of at least 25, 30, or 35 of the genes corresponding to the listed sequences. Also more preferred are those postpartum-derived cells having expression that is reduced, relative to that of a human fibroblast, a rnesenchymal stem cell, or an iliac crest bone marrow cell, of genes corresponding to 35 or more, 40 or more, or even all of the sequences listed.
Secretion of certain growth factors and other cellular proteins can make cells of the invention particularly useful. Preferred placenta-derived cells secrete at least one, two, three, or four of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-lalpha), interleukin 8 (IL8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin. Cells which secrete more than five, six, seven or eight of the listed proteins are also useful and preferred. Cells which can secrete at least
cholesterol 25-hydroxylase;
runt-related transcription factor 3; hypothetical protein FLJ23191;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer; frizzled homolog 7; hypothetical gene BC008967;
collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5;
hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; cDNA FL.T12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; DKFZP586L151 protein;
transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2; KIAA1034 protein; early growth response 3; distal-less homeobox 5; hypothetical protein F1120373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan;
fibronectin 1;
= proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); cDNA
clone EUROIMAGE
1968422; EphA3; KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C
(atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; cDNA
DKFZp564B222 (from clone DKFZp564B222); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus ElB 19kDa interacting protein 3-like; AE
binding protein 1; cytochrome c oxidase subunit Vila polypeptide 1 (muscle);
neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa. More preferred are cells that have, relative to human fibroblasts, mesenchymal stem cells, or iliac crest bone marrow cells, reduced expression of at least 5, 10, 15 or 20 genes corresponding to those listed above. Presently more preferred are cells with reduced relative expression of at least 25, 30, or 35 of the genes corresponding to the listed sequences. Also more preferred are those postpartum-derived cells having expression that is reduced, relative to that of a human fibroblast, a rnesenchymal stem cell, or an iliac crest bone marrow cell, of genes corresponding to 35 or more, 40 or more, or even all of the sequences listed.
Secretion of certain growth factors and other cellular proteins can make cells of the invention particularly useful. Preferred placenta-derived cells secrete at least one, two, three, or four of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-lalpha), interleukin 8 (IL8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin. Cells which secrete more than five, six, seven or eight of the listed proteins are also useful and preferred. Cells which can secrete at least
-25-nine, ten, eleven or more of the factors are more preferred, as are cells which can secrete twelve thirteen, or fourteen, or even all of the proteins in the foregoing list.
While secretion of such factors is useful, PDCs can also be characterized by their lack of secretion of factors into the medium. Postpartum-derived cells that lack secretion of at least one, two, three, or four of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, are preferred for use. Cells that are characterized in their lack secretion of five, six, or seven of the foregoing proteins are more preferred. Cells which lack secretion of all of the factors listed above are also preferred.
Examples of placenta-derived cells of the invention were deposited with the American Type Culture Collection (ATCC, Manassas, VA) and assigned ATCC Accession Numbers as follows: (1) strain designation PLA 071003 (P8) was deposited June 15, 2004 and assigned Accession No. PTA-6074; (2) strain designation PLA 071003 (P11) was deposited June 15, 2004 and assigned Accession No. PTA-6075; and (3) strain designation PLA
071003 (P16) was deposited June 16, 2004 and assigned Accession No. PTA-6079.
PDCs of the invention may be isolated. The invention provides compositions of PDCs, including populations of PDCs. In some embodiments, the population is heterogeneous. A
heterogeneous cell population of the invention may comprise at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% PDCs of the invention. The heterogeneous cell populations of the invention may further comprise stem cells or progenitor cells. In some embodiments, the population is substantially homogeneous, i.e., comprises substantially only PPDCs (preferably at least about 96%, 97%, 98%, 99% or more PPDCs). The homogeneous cell population of the invention may comprise neonatal placenta-derived cells or maternal placenta-derived cells. Homogeneity of a cell population may be achieved by any method known in the art, for example, by cell sorting (e.g., flow cytometry), bead separation, or by clonal expansion.
The cells of the invention can be induced to differentiate to cells of mesodermal, ectodennal, or endodemial phenotype or lineage.
While secretion of such factors is useful, PDCs can also be characterized by their lack of secretion of factors into the medium. Postpartum-derived cells that lack secretion of at least one, two, three, or four of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein lbeta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, are preferred for use. Cells that are characterized in their lack secretion of five, six, or seven of the foregoing proteins are more preferred. Cells which lack secretion of all of the factors listed above are also preferred.
Examples of placenta-derived cells of the invention were deposited with the American Type Culture Collection (ATCC, Manassas, VA) and assigned ATCC Accession Numbers as follows: (1) strain designation PLA 071003 (P8) was deposited June 15, 2004 and assigned Accession No. PTA-6074; (2) strain designation PLA 071003 (P11) was deposited June 15, 2004 and assigned Accession No. PTA-6075; and (3) strain designation PLA
071003 (P16) was deposited June 16, 2004 and assigned Accession No. PTA-6079.
PDCs of the invention may be isolated. The invention provides compositions of PDCs, including populations of PDCs. In some embodiments, the population is heterogeneous. A
heterogeneous cell population of the invention may comprise at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% PDCs of the invention. The heterogeneous cell populations of the invention may further comprise stem cells or progenitor cells. In some embodiments, the population is substantially homogeneous, i.e., comprises substantially only PPDCs (preferably at least about 96%, 97%, 98%, 99% or more PPDCs). The homogeneous cell population of the invention may comprise neonatal placenta-derived cells or maternal placenta-derived cells. Homogeneity of a cell population may be achieved by any method known in the art, for example, by cell sorting (e.g., flow cytometry), bead separation, or by clonal expansion.
The cells of the invention can be induced to differentiate to cells of mesodermal, ectodennal, or endodemial phenotype or lineage.
- 26 -Culture of PDCs in a Chondrogenic Medium PDCs may be induced to differentiate into a chondrogenic lineage by subjecting them to differentiation-inducing cell culture conditions. In some embodiments, PDCs may be induced to differentiate to a chondrogenic lineage by, for example, contacting PDCs with specific exogenous growth factors (e.g., in culture), such as, for example, one or more of GDF-5 or transforming growth factor beta3 (TGF-beta3), with or without ascorbate.
Preferred chondrogenic medium is supplemented with an antibiotic agent, amino acids including proline and glutamine, sodium pyruvate, dexamethasone, ascorbic acid, and insulin/tranferrin/selenium. Chondrogenic medium is preferably supplemented with sodium hydroxide and/or collagen. Most preferably, chondrogenic culture medium is supplemented with collagen. The cells may be cultured at high or low density. Cells are preferably cultured in the absence of serum.
Chondrogenic differentiation may be assessed, for example, by Safranin-O
staining for glycosaminoglycan expression or hematoxylin/eosin staining.
Culture of PDCs in an Adipogenic Medium PDCs may be induced to differentiate into an adipogenic lineage phenotype by subjecting them to differentiation-inducing cell culture conditions. In some embodiments, PDCs are cultured in a defined medium for inducing differentiation to an adipogenic lineage. Examples of adipogenic media include, but are not limited to, media containing one or more glucocorticoids (e.g., dexamethasone, indomethasone, hydrocortisone, cortisone), insulin, a compound which elevates intracellular levels of cAMP (e.g., dibutyryl-cAMP; 8-CPT- cAMP (8-(4)chlorophenylthio)-adenosine, 3',5' cyclic monophosphate); 8- bromo-cAMP;
dioctanoyl-cAMP; forskolin) and/or a compound which inhibits degradation of cAMP (e.g., a phosphodiesterase inhibitor such as isobutylmethylxanthine (IBMX), methyl isobutylxanthine, theophylline, caffeine, indomethacin), and serum.
Adipogenesis may be assessed by Oil-Red-0 staining to determine the presence of lipid droplet formation or by detecting the expression of PPAR gamma or leptin.
Culture of PDCs in an Osteogenie Medium PDCs may be induced to differentiate into an osteogenic lineage phenotype by subjecting them to differentiation-inducing cell culture conditions. In some embodiments, PDCs are cultured in osteogenic medium such as, but not limited to, media (e.g., DMEM-low glucose) containing about 10-7 molar and about le molar dexamethasone in combination with about 10
Preferred chondrogenic medium is supplemented with an antibiotic agent, amino acids including proline and glutamine, sodium pyruvate, dexamethasone, ascorbic acid, and insulin/tranferrin/selenium. Chondrogenic medium is preferably supplemented with sodium hydroxide and/or collagen. Most preferably, chondrogenic culture medium is supplemented with collagen. The cells may be cultured at high or low density. Cells are preferably cultured in the absence of serum.
Chondrogenic differentiation may be assessed, for example, by Safranin-O
staining for glycosaminoglycan expression or hematoxylin/eosin staining.
Culture of PDCs in an Adipogenic Medium PDCs may be induced to differentiate into an adipogenic lineage phenotype by subjecting them to differentiation-inducing cell culture conditions. In some embodiments, PDCs are cultured in a defined medium for inducing differentiation to an adipogenic lineage. Examples of adipogenic media include, but are not limited to, media containing one or more glucocorticoids (e.g., dexamethasone, indomethasone, hydrocortisone, cortisone), insulin, a compound which elevates intracellular levels of cAMP (e.g., dibutyryl-cAMP; 8-CPT- cAMP (8-(4)chlorophenylthio)-adenosine, 3',5' cyclic monophosphate); 8- bromo-cAMP;
dioctanoyl-cAMP; forskolin) and/or a compound which inhibits degradation of cAMP (e.g., a phosphodiesterase inhibitor such as isobutylmethylxanthine (IBMX), methyl isobutylxanthine, theophylline, caffeine, indomethacin), and serum.
Adipogenesis may be assessed by Oil-Red-0 staining to determine the presence of lipid droplet formation or by detecting the expression of PPAR gamma or leptin.
Culture of PDCs in an Osteogenie Medium PDCs may be induced to differentiate into an osteogenic lineage phenotype by subjecting them to differentiation-inducing cell culture conditions. In some embodiments, PDCs are cultured in osteogenic medium such as, but not limited to, media (e.g., DMEM-low glucose) containing about 10-7 molar and about le molar dexamethasone in combination with about 10
-27 -micromolar to about 50 micromolar ascorbate phosphate salt (e.g., ascorbate-2-phosphate) and between about 10 nanomolar and about 10 millimolar beta-glycerophosphate. The medium preferably includes serum (e.g., bovine serum, horse serum). Osteogenic medium also may comprise one or more antibiotic/antimycotic agents. The osteogenic medium is preferably supplemented with transforming growth factor-beta (e.g., TGF-betal) and/or bone molphogenic protein (e.g., BMP-2, BMP-4, or a combination thereof; most preferably BMP-4) Cells may be analyzed for an osteogenic phenotype by any method known in the art, e.g., von Kossa staining or by detection of osteogenic markers such as osteocalcin, bone sialoprotein, or alkaline phosphatase.
Culture of PDCs in Neurogenic Medium PDCs may be induced to differentiate into a neural lineage phenotype by subjecting them to differentiation-inducing cell culture conditions. This may be accomplished by one or more methods known in the art. For instance, as exemplified herein, PDCs may be cultured in a neurogenic medium such as a serum-free DMEM/F12 composition containing butylated hydroxanisole, potassium chloride, insulin, forskolin, valproic acid, and hydrocortisone.
Alternatively, PDCs may be plated on flasks coated with laminin in Neurobasal-A
medium (Invitrogen, Carlsbad, CA) containing B27 (B27 supplement, Invitrogen), L-glutamine and Penicillin/Streptomycin, the combination of which is referred to herein as Neural Progenitor Expansion (NPE) media. NPE media may be further supplemented with bFGF and/or EGF.
Alternatively, PDCs may be induced to differentiate in vitro by (1) co-culturing the PDCs with neural progenitor cells, or (2) growing the PDCs in neural progenitor cell-conditioned medium.
Differentiation of the PDCs to a neurogenic lineage may be demonstrated by a bipolar cell morphology with extended processes. The induced cell populations may stain positive for the presence of nestin. Differentiated PDCs may be assessed by detection of nestin, TuJ1 (Bill tubulin), GFAP, tyrosine hydroxylase, 04, GABA, and myelin basic protein (MBP). In some embodiments, PDCs have the ability to fon-n three-dimensional bodies characteristic of neural stem cell foimation of neuro spheres.
Assessment of Differentiation PDCs may be induced to differentiate to an ectodermal, endodermal, or mesodermal lineage. Methods to characterize differentiated cells that develop from the PDCs of the invention, include,sbut are not limited to, histological, morphological, biochemical and
Culture of PDCs in Neurogenic Medium PDCs may be induced to differentiate into a neural lineage phenotype by subjecting them to differentiation-inducing cell culture conditions. This may be accomplished by one or more methods known in the art. For instance, as exemplified herein, PDCs may be cultured in a neurogenic medium such as a serum-free DMEM/F12 composition containing butylated hydroxanisole, potassium chloride, insulin, forskolin, valproic acid, and hydrocortisone.
Alternatively, PDCs may be plated on flasks coated with laminin in Neurobasal-A
medium (Invitrogen, Carlsbad, CA) containing B27 (B27 supplement, Invitrogen), L-glutamine and Penicillin/Streptomycin, the combination of which is referred to herein as Neural Progenitor Expansion (NPE) media. NPE media may be further supplemented with bFGF and/or EGF.
Alternatively, PDCs may be induced to differentiate in vitro by (1) co-culturing the PDCs with neural progenitor cells, or (2) growing the PDCs in neural progenitor cell-conditioned medium.
Differentiation of the PDCs to a neurogenic lineage may be demonstrated by a bipolar cell morphology with extended processes. The induced cell populations may stain positive for the presence of nestin. Differentiated PDCs may be assessed by detection of nestin, TuJ1 (Bill tubulin), GFAP, tyrosine hydroxylase, 04, GABA, and myelin basic protein (MBP). In some embodiments, PDCs have the ability to fon-n three-dimensional bodies characteristic of neural stem cell foimation of neuro spheres.
Assessment of Differentiation PDCs may be induced to differentiate to an ectodermal, endodermal, or mesodermal lineage. Methods to characterize differentiated cells that develop from the PDCs of the invention, include,sbut are not limited to, histological, morphological, biochemical and
- 28 -immunohistochemical methods, or using cell surface markers, or genetically or molecularly, or by identifying factors secreted by the differentiated cell, and by the inductive qualities of the differentiated PDCs.
Methods of using PDCs or components or products thereof Genetic Engineering of PDCs =
The cells of the invention can be engineered to express a therapeutic protein using any of a variety of vectors including, but not limited to, integrating viral vectors, e.g., retrovirus vector or adeno-associated viral vectors; non-integrating replicating vectors, e.g., papilloma virus vectors, SV40 vectors, adenoviral vectors; or replication-defective viral vectors. Other methods of introducing DNA into cells include the use of liposomes, electroporation, a particle gun, or by direct DNA injection.
Hosts cells are preferably transformed or transfected with DNA controlled by or in operative association with, one or more appropriate expression control elements such as promoter or enhancer sequences, transcription terminators, polyadenylation sites, among others, and a selectable marker.
Following the introduction of the foreign DNA, engineered cells may be allowed to grow in enriched media and then switched to selective media. The selectable marker in the foreign DNA confers resistance to the selection and allows cells to stably integrate the foreign DNA as, for example, on a plasmid, into their chromosomes and grow to form foci which, in turn, can be cloned and expanded into cell lines.
This method can be advantageously used to engineer cell lines which express the gene product.
Any promoter may be used to drive the expression of the inserted gene. For example, viral promoters include, but are not limited to, the CMV promoter/enhancer, SV40, papillomavirus, Epstein-Barr virus or elastin gene promoter. Preferably, the control elements used to control expression of the gene of interest should allow for the regulated expression of the gene so that the product is synthesized only when needed in vivo. If transient expression is desired, constitutive promoters are preferably used in a non-integrating and/or replication-defective vector. Alternatively, inducible promoters could be used to drive the expression of the inserted gene when necessary.
Inducible promoters include, but are not limited to, those associated with metallothionein and heat shock proteins.
Methods of using PDCs or components or products thereof Genetic Engineering of PDCs =
The cells of the invention can be engineered to express a therapeutic protein using any of a variety of vectors including, but not limited to, integrating viral vectors, e.g., retrovirus vector or adeno-associated viral vectors; non-integrating replicating vectors, e.g., papilloma virus vectors, SV40 vectors, adenoviral vectors; or replication-defective viral vectors. Other methods of introducing DNA into cells include the use of liposomes, electroporation, a particle gun, or by direct DNA injection.
Hosts cells are preferably transformed or transfected with DNA controlled by or in operative association with, one or more appropriate expression control elements such as promoter or enhancer sequences, transcription terminators, polyadenylation sites, among others, and a selectable marker.
Following the introduction of the foreign DNA, engineered cells may be allowed to grow in enriched media and then switched to selective media. The selectable marker in the foreign DNA confers resistance to the selection and allows cells to stably integrate the foreign DNA as, for example, on a plasmid, into their chromosomes and grow to form foci which, in turn, can be cloned and expanded into cell lines.
This method can be advantageously used to engineer cell lines which express the gene product.
Any promoter may be used to drive the expression of the inserted gene. For example, viral promoters include, but are not limited to, the CMV promoter/enhancer, SV40, papillomavirus, Epstein-Barr virus or elastin gene promoter. Preferably, the control elements used to control expression of the gene of interest should allow for the regulated expression of the gene so that the product is synthesized only when needed in vivo. If transient expression is desired, constitutive promoters are preferably used in a non-integrating and/or replication-defective vector. Alternatively, inducible promoters could be used to drive the expression of the inserted gene when necessary.
Inducible promoters include, but are not limited to, those associated with metallothionein and heat shock proteins.
- 29 -CA 02530416 2011-10-19 =
. .
= Examples of transcriptional control regions that exhibit tissue specificity which have been described and could be used include but are not limited to: elastase I
gene control region, which is active in pancreatic acinar cells (Swift et at., 1984, Cell 38:639;
Ornitz et at., 1985, Cold Spring Harbor Symp. Quant. Biol. 50:399; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region, which is active in pancreatic beta cells (Han.ahan, 1985, Nature 315:115); myelin basic protein gene control region, which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703); myosin light chain-2 gene control region, which ia active in skeletal muscle (Shani, 1985, Nature 314:283); and gonadotropic releasing hormone gene control region, which is active in the hypothalamus (Mason etal., 1986, Science 234:1372).
The cells of the invention may be genetically engineered to "knock out" or "knock down"
expression of factors that promote inflammation or rejection at the implant site. Negative modulatory techniques for the reduction of target gene expression levels or target gene product activity levels are discussed below. "Negative modulation," as used herein, refers to a reduction in the level and/or activity of target gene product relative to the level and/or activity of the target gene product in the absence of the modulatory treatment. The expression of a gene native to a cell can be reduced. or knocked out using a number of techniques including, for example, inhibition of expression by inactivating the gene completely (commonly termed "knockout") using the homologous recombination technique. Usually, an exon encoding an important region of the protein (or an exon 5' to that region) is interrupted by a positive selectable marker, e.g, neo, preventing the production of normal mRNA from the target gene and resulting in inactivation of the gene. A gene may also be inactivated by creating a deletion in part of a gene or by deleting the entire gene. By using a construct with two regions of homology to the target gene that are far apart in the genome, the sequences intervening the two regions can be deleted (Mombaerts et at., 1991, Proc. Nat. Acad. Sci. U.S.A. fi8:3084).
Antisense, DNAzymes, small interfering RNA, and ribozyme molecules which inhibit expression of the target gene can also be used in accordance with the invention to reduce the level of target gene activity. For example, antisense RNA molecules which inhibit the expression of major histocompatibility gene complexes (HLA) have been shown to be most versatile with respect to immune responses. Still further, triple helix molecules can be utilized in reducing the level of target gene activity.
These techniques are described in detail by L.G. Davis et at. (eds), 1994, BASIC
METHODS IN MOLECULAR BIOLOGY, 2nd ed., Appleton & Lange, Norwalk, Conn.
. .
= Examples of transcriptional control regions that exhibit tissue specificity which have been described and could be used include but are not limited to: elastase I
gene control region, which is active in pancreatic acinar cells (Swift et at., 1984, Cell 38:639;
Ornitz et at., 1985, Cold Spring Harbor Symp. Quant. Biol. 50:399; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region, which is active in pancreatic beta cells (Han.ahan, 1985, Nature 315:115); myelin basic protein gene control region, which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703); myosin light chain-2 gene control region, which ia active in skeletal muscle (Shani, 1985, Nature 314:283); and gonadotropic releasing hormone gene control region, which is active in the hypothalamus (Mason etal., 1986, Science 234:1372).
The cells of the invention may be genetically engineered to "knock out" or "knock down"
expression of factors that promote inflammation or rejection at the implant site. Negative modulatory techniques for the reduction of target gene expression levels or target gene product activity levels are discussed below. "Negative modulation," as used herein, refers to a reduction in the level and/or activity of target gene product relative to the level and/or activity of the target gene product in the absence of the modulatory treatment. The expression of a gene native to a cell can be reduced. or knocked out using a number of techniques including, for example, inhibition of expression by inactivating the gene completely (commonly termed "knockout") using the homologous recombination technique. Usually, an exon encoding an important region of the protein (or an exon 5' to that region) is interrupted by a positive selectable marker, e.g, neo, preventing the production of normal mRNA from the target gene and resulting in inactivation of the gene. A gene may also be inactivated by creating a deletion in part of a gene or by deleting the entire gene. By using a construct with two regions of homology to the target gene that are far apart in the genome, the sequences intervening the two regions can be deleted (Mombaerts et at., 1991, Proc. Nat. Acad. Sci. U.S.A. fi8:3084).
Antisense, DNAzymes, small interfering RNA, and ribozyme molecules which inhibit expression of the target gene can also be used in accordance with the invention to reduce the level of target gene activity. For example, antisense RNA molecules which inhibit the expression of major histocompatibility gene complexes (HLA) have been shown to be most versatile with respect to immune responses. Still further, triple helix molecules can be utilized in reducing the level of target gene activity.
These techniques are described in detail by L.G. Davis et at. (eds), 1994, BASIC
METHODS IN MOLECULAR BIOLOGY, 2nd ed., Appleton & Lange, Norwalk, Conn.
- 30 -Using any of the foregoing techniques, for example, the expression of IL-1 can be knocked out or knocked down in the cells of the invention to reduce the production of inflammatory mediators by the cells of the invention. Likewise, the expression of MHC class II
molecules can be knocked out or knocked down in order to reduce the risk of rejection of the implanted tissue.
Once the cells of the invention have been genetically engineered, they may be directly implanted into the patient.
Alternatively, the genetically engineered cells may be used to produce new tissue in vitro, which is then implanted in the subject.
Secretion of Trophic Factors by PDCs The secretion of growth factors by PDCs may provide trophic support for a second cell type in vitro or in vivo. PDCs may secrete, for example, interleukin 8 (IL8), tissue factor, hepatocyte growth factor (HGF), monocyte chemotactic protein 1 (MCP-1), keratinocyte growth factor (KGF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), heparin-binding epidermal growth factor (HB-EGF), stromal-derived factor lalpha (SDF-1alpha), brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), granulocyte chemotactic protein-2 (GCP-2), macrophage inflammatory protein lalpha (M1P 1 a), monocyte chemoattractant-1 (MCP-1), Rantes (regulated on activation, noillial T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), Eotaxin, NGF, NT-3, IL-7, IL-1, SCF, AMPS, or Cystatin-C in substantially homogeneous populations of cells, which can be augmented by a variety of techniques, including ex vivo cultivation of the cells in chemically defined medium.
In some aspects of the invention, a population of PDCs supports the survival, proliferation, growth, maintenance, maturation, differentiation, or increased activity of cells including stem cells, such as neural stem cells (NSC), hematopoietic stem cells (HPC, particularly CD34+ stem cells), embryonic stem cells (ESC), and mixtures thereof. In other , embodiments, the population supported by the PDCs is substantially homogeneous, substantially homogeneous, i.e., comprises substantially only PDCs (preferably at least about 96%, 97%, 98%, 99% or more PDCs).
Conditioned medium of PDCs Another embodiment of the invention features use of PDCs for production of conditioned medium, either from undifferentiated PDCs or from PDCs incubated under conditions that stimulate differentiation into a given lineage. Such conditioned media are contemplated for use
molecules can be knocked out or knocked down in order to reduce the risk of rejection of the implanted tissue.
Once the cells of the invention have been genetically engineered, they may be directly implanted into the patient.
Alternatively, the genetically engineered cells may be used to produce new tissue in vitro, which is then implanted in the subject.
Secretion of Trophic Factors by PDCs The secretion of growth factors by PDCs may provide trophic support for a second cell type in vitro or in vivo. PDCs may secrete, for example, interleukin 8 (IL8), tissue factor, hepatocyte growth factor (HGF), monocyte chemotactic protein 1 (MCP-1), keratinocyte growth factor (KGF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), heparin-binding epidermal growth factor (HB-EGF), stromal-derived factor lalpha (SDF-1alpha), brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), granulocyte chemotactic protein-2 (GCP-2), macrophage inflammatory protein lalpha (M1P 1 a), monocyte chemoattractant-1 (MCP-1), Rantes (regulated on activation, noillial T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), Eotaxin, NGF, NT-3, IL-7, IL-1, SCF, AMPS, or Cystatin-C in substantially homogeneous populations of cells, which can be augmented by a variety of techniques, including ex vivo cultivation of the cells in chemically defined medium.
In some aspects of the invention, a population of PDCs supports the survival, proliferation, growth, maintenance, maturation, differentiation, or increased activity of cells including stem cells, such as neural stem cells (NSC), hematopoietic stem cells (HPC, particularly CD34+ stem cells), embryonic stem cells (ESC), and mixtures thereof. In other , embodiments, the population supported by the PDCs is substantially homogeneous, substantially homogeneous, i.e., comprises substantially only PDCs (preferably at least about 96%, 97%, 98%, 99% or more PDCs).
Conditioned medium of PDCs Another embodiment of the invention features use of PDCs for production of conditioned medium, either from undifferentiated PDCs or from PDCs incubated under conditions that stimulate differentiation into a given lineage. Such conditioned media are contemplated for use
- 31 -in in vitro or ex vivo culture of cells, for example, stem or progenitor cells, or for use in vivo, for example, to support transplanted cells (e.g., homogeneous or heterogeneous populations of PDCs).
Co-cultures of PD Cs with Other Cell Types PDCs have the ability to support survival, growth, and differentiation of other cell types in co-culture. Accordingly, in another embodiment, PDCs are co-cultured in vitro to provide trophic support to other cells. For co-culture, it may be desirable for the PDCs and the desired other cells to be co-cultured under conditions in which the two cell types are in contact. This can be achieved, for example, by seeding the cells as a heterogeneous population of cells in culture medium or onto a suitable culture substrate. Alternatively, the PDCs can first be grown to confluence and employed as a substrate for the second desired cell type in culture. In this latter embodiment, the cells may further be physically separated, e.g., by a membrane or similar device, such that the other cell type may be removed and used separately following the co-culture period. Use of PDCs in co-culture to promote expansion and differentiation of other cell types may find applicability in research and in clinical/therapeutic areas.
For instance, PDC co-culture may be utilized to facilitate growth and differentiation of cells of a given phenotype in culture, for basic research purposes or for use in drug screening assays, for example. PDC co-culture may also be utilized for ex vivo expansion of cells of a given phenotype for later administration for therapeutic purposes. For example, cells may be harvested from an individual, expanded ex vivo in co-culture with PDCs, then returned to that individual (autologous transfer) or another individual (syngeneic or allogeneic transfer). In these embodiments, it will be appreciated that, following ex vivo expansion, the mixed population of cells comprising the PDCs could be administered to a patient in need of treatment. Alternatively, in situations where autologous transfer is appropriate or desirable, the co-cultured cell populations may be physically separated in culture, enabling removal of the autologous cells for administration to the patient.
Cell Therapy As demonstrated herein, PDCs have been shown to be effectively transplanted into the body and to supply lost function in animal models accepted for predictability of efficacy in humans. These results support a preferred embodiment of the invention, wherein PDCs are used in cell therapy for treating a condition, injury, or disease. For example, PDCs of the invention may be used to treat patients requiring the repair or replacement of a tissue or organ resulting
Co-cultures of PD Cs with Other Cell Types PDCs have the ability to support survival, growth, and differentiation of other cell types in co-culture. Accordingly, in another embodiment, PDCs are co-cultured in vitro to provide trophic support to other cells. For co-culture, it may be desirable for the PDCs and the desired other cells to be co-cultured under conditions in which the two cell types are in contact. This can be achieved, for example, by seeding the cells as a heterogeneous population of cells in culture medium or onto a suitable culture substrate. Alternatively, the PDCs can first be grown to confluence and employed as a substrate for the second desired cell type in culture. In this latter embodiment, the cells may further be physically separated, e.g., by a membrane or similar device, such that the other cell type may be removed and used separately following the co-culture period. Use of PDCs in co-culture to promote expansion and differentiation of other cell types may find applicability in research and in clinical/therapeutic areas.
For instance, PDC co-culture may be utilized to facilitate growth and differentiation of cells of a given phenotype in culture, for basic research purposes or for use in drug screening assays, for example. PDC co-culture may also be utilized for ex vivo expansion of cells of a given phenotype for later administration for therapeutic purposes. For example, cells may be harvested from an individual, expanded ex vivo in co-culture with PDCs, then returned to that individual (autologous transfer) or another individual (syngeneic or allogeneic transfer). In these embodiments, it will be appreciated that, following ex vivo expansion, the mixed population of cells comprising the PDCs could be administered to a patient in need of treatment. Alternatively, in situations where autologous transfer is appropriate or desirable, the co-cultured cell populations may be physically separated in culture, enabling removal of the autologous cells for administration to the patient.
Cell Therapy As demonstrated herein, PDCs have been shown to be effectively transplanted into the body and to supply lost function in animal models accepted for predictability of efficacy in humans. These results support a preferred embodiment of the invention, wherein PDCs are used in cell therapy for treating a condition, injury, or disease. For example, PDCs of the invention may be used to treat patients requiring the repair or replacement of a tissue or organ resulting
-32-from disease or trauma or failure of the tissue to develop normally, or to provide a cosmetic function, such as to augment features of the body. Once transplanted into a target location in the body, PDCs may themselves differentiate into one or more phenotypes, or they may provide trophic support for other cell types in vivo, or they may exert a beneficial effect in both of those t, fashions, among others.
PDCs may be administered alone (e.g., as substantially homogeneous populations) or as admixtures with other cells. PDCs may be administered as formulated in a pharmaceutical preparation with a matrix, or with conventional pharmaceutically acceptable carriers. Where PDCs are administered with other cells, they may be administered simultaneously or sequentially with the other cells (either before or after the other cells). Cells that may be administered in conjunction with PDCs include, but are not limited to, other multipotent or pluripotent cells. The cells of different types may be admixed with the PDCs immediately or shortly prior to administration, or they may be co-cultured together for a period of time prior to administration.
PDCs may be administered with other beneficial drugs or biological molecules (growth factors, trophic factors). When PDCs are administered with other agents, they may be administered together in a single pharmaceutical composition, or in separate pharmaceutical compositions, simultaneously or sequentially with the other bioactive factors (either before or after administration of the other agents). Examples of bioactive factors include anti-apoptotic agents (e.g., EPO, EPO mimetibody, TPO, IGF-I and IGF-II, HGF, caspase inhibitors); anti-inflammatory agents (e.g., p38 MAPK inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLIMUS, and NSAIDs (non-steroidal anti-inflammatory drugs; e.g., TEPDXALIN, TOLMETIN, SUPROFEN);
immunosupressive/immunomodulatory agents (e.g., calcineurin inhibitors, such as cyclosporine, tacrolimus; mTOR inhibitors (e.g., S1ROLIMUS, EVEROLIMUS); anti-proliferatives (e.g., azathioprine, mycophenolate mofetil); corticosteroids (e.g., prednisolone, hydrocortisone);
antibodies such as monoclonal anti-IL-2Ralpha receptor antibodies (e.g., basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g., anti-thymocyte globulin (ATG); anti-lymphocyte globulin (ALG); monoclonal anti-T cell antibody OKT3)); anti-thrombogenic agents (e.g., heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine chloromethylketone), antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, dipyridamole, protamine, hirudin, prostaglandin inhibitors, and platelet inhibitors); and anti-oxidants (e.g., probucol, vitamin A, ascorbic acid, tocopherol, coenzyme Q-10, glutathione, L-cysteine, N-acetylcysteine). Drugs which may be co-administered include local anesthetics. As another example, the cells may be
PDCs may be administered alone (e.g., as substantially homogeneous populations) or as admixtures with other cells. PDCs may be administered as formulated in a pharmaceutical preparation with a matrix, or with conventional pharmaceutically acceptable carriers. Where PDCs are administered with other cells, they may be administered simultaneously or sequentially with the other cells (either before or after the other cells). Cells that may be administered in conjunction with PDCs include, but are not limited to, other multipotent or pluripotent cells. The cells of different types may be admixed with the PDCs immediately or shortly prior to administration, or they may be co-cultured together for a period of time prior to administration.
PDCs may be administered with other beneficial drugs or biological molecules (growth factors, trophic factors). When PDCs are administered with other agents, they may be administered together in a single pharmaceutical composition, or in separate pharmaceutical compositions, simultaneously or sequentially with the other bioactive factors (either before or after administration of the other agents). Examples of bioactive factors include anti-apoptotic agents (e.g., EPO, EPO mimetibody, TPO, IGF-I and IGF-II, HGF, caspase inhibitors); anti-inflammatory agents (e.g., p38 MAPK inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLIMUS, and NSAIDs (non-steroidal anti-inflammatory drugs; e.g., TEPDXALIN, TOLMETIN, SUPROFEN);
immunosupressive/immunomodulatory agents (e.g., calcineurin inhibitors, such as cyclosporine, tacrolimus; mTOR inhibitors (e.g., S1ROLIMUS, EVEROLIMUS); anti-proliferatives (e.g., azathioprine, mycophenolate mofetil); corticosteroids (e.g., prednisolone, hydrocortisone);
antibodies such as monoclonal anti-IL-2Ralpha receptor antibodies (e.g., basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g., anti-thymocyte globulin (ATG); anti-lymphocyte globulin (ALG); monoclonal anti-T cell antibody OKT3)); anti-thrombogenic agents (e.g., heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine chloromethylketone), antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, dipyridamole, protamine, hirudin, prostaglandin inhibitors, and platelet inhibitors); and anti-oxidants (e.g., probucol, vitamin A, ascorbic acid, tocopherol, coenzyme Q-10, glutathione, L-cysteine, N-acetylcysteine). Drugs which may be co-administered include local anesthetics. As another example, the cells may be
-33-co-administered with scar inhibitory factor as described in U.S. Patent No.
5,827,735, In one embodiment, PDCs are administered as undifferentiated cells, i.e., as cultured in Growth Medium. Alternatively, PDCs may be administered following exposure in culture to conditions that stimulate differentiation toward a desired phenotype. =
The cells of the invention may be surgically implanted, injected, delivered (e.g., by way of a catheter or syringe), or otherwise administered directly or indirectly to the site in need of repair or augmentation. Routes of administration of the cells of the invention or compositions thereof include, but are not limited to, oral, nasal, intraarterial, parenteral, intravenous, ophthalmic, intramuscular, subcutaneous, intraperitoneal, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracistemal, intraspinal and/or pen-spinal routes of administration by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices.
When cells are administered in semi-solid or solid devices, surgical implantation into a precise location in the body is typically a suitable means of administration.
Liquid or fluid pharmaceutical compositions, however, may be administered to a more general location (e.g., throughout a diffusely affected area, for example), from which they migrate to a particular location, e.g., by responding to chemical signals.
Other embodiments encompass methods of treatment by administering pharmaceutical compositions comprising PDC cellular components (e.g., cell lysates or components thereof) or products (e.g., extracellular matrix, trophic and other biological factors produced naturally by PDCs or through genetic modification, conditioned medium from PDC culture).
Again, these methods may further comprise administering bioactive factors, such as anti-apoptotic agents (e.g., EPO, EPO mimetibody, TPO, IGF-I and IGF-II, HGF, caspase inhibitors);
anti-inflammatory agents (e.g., p38 MAPK inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMEROLAST, TRANILAST, REMICADE, SIROLIMUS, and NSAlDs (non-steroidal anti-inflammatory drugs; e.g., TEPDXALM, TOLMETIN, SUPROFEN);
immunosupressive/imrnunomodulatory agents (e.g., calcineurin inhibitors, such as cyclosporine, tacrolimus; mTOR inhibitors (e.g., SlROLIMUS, EVEROLIMUS); anti-proliferatives (e.g., azathioprine, mycophenolate mofetil); corticosteroids (e.g., prednisolone, hydrocortisone);
antibodies such as monoclonal anti-IL-2Ralpha receptor antibodies (e.g., basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g., anti-thymocyte globulin (ATG); anti-lymphocyte globulin (ALG); monoclonal anti-T cell antibody OKT3)); anti-thrombogenic agents (e.g., heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine
5,827,735, In one embodiment, PDCs are administered as undifferentiated cells, i.e., as cultured in Growth Medium. Alternatively, PDCs may be administered following exposure in culture to conditions that stimulate differentiation toward a desired phenotype. =
The cells of the invention may be surgically implanted, injected, delivered (e.g., by way of a catheter or syringe), or otherwise administered directly or indirectly to the site in need of repair or augmentation. Routes of administration of the cells of the invention or compositions thereof include, but are not limited to, oral, nasal, intraarterial, parenteral, intravenous, ophthalmic, intramuscular, subcutaneous, intraperitoneal, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracistemal, intraspinal and/or pen-spinal routes of administration by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices.
When cells are administered in semi-solid or solid devices, surgical implantation into a precise location in the body is typically a suitable means of administration.
Liquid or fluid pharmaceutical compositions, however, may be administered to a more general location (e.g., throughout a diffusely affected area, for example), from which they migrate to a particular location, e.g., by responding to chemical signals.
Other embodiments encompass methods of treatment by administering pharmaceutical compositions comprising PDC cellular components (e.g., cell lysates or components thereof) or products (e.g., extracellular matrix, trophic and other biological factors produced naturally by PDCs or through genetic modification, conditioned medium from PDC culture).
Again, these methods may further comprise administering bioactive factors, such as anti-apoptotic agents (e.g., EPO, EPO mimetibody, TPO, IGF-I and IGF-II, HGF, caspase inhibitors);
anti-inflammatory agents (e.g., p38 MAPK inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMEROLAST, TRANILAST, REMICADE, SIROLIMUS, and NSAlDs (non-steroidal anti-inflammatory drugs; e.g., TEPDXALM, TOLMETIN, SUPROFEN);
immunosupressive/imrnunomodulatory agents (e.g., calcineurin inhibitors, such as cyclosporine, tacrolimus; mTOR inhibitors (e.g., SlROLIMUS, EVEROLIMUS); anti-proliferatives (e.g., azathioprine, mycophenolate mofetil); corticosteroids (e.g., prednisolone, hydrocortisone);
antibodies such as monoclonal anti-IL-2Ralpha receptor antibodies (e.g., basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g., anti-thymocyte globulin (ATG); anti-lymphocyte globulin (ALG); monoclonal anti-T cell antibody OKT3)); anti-thrombogenic agents (e.g., heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine
-34-.-= 53471-3 chloromethyllcetone), antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, dipyridamole, protamine, hfrudin, prostaglandin inhibitors, and platelet inhibitors); and anti-oxidants (e.g., probucol, vitamin A, ascorbic acid, tocopherol, coenzyme Q-10, glutathione, L-cysteine, N-acetylcysteine), local anesthetics, and scar inhibitory factor as described in U.S. Patent No.
5,827,735.
Dosage forms and regimes for administering PDCs or any of the other pharmaceutical compositions described herein are developed in accordance with good medical practice, taking into account the condition of the individual patient, e.g., nature and extent of the condition being treated, age, sex, body weight and general medical condition, and other factors known to medical practitioners. Thus, the effective amount of a pharmaceutical composition to be administered to a patient is determined by these considerations as known in the art.
In some embodiments of the invention, it may not be necessary or desirable to immunosuppress a patient prior to initiation of cell therapy with PDCs. In addition, PDCs have . been shown not to stimulate allogeneic PBMCs (for example, allogeneic lymphocytes, e.g., naïve CD4+ T cells) in a mixed lymphocyte reaction. Accordingly, transplantation with allogeneic, or even xenogeneic, PDCs may be tolerated in some instances.
However, in other instances it may be desirable or appropriate to pharmacologically immunosuppress a patient prior to initiating cell therapy. This may be accomplished through the use of systemic or local immunosuppressive agents, or it may be accomplished by delivering the cells in an encapsulated device. PDCs may be encapsulated in a capsule that is permeable to nutrients and oxygen required by the cell and therapeutic factors the cell is yet impermeable to immune humoral factors and cells. Preferably the encapsulant is hypoallergenic, is easily and stably situated in a target tissue, and provides added protection to the implanted structure. These and other means for reducing or eliminating an immune response to the transplanted cells are known in the art. As an alternative, PDCs may be genetically modified to reduce their immunogenicity.
Survival of transplanted PDCs in a living patient can be determined through the use of a variety of scanning techniques, e.g., computerized axial tomography (CAT or CT) scan, magnetic resonance imaging (M21) or positron emission tomography (PET) scans.
= Determination of transplant survival can also be done post mortem by removing the target tissue, and examining it visually or through a microscope. Alternatively, cells can be treated with stains that are specific for cells of a specific lineage. Transplanted cells can also be identified by prior incorporation of tracer dyes such, as rhodanaine- or fluorescein-labeled microspheres, fast blue,
5,827,735.
Dosage forms and regimes for administering PDCs or any of the other pharmaceutical compositions described herein are developed in accordance with good medical practice, taking into account the condition of the individual patient, e.g., nature and extent of the condition being treated, age, sex, body weight and general medical condition, and other factors known to medical practitioners. Thus, the effective amount of a pharmaceutical composition to be administered to a patient is determined by these considerations as known in the art.
In some embodiments of the invention, it may not be necessary or desirable to immunosuppress a patient prior to initiation of cell therapy with PDCs. In addition, PDCs have . been shown not to stimulate allogeneic PBMCs (for example, allogeneic lymphocytes, e.g., naïve CD4+ T cells) in a mixed lymphocyte reaction. Accordingly, transplantation with allogeneic, or even xenogeneic, PDCs may be tolerated in some instances.
However, in other instances it may be desirable or appropriate to pharmacologically immunosuppress a patient prior to initiating cell therapy. This may be accomplished through the use of systemic or local immunosuppressive agents, or it may be accomplished by delivering the cells in an encapsulated device. PDCs may be encapsulated in a capsule that is permeable to nutrients and oxygen required by the cell and therapeutic factors the cell is yet impermeable to immune humoral factors and cells. Preferably the encapsulant is hypoallergenic, is easily and stably situated in a target tissue, and provides added protection to the implanted structure. These and other means for reducing or eliminating an immune response to the transplanted cells are known in the art. As an alternative, PDCs may be genetically modified to reduce their immunogenicity.
Survival of transplanted PDCs in a living patient can be determined through the use of a variety of scanning techniques, e.g., computerized axial tomography (CAT or CT) scan, magnetic resonance imaging (M21) or positron emission tomography (PET) scans.
= Determination of transplant survival can also be done post mortem by removing the target tissue, and examining it visually or through a microscope. Alternatively, cells can be treated with stains that are specific for cells of a specific lineage. Transplanted cells can also be identified by prior incorporation of tracer dyes such, as rhodanaine- or fluorescein-labeled microspheres, fast blue,
- 35 -bisbenzamide, ferric microparticles, or genetically introduced reporter gene products, such as beta-galactosidase or beta-glucuronidase.
Functional integration of transplanted PDCs into a subject can be assessed by examining restoration of the function that was damaged or diseased or augmentation of function.
Compositions and pharmaceutical compositions Compositions of PDCs and related products (e.g., extracellular matrix, lysate, cell lysate, conditioned medium), including for example pharmaceutical compositions, are included within the scope of the invention. Compositions of the invention may include one or more bioactive factors, for example but not limited to a growth factor, a differentiation-inducing factor, a cell survival factor such as caspase inhibitor, an anti-inflammatory agent such as p38 lcinase inhibitor, or an angiogenic factor such as VEGF or bFGF. Some examples of bioactive factors include PDGF-bb, EGF, FGF, IGF, and LIF. In some embodiments, undifferentiated or differentiation-induced PDCs are cultured in contact with the bioactive factor. In some embodiments, undifferentiated PDCs remain undifferentiated upon contact with the bioactive factor. In other embodiments, the bioactive factor induces differentiation of the PDCs.
Pharmaceutical compositions of the invention may comprise homogeneous or hetereogeneous populations of differentiated and/or undifferentiated PDCs, cultures thereof, cell lysates thereof, extracellular matrix produced thereby, or conditioned medium derived therefrom in a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carriers for the cells of the invention include organic or inorganic carrier substances which do not deleteriously react with the cells of the invention or compositions or components thereof. To the extent they are biocompatible, suitable pharmaceutically acceptable carriers include water, salt solution (such as Ringer's solution), alcohols, oils, gelatins, and carbohydrates, such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, and polyvinyl pyrolidine. Such preparations can be sterilized, and if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers; salts for influencing osmotic pressure, buffers, and coloring.
Pharmaceutical carriers suitable for use in the present invention are known in the art and are described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309.
The dosage (e.g., number of cells to be administered) and frequency of administration -will depend upon a number of factors, including but not limited to, the nature of the condition to
Functional integration of transplanted PDCs into a subject can be assessed by examining restoration of the function that was damaged or diseased or augmentation of function.
Compositions and pharmaceutical compositions Compositions of PDCs and related products (e.g., extracellular matrix, lysate, cell lysate, conditioned medium), including for example pharmaceutical compositions, are included within the scope of the invention. Compositions of the invention may include one or more bioactive factors, for example but not limited to a growth factor, a differentiation-inducing factor, a cell survival factor such as caspase inhibitor, an anti-inflammatory agent such as p38 lcinase inhibitor, or an angiogenic factor such as VEGF or bFGF. Some examples of bioactive factors include PDGF-bb, EGF, FGF, IGF, and LIF. In some embodiments, undifferentiated or differentiation-induced PDCs are cultured in contact with the bioactive factor. In some embodiments, undifferentiated PDCs remain undifferentiated upon contact with the bioactive factor. In other embodiments, the bioactive factor induces differentiation of the PDCs.
Pharmaceutical compositions of the invention may comprise homogeneous or hetereogeneous populations of differentiated and/or undifferentiated PDCs, cultures thereof, cell lysates thereof, extracellular matrix produced thereby, or conditioned medium derived therefrom in a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carriers for the cells of the invention include organic or inorganic carrier substances which do not deleteriously react with the cells of the invention or compositions or components thereof. To the extent they are biocompatible, suitable pharmaceutically acceptable carriers include water, salt solution (such as Ringer's solution), alcohols, oils, gelatins, and carbohydrates, such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, and polyvinyl pyrolidine. Such preparations can be sterilized, and if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers; salts for influencing osmotic pressure, buffers, and coloring.
Pharmaceutical carriers suitable for use in the present invention are known in the art and are described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309.
The dosage (e.g., number of cells to be administered) and frequency of administration -will depend upon a number of factors, including but not limited to, the nature of the condition to
-36-be treated, the extent of the symptoms of the condition, characteristics of the patient (e.g., age, size, gender, health).
Use of PD Cs for Transplantation The treatment methods of the subject invention involves the implantation of PDCs into individuals in need thereof. The cells of the present invention may be delivered to the site of therapeutic need or "home" to the site.
The cells of the present invention may differentiate in vivo or provide trophic support to endogenous cells. The appropriate cell implantation dosage in humans can be determined from existing information relating to, e.g., the activity of the cells. From in vitro culture and in vivo animal experiments, the amount of factors produced can be quantitated. This information is also useful in calculating an appropriate dosage of implanted material.
Additionally, the patient can be monitored to determine if additional implantation can be made or implanted material reduced accordingly.
To enhance vascularization and survival of the transplanted cells, angiogenic factors such as VEGF, PDGF or bFGF can be added either alone or in combination with endothelial cells or their precursors including CD34+, CD34+/CD117+ cells.
One or more other components may be added to transplanted cells, including selected extracellular matrix components, such as one or more types of collagen known in the art, and/or growth factors, platelet-rich plasma, and drugs. Alternatively, the cells of the invention may be genetically engineered to express and produce growth factors. Bioactive factors which may be usefully incorporated into the cell formulation include anti-apoptotic agents (e.g., EPO, EPO
mimetibody, TPO, IGF-I and IGF-II, HGF, caspase inhibitors); anti-inflammatory agents (e.g., p38 MAPK inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLLMUS, and NSAIDs (non-steroidal anti-inflammatory drugs;
e.g., TEPDXALIN, TOLMETIN, SLTPROFEN); immunosupressive/immunomodulatory agents (e.g., calcineurin inhibitors, such as cyclosporine, tacrolimus; mTOR
inhibitors (e.g., SIROLIMUS, EVEROLIMUS); anti-proliferatives (e.g., azathioprine, mycophenolate mofetil);
corticosteroids (e.g., prednisolone, hydrocortisone); antibodies such as monoclonal anti-IL-2Ralpha receptor antibodies (e.g., basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g., anti-thymocyte globulin (ATG); anti-lymphocyte globulin (ALG);
monoclonal anti-T cell antibody OKT3)); anti-thrombogenic agents (e.g., heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine chloromethylketone), antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin,
Use of PD Cs for Transplantation The treatment methods of the subject invention involves the implantation of PDCs into individuals in need thereof. The cells of the present invention may be delivered to the site of therapeutic need or "home" to the site.
The cells of the present invention may differentiate in vivo or provide trophic support to endogenous cells. The appropriate cell implantation dosage in humans can be determined from existing information relating to, e.g., the activity of the cells. From in vitro culture and in vivo animal experiments, the amount of factors produced can be quantitated. This information is also useful in calculating an appropriate dosage of implanted material.
Additionally, the patient can be monitored to determine if additional implantation can be made or implanted material reduced accordingly.
To enhance vascularization and survival of the transplanted cells, angiogenic factors such as VEGF, PDGF or bFGF can be added either alone or in combination with endothelial cells or their precursors including CD34+, CD34+/CD117+ cells.
One or more other components may be added to transplanted cells, including selected extracellular matrix components, such as one or more types of collagen known in the art, and/or growth factors, platelet-rich plasma, and drugs. Alternatively, the cells of the invention may be genetically engineered to express and produce growth factors. Bioactive factors which may be usefully incorporated into the cell formulation include anti-apoptotic agents (e.g., EPO, EPO
mimetibody, TPO, IGF-I and IGF-II, HGF, caspase inhibitors); anti-inflammatory agents (e.g., p38 MAPK inhibitors, TGF-beta inhibitors, statins, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLLMUS, and NSAIDs (non-steroidal anti-inflammatory drugs;
e.g., TEPDXALIN, TOLMETIN, SLTPROFEN); immunosupressive/immunomodulatory agents (e.g., calcineurin inhibitors, such as cyclosporine, tacrolimus; mTOR
inhibitors (e.g., SIROLIMUS, EVEROLIMUS); anti-proliferatives (e.g., azathioprine, mycophenolate mofetil);
corticosteroids (e.g., prednisolone, hydrocortisone); antibodies such as monoclonal anti-IL-2Ralpha receptor antibodies (e.g., basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g., anti-thymocyte globulin (ATG); anti-lymphocyte globulin (ALG);
monoclonal anti-T cell antibody OKT3)); anti-thrombogenic agents (e.g., heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine chloromethylketone), antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin,
-37-dipyridamole, protamine, hirudin, prostaglandin inhibitors, and platelet inhibitors); and anti-oxidants (e.g., probucol, vitamin A, ascorbic acid, tocopherol, coenzyme Q-10, glutathione, L-cysteine, N-acetylcysteine) as well as local anesthetics. As another example, the cells may be co-administered with scar inhibitory factor as described in U.S. Patent No.
5,827,735.
Formulation of PDCs for Transplantation In a non-limiting embodiment, a formulation comprising the cells of the invention is prepared for injection directly to the site where the production of new tissue is desired. For example, and not by way of limitation, the cells of the invention may be suspended in a hydrogel solution for injection. Examples of suitable hydrogels for use in the invention include self-assembling peptides, such as RAD16. Alternatively, the hydrogel solution containing the cells may be allowed to harden, for instance in a mold, to form a matrix having cells dispersed therein prior to implantation. Or, once the matrix has hardened, the cell formations may be cultured so that the cells are mitotically expanded prior to implantation. The hydrogel is an organic polymer (natural or synthetic) which is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel. Examples of materials which can be used to form a hydrogel include polysaccharides such as alginate and salts thereof, peptides, polyphosphazines, and polyacrylates, which are crosslinked ionically, or block polymers such as polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively. In some embodiments, the support for the PDCs of the invention is biodegradable.
In some embodiments of the invention, the formulation comprises an in situ polymerizable gel, as described, for example, in U.S. Patent Application Publication 2002/0022676; Anseth et al., J. Control Release, 78(1-3):199-209 (2002); Wang et aL, Biomaterials, 24(22):3969-80 (2003).
In some embodiments, the polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof. Examples of polymers with acidic side groups that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic acid), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene. Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used. Examples of
5,827,735.
Formulation of PDCs for Transplantation In a non-limiting embodiment, a formulation comprising the cells of the invention is prepared for injection directly to the site where the production of new tissue is desired. For example, and not by way of limitation, the cells of the invention may be suspended in a hydrogel solution for injection. Examples of suitable hydrogels for use in the invention include self-assembling peptides, such as RAD16. Alternatively, the hydrogel solution containing the cells may be allowed to harden, for instance in a mold, to form a matrix having cells dispersed therein prior to implantation. Or, once the matrix has hardened, the cell formations may be cultured so that the cells are mitotically expanded prior to implantation. The hydrogel is an organic polymer (natural or synthetic) which is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel. Examples of materials which can be used to form a hydrogel include polysaccharides such as alginate and salts thereof, peptides, polyphosphazines, and polyacrylates, which are crosslinked ionically, or block polymers such as polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively. In some embodiments, the support for the PDCs of the invention is biodegradable.
In some embodiments of the invention, the formulation comprises an in situ polymerizable gel, as described, for example, in U.S. Patent Application Publication 2002/0022676; Anseth et al., J. Control Release, 78(1-3):199-209 (2002); Wang et aL, Biomaterials, 24(22):3969-80 (2003).
In some embodiments, the polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof. Examples of polymers with acidic side groups that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic acid), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene. Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used. Examples of
-38-acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH groups.
Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines), poly(vinyl pyridine), poly(vinyl imidazole), and some imino substituted polyphosphazenes. The ammonium or quaternary salt of the polymers can also be foimed from the backbone nitrogens or pendant imino groups. Examples of basic side groups are amino and imino groups.
Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S.
Patent No. 4,352,883 to Lim. In the Lim process, an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is crosslinked with polyamino acids to foali a semipermeable membrane around the encapsulated materials.
Polyphosphazenes are polymers with backbones consisting of nitrogen and phosphorous separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two side chains.
The polyphosphazenes suitable for cross-linking have a majority of side chain groups which are acidic and capable of forming salt bridges with di- or trivalent cations. Examples of preferred acidic side groups are carboxylic acid groups and sulfonic acid groups. Hydrolytically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are crosslinked by divalent or trivalent cations such as Ca2+ or A13+. Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups. For example, a polyanionic poly[bis(carboxylatophenoxy)]phosphazene (PCPP) can be synthesized, which is cross-linked with dissolved multivalent cations in aqueous media at room temperature or below to form hydrogel matrices.
Biodegradable polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl.
Hydrolysis of the side chain results in erosion of the polymer. Examples of hydrolyzing side chains are unsubstituted and substituted imidizoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage (polyphosphazene polymers in
Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines), poly(vinyl pyridine), poly(vinyl imidazole), and some imino substituted polyphosphazenes. The ammonium or quaternary salt of the polymers can also be foimed from the backbone nitrogens or pendant imino groups. Examples of basic side groups are amino and imino groups.
Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S.
Patent No. 4,352,883 to Lim. In the Lim process, an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is crosslinked with polyamino acids to foali a semipermeable membrane around the encapsulated materials.
Polyphosphazenes are polymers with backbones consisting of nitrogen and phosphorous separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two side chains.
The polyphosphazenes suitable for cross-linking have a majority of side chain groups which are acidic and capable of forming salt bridges with di- or trivalent cations. Examples of preferred acidic side groups are carboxylic acid groups and sulfonic acid groups. Hydrolytically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are crosslinked by divalent or trivalent cations such as Ca2+ or A13+. Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups. For example, a polyanionic poly[bis(carboxylatophenoxy)]phosphazene (PCPP) can be synthesized, which is cross-linked with dissolved multivalent cations in aqueous media at room temperature or below to form hydrogel matrices.
Biodegradable polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl.
Hydrolysis of the side chain results in erosion of the polymer. Examples of hydrolyzing side chains are unsubstituted and substituted imidizoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage (polyphosphazene polymers in
-39-which both R groups are attached in this manner are known as polyaminophosphazenes). For polyimidazolephosphazenes, some of the "R" groups on the polyphosphazene backbone are imidazole rings, attached to phosphorous in the backbone through a ring nitrogen atom. Other "R" groups can be organic residues that do not participate in hydrolysis, such as methyl phenoxy groups or other groups shown in the scientific paper of Allcock, et al., Macromolecule 10:824 (1977). Methods of synthesis of the hydrogel materials, as well as methods for preparing such hydrogels, are known in the art.
Other components may also be included in the formulation, including but not limited to any of the following: (1) buffers to provide appropriate pH and isotonicity;
(2) lubricants; (3) viscous materials to retain the cells at or near the site of administration, including, for example, alginates, agars and plant gums; and (4) other cell types that may produce a desired effect at the site of administration, such as, for example, enhancement or modification of the formation of tissue or its physicochemical characteristics, or is support for the viability of the cells, or inhibition of inflammation or rejection. The cells may be covered by an appropriate wound covering to prevent cells from leaving the site. Such wound coverings are known as those of skill in the art.
Transplantation of PD Cs using Scaffolds The cells of the invention or co-cultures thereof may be seeded onto a three-dimensional framework or scaffold and implanted in vivo, where the seeded cells will proliferate on the surface of the framework and form a replacement tissue in vivo in cooperation with the cells of the subject. Such a framework can be implanted in combination with any one or more growth factors, cells, drugs or other components described above that stimulate tissue formation or otherwise enhance or improve the practice of the invention.
The cells of the invention can be used to produce new tissue in vitro, which can then be implanted, transplanted or otherwise inserted into a site requiring tissue repair, replacement or augmentation in a subject.
In a non-limiting embodiment, the cells of the invention are used to produce a three-dimensional tissue construct in vitro, which is then implanted in vivo. As an example of the production of three-dimensional tissue constructs, see U.S. Patent No.
4,963,489.
For example, the cells of the invention may be inoculated or "seeded" onto a three-dimensional framework or scaffold, and proliferated or grown in vitro to form a living tissue that can be implanted in vivo.
Other components may also be included in the formulation, including but not limited to any of the following: (1) buffers to provide appropriate pH and isotonicity;
(2) lubricants; (3) viscous materials to retain the cells at or near the site of administration, including, for example, alginates, agars and plant gums; and (4) other cell types that may produce a desired effect at the site of administration, such as, for example, enhancement or modification of the formation of tissue or its physicochemical characteristics, or is support for the viability of the cells, or inhibition of inflammation or rejection. The cells may be covered by an appropriate wound covering to prevent cells from leaving the site. Such wound coverings are known as those of skill in the art.
Transplantation of PD Cs using Scaffolds The cells of the invention or co-cultures thereof may be seeded onto a three-dimensional framework or scaffold and implanted in vivo, where the seeded cells will proliferate on the surface of the framework and form a replacement tissue in vivo in cooperation with the cells of the subject. Such a framework can be implanted in combination with any one or more growth factors, cells, drugs or other components described above that stimulate tissue formation or otherwise enhance or improve the practice of the invention.
The cells of the invention can be used to produce new tissue in vitro, which can then be implanted, transplanted or otherwise inserted into a site requiring tissue repair, replacement or augmentation in a subject.
In a non-limiting embodiment, the cells of the invention are used to produce a three-dimensional tissue construct in vitro, which is then implanted in vivo. As an example of the production of three-dimensional tissue constructs, see U.S. Patent No.
4,963,489.
For example, the cells of the invention may be inoculated or "seeded" onto a three-dimensional framework or scaffold, and proliferated or grown in vitro to form a living tissue that can be implanted in vivo.
- 40 -The cells of the invention can be grown freely in a culture vessel to sub-confluency or confluency, lifted from the culture and inoculated onto a three-dimensional framework.
Inoculation of the three-dimensional framework with a high concentration of cells, e.g., approximately 105 to 108 cells per milliliter, will result in the establishment of the three-dimensional support in relatively shorter periods of time.
Examples of scaffolds which may be used in the present invention include nonwoven mats, porous foams, or self assembling peptides. Nonwoven mats may, for example, be fon-ned using fibers comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA), sold under the tradename VICRYL (Ethicon, Inc., Somerville, NJ), Foams, composed of, for example, poly(epsilon-caprolactone)/poly(glycolic acid) (PCL/PGA) copolymer, formed by processes such as freeze-drying, or lyophilized, as discussed in U.S.
Patent No. 6,355,699, are also possible scaffolds. Hydrogels such as self-assembling peptides (e.g., RAD16) may also be used. These materials are frequently used as supports for growth of tissue.
The three-dimensional framework also may be made of ceramic materials including, but not limited to: mono-, di-, tri-, alpha-tri-, beta-tri-, and tetra-calcium phosphate, hydroxyapatite, fluoroapatites, calcium sulfates, calcium fluorides, calcium oxides, calcium carbonates, magnesium calcium phosphates, biologically active glasses such as BIOGLASS
(University of Florida, Gainesville, FL), and mixtures thereof. There are a number of suitable porous biocompatible ceramic materials currently available on the commercial market such as SLTRGIBON (Unilab Surgibone, Inc., Canada), ENDOBON (Merck Biomaterial France, France), CEROS (Mathys, A. G., Bettlach, Switzerland), and INTERPORE (Interpore, Irvine, CA, United States), and mineralized collagen bone grafting products such as HEALOS
(Orquest, Inc., Mountain View, CA) and VITOSS, RHAKOSS, and CORTOSS (Orthovita, Malvern, PA).
The framework may be a mixture, blend or composite of natural and/or synthetic materials.
According to a preferred embodiment, the framework is a felt, which can be composed of a multifilament yarn made from a bioabsorbable material, e.g., PGA, PLA, PCL
copolymers or blends, or hyaluronic acid. The yarn is made into a felt using standard textile processing techniques consisting of crimping, cutting, carding and needling.
In another preferred embodiment the cells of the invention are seeded onto foam scaffolds that may be composite structures. In addition, the three-dimensional framework may be molded into a useful shape, such as that of the external portion of the ear, or other specific structure in the body to be repaired, replaced or augmented.
Inoculation of the three-dimensional framework with a high concentration of cells, e.g., approximately 105 to 108 cells per milliliter, will result in the establishment of the three-dimensional support in relatively shorter periods of time.
Examples of scaffolds which may be used in the present invention include nonwoven mats, porous foams, or self assembling peptides. Nonwoven mats may, for example, be fon-ned using fibers comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA), sold under the tradename VICRYL (Ethicon, Inc., Somerville, NJ), Foams, composed of, for example, poly(epsilon-caprolactone)/poly(glycolic acid) (PCL/PGA) copolymer, formed by processes such as freeze-drying, or lyophilized, as discussed in U.S.
Patent No. 6,355,699, are also possible scaffolds. Hydrogels such as self-assembling peptides (e.g., RAD16) may also be used. These materials are frequently used as supports for growth of tissue.
The three-dimensional framework also may be made of ceramic materials including, but not limited to: mono-, di-, tri-, alpha-tri-, beta-tri-, and tetra-calcium phosphate, hydroxyapatite, fluoroapatites, calcium sulfates, calcium fluorides, calcium oxides, calcium carbonates, magnesium calcium phosphates, biologically active glasses such as BIOGLASS
(University of Florida, Gainesville, FL), and mixtures thereof. There are a number of suitable porous biocompatible ceramic materials currently available on the commercial market such as SLTRGIBON (Unilab Surgibone, Inc., Canada), ENDOBON (Merck Biomaterial France, France), CEROS (Mathys, A. G., Bettlach, Switzerland), and INTERPORE (Interpore, Irvine, CA, United States), and mineralized collagen bone grafting products such as HEALOS
(Orquest, Inc., Mountain View, CA) and VITOSS, RHAKOSS, and CORTOSS (Orthovita, Malvern, PA).
The framework may be a mixture, blend or composite of natural and/or synthetic materials.
According to a preferred embodiment, the framework is a felt, which can be composed of a multifilament yarn made from a bioabsorbable material, e.g., PGA, PLA, PCL
copolymers or blends, or hyaluronic acid. The yarn is made into a felt using standard textile processing techniques consisting of crimping, cutting, carding and needling.
In another preferred embodiment the cells of the invention are seeded onto foam scaffolds that may be composite structures. In addition, the three-dimensional framework may be molded into a useful shape, such as that of the external portion of the ear, or other specific structure in the body to be repaired, replaced or augmented.
- 41 -In some embodiments, the framework is treated prior to inoculation of the cells of the invention in order to enhance cell attachment. For example, prior to inoculation with the cells of the invention, nylon matrices could be treated with 0.1 molar acetic acid and incubated in polylysine, PBS, and/or collagen to coat the nylon. Polystyrene could be similarly treated using sulfuric acid.
The external surfaces of the three-dimensional framework may be modified to improve the attachment or growth of cells and differentiation of tissue, such as by plasma coating the framework or addition of one or more proteins (e.g., collagens, elastic fibers, reticular fibers), glycoproteins, glycosaminoglycans (e.g., heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, derrnatan sulfate, keratin sulfate), a cellular matrix, and/or other materials such as, but not limited to, gelatin, alginates, agar, agarose, and plant gums, among others.
In some embodiments, the scaffold is comprised of or is treated with materials that render it non-thrombogenic. These treatments and materials may also promote and sustain endothelial growth, migration, and extracellular matrix deposition. Examples of these materials and treatments include but are not limited to natural materials such as basement membrane proteins such as laminin and Type IV collagen, synthetic materials such as ePTFE, and segmented polyurethaneurea silicones, such as PURSPAN (The Polymer Technology Group, Inc., Berkeley, CA). These materials can be further treated to render the scaffold non-thrombogenic. Such treatments include anti-thrombotic agents such as heparin, and treatments which alter the surface charge of the material such as plasma coating.
In some aspects of the invention, it is important to re-create in culture the cellular microenvironment found in vivo, such that the extent to which the cells of the invention are grown prior to implantation in vivo or use in vitro may vary. In addition, growth factors may be added to the culture medium prior to, during, or subsequent to inoculation of the cells to trigger differentiation and tissue formation by the PDCs.
The three-dimensional framework may be modified so that the growth of cells and the production of tissue thereon is enhanced, or so that the risk of rejection of the implant is reduced.
Thus, one or more biologically active compounds, including, but not limited to, anti-inflammatories, immunosuppressants or growth factors, may be added to the framework.
Therapeutic Uses for Extracellular Matrix and Cell lysates Derived From PDCs As an alternative to implanting the cells of the invention, or living tissue produced therefrom, a subject in need of tissue repair, replacement, or augmentation may benefit from the
The external surfaces of the three-dimensional framework may be modified to improve the attachment or growth of cells and differentiation of tissue, such as by plasma coating the framework or addition of one or more proteins (e.g., collagens, elastic fibers, reticular fibers), glycoproteins, glycosaminoglycans (e.g., heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, derrnatan sulfate, keratin sulfate), a cellular matrix, and/or other materials such as, but not limited to, gelatin, alginates, agar, agarose, and plant gums, among others.
In some embodiments, the scaffold is comprised of or is treated with materials that render it non-thrombogenic. These treatments and materials may also promote and sustain endothelial growth, migration, and extracellular matrix deposition. Examples of these materials and treatments include but are not limited to natural materials such as basement membrane proteins such as laminin and Type IV collagen, synthetic materials such as ePTFE, and segmented polyurethaneurea silicones, such as PURSPAN (The Polymer Technology Group, Inc., Berkeley, CA). These materials can be further treated to render the scaffold non-thrombogenic. Such treatments include anti-thrombotic agents such as heparin, and treatments which alter the surface charge of the material such as plasma coating.
In some aspects of the invention, it is important to re-create in culture the cellular microenvironment found in vivo, such that the extent to which the cells of the invention are grown prior to implantation in vivo or use in vitro may vary. In addition, growth factors may be added to the culture medium prior to, during, or subsequent to inoculation of the cells to trigger differentiation and tissue formation by the PDCs.
The three-dimensional framework may be modified so that the growth of cells and the production of tissue thereon is enhanced, or so that the risk of rejection of the implant is reduced.
Thus, one or more biologically active compounds, including, but not limited to, anti-inflammatories, immunosuppressants or growth factors, may be added to the framework.
Therapeutic Uses for Extracellular Matrix and Cell lysates Derived From PDCs As an alternative to implanting the cells of the invention, or living tissue produced therefrom, a subject in need of tissue repair, replacement, or augmentation may benefit from the
- 42 -administration of a component or product of PDCs, such as the extracellular matrix (ECM) or cell lysate produced by those cells.
In some embodiments, after the cells of the invention have been cultured in vitro, such as, for example, by using a three-dimensional scaffold system described herein, such that a desired amount of ECM has been secreted onto the framework. Once ECM is secreted onto the framework, the cells may be removed. The ECM may be processed for further use, for example, as an injectable preparation.
In some embodiments, the cells are killed and cellular debris (e.g., cellular membranes) is removed from the framework. This process may be carried out in a number of different ways.
For example, the living tissue can be flash-frozen in liquid nitrogen without a cryopreservative, or the tissue can be immersed in sterile distilled water so that the cells burst in response to osmotic pressure. Once the cells have been killed, the cellular membranes may be disrupted and cellular debris removed by treatment with a mild detergent rinse, such as EDTA, CHAPS or a zwitteiionic detergent. An advantage to using a mild detergent rinse is that it solubilizes membrane-bound proteins, which are often highly antigenic.
Alternatively, the tissue can be enzymatically digested and/or extracted with reagents that break down cellular membranes. Example of such enzymes include, but are not limited to, TM
hyaluronidase, dispase, proteases, and nucleases (for example, deoxyribonuclease and ribonuclease). Examples of detergents include non-ionic detergents such as, for example, alkylaryl polyether alcohol (TRITON X-l00), octylphenoxy polyethoxy-ethanol (Rohm and Haas Philadelphia, PA), BRIJ-35, a polyethoxyethanol lauryl ether (Atlas Chemical Co., San Diego, CA), polysorbate 20 (TWEEN 208), a polyethoxyethanol sorbitan monolaureate (Rohm and Haas), polyethylene lauryl ether (Rohm and Haas); and ionic detergents such as, for example, sodium dodecyl sulphate, sulfated higher aliphatic alcohols, sulfonated alkanes and sulfonated alkylarenes containing 7 to 22 carbon atoms in a branched or unbranched chain.
The scaffold comprising the ECM may be used therapeutically as described above.
Alternatively, ECM may be collected from the scaffold. Collection of ECM can be accomplished in a variety of ways, depending, for example, on whether the framework is biodegradable or non-biodegradable. For example, if the framework is non-biodegradable, the ECM can be removed by subjecting the framework to sonication, high pressure water jets, inechanical scraping, or mild treatment with detergents or enzymes, or any combination of the above.
If the framework is biodegradable, the ECM can be collected, for example, by allowing the framework to degrade or dissolve in solution. Alternatively, if the biodegradable framework
In some embodiments, after the cells of the invention have been cultured in vitro, such as, for example, by using a three-dimensional scaffold system described herein, such that a desired amount of ECM has been secreted onto the framework. Once ECM is secreted onto the framework, the cells may be removed. The ECM may be processed for further use, for example, as an injectable preparation.
In some embodiments, the cells are killed and cellular debris (e.g., cellular membranes) is removed from the framework. This process may be carried out in a number of different ways.
For example, the living tissue can be flash-frozen in liquid nitrogen without a cryopreservative, or the tissue can be immersed in sterile distilled water so that the cells burst in response to osmotic pressure. Once the cells have been killed, the cellular membranes may be disrupted and cellular debris removed by treatment with a mild detergent rinse, such as EDTA, CHAPS or a zwitteiionic detergent. An advantage to using a mild detergent rinse is that it solubilizes membrane-bound proteins, which are often highly antigenic.
Alternatively, the tissue can be enzymatically digested and/or extracted with reagents that break down cellular membranes. Example of such enzymes include, but are not limited to, TM
hyaluronidase, dispase, proteases, and nucleases (for example, deoxyribonuclease and ribonuclease). Examples of detergents include non-ionic detergents such as, for example, alkylaryl polyether alcohol (TRITON X-l00), octylphenoxy polyethoxy-ethanol (Rohm and Haas Philadelphia, PA), BRIJ-35, a polyethoxyethanol lauryl ether (Atlas Chemical Co., San Diego, CA), polysorbate 20 (TWEEN 208), a polyethoxyethanol sorbitan monolaureate (Rohm and Haas), polyethylene lauryl ether (Rohm and Haas); and ionic detergents such as, for example, sodium dodecyl sulphate, sulfated higher aliphatic alcohols, sulfonated alkanes and sulfonated alkylarenes containing 7 to 22 carbon atoms in a branched or unbranched chain.
The scaffold comprising the ECM may be used therapeutically as described above.
Alternatively, ECM may be collected from the scaffold. Collection of ECM can be accomplished in a variety of ways, depending, for example, on whether the framework is biodegradable or non-biodegradable. For example, if the framework is non-biodegradable, the ECM can be removed by subjecting the framework to sonication, high pressure water jets, inechanical scraping, or mild treatment with detergents or enzymes, or any combination of the above.
If the framework is biodegradable, the ECM can be collected, for example, by allowing the framework to degrade or dissolve in solution. Alternatively, if the biodegradable framework
- 43 -is composed of a material that can itself be injected along with the ECM, the framework and the ECM can be processed in tow for subsequent injection. Alternatively, the ECM
can be removed from the biodegradable framework by any of the methods described above for collection of ECM
from a non-biodegradable framework. All collection processes are preferably designed so as not to denature the ECM produced by the cells of the invention.
Once the ECM has been collected, it may be processed further. The ECM can be homogenized to fine particles using techniques well known in the art such as, for example, by sonication, so that they can pass through a surgical needle. ECM components can be crosslinked, if desired, by gamma irradiation. Preferably, the ECM can be irradiated between 0.25 to 2 mega rads to sterilize and crosslink the ECM. Chemical crosslinking using agents that are toxic, such as glutaraldehyde, is possible but not generally preferred.
Cell lysates prepared from the populations of the postpartum-derived cells also have many utilities. In one embodiment, whole cell lysates are prepared, e.g., by disrupting cells without subsequent separation of cell fractions. In another embodiment, a cell membrane fraction is separated from a soluble fraction of the cells by routine methods known in the art, e.g., centrifugation, filtration, or similar methods. Use of soluble cell fractions in vivo allows the beneficial intracellular milieu to be used in a patient without triggering rejection or an adverse response. Methods of lysing cells are well-known in the art and include various means of mechanical disruption, erwymatic disruption, or chemical disruption, or combinations thereof.
Such cell lysates may be prepared from cells directly in their growth medium and thus containing secreted growth factors and the like, or may be prepared from cells washed free of medium in, for example, PBS or other solution. Washed cells may be resuspended at concentrations greater than the original population density if preferred. Cell lysates prepared from populations of postpartum-derived cells may be used as is, further concentrated, by for example, ultrafiltration or lyophilization, or even dried, partially purified, combined with pharmaceutically acceptable carriers or diluents as are known in the art, or combined with other compounds such as biologicals, for example pharmaceutically useful protein compositions. Cell lysates may be used in vitro or in vivo, alone or for example, with cells. The cell lysates, if introduced in vivo, may be introduced locally at a site of treatment, or remotely to provide, for example needed cellular growth factors to a patient.
The amounts and/or ratios of proteins may be adjusted by mixing the ECM or cell lysate produced by the cells of the invention with ECM or cell lysate of one or more other cell types. In addition, biologically active substances such as proteins, growth factors and/or drugs, can be incorporated into the ECM or cell lysate preparation. Exemplary biologically active substances
can be removed from the biodegradable framework by any of the methods described above for collection of ECM
from a non-biodegradable framework. All collection processes are preferably designed so as not to denature the ECM produced by the cells of the invention.
Once the ECM has been collected, it may be processed further. The ECM can be homogenized to fine particles using techniques well known in the art such as, for example, by sonication, so that they can pass through a surgical needle. ECM components can be crosslinked, if desired, by gamma irradiation. Preferably, the ECM can be irradiated between 0.25 to 2 mega rads to sterilize and crosslink the ECM. Chemical crosslinking using agents that are toxic, such as glutaraldehyde, is possible but not generally preferred.
Cell lysates prepared from the populations of the postpartum-derived cells also have many utilities. In one embodiment, whole cell lysates are prepared, e.g., by disrupting cells without subsequent separation of cell fractions. In another embodiment, a cell membrane fraction is separated from a soluble fraction of the cells by routine methods known in the art, e.g., centrifugation, filtration, or similar methods. Use of soluble cell fractions in vivo allows the beneficial intracellular milieu to be used in a patient without triggering rejection or an adverse response. Methods of lysing cells are well-known in the art and include various means of mechanical disruption, erwymatic disruption, or chemical disruption, or combinations thereof.
Such cell lysates may be prepared from cells directly in their growth medium and thus containing secreted growth factors and the like, or may be prepared from cells washed free of medium in, for example, PBS or other solution. Washed cells may be resuspended at concentrations greater than the original population density if preferred. Cell lysates prepared from populations of postpartum-derived cells may be used as is, further concentrated, by for example, ultrafiltration or lyophilization, or even dried, partially purified, combined with pharmaceutically acceptable carriers or diluents as are known in the art, or combined with other compounds such as biologicals, for example pharmaceutically useful protein compositions. Cell lysates may be used in vitro or in vivo, alone or for example, with cells. The cell lysates, if introduced in vivo, may be introduced locally at a site of treatment, or remotely to provide, for example needed cellular growth factors to a patient.
The amounts and/or ratios of proteins may be adjusted by mixing the ECM or cell lysate produced by the cells of the invention with ECM or cell lysate of one or more other cell types. In addition, biologically active substances such as proteins, growth factors and/or drugs, can be incorporated into the ECM or cell lysate preparation. Exemplary biologically active substances
- 44-include anti-inflammatory agents and growth factors which promote healing and tissue repair.
Cells may be co-administered with the ECM or cell lysates of the invention.
ECM or cell lysate of PDCs may be formulated for administration as described above for PDCs.
Use of PDCs for In Vitro Screening of Drug Efficacy or Toxicity The cells and tissues of the invention may be used in vitro to screen a wide variety of compounds for effectiveness and cytotoxicity of pharmaceutical agents, growth/regulatory factors, anti-inflammatory agents. To this end, the cells of the invention, or tissue cultures described above, are maintained in vitro and exposed to the compound to be tested. The activity of a cytotoxic compound can be measured by its ability to damage or kill cells in culture. This may readily be assessed by vital staining techniques. The effect of growth/regulatory factors may be assessed by analyzing the number of living cells in vitro, e.g., by total cell counts, and differential cell counts. This may be accomplished using standard cytological and/or histological techniques, including the use of immunocytochemical techniques employing antibodies that define type-specific cellular antigens. The effect of various drugs on the cells of the invention either in suspension culture or in the three-dimensional system described above may be assessed.
The cells and tissues of the invention may be used as model systems for the study of , physiological or pathological conditions. The cells and tissues of the invention may also be used to study the mechanism of action of cytokines, growth factors and inflammatory mediators, e.g., IL-I, TNF and prostaglandins. In addition, cytotoxic and/or pharmaceutical agents can be screened for those that are most efficacious for a particular patient. Agents that prove to be efficacious in vitro could then be used to treat the patient therapeutically.
Use of PDCs to Produce Biological Molecules In a further embodiment, the cells of the invention can be cultured in vitro to produce biological products in high yield. For example, such cells, which either naturally produce a particular biological product of interest (e.g., a growth factor, regulatory factor, or peptide hormone), or have been genetically engineered to produce a biological product, could be clonally expanded using, for example, the three-dimensional culture system described above. If the cells excrete the biological product into the nutrient medium, the product can be readily isolated from the spent or conditioned medium using standard separation techniques, e.g., such as differential protein precipitation, ion-exchange chromatography, gel filtration chromatography, electrophoresis, and high performance liquid chromatography. A "bioreactor"
may be used to take advantage of the flow method for feeding, for example, a three-dimensional culture in vitro.
Cells may be co-administered with the ECM or cell lysates of the invention.
ECM or cell lysate of PDCs may be formulated for administration as described above for PDCs.
Use of PDCs for In Vitro Screening of Drug Efficacy or Toxicity The cells and tissues of the invention may be used in vitro to screen a wide variety of compounds for effectiveness and cytotoxicity of pharmaceutical agents, growth/regulatory factors, anti-inflammatory agents. To this end, the cells of the invention, or tissue cultures described above, are maintained in vitro and exposed to the compound to be tested. The activity of a cytotoxic compound can be measured by its ability to damage or kill cells in culture. This may readily be assessed by vital staining techniques. The effect of growth/regulatory factors may be assessed by analyzing the number of living cells in vitro, e.g., by total cell counts, and differential cell counts. This may be accomplished using standard cytological and/or histological techniques, including the use of immunocytochemical techniques employing antibodies that define type-specific cellular antigens. The effect of various drugs on the cells of the invention either in suspension culture or in the three-dimensional system described above may be assessed.
The cells and tissues of the invention may be used as model systems for the study of , physiological or pathological conditions. The cells and tissues of the invention may also be used to study the mechanism of action of cytokines, growth factors and inflammatory mediators, e.g., IL-I, TNF and prostaglandins. In addition, cytotoxic and/or pharmaceutical agents can be screened for those that are most efficacious for a particular patient. Agents that prove to be efficacious in vitro could then be used to treat the patient therapeutically.
Use of PDCs to Produce Biological Molecules In a further embodiment, the cells of the invention can be cultured in vitro to produce biological products in high yield. For example, such cells, which either naturally produce a particular biological product of interest (e.g., a growth factor, regulatory factor, or peptide hormone), or have been genetically engineered to produce a biological product, could be clonally expanded using, for example, the three-dimensional culture system described above. If the cells excrete the biological product into the nutrient medium, the product can be readily isolated from the spent or conditioned medium using standard separation techniques, e.g., such as differential protein precipitation, ion-exchange chromatography, gel filtration chromatography, electrophoresis, and high performance liquid chromatography. A "bioreactor"
may be used to take advantage of the flow method for feeding, for example, a three-dimensional culture in vitro.
- 45 -Essentially, as fresh media is passed through the three-dimensional culture, the biological product is washed out of the culture and may then be isolated from the outflow, as above.
Alternatively, a biological product of interest may remain within the cell and, thus, its collection may require that the cells are lysed. The biological product may then be purified using any one or more of the above-listed techniques.
Kits The PDCs and components and products thereof can conveniently be employed as part of a kit, for example, for culture or implantation. Accordingly, the invention provides a kit including the PDCs and additional components, such as a matrix (e.g., a scaffold), hydrating agents (e.g., physiologically-compatible saline solutions, prepared cell culture media), cell culture substrates (e.g., culture dishes, plates, vials, etc.), cell culture media (whether in liquid or powdered form), antibiotic compounds, hormones, and the like. While the kit can include any such components, preferably it includes all ingredients necessary for its intended use. If desired, the kit also can include cells (typically cryopreserved), which can be seeded into the lattice as described herein.
In another aspect, the invention provides kits that utilize the PDCs, PDC
populations, components and products of PDCs in various methods for augmentation, regeneration, and repair as described above. In some embodiments, the kits may include one or more cell populations, including at least PDCs and a pharmaceutically acceptable carrier (liquid, semi-solid or solid).
The kits also optionally may include a means of administering the cells, for example by injection. The kits further may include instructions for use of the cells.
Kits prepared for field hospital use, such as for military use, may include full-procedure supplies including tissue scaffolds, surgical sutures, and the like, where the cells are to be used in conjunction with repair of acute injuries. Kits for assays and in vitro methods as described herein may contain one or more of (1) PDCs or components or products of PDCs, (2) reagents for practicing the in vitro method, (3) other cells or cell populations, as appropriate, and (4) instructions for conducting the in vitro method.
Cryopreservation and Banking PDCs PDCs of the invention can be cryopreserved and maintained or stored in a "cell bank".
Cryopreservation of cells of the invention may be carried out according to known methods. For example, but not by way of limitation, cells may be suspended in a "freeze medium" such as, for example, culture medium further comprising 0 to 95 percent PBS and 0 to 10 percent dimethylsulfoxide (DMSO), with or without 5 to 10 percent glycerol, at a density, for example,
Alternatively, a biological product of interest may remain within the cell and, thus, its collection may require that the cells are lysed. The biological product may then be purified using any one or more of the above-listed techniques.
Kits The PDCs and components and products thereof can conveniently be employed as part of a kit, for example, for culture or implantation. Accordingly, the invention provides a kit including the PDCs and additional components, such as a matrix (e.g., a scaffold), hydrating agents (e.g., physiologically-compatible saline solutions, prepared cell culture media), cell culture substrates (e.g., culture dishes, plates, vials, etc.), cell culture media (whether in liquid or powdered form), antibiotic compounds, hormones, and the like. While the kit can include any such components, preferably it includes all ingredients necessary for its intended use. If desired, the kit also can include cells (typically cryopreserved), which can be seeded into the lattice as described herein.
In another aspect, the invention provides kits that utilize the PDCs, PDC
populations, components and products of PDCs in various methods for augmentation, regeneration, and repair as described above. In some embodiments, the kits may include one or more cell populations, including at least PDCs and a pharmaceutically acceptable carrier (liquid, semi-solid or solid).
The kits also optionally may include a means of administering the cells, for example by injection. The kits further may include instructions for use of the cells.
Kits prepared for field hospital use, such as for military use, may include full-procedure supplies including tissue scaffolds, surgical sutures, and the like, where the cells are to be used in conjunction with repair of acute injuries. Kits for assays and in vitro methods as described herein may contain one or more of (1) PDCs or components or products of PDCs, (2) reagents for practicing the in vitro method, (3) other cells or cell populations, as appropriate, and (4) instructions for conducting the in vitro method.
Cryopreservation and Banking PDCs PDCs of the invention can be cryopreserved and maintained or stored in a "cell bank".
Cryopreservation of cells of the invention may be carried out according to known methods. For example, but not by way of limitation, cells may be suspended in a "freeze medium" such as, for example, culture medium further comprising 0 to 95 percent PBS and 0 to 10 percent dimethylsulfoxide (DMSO), with or without 5 to 10 percent glycerol, at a density, for example,
- 46 -of about 0.5 to 10 x 106 cells per milliliter. The cryopreservation medium may comprise cryopreservation agents including but not limited to methylcellulose. The cells are dispensed into glass or plastic ampoules that are then sealed and transferred to the freezing chamber of a controlled rate freezer. The optimal rate of freezing may be determined empirically. A
programmable rate freezer for example, can give a change in temperature of -1 to ¨10 C per minute. The preferred cryopreservation temperature is about -80 C to about -180 C, more preferably is about -90 C to about -160 C, and most preferably is about -125 to about -140 C.
Cryopreserved cells preferably are transferred to liquid nitrogen prior to thawing for use. In some embodiments, for example, once the ampoules have reached about ¨90 C, they are transferred to a liquid nitrogen storage area. Cryopreserved cells can be stored for a period of years.
The cryopreserved cells of the invention constitute a bank of cells, portions of which can be "withdrawn" by thawing and then used as needed. Thawing should generally be carried out rapidly, for example, by transferring an ampoule from liquid nitrogen to a 37 C water bath. The thawed contents of the ampoule should be immediately transferred under sterile conditions to a culture vessel containing an appropriate medium such as DMEM conditioned with 10 percent FBS.
In yet another aspect, the invention also provides for banking of tissues, cells, cellular components and cell populations of the invention. As discussed above, the cells are readily cryopreserved. The invention therefore provides methods of cryopreserving the cells in a bank, wherein the cells are stored frozen and associated with a complete characterization of the cells based on immunological, biochemical and genetic properties of the cells. The cells so frozen can be used for autologous, syngeneic, or allogeneic therapy, depending on the requirements of the procedure and the needs of the patient. Preferably, the information on each cryopreserved sample is stored in a computer, which is searchable based on the requirements of the surgeon, procedure and patient with suitable matches being made based on the characterization of the cells or populations. Preferably, the cells of the invention are grown and expanded to the desired quantity of cells and therapeutic cell compositions are prepared either separately or as co-cultures, in the presence or absence of a matrix or support. While for some applications it may be preferable to use cells freshly prepared, the remainder can be cryopreserved and banked by freezing the cells and entering the information in the computer to associate the computer entry with the samples. Even where it is not necessary to match a source or donor with a recipient of such cells, for immunological purposes, the bank system makes it easy to match, for example, desirable biochemical or genetic properties of the banked cells to the therapeutic needs. Upon
programmable rate freezer for example, can give a change in temperature of -1 to ¨10 C per minute. The preferred cryopreservation temperature is about -80 C to about -180 C, more preferably is about -90 C to about -160 C, and most preferably is about -125 to about -140 C.
Cryopreserved cells preferably are transferred to liquid nitrogen prior to thawing for use. In some embodiments, for example, once the ampoules have reached about ¨90 C, they are transferred to a liquid nitrogen storage area. Cryopreserved cells can be stored for a period of years.
The cryopreserved cells of the invention constitute a bank of cells, portions of which can be "withdrawn" by thawing and then used as needed. Thawing should generally be carried out rapidly, for example, by transferring an ampoule from liquid nitrogen to a 37 C water bath. The thawed contents of the ampoule should be immediately transferred under sterile conditions to a culture vessel containing an appropriate medium such as DMEM conditioned with 10 percent FBS.
In yet another aspect, the invention also provides for banking of tissues, cells, cellular components and cell populations of the invention. As discussed above, the cells are readily cryopreserved. The invention therefore provides methods of cryopreserving the cells in a bank, wherein the cells are stored frozen and associated with a complete characterization of the cells based on immunological, biochemical and genetic properties of the cells. The cells so frozen can be used for autologous, syngeneic, or allogeneic therapy, depending on the requirements of the procedure and the needs of the patient. Preferably, the information on each cryopreserved sample is stored in a computer, which is searchable based on the requirements of the surgeon, procedure and patient with suitable matches being made based on the characterization of the cells or populations. Preferably, the cells of the invention are grown and expanded to the desired quantity of cells and therapeutic cell compositions are prepared either separately or as co-cultures, in the presence or absence of a matrix or support. While for some applications it may be preferable to use cells freshly prepared, the remainder can be cryopreserved and banked by freezing the cells and entering the information in the computer to associate the computer entry with the samples. Even where it is not necessary to match a source or donor with a recipient of such cells, for immunological purposes, the bank system makes it easy to match, for example, desirable biochemical or genetic properties of the banked cells to the therapeutic needs. Upon
- 47 -matching of the desired properties with a banked sample, the sample is retrieved, and readied for therapeutic use. Cell lysates or components prepared as described herein may also be preserved (e.g., cryopreserved, lyophilized) and banked in accordance with the present invention.
The following examples describe several aspects of embodiments of the invention in greater detail. These examples are provided to further illustrate, not to limit, aspects of the invention described herein.
EXAMPLES
Derivation of Cells from Postpartum Placental Tissue Postpartum placentas were obtained upon birth of either a full term or pre-term pregnancy. Cells were harvested from five separate donors of placental tissue.
Different methods of cell isolation were tested for their ability to yield cells with:
1) the potential to differentiate into cells with different phenotypes, or 2) the potential to provide critical trophic factors useful for other cells and tissues.
Methods & Materials Isolation of cells from placenta. Placental tissue was obtained from National Disease Resarch Interchange (NDRI) (Philadelphia, PA). The tissues were obtained from a pregnancy at the time of a normal surgical delivery. Placental cells were isolated aseptically in a laminar flow hood. To remove blood and debris, the tissue was washed in phosphate buffered saline (PBS;
Invitrogen, Carlsbad, CA) in the presence of 100 Units/milliliter penicillin, micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin (Invitrogen Carlsbad, CA). The tissues were then mechanically dissociated in 150 cm2 tissue culture plates in the presence of 50 milliliters of medium (DM:BM-Low glucose or DMEM-High glucose;
Invitrogen), until the tissue was minced into a fine pulp. The chopped tissues were transferred to 50 milliliter conical tubes (approximately 5 grams of tissue per tube).
The tissue was then digested in either DMEM-Low glucose medium or DMEM-High glucose medium, each containing 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin and digeStion enzymes. In some TM
experiments an enzyme mixture of collagenase and dispase was used ("C:D;"
collagenase TM
(Sigma, St Louis, MO), 500 Units/milliliter; and dispase (Invitrogen), 50 Units/milliliter in
The following examples describe several aspects of embodiments of the invention in greater detail. These examples are provided to further illustrate, not to limit, aspects of the invention described herein.
EXAMPLES
Derivation of Cells from Postpartum Placental Tissue Postpartum placentas were obtained upon birth of either a full term or pre-term pregnancy. Cells were harvested from five separate donors of placental tissue.
Different methods of cell isolation were tested for their ability to yield cells with:
1) the potential to differentiate into cells with different phenotypes, or 2) the potential to provide critical trophic factors useful for other cells and tissues.
Methods & Materials Isolation of cells from placenta. Placental tissue was obtained from National Disease Resarch Interchange (NDRI) (Philadelphia, PA). The tissues were obtained from a pregnancy at the time of a normal surgical delivery. Placental cells were isolated aseptically in a laminar flow hood. To remove blood and debris, the tissue was washed in phosphate buffered saline (PBS;
Invitrogen, Carlsbad, CA) in the presence of 100 Units/milliliter penicillin, micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin (Invitrogen Carlsbad, CA). The tissues were then mechanically dissociated in 150 cm2 tissue culture plates in the presence of 50 milliliters of medium (DM:BM-Low glucose or DMEM-High glucose;
Invitrogen), until the tissue was minced into a fine pulp. The chopped tissues were transferred to 50 milliliter conical tubes (approximately 5 grams of tissue per tube).
The tissue was then digested in either DMEM-Low glucose medium or DMEM-High glucose medium, each containing 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin and digeStion enzymes. In some TM
experiments an enzyme mixture of collagenase and dispase was used ("C:D;"
collagenase TM
(Sigma, St Louis, MO), 500 Units/milliliter; and dispase (Invitrogen), 50 Units/milliliter in
-48-TM
DMEM-Low glucose medium). In other experiments a mixture of collagenase, dispase and TM
hyaluronidase ("C:D:H") was used (collagenase, 500 Units/milliliter; dispase, 50 Units/milliliter;
and hyaluronidase (Sigma), 5 Units/milliliter, in DMEM-Low glucose). The conical tubes containing the tissue, medium and digestion enzymes were incubated at 37 C in an orbital shaker (Environ, Brooklyn, NY) at 225 rpm for 2 hours.
After digestion, the tissues were centrifuged at 150 x g for 5 minutes, and the supernatant was aspirated. The pellet was resuspended in 20 milliliter of Growth medium (DMEM:Low glucose (Invitrogen), 15 percent (v/v) fetal bovine serum (PBS; defmed bovine serum;
Lot#AND18475; Hyclone, Logan, UT), 0.001% (v/v) 2-mercaptoethanol (Sigma), 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, 0.25 micrograms/milliliter amphotericin B; Invitrogen, Carlsbad, CA)). The cell suspension was filtered through a 70-micrometer nylon cell strainer pp Biosciences). An additional 5 milliliters rinse comprising Growth medium was passed through the strainer. The cell suspension was then passed through a 40-micrometer nylon cell strainer (ED Biosciences) and chased with a rinse of an additional 5 milliliters of Growth medium.
The filtrate was resuspended in Growth medium (total volume 50 milliliters) and centrifuged at 150 x g for 5 minutes. The supernatant was aspirated and the cells were resuspended in 50 milliliters of fresh growth medium. This process e., resuspension, centrifugation, and aspiration) was repeated twice more.
After the final centrifu.gation, supernatant was aspirated and the cell pellet was resuspended in 5 milliliters of fresh growth medium. The number of viable cells was determined using Trypan Blue staining. Cells were then cultured under standard conditions.
The cells isolated from placenta were seeded at 5,000 cells/cm2 onto gelatin-coated T-75cm2 flasks (Corning Inc., Corning, NY) in Growth medium (DMEM-Low glucose (Invitrogen), 15 percent (v/v) defined bovine serum (Hyclone, Logan, UT;
Lot#AND18475), 0.001 percent (v/v) 2-mercaptoethanol (Sigma), 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin (Invitrogen)).
After about 2-4 days, spent medium was aspirated from the flasks. Cells were washed with PBS
three times to remove debris and blood-derived cells. Cells were then replenished with Growth medium and allowed to grow to confluence (about 10 days from passage 0 to passage 1). On subsequent passages (from passage 1 to 2, etc.), cells reached sub-confluence (75-85 percent confluence) in 4-5 days. For these subsequent passages, cells were seeded at 5,000 cells/cm2.
Cells were grown in a humidified incubator with 5 percent carbon dioxide and 20 percent oxygen, at 37 C.
DMEM-Low glucose medium). In other experiments a mixture of collagenase, dispase and TM
hyaluronidase ("C:D:H") was used (collagenase, 500 Units/milliliter; dispase, 50 Units/milliliter;
and hyaluronidase (Sigma), 5 Units/milliliter, in DMEM-Low glucose). The conical tubes containing the tissue, medium and digestion enzymes were incubated at 37 C in an orbital shaker (Environ, Brooklyn, NY) at 225 rpm for 2 hours.
After digestion, the tissues were centrifuged at 150 x g for 5 minutes, and the supernatant was aspirated. The pellet was resuspended in 20 milliliter of Growth medium (DMEM:Low glucose (Invitrogen), 15 percent (v/v) fetal bovine serum (PBS; defmed bovine serum;
Lot#AND18475; Hyclone, Logan, UT), 0.001% (v/v) 2-mercaptoethanol (Sigma), 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, 0.25 micrograms/milliliter amphotericin B; Invitrogen, Carlsbad, CA)). The cell suspension was filtered through a 70-micrometer nylon cell strainer pp Biosciences). An additional 5 milliliters rinse comprising Growth medium was passed through the strainer. The cell suspension was then passed through a 40-micrometer nylon cell strainer (ED Biosciences) and chased with a rinse of an additional 5 milliliters of Growth medium.
The filtrate was resuspended in Growth medium (total volume 50 milliliters) and centrifuged at 150 x g for 5 minutes. The supernatant was aspirated and the cells were resuspended in 50 milliliters of fresh growth medium. This process e., resuspension, centrifugation, and aspiration) was repeated twice more.
After the final centrifu.gation, supernatant was aspirated and the cell pellet was resuspended in 5 milliliters of fresh growth medium. The number of viable cells was determined using Trypan Blue staining. Cells were then cultured under standard conditions.
The cells isolated from placenta were seeded at 5,000 cells/cm2 onto gelatin-coated T-75cm2 flasks (Corning Inc., Corning, NY) in Growth medium (DMEM-Low glucose (Invitrogen), 15 percent (v/v) defined bovine serum (Hyclone, Logan, UT;
Lot#AND18475), 0.001 percent (v/v) 2-mercaptoethanol (Sigma), 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin (Invitrogen)).
After about 2-4 days, spent medium was aspirated from the flasks. Cells were washed with PBS
three times to remove debris and blood-derived cells. Cells were then replenished with Growth medium and allowed to grow to confluence (about 10 days from passage 0 to passage 1). On subsequent passages (from passage 1 to 2, etc.), cells reached sub-confluence (75-85 percent confluence) in 4-5 days. For these subsequent passages, cells were seeded at 5,000 cells/cm2.
Cells were grown in a humidified incubator with 5 percent carbon dioxide and 20 percent oxygen, at 37 C.
- 49 -Isolation of populations of maternal-derived and neonatal-derived cells from placenta. The cell isolation protocol was performed aseptically in a laminar flow hood. The placental tissue was washed in phosphate buffered saline (PBS; Invitrogen, Carlsbad, CA) in the presence of antimycotic and antibiotic (100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 microgram/milliliter amphotericin B; Invitrogen) to remove blood and debris.
The placental tissue was then dissected into three sections: top-line (neonatal side or aspect), mid-line (mixed cell isolation neonatal and maternal, or villous region), and bottom line (maternal side or aspect).
" The separated sections were individually washed several times in PBS
with antibiotic/antimycotic to further remove blood and debris. Each section was then mechanically dissociated in 150 cm2 tissue culture plates in the presence of 50 milliliters of DMEM-Low glucose (Invitrogen) to a fine pulp. The pulp was transferred to 50 milliliter conical tubes. Each tube contained approximately 5 grams of tissue. The tissue was digested in either DMEM-Low glucose or DMEM-High glucose medium containing 100 Units/milliliter penicillin, 100 . micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin and digestion TM
enzymes. In some experiments an enzyme mixture of collagenase and dispase ("C:D") was used containing collagenase (Sigma, St Louis, MO) at 500 Units/milliliter and dispase (Invitrogen) at
The placental tissue was then dissected into three sections: top-line (neonatal side or aspect), mid-line (mixed cell isolation neonatal and maternal, or villous region), and bottom line (maternal side or aspect).
" The separated sections were individually washed several times in PBS
with antibiotic/antimycotic to further remove blood and debris. Each section was then mechanically dissociated in 150 cm2 tissue culture plates in the presence of 50 milliliters of DMEM-Low glucose (Invitrogen) to a fine pulp. The pulp was transferred to 50 milliliter conical tubes. Each tube contained approximately 5 grams of tissue. The tissue was digested in either DMEM-Low glucose or DMEM-High glucose medium containing 100 Units/milliliter penicillin, 100 . micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin and digestion TM
enzymes. In some experiments an enzyme mixture of collagenase and dispase ("C:D") was used containing collagenase (Sigma, St Louis, MO) at 500 Units/milliliter and dispase (Invitrogen) at
50 Units/milliliter in DMEM-Low glucose medium. In other experiments a mixture of TM
collagenase, dispase, and hyaluronidase ("C:D:H") was used (collagenase, 500 Units/milliliter;
dispasr, 50 Units/milliliter; and hyaluronidase (Sigma), 5 Units/milliliter in DMEM-Low glucose). The conical tubes containing the tissue, medium, and digestion enzymes were incubated for 2 hours at 37 C in an orbital shaker (Environ, Brooklyn, NY) at 225 rpm.
After digestion, the tissues were centrifuged at 150 x g for 5 minutes, and the resultant supernatant was aspirated off. The pellet was resuspended in 20 milliliters of Growth medium (DMEM-Low glucose (Invitrogen), 15% (v/v) fetal bovine serum (PBS; defined bovine serum;
Lot#AND18475; Hyclone, Logan, UT), 0.001% (v/v) 2-mercaptoethanol (Sigma, St.
Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 microgram/milliliter amphotericin B; Invitrogen)). The cell suspension was filtered through a 70 micrometer nylon bell strainer (BD Biosciences), chased by a rinse with an additional 5 milliliters of Growth medium. The total cell suspension was passed through a 40 micrometer nylon cell strainer (BD Biosciences) followed with an additional 5 milliliters of Growth medium as a rinse.
The filtrate was resuspended in Growth medium (total volume 50 milliliters) and centrifuged at 150 x g for 5 minutes. The supernatant was aspirated, and the cell pellet was resuspended in 50 milliliters of fresh Growth medium. This process (i.e., resuspension, centrifugation, and aspiration) was repeated twice more.
After the final centrifugation, supernatant was aspirated, and the cell pellet was resuspended in 5 milliliters of fresh Growth medium. A cell count was determined using the Trypan Blue Exclusion test. Cells were then cultured at standard conditions.
Isolation of PDCs using different growth conditions. Placenta-derived cells were digested in growth medium with or without 0.001% (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO), using the enzyme combination of C:D:11, according to the procedures provided above.
Placenta-derived cells so isolated were seeded under conditions set forth in Table 1-1 and grown in the presence of penicillin/streptomycin. Cells were passaged up to four times after seeding and cryopreserved. The cryopreserved cells were banked.
Table 1-1. Isolation and culture expansion of placental cells under varying conditions:
Condition Medium FBS BME Gelatin 02 Growth Factors 1 DMEM-Lg 15% Y Y 20% N
2 DMEM-Lg 15% Y Y 5% N
3 DMEM-Lg 15% Y N 20% N
4 DMEM-Lg 15% Y N 5% N
- 5 DMEM-Lg 2% Y N (Laminin) 20% EGF/FGF (20 ng/ml) 6 DMEM-Lg 2% Y N (Laminin) 5% EGF/FGF (20 ng/ml) 7 DMEM-Lg 2% Y N 20% PDGF/VEGF
(Fibronectin) 8 DMEM-Lg 2% Y N 5% PDGF/VEGF
(Fibronectin) _ 9 DMEM-Lg 15% N Y 20% N
DMEM-Lg 15% N Y 5% N
11 DMEM-Lg 15% N N 20% N
12 DMEM-Lg 15% N N 5% N
13 DMEM-Lg 2% N N (Laminin) 20% EGF/FGF (20 ng/ml) 14 DMEM-Lg 2% N N (Laminin) 5% EGF/FGF (20 ng/ml) DMEM-Lg 2% N N 20% PDGF/VEGF
(Fibronectin) 16 DMEM-Lg 2% N N 5% PDGF/VEGF
(Fibronectin)
collagenase, dispase, and hyaluronidase ("C:D:H") was used (collagenase, 500 Units/milliliter;
dispasr, 50 Units/milliliter; and hyaluronidase (Sigma), 5 Units/milliliter in DMEM-Low glucose). The conical tubes containing the tissue, medium, and digestion enzymes were incubated for 2 hours at 37 C in an orbital shaker (Environ, Brooklyn, NY) at 225 rpm.
After digestion, the tissues were centrifuged at 150 x g for 5 minutes, and the resultant supernatant was aspirated off. The pellet was resuspended in 20 milliliters of Growth medium (DMEM-Low glucose (Invitrogen), 15% (v/v) fetal bovine serum (PBS; defined bovine serum;
Lot#AND18475; Hyclone, Logan, UT), 0.001% (v/v) 2-mercaptoethanol (Sigma, St.
Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 microgram/milliliter amphotericin B; Invitrogen)). The cell suspension was filtered through a 70 micrometer nylon bell strainer (BD Biosciences), chased by a rinse with an additional 5 milliliters of Growth medium. The total cell suspension was passed through a 40 micrometer nylon cell strainer (BD Biosciences) followed with an additional 5 milliliters of Growth medium as a rinse.
The filtrate was resuspended in Growth medium (total volume 50 milliliters) and centrifuged at 150 x g for 5 minutes. The supernatant was aspirated, and the cell pellet was resuspended in 50 milliliters of fresh Growth medium. This process (i.e., resuspension, centrifugation, and aspiration) was repeated twice more.
After the final centrifugation, supernatant was aspirated, and the cell pellet was resuspended in 5 milliliters of fresh Growth medium. A cell count was determined using the Trypan Blue Exclusion test. Cells were then cultured at standard conditions.
Isolation of PDCs using different growth conditions. Placenta-derived cells were digested in growth medium with or without 0.001% (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO), using the enzyme combination of C:D:11, according to the procedures provided above.
Placenta-derived cells so isolated were seeded under conditions set forth in Table 1-1 and grown in the presence of penicillin/streptomycin. Cells were passaged up to four times after seeding and cryopreserved. The cryopreserved cells were banked.
Table 1-1. Isolation and culture expansion of placental cells under varying conditions:
Condition Medium FBS BME Gelatin 02 Growth Factors 1 DMEM-Lg 15% Y Y 20% N
2 DMEM-Lg 15% Y Y 5% N
3 DMEM-Lg 15% Y N 20% N
4 DMEM-Lg 15% Y N 5% N
- 5 DMEM-Lg 2% Y N (Laminin) 20% EGF/FGF (20 ng/ml) 6 DMEM-Lg 2% Y N (Laminin) 5% EGF/FGF (20 ng/ml) 7 DMEM-Lg 2% Y N 20% PDGF/VEGF
(Fibronectin) 8 DMEM-Lg 2% Y N 5% PDGF/VEGF
(Fibronectin) _ 9 DMEM-Lg 15% N Y 20% N
DMEM-Lg 15% N Y 5% N
11 DMEM-Lg 15% N N 20% N
12 DMEM-Lg 15% N N 5% N
13 DMEM-Lg 2% N N (Laminin) 20% EGF/FGF (20 ng/ml) 14 DMEM-Lg 2% N N (Laminin) 5% EGF/FGF (20 ng/ml) DMEM-Lg 2% N N 20% PDGF/VEGF
(Fibronectin) 16 DMEM-Lg 2% N N 5% PDGF/VEGF
(Fibronectin)
-51 -Key: Lg: Low glucose; N: none; Y: yes; BME: beta-mercaptoethanol; FGF:
fibroblast growth factor; EGF: epidermal growth factor; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor.
Results Isolation of PDCs using different growth conditions. In all conditions set forth in Table 1-1, cells attached and expanded well between passage 0 and 1. Cells in condition 5 to 8 and 13 to16 were demonstrated to proliferate well up to at least four passages after seeding.
Isolation of cells from placenta using different enzyme combinations. Tissue TM TM
digestion with collagenase:dispase and collagenase:dispase:hyaluronidase resulted in the isolation of cell populations from placental tissues that expanded readily.
Summary. PDCs can be isolated using a combination of a matrix metalloprotease and TM
neutral protease, such as but not limited to a combination of collagenase and dispase. PDCs are preferably isolated using an enzyme combination of a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that degrades hyaluronic acid, such as but not limited to a combination TM
of collagenase, dispase, and hyaluronidase or a combination of LIBERASE
(Boehringer Mannheim Corp., Indianapolis, IN) and hyaluronidase. Blendzyme 3, which is collagenase (4 Wunsch units/g) and themiolysin (1714 casein Units/g) may be used together with hyaluronidase to isolate cells.
Evaluation of Growth Media for Placenta-Derived Cells Several cell culture media were evaluated for their ability to support the growth of placenta-derived cells. The growth of placenta-derived cells in normal (20%) and low (5%) oxygen was assessed after 3 days using the MTS colorimetric assay.
Methods & Materials Placenta-derived cells at passage 8 (P8) were seeded at 1 x 103 cells/well in 96 well plates in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco). After 8 hours the medium was changed to that described in Table 2-1 and cells were incubated in normal (20%, v/v) or low (5%, v/v) oxygen at 37 C, 5% CO? for 48 hours. MTS was added to the culture medium (CELLTITER96 AQueous One Solution Cell Proliferation Assay, Promega, Madison, WI) for 3 hours and the absorbance measured at 490 nanometer (Molecular Devices, Sunnyvale CA).
fibroblast growth factor; EGF: epidermal growth factor; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor.
Results Isolation of PDCs using different growth conditions. In all conditions set forth in Table 1-1, cells attached and expanded well between passage 0 and 1. Cells in condition 5 to 8 and 13 to16 were demonstrated to proliferate well up to at least four passages after seeding.
Isolation of cells from placenta using different enzyme combinations. Tissue TM TM
digestion with collagenase:dispase and collagenase:dispase:hyaluronidase resulted in the isolation of cell populations from placental tissues that expanded readily.
Summary. PDCs can be isolated using a combination of a matrix metalloprotease and TM
neutral protease, such as but not limited to a combination of collagenase and dispase. PDCs are preferably isolated using an enzyme combination of a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that degrades hyaluronic acid, such as but not limited to a combination TM
of collagenase, dispase, and hyaluronidase or a combination of LIBERASE
(Boehringer Mannheim Corp., Indianapolis, IN) and hyaluronidase. Blendzyme 3, which is collagenase (4 Wunsch units/g) and themiolysin (1714 casein Units/g) may be used together with hyaluronidase to isolate cells.
Evaluation of Growth Media for Placenta-Derived Cells Several cell culture media were evaluated for their ability to support the growth of placenta-derived cells. The growth of placenta-derived cells in normal (20%) and low (5%) oxygen was assessed after 3 days using the MTS colorimetric assay.
Methods & Materials Placenta-derived cells at passage 8 (P8) were seeded at 1 x 103 cells/well in 96 well plates in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco). After 8 hours the medium was changed to that described in Table 2-1 and cells were incubated in normal (20%, v/v) or low (5%, v/v) oxygen at 37 C, 5% CO? for 48 hours. MTS was added to the culture medium (CELLTITER96 AQueous One Solution Cell Proliferation Assay, Promega, Madison, WI) for 3 hours and the absorbance measured at 490 nanometer (Molecular Devices, Sunnyvale CA).
- 52 -Table 2-1. Culture media evaluated Culture Medium Supplier Added fetal bovine serum % (v/v) DMEM-low glucose Gibco Carlsbad CA 0, 2, or 10 DMEM-high glucose Gibco Carlsbad CA 0, 2, or 10 RPMI 1640 Mediatech, Inc. 0, 2, or 10 Herndon, VA
Cell gro-free Mediatech, Inc.
(Serum-free, Protein-free) Herndon, VA
Ham's F10 Mediatech, Inc. 0, 2, or 10 Herndon, VA
MSCGM (complete with Cambrex, Walkersville, MD 0, 2, or 10 serum) Complete-serum free Mediatech, Inc.
w/albumin Herndon, VA
Growth medium NA
Ham's F12 Mediatech, Inc. 0, 2, or 10 Herndon, VA
Iscove's Mediatech, Inc. 0, 2, or 10 Herndon, VA
Basal Medium Eagle's Mediatech, Inc. 0,2, or 10 Herndon, VA
DMEM/F12 (1:1) Mediatech, Inc. 0, 2, or 10 Herndon, VA
MSCGM: Mesenchymal Stem Cell Growth Medium Results Standard curves for the MTS assay established a linear correlation between an increase in absorbance and an increase in cell number. The absorbance values obtained were converted into estimated cell numbers and the change (%) relative to the initial seeding was calculated.
The addition of serum to media at normal oxygen conditions resulted in a reproducible dose-dependent increase in absorbance and thus the viable cell number (extrapolated). The addition of serum to complete MSCGM resulted in a dose-dependent decrease in absorbance. In the media without added serum, cells only grew in Cellgro, Ham's F10, and DMEM.
Cell gro-free Mediatech, Inc.
(Serum-free, Protein-free) Herndon, VA
Ham's F10 Mediatech, Inc. 0, 2, or 10 Herndon, VA
MSCGM (complete with Cambrex, Walkersville, MD 0, 2, or 10 serum) Complete-serum free Mediatech, Inc.
w/albumin Herndon, VA
Growth medium NA
Ham's F12 Mediatech, Inc. 0, 2, or 10 Herndon, VA
Iscove's Mediatech, Inc. 0, 2, or 10 Herndon, VA
Basal Medium Eagle's Mediatech, Inc. 0,2, or 10 Herndon, VA
DMEM/F12 (1:1) Mediatech, Inc. 0, 2, or 10 Herndon, VA
MSCGM: Mesenchymal Stem Cell Growth Medium Results Standard curves for the MTS assay established a linear correlation between an increase in absorbance and an increase in cell number. The absorbance values obtained were converted into estimated cell numbers and the change (%) relative to the initial seeding was calculated.
The addition of serum to media at normal oxygen conditions resulted in a reproducible dose-dependent increase in absorbance and thus the viable cell number (extrapolated). The addition of serum to complete MSCGM resulted in a dose-dependent decrease in absorbance. In the media without added serum, cells only grew in Cellgro, Ham's F10, and DMEM.
- 53 -Reduced oxygen increased the growth rate of cells in Growth medium, Ham's F10, and, MSCGM.
In decreasing order of growth, the media resulting in the best growth of the PDCs were Growth medium > MSCGM > Iscove's+10% FBS =DMEM-High glucose +10% FBS = Ham's F12 + 10% FBS = RPMI 1640 +10% FBS.
Summary. Placenta-derived cells may be grown in a variety of culture media in normal or low oxygen. PDCs grew in serum-free conditions, for example, in Ham's F10, Cellgro-free, and DMEM. PDCs also grew in protein-free conditions, for example, in Ham's F10 and Cellgro-free. Reduced oxygen increased the growth rate of cells in Growth medium, Ham's F10, and, MSCGM.
Reference U.S. Application Publication No. 20040005704 Growth of Postpartum Cells in Medium Containing D-Valine It has been reported that medium containing D-valine instead of the normal L-valine isoform can be used to selectively inhibit the growth of fibroblast-like cells in culture (Hongpaisan (2000) Cell Biol Int. 24:1-7; Sordillo et al. (1988) Cell Biol Int Rep .12:355-64).
Experiments were performed to determine whether placenta-derived cells could grow in medium containing D-valine.
Methods & Materials Placenta-derived cells (P3) and fibroblasts (P9) were seeded at 5 x 103 cells/cm2 in gelatin-coated T75 flasks (Corning, Corning, NY). After 24 hours the medium was removed and the cells were washed with phosphate buffered saline (PBS) (Gibco, Carlsbad, CA) to remove residual medium. The medium was replaced with a Modified Growth medium (DMEM
with D-valine (special order, Gibco), 15% (v/v) dialyzed fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma), 50 Units/milliliter penicillin, 50 micrograms/milliliter streptomycin (Gibco)).
Results Placenta-derived and fibroblast cells seeded in the D-valine-containing medium did not proliferate, unlike cells seeded in growth medium containing dialyzed serum.
Fibroblast cells
In decreasing order of growth, the media resulting in the best growth of the PDCs were Growth medium > MSCGM > Iscove's+10% FBS =DMEM-High glucose +10% FBS = Ham's F12 + 10% FBS = RPMI 1640 +10% FBS.
Summary. Placenta-derived cells may be grown in a variety of culture media in normal or low oxygen. PDCs grew in serum-free conditions, for example, in Ham's F10, Cellgro-free, and DMEM. PDCs also grew in protein-free conditions, for example, in Ham's F10 and Cellgro-free. Reduced oxygen increased the growth rate of cells in Growth medium, Ham's F10, and, MSCGM.
Reference U.S. Application Publication No. 20040005704 Growth of Postpartum Cells in Medium Containing D-Valine It has been reported that medium containing D-valine instead of the normal L-valine isoform can be used to selectively inhibit the growth of fibroblast-like cells in culture (Hongpaisan (2000) Cell Biol Int. 24:1-7; Sordillo et al. (1988) Cell Biol Int Rep .12:355-64).
Experiments were performed to determine whether placenta-derived cells could grow in medium containing D-valine.
Methods & Materials Placenta-derived cells (P3) and fibroblasts (P9) were seeded at 5 x 103 cells/cm2 in gelatin-coated T75 flasks (Corning, Corning, NY). After 24 hours the medium was removed and the cells were washed with phosphate buffered saline (PBS) (Gibco, Carlsbad, CA) to remove residual medium. The medium was replaced with a Modified Growth medium (DMEM
with D-valine (special order, Gibco), 15% (v/v) dialyzed fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma), 50 Units/milliliter penicillin, 50 micrograms/milliliter streptomycin (Gibco)).
Results Placenta-derived and fibroblast cells seeded in the D-valine-containing medium did not proliferate, unlike cells seeded in growth medium containing dialyzed serum.
Fibroblast cells
- 54 -changed morphologically, increasing in size and changing shape. All of the cells died and eventually detached from the flask surface after 4 weeks.
Summary. PDCs require L-valine for cell growth and to maintain long-term viability.
Cryopreservation Media for Placenta-Derived Cells The objective of this study was to determine a suitable cryopreservation medium for the cryopreservation of placenta-derived cells.
Methods & Materials Placenta-derived cells grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03, Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)), in a gelatin-coated T75 flask were washed with phosphate buffered saline (PBS; Gibco) and trypsinized using 1 milliliter Trypsin/EDTA
(Gibco). The trypsinization was stopped by adding 10 milliliters Growth medium. The cells were centrifuged at 150 x g, supernatant removed, and the cell pellet was resuspended in 1 milliliter Growth medium. An aliquot of cell suspension, 60 microliter, was removed and added to 60 microliter trypan blue (Sigma). The viable cell number was estimated using a hemocytometer.
The cell suspension was divided into four equal aliquots each containing 88 x 104 cells each. The cell suspension was centrifuged and resuspended in 1 milliliter of each media below and transferred into Cryovials (Nalgene).
1.) Growth medium +10% (v/v) DMSO (Hybrimax, Sigma, St. Louis, MO) 2.) Cell Freezing medium w/DMSO, w/methylcellulose, serum-free (C6295, Sigma, St. Louis, MO) 3.) Cell Freezing medium serum-free (C2639, Sigma, St. Louis, MO) 4.) Cell Freezing Medium w/glycerol (C6039, Sigma, St. Louis, MO) The cells were cooled at approximately 1 C/min overnight in a -80 C freezer using a "Mr Frosty" freezing container according to the manufacturer's instructions (Nalgene, Rochester, NY). Vials of cells were transferred into liquid nitrogen for 2 days before thawing rapidly in a 37 C water bath. The cells were added to 10 milliliters Growth medium and centrifuged before
Summary. PDCs require L-valine for cell growth and to maintain long-term viability.
Cryopreservation Media for Placenta-Derived Cells The objective of this study was to determine a suitable cryopreservation medium for the cryopreservation of placenta-derived cells.
Methods & Materials Placenta-derived cells grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03, Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)), in a gelatin-coated T75 flask were washed with phosphate buffered saline (PBS; Gibco) and trypsinized using 1 milliliter Trypsin/EDTA
(Gibco). The trypsinization was stopped by adding 10 milliliters Growth medium. The cells were centrifuged at 150 x g, supernatant removed, and the cell pellet was resuspended in 1 milliliter Growth medium. An aliquot of cell suspension, 60 microliter, was removed and added to 60 microliter trypan blue (Sigma). The viable cell number was estimated using a hemocytometer.
The cell suspension was divided into four equal aliquots each containing 88 x 104 cells each. The cell suspension was centrifuged and resuspended in 1 milliliter of each media below and transferred into Cryovials (Nalgene).
1.) Growth medium +10% (v/v) DMSO (Hybrimax, Sigma, St. Louis, MO) 2.) Cell Freezing medium w/DMSO, w/methylcellulose, serum-free (C6295, Sigma, St. Louis, MO) 3.) Cell Freezing medium serum-free (C2639, Sigma, St. Louis, MO) 4.) Cell Freezing Medium w/glycerol (C6039, Sigma, St. Louis, MO) The cells were cooled at approximately 1 C/min overnight in a -80 C freezer using a "Mr Frosty" freezing container according to the manufacturer's instructions (Nalgene, Rochester, NY). Vials of cells were transferred into liquid nitrogen for 2 days before thawing rapidly in a 37 C water bath. The cells were added to 10 milliliters Growth medium and centrifuged before
- 55 -the cell number and viability was estimated as before. Cells were seeded onto gelatin-coated flasks at 5,000 cells/cm2 to determine whether the cells would attach and proliferate.
Results The initial viability of the cells to be cryopreserved was assessed by trypan blue staining to be 100%.
There was a commensurate reduction in cell number with viability for C6295 due to cell lysis. The viable cells cryopreserved in all four solutions attached, divided, and produced a confluent monolayer within 3 days. There was no discernable difference in estimated growth rate.
Summary. The cryopreservation of cells is one procedure available for preparation of a cell bank or a cell product. Four cryopreservation mixtures were compared for their ability to protect human placenta-derived cells from freezing damage. Dulbecco's modified Eagle's medium (DMEM) and 10% (v/v) dimethylsulfoxide (DMSO) is a preferred medium of those compared for cryopreservation of placenta-derived cells.
Growth Characteristics of Placenta-Derived Cells The cell expansion potential of placenta-derived cells was compared to other populations of isolated stem cells. The process of cell expansion to senescence is referred to as Hayflick's limit (Hayflick (1974)J. Am. Geriatr. Soc. 22:1-12; Hayflick (1974) Gerontologist 14:37-45).
Materials and Methods Gelatin-coating flasks. Tissue culture plastic flasks were coated by adding 20 milliliters 2% (w/v) porcine gelatin (Type B: 225 Bloom; Sigma, St Louis, MO) to a T75 flask (Corning, Corning, NY) for 20 minutes at room temperature. After removing the gelatin solution, 10 milliliters phosphate-buffered saline (PBS) (Invitrogen, Carlsbad, CA) were added and then aspirated.
Comparison of expansion potential of placenta-derived cells with other cell populations. For comparison of growth expansion potential, the following cell populations were utilized: i) Mesenchymal stem cells (MSC; Cambrex, Walkersville, MD); ii) Adipose-derived cells (U.S. Patent No. 6,555,374 Bl; U.S. Patent Application US20040058412);
iii) Normal dermal skin fibroblasts (cc-2509 lot # 9F0844; Cambrex, Walkersville, MD); and iv) Placenta-derived cells. Cells were initially seeded at 5,000 cells/cm2 on gelatin-coated T75 flasks in
Results The initial viability of the cells to be cryopreserved was assessed by trypan blue staining to be 100%.
There was a commensurate reduction in cell number with viability for C6295 due to cell lysis. The viable cells cryopreserved in all four solutions attached, divided, and produced a confluent monolayer within 3 days. There was no discernable difference in estimated growth rate.
Summary. The cryopreservation of cells is one procedure available for preparation of a cell bank or a cell product. Four cryopreservation mixtures were compared for their ability to protect human placenta-derived cells from freezing damage. Dulbecco's modified Eagle's medium (DMEM) and 10% (v/v) dimethylsulfoxide (DMSO) is a preferred medium of those compared for cryopreservation of placenta-derived cells.
Growth Characteristics of Placenta-Derived Cells The cell expansion potential of placenta-derived cells was compared to other populations of isolated stem cells. The process of cell expansion to senescence is referred to as Hayflick's limit (Hayflick (1974)J. Am. Geriatr. Soc. 22:1-12; Hayflick (1974) Gerontologist 14:37-45).
Materials and Methods Gelatin-coating flasks. Tissue culture plastic flasks were coated by adding 20 milliliters 2% (w/v) porcine gelatin (Type B: 225 Bloom; Sigma, St Louis, MO) to a T75 flask (Corning, Corning, NY) for 20 minutes at room temperature. After removing the gelatin solution, 10 milliliters phosphate-buffered saline (PBS) (Invitrogen, Carlsbad, CA) were added and then aspirated.
Comparison of expansion potential of placenta-derived cells with other cell populations. For comparison of growth expansion potential, the following cell populations were utilized: i) Mesenchymal stem cells (MSC; Cambrex, Walkersville, MD); ii) Adipose-derived cells (U.S. Patent No. 6,555,374 Bl; U.S. Patent Application US20040058412);
iii) Normal dermal skin fibroblasts (cc-2509 lot # 9F0844; Cambrex, Walkersville, MD); and iv) Placenta-derived cells. Cells were initially seeded at 5,000 cells/cm2 on gelatin-coated T75 flasks in
- 56 Growth medium (DMEM-Low glucose (Invitrogen, Carlsbad, CA), 15 % (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001 % (v/v) 2-mercaptoethanol (Sigma, St.
Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms/ milliliter amphotericin B; Invitrogen, Carlsbad, CA)). For subsequent passages, cell cultures were treated as follows. After trypsinization, viable cells were counted after Trypan Blue staining (e.g., cell suspension (50 microliters) was combined with Trypan Blue (50 microliters, Sigma, St. Louis MO); viable cell numbers were estimated using a hemocytometer).
Following counting, cells were seeded at 5,000 cells/cm2 onto gelatin-coated T
75 flasks in 25 milliliters of fresh growth medium. Cells were grown under standard atmosphere with 5 %
carbon dioxide at 37 C. The growth medium was changed twice per week. When cells reached about 85 percent confluence, they were passaged. This process was repeated until the cells reached senescence.
At each passage, cells were trypsinized and counted. The viable cell yield, population doubling [ln (cell final/cell initial)/hi 2], and doubling time (time in culture (h)/population doubling) were calculated. For the purposes of determining optimal cell expansion, the total cell yield per passage was determined by multiplying the total yield for the previous passage by the expansion factor for each passage (i.e., expansion factor = cell final/cell initial).
Expansion potential of cell banks at low density. The expansion potential of cells banked at passage 10 was tested. Normal dermal skin fibroblasts (cc-2509 lot #
9F0844;
Cambrex, Walkersville, MD) and placenta-derived cells were tested. These cell populations had been banked at passage 10 previously, having been seeded at 5,000 cell/cm2 and grown to confluence at each passage to that point. The effect of cell density on the cell populations following cell thaw at passage 10 was determined. Cells were thawed under standard conditions and counted using Trypan Blue staining. Thawed cells were then seeded at 1,000 cells/cm2 in Growth medium (DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15% (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001% 2-mercaptoethanol ( Sigma, St. Louis, MO), 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin (Invitrogen, Carlsbad, CA)). Cells were grown under standard atmospheric conditions at 37 C. Growth medium was changed twice a week and cells were passaged as they reached about 85% confluence. Cells were subsequently passaged until senescence. Cells were trypsinized and counted at each passage. The cell yield, population doubling (In (cell final/cell initial)/1n2), and doubling time (time in culture (h)/population doubling) were calculated for each passage. The total cell yield per passage was determined by
Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms/ milliliter amphotericin B; Invitrogen, Carlsbad, CA)). For subsequent passages, cell cultures were treated as follows. After trypsinization, viable cells were counted after Trypan Blue staining (e.g., cell suspension (50 microliters) was combined with Trypan Blue (50 microliters, Sigma, St. Louis MO); viable cell numbers were estimated using a hemocytometer).
Following counting, cells were seeded at 5,000 cells/cm2 onto gelatin-coated T
75 flasks in 25 milliliters of fresh growth medium. Cells were grown under standard atmosphere with 5 %
carbon dioxide at 37 C. The growth medium was changed twice per week. When cells reached about 85 percent confluence, they were passaged. This process was repeated until the cells reached senescence.
At each passage, cells were trypsinized and counted. The viable cell yield, population doubling [ln (cell final/cell initial)/hi 2], and doubling time (time in culture (h)/population doubling) were calculated. For the purposes of determining optimal cell expansion, the total cell yield per passage was determined by multiplying the total yield for the previous passage by the expansion factor for each passage (i.e., expansion factor = cell final/cell initial).
Expansion potential of cell banks at low density. The expansion potential of cells banked at passage 10 was tested. Normal dermal skin fibroblasts (cc-2509 lot #
9F0844;
Cambrex, Walkersville, MD) and placenta-derived cells were tested. These cell populations had been banked at passage 10 previously, having been seeded at 5,000 cell/cm2 and grown to confluence at each passage to that point. The effect of cell density on the cell populations following cell thaw at passage 10 was determined. Cells were thawed under standard conditions and counted using Trypan Blue staining. Thawed cells were then seeded at 1,000 cells/cm2 in Growth medium (DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15% (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001% 2-mercaptoethanol ( Sigma, St. Louis, MO), 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin (Invitrogen, Carlsbad, CA)). Cells were grown under standard atmospheric conditions at 37 C. Growth medium was changed twice a week and cells were passaged as they reached about 85% confluence. Cells were subsequently passaged until senescence. Cells were trypsinized and counted at each passage. The cell yield, population doubling (In (cell final/cell initial)/1n2), and doubling time (time in culture (h)/population doubling) were calculated for each passage. The total cell yield per passage was determined by
- 57 -multiplying total yield for the previous passage by the expansion factor for each passage (i.e., expansion factor = cell final/cell initial).
Expansion of placenta-derived cells at low density from initial cell seeding.
The expansion potential of freshly isolated placenta-derived cell cultures under low cell seeding conditions was tested in another experiment. Placenta-derived cells were isolated as described in Example 1. Cells were seeded at 1,000 cells/cm2 and passaged as described above until senescence. Cells were grown under standard atmospheric conditions at 37 C.
Growth medium was changed twice per week. Cells were passaged as they reached about 85%
confluence. At each passage, cells were trypsinized and counted by Trypan Blue staining. The cell yield, population doubling (in (cell final/cell initial)/In 2) and doubling time (time in culture (h)/population doubling) were calculated for each passage. The total cell yield per passage was determined by multiplying the total yield for the previous passage by the expansion factor for each passage (i.e., expansion factor = cell final/cell initial). Cells were grown on gelatin and non-gelatin coated flasks.
Expansion of Clonal Neonatal or Maternal Placenta-derived Cells. Cloning may be used in order to expand a population of neonatal or maternal cells successfully from placental tissue. Following isolation of three different cell populations from the placenta (neonatal aspect, maternal aspect, and villous region), these cell populations are expanded under standard growth conditions and then karyotyped to reveal the identity of the isolated cell populations. By isolating the cells from a mother who delivers a boy, it is possible to distinguish between the male and female chromosomes by performing metaphase spreads. These experiments can be used to demonstrate that top-line cells are karyotype positive for neonatal phenotype, mid-line cells are karyotype positive for both neonatal and maternal phenotypes, and bottom-line cells are karyotype positive for maternal cells.
Other growth conditions. In other experiments cells were expanded on either non-coated, collagen-coated, fibronectin-coated, laminin-coated, or extracellular membrane protein (e.g., MATRIGEL (BD Discovery Labware, Bedford, MA))-coated plates. Cultures have been demonstrated to expand well on these different matrices.
Results Comparison of expansion potential of placenta-derived cells with other cell populations. Placenta-derived cells expanded for greater than 40 passages, generating cell yields of >1x1017 cells in 60 days. In contrast, MSCs and fibroblasts senesced after < 25 days and < 60 days, respectively. Although both adipose-derived and omental cells expanded for
Expansion of placenta-derived cells at low density from initial cell seeding.
The expansion potential of freshly isolated placenta-derived cell cultures under low cell seeding conditions was tested in another experiment. Placenta-derived cells were isolated as described in Example 1. Cells were seeded at 1,000 cells/cm2 and passaged as described above until senescence. Cells were grown under standard atmospheric conditions at 37 C.
Growth medium was changed twice per week. Cells were passaged as they reached about 85%
confluence. At each passage, cells were trypsinized and counted by Trypan Blue staining. The cell yield, population doubling (in (cell final/cell initial)/In 2) and doubling time (time in culture (h)/population doubling) were calculated for each passage. The total cell yield per passage was determined by multiplying the total yield for the previous passage by the expansion factor for each passage (i.e., expansion factor = cell final/cell initial). Cells were grown on gelatin and non-gelatin coated flasks.
Expansion of Clonal Neonatal or Maternal Placenta-derived Cells. Cloning may be used in order to expand a population of neonatal or maternal cells successfully from placental tissue. Following isolation of three different cell populations from the placenta (neonatal aspect, maternal aspect, and villous region), these cell populations are expanded under standard growth conditions and then karyotyped to reveal the identity of the isolated cell populations. By isolating the cells from a mother who delivers a boy, it is possible to distinguish between the male and female chromosomes by performing metaphase spreads. These experiments can be used to demonstrate that top-line cells are karyotype positive for neonatal phenotype, mid-line cells are karyotype positive for both neonatal and maternal phenotypes, and bottom-line cells are karyotype positive for maternal cells.
Other growth conditions. In other experiments cells were expanded on either non-coated, collagen-coated, fibronectin-coated, laminin-coated, or extracellular membrane protein (e.g., MATRIGEL (BD Discovery Labware, Bedford, MA))-coated plates. Cultures have been demonstrated to expand well on these different matrices.
Results Comparison of expansion potential of placenta-derived cells with other cell populations. Placenta-derived cells expanded for greater than 40 passages, generating cell yields of >1x1017 cells in 60 days. In contrast, MSCs and fibroblasts senesced after < 25 days and < 60 days, respectively. Although both adipose-derived and omental cells expanded for
- 58 -almost 60 days, they generated total cell yields of 4.5x1012 and 4.24x1013, respectively. Thus, when seeded at 5,000 cells/cm2 under the experimental conditions utilized, PDCs expanded much better than the other cell types grown under the same conditions (Table 5-1).
Table 5-1. Growth characteristics for different cell populations grown to senescence Cell Type Senescence Total Population Total Cell Doublings Yield MSC 24 day 8 4.72x107 Adipose- 57 day 24 4.5x1012 derived cells (Artecel, U.S.
Patent No.
6,555,374) Fibroblasts 53 day 26 2.82x1013 Placenta 80 day 46 2.49x1019 Expansion of potential of cell banks at low density. Placenta-derived and fibroblast cells expanded for greater than 10 passages generating cell yields of > lx1011 cells in 60 days (Table 5-2). After 60 days under these conditions, the placenta-derived cells became senescent whereas the fibroblast cell populations senesced after 80 days, completing >
40 population doublings.
Table 5-2. Growth characteristics for different cell populations using low density growth expansion from passage 10 through senescence Cell Type Senescence Total Population Total Cell (Passage No.) Doublings Yield Fibroblast (P10) 80 day 43.68 2.59x1011 Placental (P10) 60 day 32.96 6.09x1012 Expansion of placenta-derived cells at low density from initial cell seeding.
Placenta-derived cells were expanded at low density (1,000 cells/cm2) on gelatin-coated and uncoated plates or flasks. Growth potential of these cells under these conditions was good. The cells expanded readily in a log phase growth. The rate of cell expansion was similar to that observed when placenta-derived cells were seeded at 5,000 cells/cm2 on gelatin-coated flasks in growth
Table 5-1. Growth characteristics for different cell populations grown to senescence Cell Type Senescence Total Population Total Cell Doublings Yield MSC 24 day 8 4.72x107 Adipose- 57 day 24 4.5x1012 derived cells (Artecel, U.S.
Patent No.
6,555,374) Fibroblasts 53 day 26 2.82x1013 Placenta 80 day 46 2.49x1019 Expansion of potential of cell banks at low density. Placenta-derived and fibroblast cells expanded for greater than 10 passages generating cell yields of > lx1011 cells in 60 days (Table 5-2). After 60 days under these conditions, the placenta-derived cells became senescent whereas the fibroblast cell populations senesced after 80 days, completing >
40 population doublings.
Table 5-2. Growth characteristics for different cell populations using low density growth expansion from passage 10 through senescence Cell Type Senescence Total Population Total Cell (Passage No.) Doublings Yield Fibroblast (P10) 80 day 43.68 2.59x1011 Placental (P10) 60 day 32.96 6.09x1012 Expansion of placenta-derived cells at low density from initial cell seeding.
Placenta-derived cells were expanded at low density (1,000 cells/cm2) on gelatin-coated and uncoated plates or flasks. Growth potential of these cells under these conditions was good. The cells expanded readily in a log phase growth. The rate of cell expansion was similar to that observed when placenta-derived cells were seeded at 5,000 cells/cm2 on gelatin-coated flasks in growth
-59-medium. No differences were observed in cell expansion potential between culturing on either uncoated flasks or gelatin-coated flasks. Cells grown in gelatin-coated flasks appeared phenotypically smaller than cells grown in uncoated flasks.
Expansion of Clonal Neonatal or Maternal Placenta-Derived Cells. A clonal neonatal or maternal cell population can be expanded from placenta-derived cells isolated from the neonatal aspect or the maternal aspect, respectively, of the placenta. Cells are serially diluted and then seeded onto gelatin-coated plates in Growth medium for expansion at 1 cell/well in 96-well gelatin coated plates. From this initial cloning, expansive clones are identified, trypsinized, and reseeded in 12-well gelatin-coated plates in Growth medium and then subsequently passaged into T25 gelatin-coated flasks at 5,000 cells/cm2 in Growth medium. Subcloning is performed to ensure that a clonal population of cells has been identified. For subcloning experiments, cells are trypsinized and reseeded at 0.5 cells/well. The subclones that grow well are expanded in gelatin-coated T25 flasks at 5,000 cells cm2 /flask. Cells are passaged at 5,000 cells cm2 /T75 flask.
The growth characteristics of the best clone are plotted, to demonstrate cell expansion.
Karyotyping analysis can confirm that the clone is either neonatal or maternal.
Summary. The current cell expansion conditions of growing isolated PDCs at densities of about 5,000 cells/cm2 in growth medium on gelatin-coated or uncoated flasks under standard atmospheric oxygen are sufficient to generate large numbers of cells at passage 11. PDCs also can be readily expanded using lower density culture conditions (e.g., about 1,000 cells/cm2). It is preferred to culture placenta-derived cells under standard atmospheric conditions to generate large pools of cells. Culture conditions may be altered to achieve alternative proliferative and/or differentiative capacity of placenta-derived cells.
Under the conditions utilized, while the expansion potential of MSCs and adipose-derived cells was limited, placenta-derived cells expand readily to large numbers. The data demonstrate that placenta-derived cell lines as developed herein can expand for greater than 40 doublings to provide sufficient cell numbers, for example, for cell banks, whereas mesenchymal stem cells cannot be expanded to obtain large quantities of cells.
References Hayflick (1974)1 Am. Geriatr. Soc. 22(1):1-12 Karyotype Analysis of Placenta-Derived Cells
Expansion of Clonal Neonatal or Maternal Placenta-Derived Cells. A clonal neonatal or maternal cell population can be expanded from placenta-derived cells isolated from the neonatal aspect or the maternal aspect, respectively, of the placenta. Cells are serially diluted and then seeded onto gelatin-coated plates in Growth medium for expansion at 1 cell/well in 96-well gelatin coated plates. From this initial cloning, expansive clones are identified, trypsinized, and reseeded in 12-well gelatin-coated plates in Growth medium and then subsequently passaged into T25 gelatin-coated flasks at 5,000 cells/cm2 in Growth medium. Subcloning is performed to ensure that a clonal population of cells has been identified. For subcloning experiments, cells are trypsinized and reseeded at 0.5 cells/well. The subclones that grow well are expanded in gelatin-coated T25 flasks at 5,000 cells cm2 /flask. Cells are passaged at 5,000 cells cm2 /T75 flask.
The growth characteristics of the best clone are plotted, to demonstrate cell expansion.
Karyotyping analysis can confirm that the clone is either neonatal or maternal.
Summary. The current cell expansion conditions of growing isolated PDCs at densities of about 5,000 cells/cm2 in growth medium on gelatin-coated or uncoated flasks under standard atmospheric oxygen are sufficient to generate large numbers of cells at passage 11. PDCs also can be readily expanded using lower density culture conditions (e.g., about 1,000 cells/cm2). It is preferred to culture placenta-derived cells under standard atmospheric conditions to generate large pools of cells. Culture conditions may be altered to achieve alternative proliferative and/or differentiative capacity of placenta-derived cells.
Under the conditions utilized, while the expansion potential of MSCs and adipose-derived cells was limited, placenta-derived cells expand readily to large numbers. The data demonstrate that placenta-derived cell lines as developed herein can expand for greater than 40 doublings to provide sufficient cell numbers, for example, for cell banks, whereas mesenchymal stem cells cannot be expanded to obtain large quantities of cells.
References Hayflick (1974)1 Am. Geriatr. Soc. 22(1):1-12 Karyotype Analysis of Placenta-Derived Cells
- 60 -Cell lines used in cell therapy are preferably homogeneous and free from any contaminating cell type. Human cells used in cell therapy should have a normal chromosome number (46) and structure. To identify placenta-derived cell lines that are homogeneous and free from cells of non-placental tissue origin, karyotypes of cell samples were analyzed.
Materials and Methods PDCs from postpartum tissue of a male neonate were cultured in Growth medium (DMEM-low glucose (Gibco Carlsbad, CA), 15% (v/v) fetal bovine serum (PBS) (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)).
Postpartum tissue from a male neonate (X,Y) was selected to allow distinction between neonatal-derived cells and maternal-derived cells (X,X). Cells were seeded at 5,000 cells/cm2 in Growth medium in a T25 flask (Corning, Corning, NY) and expanded to about 80% confluence. A T25 flask containing cells was filled to the neck with Growth medium. Samples were delivered to a clinical cytogenetics lab by courier (estimated lab to lab transport time is one hour).
Chromosome analysis was performed by the Center for Human & Molecular Genetics at the New Jersey Medical School, Newark, NJ. Cells were .nalyzed during metaphase when the chromosomes are best visualized. Of twenty cells in metaphase counted, five were analyzed for normal homogeneous karyotype number (two). A cell sample was characterized as homogeneous if two karyotypes were observed. A cell sample was characterized as heterogeneous if more than two karyotypes were observed. Additional metaphase cells were counted and analyzed when a heterogeneous karyotype number (four) was identified.
Results All cell samples sent for chromosome analysis were interpreted as exhibiting a normal appearance. Three of the thirteen cell lines analyzed exhibited a heterogeneous phenotype (XX
and XY) indicating the presence of cells derived from both neonatal and maternal origins (Table 6-1). Cells derived from tissue Placenta-N were isolated from the neonatal aspect of placenta.
At passage zero, this cell line appeared homogeneous XY. However, at passage nine, the cell line was heterogeneous (XX/XY), indicating a previously undetected presence of cells of maternal origin.
Table 6-1. Karyotype analysis of PDCs Metaphase cells Metaphase cells Number of Tissue passage counted analyzed karyotypes ISCN Karyotype
Materials and Methods PDCs from postpartum tissue of a male neonate were cultured in Growth medium (DMEM-low glucose (Gibco Carlsbad, CA), 15% (v/v) fetal bovine serum (PBS) (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)).
Postpartum tissue from a male neonate (X,Y) was selected to allow distinction between neonatal-derived cells and maternal-derived cells (X,X). Cells were seeded at 5,000 cells/cm2 in Growth medium in a T25 flask (Corning, Corning, NY) and expanded to about 80% confluence. A T25 flask containing cells was filled to the neck with Growth medium. Samples were delivered to a clinical cytogenetics lab by courier (estimated lab to lab transport time is one hour).
Chromosome analysis was performed by the Center for Human & Molecular Genetics at the New Jersey Medical School, Newark, NJ. Cells were .nalyzed during metaphase when the chromosomes are best visualized. Of twenty cells in metaphase counted, five were analyzed for normal homogeneous karyotype number (two). A cell sample was characterized as homogeneous if two karyotypes were observed. A cell sample was characterized as heterogeneous if more than two karyotypes were observed. Additional metaphase cells were counted and analyzed when a heterogeneous karyotype number (four) was identified.
Results All cell samples sent for chromosome analysis were interpreted as exhibiting a normal appearance. Three of the thirteen cell lines analyzed exhibited a heterogeneous phenotype (XX
and XY) indicating the presence of cells derived from both neonatal and maternal origins (Table 6-1). Cells derived from tissue Placenta-N were isolated from the neonatal aspect of placenta.
At passage zero, this cell line appeared homogeneous XY. However, at passage nine, the cell line was heterogeneous (XX/XY), indicating a previously undetected presence of cells of maternal origin.
Table 6-1. Karyotype analysis of PDCs Metaphase cells Metaphase cells Number of Tissue passage counted analyzed karyotypes ISCN Karyotype
-61-Placenta 22 20 5 2 46 , XX
Placenta 2 20 5 2 46, XX
Placenta-N 0 20 5 2 46, XY
Placenta-V 0 20 5 2 46, XY
46, XY[18]/46, Placenta-M 0 21 5 4 XX[3]
Placenta-M 4 20 5 2 46,XX
46, XY[5]/46, Placenta-N 9 25 5 4 XX[20]
Placenta-N
Cl 1 20 5 2 46, XY
Placenta-N 46, XY[2]/46, C3 1 20 6 4 XX[18]
Placenta-N
C4 1 20 5 2 46, XY
Placenta-N
C15 1 20 5 2 46, XY
Placenta-N
C20 1 20 5 2 46, XY
Placenta-N
C22 1 20 5 2 46, XY
Key: N- Neonatal side; V- villous region; M- maternal side; C- clone Summary. Chromosome analysis identified placenta-derived cells whose karyotypes appear normal as interpreted by a clinical cytogenetic laboratory. Karyotype analysis also identified cell lines free from maternal cells, as determined by homogeneous karyotype.
Evaluation of Human Placenta-Derived Cell Surface Markers by Flow Cytometry Characterization of cell surface proteins or "markers" by flow cytometry can be used to determine a cell line's identity. The consistency of expression can be determined from multiple donors and in cells exposed to different processing and culturing conditions.
Postpartum cell lines derived from the placenta were characterized (by flow cytometry) providing a profile for the identification of these cell lines.
Materials and Methods Media. Cells were cultured in Growth medium (DMEM-low glucose (Gibco Carlsbad, CA), 15% (v/v) fetal bovine serum (FBS); (Hylcone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)).
Culture vessels. Cells were cultured in plasma-treated T75, T150, and T225 tissue culture flasks (Corning, Corning, NY) until confluent. The growth surfaces of the flasks were
Placenta 2 20 5 2 46, XX
Placenta-N 0 20 5 2 46, XY
Placenta-V 0 20 5 2 46, XY
46, XY[18]/46, Placenta-M 0 21 5 4 XX[3]
Placenta-M 4 20 5 2 46,XX
46, XY[5]/46, Placenta-N 9 25 5 4 XX[20]
Placenta-N
Cl 1 20 5 2 46, XY
Placenta-N 46, XY[2]/46, C3 1 20 6 4 XX[18]
Placenta-N
C4 1 20 5 2 46, XY
Placenta-N
C15 1 20 5 2 46, XY
Placenta-N
C20 1 20 5 2 46, XY
Placenta-N
C22 1 20 5 2 46, XY
Key: N- Neonatal side; V- villous region; M- maternal side; C- clone Summary. Chromosome analysis identified placenta-derived cells whose karyotypes appear normal as interpreted by a clinical cytogenetic laboratory. Karyotype analysis also identified cell lines free from maternal cells, as determined by homogeneous karyotype.
Evaluation of Human Placenta-Derived Cell Surface Markers by Flow Cytometry Characterization of cell surface proteins or "markers" by flow cytometry can be used to determine a cell line's identity. The consistency of expression can be determined from multiple donors and in cells exposed to different processing and culturing conditions.
Postpartum cell lines derived from the placenta were characterized (by flow cytometry) providing a profile for the identification of these cell lines.
Materials and Methods Media. Cells were cultured in Growth medium (DMEM-low glucose (Gibco Carlsbad, CA), 15% (v/v) fetal bovine serum (FBS); (Hylcone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)).
Culture vessels. Cells were cultured in plasma-treated T75, T150, and T225 tissue culture flasks (Corning, Corning, NY) until confluent. The growth surfaces of the flasks were
- 62 -coated with gelatin by incubating 2% (w/v) gelatin (Sigma, St. Louis, MO) for 20 minutes at room temperature.
Antibody staining. Adherent cells in flasks were washed in phosphate buffered saline (PBS); (Gibco, Carlsbad, CA) and detached with Trypsin/EDTA (Gibco, Carlsbad, CA). Cells were harvested, centrifuged, and resuspended in 3% (v/v) FBS in PBS at a cell concentration of lx107 per milliliter. In accordance with the manufacturer's specifications, antibody to the cell surface marker of interest (Table 7-1) was added to one hundred microliters of cell suspension, and the mixture was incubated in the dark for 30 minutes at 4 C. After incubation, cells were washed with PBS and centrifuged to remove unbound antibody. Cells were resuspended in 500 microliters PBS and analyzed by flow cytometry.
Flow cytometry analysis. Flow cytometry analysis was perfoimed with a FACScalibur instrument (Becton Dickinson, San Jose, CA).
Antibodies to cell surface markers. The following antibodies to cell surface markers were used.
Table 7-1. Antibodies to cell surface markers Antibody Manufacture Catalog Number CD10 BD Pharmingen (San Diego, CA) 555375 CD13 BD Pharmingen (San Diego, CA) 555394 CD31 BD Pharmingen (San Diego, CA) 555446 CD34 BD Pharmingen (San Diego, CA) 555821 CD44 BD Pharmingen (San Diego, CA) 555478 CD45RA BD Pharmingen (San Diego, CA) 555489 CD73 BD Pharmingen (San Diego, CA) 550257 CD90 BD Pharmingen (San Diego, CA) 555596 CD117 BD Biosciences (San Jose, CA) 340529 CD141 BD Pharmingen (San Diego, CA) 559781 PDGFr-alpha BD Pharmingen (San Diego, CA) 556002 HLA-A, B, C BD Pharmingen (San Diego, CA) 555553 HLA-DR, DP, DQ BD Pharmingen (San Diego, CA) 555558 IgG-FITC Sigma (St. Louis, MO) F-6522 IgG- PE Sigma (St. Louis, MO) P-4685 Passage to passage comparison. Placenta-derived cells were analyzed at passages 8, 15, and 20.
Donor to donor comparison. To compare differences among donors, placenta cells from different donors were compared to each other.
Surface coating comparison. Placenta-derived cells cultured on gelatin-coated flasks was compared to placenta-derived cells cultured on uncoated flasks.
Antibody staining. Adherent cells in flasks were washed in phosphate buffered saline (PBS); (Gibco, Carlsbad, CA) and detached with Trypsin/EDTA (Gibco, Carlsbad, CA). Cells were harvested, centrifuged, and resuspended in 3% (v/v) FBS in PBS at a cell concentration of lx107 per milliliter. In accordance with the manufacturer's specifications, antibody to the cell surface marker of interest (Table 7-1) was added to one hundred microliters of cell suspension, and the mixture was incubated in the dark for 30 minutes at 4 C. After incubation, cells were washed with PBS and centrifuged to remove unbound antibody. Cells were resuspended in 500 microliters PBS and analyzed by flow cytometry.
Flow cytometry analysis. Flow cytometry analysis was perfoimed with a FACScalibur instrument (Becton Dickinson, San Jose, CA).
Antibodies to cell surface markers. The following antibodies to cell surface markers were used.
Table 7-1. Antibodies to cell surface markers Antibody Manufacture Catalog Number CD10 BD Pharmingen (San Diego, CA) 555375 CD13 BD Pharmingen (San Diego, CA) 555394 CD31 BD Pharmingen (San Diego, CA) 555446 CD34 BD Pharmingen (San Diego, CA) 555821 CD44 BD Pharmingen (San Diego, CA) 555478 CD45RA BD Pharmingen (San Diego, CA) 555489 CD73 BD Pharmingen (San Diego, CA) 550257 CD90 BD Pharmingen (San Diego, CA) 555596 CD117 BD Biosciences (San Jose, CA) 340529 CD141 BD Pharmingen (San Diego, CA) 559781 PDGFr-alpha BD Pharmingen (San Diego, CA) 556002 HLA-A, B, C BD Pharmingen (San Diego, CA) 555553 HLA-DR, DP, DQ BD Pharmingen (San Diego, CA) 555558 IgG-FITC Sigma (St. Louis, MO) F-6522 IgG- PE Sigma (St. Louis, MO) P-4685 Passage to passage comparison. Placenta-derived cells were analyzed at passages 8, 15, and 20.
Donor to donor comparison. To compare differences among donors, placenta cells from different donors were compared to each other.
Surface coating comparison. Placenta-derived cells cultured on gelatin-coated flasks was compared to placenta-derived cells cultured on uncoated flasks.
- 63 -Digestion enzyme comparison. Four treatments used for isolation and preparation of cells were compared. Cells isolated from placenta by treatment with 1) collagenase;
TM TM
collagenase/dispase; 3) collagenase/hyaluronidase; and 4) collagenase/hyaluronidase/dispase were compared.
Placental layer comparison. Cells isolated from the maternal aspect of placental tissue were compared to cells isolated from the villous region of placental tissue and cells isolated from the neonatal fetal aspect of placenta.
Results Placenta-derived cell characterization. Placenta-derived cells analyzed by flow cytometry showed positive for production of CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha and HLA-A, B, C, indicated by the increased values of fluorescence relative to the IgG control.
These cells were'negative for detectable for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, indicated by fluorescence values comparable to the IgG
control.
Variations in fluorescence values of positive curves were accounted. While the mean (i.e., CD13) and range (i.e., CD90) of the positive curves showed some variation, the curves appeared normal, confirming a homogeneous population, and exhibited fluorescen.ce values greater than the IgG control.
Passage to passage comparison. Placenta-derived cells at passages 8, 15, and analyzed by flow cytometry were positive for production of CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, as reflected in the increased value of fluorescence relative to the IgG control. The cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, as indicated by fluorescence values consistent with the IgG control.
Donor to donor comparison. Placenta-derived cells isolated from separate donors analyzed by flow cytometry each expressed CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, with increased values of fluorescence relative to the IgG
control. The cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ as indicated by fluorescence value consistent with the IgG control.
The effect of surface coating with gelatin. Placenta-derived cells expanded on either gelatin-coated or uncoated flasks analyzed by flow cytometry expressed of CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, reflected in the increased values of fluorescence relative to the IgG control. These cells were negative for production of CD31, CD34, CD45, CD117, CD141,.and HLA-DR, DP, DQ indicated by fluorescence values consistent with the IgG
control.
TM TM
collagenase/dispase; 3) collagenase/hyaluronidase; and 4) collagenase/hyaluronidase/dispase were compared.
Placental layer comparison. Cells isolated from the maternal aspect of placental tissue were compared to cells isolated from the villous region of placental tissue and cells isolated from the neonatal fetal aspect of placenta.
Results Placenta-derived cell characterization. Placenta-derived cells analyzed by flow cytometry showed positive for production of CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha and HLA-A, B, C, indicated by the increased values of fluorescence relative to the IgG control.
These cells were'negative for detectable for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, indicated by fluorescence values comparable to the IgG
control.
Variations in fluorescence values of positive curves were accounted. While the mean (i.e., CD13) and range (i.e., CD90) of the positive curves showed some variation, the curves appeared normal, confirming a homogeneous population, and exhibited fluorescen.ce values greater than the IgG control.
Passage to passage comparison. Placenta-derived cells at passages 8, 15, and analyzed by flow cytometry were positive for production of CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, as reflected in the increased value of fluorescence relative to the IgG control. The cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, as indicated by fluorescence values consistent with the IgG control.
Donor to donor comparison. Placenta-derived cells isolated from separate donors analyzed by flow cytometry each expressed CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, with increased values of fluorescence relative to the IgG
control. The cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ as indicated by fluorescence value consistent with the IgG control.
The effect of surface coating with gelatin. Placenta-derived cells expanded on either gelatin-coated or uncoated flasks analyzed by flow cytometry expressed of CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, reflected in the increased values of fluorescence relative to the IgG control. These cells were negative for production of CD31, CD34, CD45, CD117, CD141,.and HLA-DR, DP, DQ indicated by fluorescence values consistent with the IgG
control.
- 64 -Effect of enzyme digestion procedure on the cell surface marker profile. PDCs isolated using various digestion enzymes analyzed by flow cytometry expressed CD10, CD13, CD44, CD73, CD 90, PDGFr-alpha, and HLA-A, B, C, as indicated by the increased values of fluorescence relative to the IgG control. These cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, as indicated by fluorescence values consistent with the IgG control.
Placental layer comparison. Cells isolated from the maternal, vinous, and neonatal layers of the placenta, respectively, analyzed by flow cytometry showed positive for production of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A, B, C, as indicated by the increased value of fluorescence relative to the IgG control. These cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, as indicated by fluorescence values consistent with the IgG control.
Summary. Analysis of placenta-derived cells by flow cytometry has established a profile useful to identify of these cell lines. Placenta-derived cells are positive for CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-A,B,C and negative for CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ. This identity was consistent between variations in variables including the donor, passage, culture vessel surface coating, digestion enzymes, and placental layer. Some variation in individual fluorescence value histogram curve means and ranges were observed, but all positive curves under all conditions tested were normal and expressed fluorescence values greater than the IgG control, thus confirming that the cells comprise a homogeneous population which has positive expression of the markers.
Analysis of Placenta-Derived Cells by Affymetrix GeneChip Arrays Affymetrix GeneChip arrays were used to compare gene expression profiles of placenta-derived cells with umbilical cord-derived cells, fibroblasts, human mesenchymal stem cells, and another cell line derived from human bone marrow. This analysis provided a characterization of the postpartum cells and identified unique molecular markers for these cells.
Materials and Methods Isolation and Culture of Cells Postpartum tissue-derived cells. Human umbilical cords and placenta were obtained from National Disease Research Interchange (NDRI, Philadelphia, PA) from normal full term deliveries with patient consent. The tissues were received and cells were isolated as described in Example 1. Cells were cultured in Growth Medium (Dulbecco's Modified Essential Media
Placental layer comparison. Cells isolated from the maternal, vinous, and neonatal layers of the placenta, respectively, analyzed by flow cytometry showed positive for production of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A, B, C, as indicated by the increased value of fluorescence relative to the IgG control. These cells were negative for production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ, as indicated by fluorescence values consistent with the IgG control.
Summary. Analysis of placenta-derived cells by flow cytometry has established a profile useful to identify of these cell lines. Placenta-derived cells are positive for CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-A,B,C and negative for CD31, CD34, CD45, CD117, CD141, and HLA-DR, DP, DQ. This identity was consistent between variations in variables including the donor, passage, culture vessel surface coating, digestion enzymes, and placental layer. Some variation in individual fluorescence value histogram curve means and ranges were observed, but all positive curves under all conditions tested were normal and expressed fluorescence values greater than the IgG control, thus confirming that the cells comprise a homogeneous population which has positive expression of the markers.
Analysis of Placenta-Derived Cells by Affymetrix GeneChip Arrays Affymetrix GeneChip arrays were used to compare gene expression profiles of placenta-derived cells with umbilical cord-derived cells, fibroblasts, human mesenchymal stem cells, and another cell line derived from human bone marrow. This analysis provided a characterization of the postpartum cells and identified unique molecular markers for these cells.
Materials and Methods Isolation and Culture of Cells Postpartum tissue-derived cells. Human umbilical cords and placenta were obtained from National Disease Research Interchange (NDRI, Philadelphia, PA) from normal full term deliveries with patient consent. The tissues were received and cells were isolated as described in Example 1. Cells were cultured in Growth Medium (Dulbecco's Modified Essential Media
- 65 -(DMEM-low glucose; Invitrogen, Carlsbad, CA) with 15% (v/v) fetal bovine serum (Hyclone, Logan UT), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin (Invitrogen, Carlsbad, CA), and 0.001% (v/v) 2-mercaptoethanol (Sigma, St. Louis MO)) on gelatin-coated tissue culture plastic flasks. The cultures were incubated under standard growth conditions.
Fibroblasts. Human dermal fibroblasts were purchased from Cambrex Incorporated (Walkersville, MD; Lot number 9F0844) and were obtained from ATCC CRL-1501 (CCD39SK). Both lines were cultured in DMEM/F12 medium (Invitrogen, Carlsbad, CA) with 10% (v/v) fetal bovine serum (Hyclone) and 100 Units/milliliter penicillin, microgram/milliliter streptomycin (Invitrogen). The cells were grown on standard tissue-treated plastic.
Human Mesenchymal Stem Cells (hMSC), hMSCs were purchased from Cambrex Incorporated (Walkersville, MD; Lot numbers 2F1655, 2F1656 and 2F1657) and cultured according to the manufacturer's specifications in MSCGM Media (Cambrex). The cells were grown on standard tissue cultured plastic at 37 C in standard atmosphere with 5 % CO2.
Human Iliac Crest Bone Marrow Cells (ICBM). Human ili ac crest bone marrow was received from NDRI with patient consent. The marrow was processed according to the method outlined by Ho, et al. (International PCT Publication No. W003/025149). The marrow was mixed with lysis buffer (155 microMolar NH4CI, 10 microMolar KHCO3, and 0.1 microMolar EDTA, pH 7.2) at a ratio of 1 part bone marrow to 20 parts lysis buffer. The cell suspension was vortexed, incubated for 2 minutes at ambient temperature, and centrifuged for 10 minutes at 500 x g. The supernatant was discarded and the cell pellet was resuspended in Minimal Essential Medium-alpha (Invitrogen) supplemented with 10 % (v/v) fetal bovine serum and 4 microMolar glutamine. The cells were centrifuged, and the cell pellet was resuspended in fresh medium.
The viable mononuclear cells were counted using trypan-blue exclusion (Sigma, St. Louis, MO).
The mononuclear cells were seeded in tissue-cultured plastic flasks at 5 x 104 cells/cm2. The cells were incubated at 37 C with 5% CO2 at either standard atmospheric 02 or at 5% 02. Cells were cultured for 5 days without a medium change. Media and non-adherent cells were removed after 5 days of culture. The adherent cells were maintained in culture.
Isolation of mRNA and GeneChip Analysis. Actively growing cultures of cells were removed from the flasks with a cell scraper in cold phosphate buffered saline (PBS). The cells were centrifuged for 5 minutes at 300 x g. The supernatant was removed, and the cells were resuspended in fresh PBS and centrifuged again. The supernatant was removed, and the cell pellet was immediately frozen and stored at ¨80 C. Cellular mRNA was extracted and transcribed into cDNA. cDNA was then transcribed into cRNA and biotin-labeled.
The biotin-
Fibroblasts. Human dermal fibroblasts were purchased from Cambrex Incorporated (Walkersville, MD; Lot number 9F0844) and were obtained from ATCC CRL-1501 (CCD39SK). Both lines were cultured in DMEM/F12 medium (Invitrogen, Carlsbad, CA) with 10% (v/v) fetal bovine serum (Hyclone) and 100 Units/milliliter penicillin, microgram/milliliter streptomycin (Invitrogen). The cells were grown on standard tissue-treated plastic.
Human Mesenchymal Stem Cells (hMSC), hMSCs were purchased from Cambrex Incorporated (Walkersville, MD; Lot numbers 2F1655, 2F1656 and 2F1657) and cultured according to the manufacturer's specifications in MSCGM Media (Cambrex). The cells were grown on standard tissue cultured plastic at 37 C in standard atmosphere with 5 % CO2.
Human Iliac Crest Bone Marrow Cells (ICBM). Human ili ac crest bone marrow was received from NDRI with patient consent. The marrow was processed according to the method outlined by Ho, et al. (International PCT Publication No. W003/025149). The marrow was mixed with lysis buffer (155 microMolar NH4CI, 10 microMolar KHCO3, and 0.1 microMolar EDTA, pH 7.2) at a ratio of 1 part bone marrow to 20 parts lysis buffer. The cell suspension was vortexed, incubated for 2 minutes at ambient temperature, and centrifuged for 10 minutes at 500 x g. The supernatant was discarded and the cell pellet was resuspended in Minimal Essential Medium-alpha (Invitrogen) supplemented with 10 % (v/v) fetal bovine serum and 4 microMolar glutamine. The cells were centrifuged, and the cell pellet was resuspended in fresh medium.
The viable mononuclear cells were counted using trypan-blue exclusion (Sigma, St. Louis, MO).
The mononuclear cells were seeded in tissue-cultured plastic flasks at 5 x 104 cells/cm2. The cells were incubated at 37 C with 5% CO2 at either standard atmospheric 02 or at 5% 02. Cells were cultured for 5 days without a medium change. Media and non-adherent cells were removed after 5 days of culture. The adherent cells were maintained in culture.
Isolation of mRNA and GeneChip Analysis. Actively growing cultures of cells were removed from the flasks with a cell scraper in cold phosphate buffered saline (PBS). The cells were centrifuged for 5 minutes at 300 x g. The supernatant was removed, and the cells were resuspended in fresh PBS and centrifuged again. The supernatant was removed, and the cell pellet was immediately frozen and stored at ¨80 C. Cellular mRNA was extracted and transcribed into cDNA. cDNA was then transcribed into cRNA and biotin-labeled.
The biotin-
- 66 -labeled cRNA was hybridized with HG-U133A GENECHIP oligonucleotide array (Affymetrix, Santa Clara CA). The hybridization and data collection was performed according to the manufacturer's specifications. Analyses were performed using "Significance Analysis of Microarrays" (SAM) version 1.21 computer software (Stanford University, Tusher, V.G. et al., 2001, Proc. Natl. Acad. Sci. USA 98: 5116-5121).
Results Fourteen different populations of cells were analyzed in this study. The cells along with passage information, culture substrate, and culture media are listed in Table 8-1.
Table 8-1. Cells analyzed by the microarray study. The cell lines are listed by their identification code along with passage at the time of analysis, cell growth substrate, and growth media.
Cell Population Passage Substrate Media - Umbilical (022803) 2 Gelatin DMEM, 15% FBS, BME
Umbilical (042103) 3 Gelatin DMEM, 15%
FBS, BME
Umbilical (071003) 4 Gelatin DMEM, 15%
FBS, BME
- Placenta (042203) 12 Gelatin DMEM, 15% FBS, BME
Placenta (042903) 4 Gelatin DMEM, 15%
FBS, BME
Placenta (071003) 3 Gelatin DMEM, 15%
FBS, BME
ICBM (070203) (5% 3 Plastic MEM 10% FBS
02) ICBM (062703) (std 02) 5 Plastic MEM 10% FBS
ICBM (062703 )(5% 5 Plastic MEM 10% FBS
02) hMSC (Lot 2F1655) 3 Plastic MSCGM
hMSC (Lot 2F1656) 3 Plastic MSCGM
hMSC (Lot 2F1657) 3 Plastic MSCGM
hFibroblast (9E0844) 9 Plastic DMEM-F12, 10 % FBS
hFibroblast (ATCC 4 Plastic DMEM-F12, 10 % FBS
CRL-1501) The data were evaluated by a Principle Component Analysis, analyzing the 290 genes that were differentially expressed in the cells. This analysis allows for a relative comparison for the similarities between the populations. Table 8-2 shows the Euclidean distances that were calculated for the comparison of the cell pairs. The Euclidean distances were based on the comparison of the cells based on the 290 genes that were differentially expressed among the cell
Results Fourteen different populations of cells were analyzed in this study. The cells along with passage information, culture substrate, and culture media are listed in Table 8-1.
Table 8-1. Cells analyzed by the microarray study. The cell lines are listed by their identification code along with passage at the time of analysis, cell growth substrate, and growth media.
Cell Population Passage Substrate Media - Umbilical (022803) 2 Gelatin DMEM, 15% FBS, BME
Umbilical (042103) 3 Gelatin DMEM, 15%
FBS, BME
Umbilical (071003) 4 Gelatin DMEM, 15%
FBS, BME
- Placenta (042203) 12 Gelatin DMEM, 15% FBS, BME
Placenta (042903) 4 Gelatin DMEM, 15%
FBS, BME
Placenta (071003) 3 Gelatin DMEM, 15%
FBS, BME
ICBM (070203) (5% 3 Plastic MEM 10% FBS
02) ICBM (062703) (std 02) 5 Plastic MEM 10% FBS
ICBM (062703 )(5% 5 Plastic MEM 10% FBS
02) hMSC (Lot 2F1655) 3 Plastic MSCGM
hMSC (Lot 2F1656) 3 Plastic MSCGM
hMSC (Lot 2F1657) 3 Plastic MSCGM
hFibroblast (9E0844) 9 Plastic DMEM-F12, 10 % FBS
hFibroblast (ATCC 4 Plastic DMEM-F12, 10 % FBS
CRL-1501) The data were evaluated by a Principle Component Analysis, analyzing the 290 genes that were differentially expressed in the cells. This analysis allows for a relative comparison for the similarities between the populations. Table 8-2 shows the Euclidean distances that were calculated for the comparison of the cell pairs. The Euclidean distances were based on the comparison of the cells based on the 290 genes that were differentially expressed among the cell
- 67 -types. The Euclidean distance is inversely proportional to similarity between the expression of the 290 genes.
Table 8-2. The Euclidean Distances for the Cell Pairs. The Euclidean distance was calculated for the cell types using the 290 genes that were differentially expressed between the cell types.
Similarity between the cells is inversely proportional to the Euclidean distance.
Cell Pair Euclidean Distance ICBM-hMSC 24.71 Placenta-umbilical 25.52 ICBM-Fibroblast 36.44 ICBM-placenta 37.09 Fibroblast-MSC 39.63 ICBM-Umbilical 40.15 Fibroblast- 41.59 Umbilical MSC-Placenta 42.84 MSC-Umbilical 46.86 ICBM-placenta 48.41 Tables 8-3, 8-4, and 8-5 show the expression of genes increased in placenta-derived cells (Table 8-3), increased in umbilical cord-derived cells (Table 8-4), and reduced in umbilical cord-and placenta-derived cells (Table 8-5). The column entitled "Probe Set ID"
refers to the manufacturer's identification code for the sets of several oligonucleotide probes located on a particular site on the chip, which hybridize to the named gene (column "Gene Name"), comprising a sequence that can be found within the NCBI (GenBank) database at the specified accession number (column "NCBI Accession Number").
Table 8-3. Genes shown to have specifically increased expression in the placenta-derived cells as compared to the other cell lines assayed.
Genes Increased in Placenta-Derived Cells Probe Set ID Gene Name NCBI Accession Number 209732 at C-type (calcium dependent, carbohydrate- AF070642 recognition domain) lectin, superfamily member 2 (activation-induced) 206067_s_at Wilms tumor 1 NM_024426 207016_s_at aldehyde dehydrogenase 1 family, member A2 AB015228
Table 8-2. The Euclidean Distances for the Cell Pairs. The Euclidean distance was calculated for the cell types using the 290 genes that were differentially expressed between the cell types.
Similarity between the cells is inversely proportional to the Euclidean distance.
Cell Pair Euclidean Distance ICBM-hMSC 24.71 Placenta-umbilical 25.52 ICBM-Fibroblast 36.44 ICBM-placenta 37.09 Fibroblast-MSC 39.63 ICBM-Umbilical 40.15 Fibroblast- 41.59 Umbilical MSC-Placenta 42.84 MSC-Umbilical 46.86 ICBM-placenta 48.41 Tables 8-3, 8-4, and 8-5 show the expression of genes increased in placenta-derived cells (Table 8-3), increased in umbilical cord-derived cells (Table 8-4), and reduced in umbilical cord-and placenta-derived cells (Table 8-5). The column entitled "Probe Set ID"
refers to the manufacturer's identification code for the sets of several oligonucleotide probes located on a particular site on the chip, which hybridize to the named gene (column "Gene Name"), comprising a sequence that can be found within the NCBI (GenBank) database at the specified accession number (column "NCBI Accession Number").
Table 8-3. Genes shown to have specifically increased expression in the placenta-derived cells as compared to the other cell lines assayed.
Genes Increased in Placenta-Derived Cells Probe Set ID Gene Name NCBI Accession Number 209732 at C-type (calcium dependent, carbohydrate- AF070642 recognition domain) lectin, superfamily member 2 (activation-induced) 206067_s_at Wilms tumor 1 NM_024426 207016_s_at aldehyde dehydrogenase 1 family, member A2 AB015228
- 68 -206367_at renin NM_000537 210004_at oxidised low density lipoprotein (lectin-like) receptor AF035776 214993_at Homo sapiens, clone IMAGE:4179671, mRNA, AF070642 partial cds 202178_at protein kinase C, zeta NM 002744 209780_at hypothetical protein DKFZp564F013 AL136883 204135_at downregulated in ovarian cancer 1 NM_014890 213542_at Homo sapiens mRNA; cDNA DKFZp547K1113 A1246730 (from clone DKFZp547K1113) Table 8-4. Genes shown to have specifically increased expression in umbilical cord-derived cells as compared to the other cell lines assayed.
Genes Increased in Umbilical Cord-Derived Cells Probe Set Gene Name NCB!
Accession Number ID
202859_x_at interleukin 8 NM_000584 211506_s_at interleukin 8 AF043337 210222_s_at reticulon 1 BC000314 204470_at chemokine (C-X-C motif) ligand 1 (melanoma NM 001511 growth stimulating activity 206336_at chemokine (C-X-C motif) ligand 6 (granulocyte NM_002993 chemotactic protein 2) 207850_at chemokine (C-X-C motif) ligand 3 NM_002090 203485_at reticulon 1 NM_021136 202644_s_at tumor necrosis factor, alpha-induced protein 3 NM_006290 Table 8-5. Genes that were shown to have decreased expression in the umbilical cord and placenta cells as compared to the other cell lines assayed.
Genes Decreased in Umbilical Cord- and Placenta-Derived Cells
Genes Increased in Umbilical Cord-Derived Cells Probe Set Gene Name NCB!
Accession Number ID
202859_x_at interleukin 8 NM_000584 211506_s_at interleukin 8 AF043337 210222_s_at reticulon 1 BC000314 204470_at chemokine (C-X-C motif) ligand 1 (melanoma NM 001511 growth stimulating activity 206336_at chemokine (C-X-C motif) ligand 6 (granulocyte NM_002993 chemotactic protein 2) 207850_at chemokine (C-X-C motif) ligand 3 NM_002090 203485_at reticulon 1 NM_021136 202644_s_at tumor necrosis factor, alpha-induced protein 3 NM_006290 Table 8-5. Genes that were shown to have decreased expression in the umbilical cord and placenta cells as compared to the other cell lines assayed.
Genes Decreased in Umbilical Cord- and Placenta-Derived Cells
-69-Probe Set Gene name NCB!
Accession Number ID
210135_s_at short stature homeobox 2 AF022654.1 205824 at heat shock 27kDa protein 2 NM 001541.1 209687_at chemokine (C-X-C motif) ligand 12 (stromal cell- U19495.1 derived factor 1) 203666_at chemokine (C-X-C motif) ligand 12 (stromal cell- NM 000609.1 derived factor 1) 212670_at elastin (supravalvular aortic stenosis, Williams- AA479278 Beuren syndrome) 213381_at Homo sapiens mRNA; cDNA DKFZp586M2022 N91149 (from clone DKFZp586M2022) 206201_s_at mesenchyme homeobox 2 (growth arrest- NM 005924.1 specific homeobox) 205817_at sine oculis homeobox homolog 1 (Drosophila) NM 005982.1 209283_at crystallin, alpha B AF007162.1 212793_at dishevelled associated activator of BF513244 morphogenesis 2 213488_at DKFZP586132420 protein AL050143.1 209763_at similar to neuralin 1 AL049176 205200 at tetranectin (plasminogen binding protein) NM 003278.1 205743_at src homology three (SH3) and cysteine rich NM 003149.1 domain 200921_s_at B-cell translocation gene 1, anti-proliferative NM 001731.1 206932_at cholesterol 25-hydroxylase NM 003956.1 204198_s_at runt-related transcription factor 3 AA541630 219747_at hypothetical protein FLJ23191 NM 024574.1 204773_at interleukin 11 receptor, alpha NM 004512.1 202465_at procollagen C-endopeptidase enhancer NM 002593.2 203706_s_at frizzled homolog 7 (Drosophila) NM 003507.1 212736_at hypothetical gene BC008967 6E299456 214587_at collagen, type VIII, alpha 1 6E877796
Accession Number ID
210135_s_at short stature homeobox 2 AF022654.1 205824 at heat shock 27kDa protein 2 NM 001541.1 209687_at chemokine (C-X-C motif) ligand 12 (stromal cell- U19495.1 derived factor 1) 203666_at chemokine (C-X-C motif) ligand 12 (stromal cell- NM 000609.1 derived factor 1) 212670_at elastin (supravalvular aortic stenosis, Williams- AA479278 Beuren syndrome) 213381_at Homo sapiens mRNA; cDNA DKFZp586M2022 N91149 (from clone DKFZp586M2022) 206201_s_at mesenchyme homeobox 2 (growth arrest- NM 005924.1 specific homeobox) 205817_at sine oculis homeobox homolog 1 (Drosophila) NM 005982.1 209283_at crystallin, alpha B AF007162.1 212793_at dishevelled associated activator of BF513244 morphogenesis 2 213488_at DKFZP586132420 protein AL050143.1 209763_at similar to neuralin 1 AL049176 205200 at tetranectin (plasminogen binding protein) NM 003278.1 205743_at src homology three (SH3) and cysteine rich NM 003149.1 domain 200921_s_at B-cell translocation gene 1, anti-proliferative NM 001731.1 206932_at cholesterol 25-hydroxylase NM 003956.1 204198_s_at runt-related transcription factor 3 AA541630 219747_at hypothetical protein FLJ23191 NM 024574.1 204773_at interleukin 11 receptor, alpha NM 004512.1 202465_at procollagen C-endopeptidase enhancer NM 002593.2 203706_s_at frizzled homolog 7 (Drosophila) NM 003507.1 212736_at hypothetical gene BC008967 6E299456 214587_at collagen, type VIII, alpha 1 6E877796
-70-201645 at tenascin C (hexabrachion) NM 002160.1 210239 at iroquois homeobox protein 5 U90304.1 203903_s_at hephaestin NM 014799.1 205816 at integrin, beta 8 NM 002214.1 203069_at synaptic vesicle glycoprotein 2 NM 014849.1 213909_at Homo sapiens cDNA FLJ12280 fis, clone AU147799 206315_at cytokine receptor-like factor 1 NM 004750.1 204401_at potassium intermediate/small conductance NM_002250.1 calcium-activated channel, subfamily N, member 216331_at integrin, alpha 7 AK022548.1 209663_s_at integrin, alpha 7 AF072132.1 213125_at DKFZP586L151 protein AW007573 202133_at transcriptional co-activator with PDZ-binding AA081084 motif (TAZ) 206511_s_at sine oculis homeobox homolog 2 (Drosophila) NM 016932.1 213435_at KIAA1034 protein AB028957.1 206115_at early growth response 3 NM_004430.1 213707_s_at distal-less homeobox 5 NM_005221.3 218181_s_at hypothetical protein FLJ20373 NM 017792.1 209160_at aldo-keto reductase family 1, member C3 (3- AB018580.1 alpha hydroxysteroid dehydrogenase, type II) 213905_x_at biglycan AA845258 201261_x_at biglycan BC002416.1 202132_at transcriptional co-activator with PDZ-binding AA081084 motif (TAZ) 214701_s_at fibronectin 1 AJ276395.1 213791_at proenkephalin NM 006211.1 205422_s_at integrin, beta-like 1 (with EGF-like repeat NM 004791.1 domains)
-71-214927_at Homo sapiens mRNA full length insert cDNA AL359052.1 clone EUROIMAGE 1968422 206070_s_at EphA3 AF213459.1 212805_at , KIAA0367 protein AB002365.1 219789_at natriuretic peptide receptor C/guanylate cyclase A1628360 C (atrionatriuretic peptide receptor C) 219054_at hypothetical protein FLJ14054 NM 024563.1 213429_at Homo sapiens mRNA; cDNA DKFZp564B222 AW025579 (from clone DKFZp56413222) 204929_s_at vesicle-associated membrane protein 5 NM_006634.1 (myobrevin) 201843_s_at EGF-containing fibulin-like extracellular matrix NM_004105.2 protein 1 221478_at BCL2/adenovirus El B 19kDa interacting protein AL132665.1 3-like 201792_at AE binding protein 1 NM_001129.2 204570_at cytochrome c oxidase subunit Vila polypeptide 1 NM_001864.1 (muscle) 201621_at neuroblastoma, suppression of tumorigenicity 1 NM 005380.1 202718_at insulin-like growth factor binding protein 2, NM 000597.1 36kDa Tables 8-6, 8-7, and 8-8 show the expression of genes increased in human fibroblasts (Table 8-6), ICBM cells (Table 8-7), and MSCs (Table 8-8).
Table 8-6. Genes that were shown to have increased expression in fibroblasts as compared to the other cell lines assayed.
Genes increased in fibroblasts dual specificity phosphatase 2 KIAA0527 protein Homo sapiens cDNA: FLJ23224 fis, clone ADSU02206 dynein, cytoplasmic, intermediate polypeptide 1 ankyrin 3, node of Ranvier (ankyrin G) inhibin, beta A (activin A, activin AB alpha polypeptide) ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) KIAA1053 protein microtubule-associated protein lA
zinc finger protein 41 HSPC019 protein
Table 8-6. Genes that were shown to have increased expression in fibroblasts as compared to the other cell lines assayed.
Genes increased in fibroblasts dual specificity phosphatase 2 KIAA0527 protein Homo sapiens cDNA: FLJ23224 fis, clone ADSU02206 dynein, cytoplasmic, intermediate polypeptide 1 ankyrin 3, node of Ranvier (ankyrin G) inhibin, beta A (activin A, activin AB alpha polypeptide) ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) KIAA1053 protein microtubule-associated protein lA
zinc finger protein 41 HSPC019 protein
- 72 -Homo sapiens cDNA: FLJ23564 fis, clone LNG10773 Homo sapiens mRNA; cDNA DKFZp564A072 (from clone DKFZp564A072) LIM protein (similar to rat protein ldnase C-binding enigma) inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein hypothetical protein FLJ22004 Human (clone CTG-A4) mRNA sequence ESTs, Moderately similar to cytokine receptor-like factor 2; cytokine receptor CRL2 precursor [Homo sapiens]
transforming growth factor, beta 2 hypothetical protein MGC29643 antigen identified by monoclonal antibody MRC OX-2 Table 8-7. Genes that were shown to have increased expression in the ICBM-derived cells as compared to the other cell lines assayed.
Genes Increased In ICBM Cells cardiac ankyrin repeat protein MHC class I region ORE
integrin, alpha 10 hypothetical protein FLJ22362 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (Ga1NAc-T3) interferon-induced protein 44 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) keratin associated protein 1-1 hippocalcin-like 1 jagged 1 (Alagille syndrome) proteoglycan 1, secretory granule Table 8-8. Genes that were shown to have increased expression in the MSC cells as compared to the other cell lines assayed.
Genes Increased In MSC Cells interleukin 26 maltase-glucoamylase (alpha-glucosidase) nuclear receptor subfamily 4, group A, member 2 v-fos FBJ murine osteosarcoma viral oncogene homolog hypothetical protein DC42 nuclear receptor subfamily 4, group A, member 2 FBJ murine osteosarcoma viral oncogene homolog B
WNT1 inducible signaling pathway protein 1 MCF.2 cell line derived transforming sequence potassium channel, subfamily K, member 15 cartilage paired-class homeoprotein 1 Homo sapiens cDNA FLJ12232 fis, clone MAMMA1001206
transforming growth factor, beta 2 hypothetical protein MGC29643 antigen identified by monoclonal antibody MRC OX-2 Table 8-7. Genes that were shown to have increased expression in the ICBM-derived cells as compared to the other cell lines assayed.
Genes Increased In ICBM Cells cardiac ankyrin repeat protein MHC class I region ORE
integrin, alpha 10 hypothetical protein FLJ22362 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (Ga1NAc-T3) interferon-induced protein 44 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) keratin associated protein 1-1 hippocalcin-like 1 jagged 1 (Alagille syndrome) proteoglycan 1, secretory granule Table 8-8. Genes that were shown to have increased expression in the MSC cells as compared to the other cell lines assayed.
Genes Increased In MSC Cells interleukin 26 maltase-glucoamylase (alpha-glucosidase) nuclear receptor subfamily 4, group A, member 2 v-fos FBJ murine osteosarcoma viral oncogene homolog hypothetical protein DC42 nuclear receptor subfamily 4, group A, member 2 FBJ murine osteosarcoma viral oncogene homolog B
WNT1 inducible signaling pathway protein 1 MCF.2 cell line derived transforming sequence potassium channel, subfamily K, member 15 cartilage paired-class homeoprotein 1 Homo sapiens cDNA FLJ12232 fis, clone MAMMA1001206
- 73 -Homo sapiens cDNA FLJ34668 fis, clone LIVER2000775 jun B proto-oncogene B-cell CLL/lymphoma 6 (zinc finger protein 51) zinc finger protein 36, C3H type, homolog (mouse) Summary. The GENECHIP analysis was performed to provide a molecular characterization of the postpartum cells derived from placenta. This analysis included cells derived from three different placentas. The study also included three different lines of umbilical cord-derived cells, two different lines of dermal fibroblasts, three lines of mesenchymal stem cells, and three lines of iliac crest bone marrow cells. The mRNA that was expressed by these cells was analyzed by AffyMetrix GENECHIP that contained oligonucleotide probes for 22,000 genes.
Results showed that 290 genes are differentially expressed in these five different cell types. These genes include ten genes that are specifically increased in the placenta-derived cells.
Fifty-four genes were found to have specifically lower expression levels in placenta.
The expression of selected genes has been confirmed by PCR in Example 9. These results demonstrate that the placenta-derived cells have a distinct gene expression profile, for example, as compared to bone marrow-derived cells and fibroblasts.
Cell Markers in Placenta-Derived Cells Similarities and differences in gene expression between cells derived from the human placenta and cells derived from other sources were assessed by comparing their gene expression profiles using an Affymetrix Genechip. Six "signature" genes were identified:
oxidized LDL
receptor 1, interleukin-8, renin, reticulon, chemolcine receptor ligand 3 (CXC
ligand 3), and granulocyte chemotactic protein 2 (GCP-2). These "signature" genes were expressed at relatively high levels in placenta-derived cells. This analysis was conducted to verify the microarray data and find accordance/divergence between gene and protein expression, as well as to establish a series of reliable assay for detection of unique identifiers for placenta-derived cells.
Methods & Materials Cells. Placenta-derived cells (three isolates, including one isolate predominately neonatal as identified by karyotyping analysis) and Normal Human Dermal Fibroblasts (NI-EDF; neonatal and adult) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15%
(v/v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, UT), 0.001% (v/v) beta-
Results showed that 290 genes are differentially expressed in these five different cell types. These genes include ten genes that are specifically increased in the placenta-derived cells.
Fifty-four genes were found to have specifically lower expression levels in placenta.
The expression of selected genes has been confirmed by PCR in Example 9. These results demonstrate that the placenta-derived cells have a distinct gene expression profile, for example, as compared to bone marrow-derived cells and fibroblasts.
Cell Markers in Placenta-Derived Cells Similarities and differences in gene expression between cells derived from the human placenta and cells derived from other sources were assessed by comparing their gene expression profiles using an Affymetrix Genechip. Six "signature" genes were identified:
oxidized LDL
receptor 1, interleukin-8, renin, reticulon, chemolcine receptor ligand 3 (CXC
ligand 3), and granulocyte chemotactic protein 2 (GCP-2). These "signature" genes were expressed at relatively high levels in placenta-derived cells. This analysis was conducted to verify the microarray data and find accordance/divergence between gene and protein expression, as well as to establish a series of reliable assay for detection of unique identifiers for placenta-derived cells.
Methods & Materials Cells. Placenta-derived cells (three isolates, including one isolate predominately neonatal as identified by karyotyping analysis) and Normal Human Dermal Fibroblasts (NI-EDF; neonatal and adult) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15%
(v/v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, UT), 0.001% (v/v) beta-
- 74 -mercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)) in a gelatin-coated T75 flask. Mesenchymal Stem Cells (MSCs) were grown in a Mesenchymal Stem Cell Growth Medium Bullet kit (MSCGM;
Cambrex, Walkerville, MD).
For IL-8 experiments, cells were thawed from liquid nitrogen and plated in gelatin-coated flasks at 5,000 cells/cm2, grown for 48 hours in Growth medium and then grown for 8 hours in milliliters of serum starvation medium [DMEM-low glucose (Gibco, Carlsbad, CA), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA) and 0.1%
(w/v) Bovine Serum Albumin (BSA; Sigma, St. Louis, MO)]. After this treatment, RNA was extracted and the supernatants were centrifuged at 150 x g for 5 minutes to remove cellular debris.
Cell culture for ELBA assay. Placenta-derived cells and human fibroblasts derived from human neonatal foreskin were cultured in Growth medium in gelatin-coated T75 flasks.
Cells were frozen at passage 11 in liquid nitrogen. Cells were thawed and transferred to 15 milliliter centrifuge tubes. After centrifugation at 150 x g for 5 minutes, the supernatant was discarded. Cells were resuspended in 4 milliliters culture medium and counted.
Cells were grown in a 75 cm2 flask containing 15 milliliters of Growth medium at 375,000 cell/flask for 24 hours. The medium was changed to a serum starvation medium for 8 hours. Serum starvation medium was collected at the end of incubation, centrifuged at 14,000 x g for 5 minutes, and stored at -20 C.
To estimate the number of cells in each flask, 2 milliliters of trypsin/EDTA
(Gibco, Carlsbad, CA) was added to each flask. After cells detached from the flask, trypsin activity was neutralized with 8 milliliters of Growth medium. Cells were transferred to a 15 milliliter centrifuge tube and centrifuged at 150 x g for 5 minutes. Supernatant was removed and 1 milliliter Growth medium was added to each tube to resuspend the cells. Cell number was estimated using a hemocytometer.
ELISA assay. The amount of IL-8 secreted by the cells into serum starvation medium was analyzed using ELISA assays (R&D Systems, Minneapolis, MN). All assays were tested according to the instructions provided by the manufacturer.
Total RNA isolation. RNA was extracted from confluent placenta-derived cells and fibroblasts or for IL-8 expression from cells treated as described above.
Cells were lysed with 350 microliter buffer RLT containing beta-mercaptoethanol (Sigma, St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini Kit; Qiagen, Valencia, CA). RNA
was extracted according to the manufacturer's instructions (RNeasy Mini Kit; Qiagen, Valencia, CA) and
Cambrex, Walkerville, MD).
For IL-8 experiments, cells were thawed from liquid nitrogen and plated in gelatin-coated flasks at 5,000 cells/cm2, grown for 48 hours in Growth medium and then grown for 8 hours in milliliters of serum starvation medium [DMEM-low glucose (Gibco, Carlsbad, CA), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA) and 0.1%
(w/v) Bovine Serum Albumin (BSA; Sigma, St. Louis, MO)]. After this treatment, RNA was extracted and the supernatants were centrifuged at 150 x g for 5 minutes to remove cellular debris.
Cell culture for ELBA assay. Placenta-derived cells and human fibroblasts derived from human neonatal foreskin were cultured in Growth medium in gelatin-coated T75 flasks.
Cells were frozen at passage 11 in liquid nitrogen. Cells were thawed and transferred to 15 milliliter centrifuge tubes. After centrifugation at 150 x g for 5 minutes, the supernatant was discarded. Cells were resuspended in 4 milliliters culture medium and counted.
Cells were grown in a 75 cm2 flask containing 15 milliliters of Growth medium at 375,000 cell/flask for 24 hours. The medium was changed to a serum starvation medium for 8 hours. Serum starvation medium was collected at the end of incubation, centrifuged at 14,000 x g for 5 minutes, and stored at -20 C.
To estimate the number of cells in each flask, 2 milliliters of trypsin/EDTA
(Gibco, Carlsbad, CA) was added to each flask. After cells detached from the flask, trypsin activity was neutralized with 8 milliliters of Growth medium. Cells were transferred to a 15 milliliter centrifuge tube and centrifuged at 150 x g for 5 minutes. Supernatant was removed and 1 milliliter Growth medium was added to each tube to resuspend the cells. Cell number was estimated using a hemocytometer.
ELISA assay. The amount of IL-8 secreted by the cells into serum starvation medium was analyzed using ELISA assays (R&D Systems, Minneapolis, MN). All assays were tested according to the instructions provided by the manufacturer.
Total RNA isolation. RNA was extracted from confluent placenta-derived cells and fibroblasts or for IL-8 expression from cells treated as described above.
Cells were lysed with 350 microliter buffer RLT containing beta-mercaptoethanol (Sigma, St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini Kit; Qiagen, Valencia, CA). RNA
was extracted according to the manufacturer's instructions (RNeasy Mini Kit; Qiagen, Valencia, CA) and
- 75 -subjected to DNase treatment (2.7 U/sample) (Sigma St. Louis, MO). RNA was eluted with 50 microliter DEPC-treated water and stored at -80 C. RNA was extracted from human placenta.
Tissue (30 milligram) was suspended in 700 microliter of buffer RLT containing beta-mercaptoethanol. Samples were mechanically homogenized, and the RNA extraction proceeded according to manufacturer's specification. RNA was extracted with 50 microliter of DEPC-treated water and stored at -80 C.
Reverse transcription. RNA was reverse transcribed using random hexamers with the TaqMan reverse -transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
Genes identified by cDNA microarray as uniquely regulated in postpartum cells ("signature genes" including oxidized LDL receptor, interleukin-8, renin, and reticulon), were further investigated using real-time and conventional PCR.
Real-time PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND
gene expression products: oxidized LDL receptor (Hs00234028); renin (Hs00166915); reticulon (Hs00382515); CXC ligand 3 (Hs00171061); GCP-2 (Hs00605742); IL-8 (Hs00174103); and GAPDH were mixed with cDNA and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI Prism 7000 SDS software (Applied Biosystems, Foster City, CA).
Thermal cycle conditions were initially 50 C for 2 minute and 95 C for 10 minute, followed by 40 cycles of 95 C for 15 second and 60 C for 1 minute. PCR data was analyzed according to manufacturer's specifications (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System).
Conventional PCR. Conventional PCR was performed using an ABI PRISM 7700 (Perkin Elmer Applied Biosystems, Boston, MA) to confirm the results from real-time PCR.
PCR was performed using 2 microliter of cDNA solution, 1 X TAQ polymerase (tradename AMPLITAQ GOLD) universal mix PCR reaction buffer (Applied Biosystems, Foster City, CA) and initial denaturation at 94 C for 5 minutes. Amplification was optimized for each primer set.
For IL-8, CXC ligand 3, and reticulon (94 C for 15 seconds, 55 C for 15 seconds, and 72 C. for 30 seconds for 30 cycles); for renin (94 C for 15 seconds, 53 C for 15 seconds, and 72 C for 30 seconds for 38 cycles); for oxidized LDL receptor and GAPDH (94 C for 15 seconds, 55 C for 15 seconds, and 72 C for 30 seconds for 33 cycles). Primers used for amplification are listed in Table 9-1. Primer concentration in the final PCR reaction was 1 microMolar except for GAPDH
which was 0.5 microMolar. GAPDH primers were the same as real-time PCR, except that the manufacturer's TaqMan probe was not added to the final PCR reaction. Samples were run on
Tissue (30 milligram) was suspended in 700 microliter of buffer RLT containing beta-mercaptoethanol. Samples were mechanically homogenized, and the RNA extraction proceeded according to manufacturer's specification. RNA was extracted with 50 microliter of DEPC-treated water and stored at -80 C.
Reverse transcription. RNA was reverse transcribed using random hexamers with the TaqMan reverse -transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
Genes identified by cDNA microarray as uniquely regulated in postpartum cells ("signature genes" including oxidized LDL receptor, interleukin-8, renin, and reticulon), were further investigated using real-time and conventional PCR.
Real-time PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND
gene expression products: oxidized LDL receptor (Hs00234028); renin (Hs00166915); reticulon (Hs00382515); CXC ligand 3 (Hs00171061); GCP-2 (Hs00605742); IL-8 (Hs00174103); and GAPDH were mixed with cDNA and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI Prism 7000 SDS software (Applied Biosystems, Foster City, CA).
Thermal cycle conditions were initially 50 C for 2 minute and 95 C for 10 minute, followed by 40 cycles of 95 C for 15 second and 60 C for 1 minute. PCR data was analyzed according to manufacturer's specifications (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System).
Conventional PCR. Conventional PCR was performed using an ABI PRISM 7700 (Perkin Elmer Applied Biosystems, Boston, MA) to confirm the results from real-time PCR.
PCR was performed using 2 microliter of cDNA solution, 1 X TAQ polymerase (tradename AMPLITAQ GOLD) universal mix PCR reaction buffer (Applied Biosystems, Foster City, CA) and initial denaturation at 94 C for 5 minutes. Amplification was optimized for each primer set.
For IL-8, CXC ligand 3, and reticulon (94 C for 15 seconds, 55 C for 15 seconds, and 72 C. for 30 seconds for 30 cycles); for renin (94 C for 15 seconds, 53 C for 15 seconds, and 72 C for 30 seconds for 38 cycles); for oxidized LDL receptor and GAPDH (94 C for 15 seconds, 55 C for 15 seconds, and 72 C for 30 seconds for 33 cycles). Primers used for amplification are listed in Table 9-1. Primer concentration in the final PCR reaction was 1 microMolar except for GAPDH
which was 0.5 microMolar. GAPDH primers were the same as real-time PCR, except that the manufacturer's TaqMan probe was not added to the final PCR reaction. Samples were run on
- 76 --=
2% (w/v) agarose gel and stained with ethidium bromide (Sigma, St. Louis, MO).
Images were captured using a 667 Universal Twinpack film (VWR International, South Plainfield, NJ) using a focal-length POLAROID camera (VWR International, South Plainfield, NJ).
Table 9-1: Primers used Primer name Primers Oxidized LDL receptor S: 5I-GAGAAATCCAAAGAGCAAATGG-3' (SEQ ID NO: 1) A: 5'-AGAATGGAAAACTGGAATAGG-3' (SEQ ID NO:2) Renin S: 5'-TCTTCGATGCTTCGGATTCC-3' (SEQ ID NO:3) A: 5 ' -GAATTCTCGGAATCTCTGTTG-3 ' (SEQ ID NO : 4 ) Reticulon 5: 5 ' - TTACAAGCAGTGCAGAAAACC-3 ' (SEQ ID NO: 5) A: 5 ' - AGTAAACATTGAAACCACAGCC-3 ' (SEQ ID NO: 6) Interleukin-8 5: 5'- TCTGCAGCTCTGTGTGAAGG-3 ' (SEQ ID NO : 7 ) A: 5 -CTTCAAAAACTTCTCCACAACC- 3' (SEQ ID NO: 8 ) Chemokine (CXC) ligand 3 5: 5'- CCCACGCCACGCTCTCC-3' (SEQ ID NO: 9) A: 5'-TCCTGTCAGTTGGTGCTCC -3' (SEQ ID NO:10) Immunofluoreseence. Cells were fixed with cold 4% (w/v) paraformaldehyde (Sigma-Aldrich, St. Louis, MO) for 10 minutes at room temperature. Placenta-derived cells at passage 0 (PO) (one isolate, directly after isolation) and passage 11 (P11) (two isolates) and fibroblasts (P11) were used. Immunocytochemistry was perfoimed using antibodies directed against the following epitopes: vixnentin (1:500, Sigma, St. Louis, MO), desmin (1:150;
Sigma - raised against rabbit; or 1:300; Chemicon, Temecula, CA ¨ raised against mouse,), alpha-smooth muscle actin (SMA; 1:400; Sigma), cytokeratin 18 (CK18; 1:400; Sigma), von Willebrand Factor (vWF; 1:200; Sigma), and CD34 (human CD34 Class III; 1:100; DAKOCytomation, Carpinteria, CA). In addition, the following markers were tested on passage 11 placenta-derived cells: anti-human GROalpha - PE (1:100; Becton Dickinson, Franklin Lakes, NJ), anti-human (1:100; Santa Cruz Biotech, Santa Cruz, CA), anti-human oxidized LDL receptor 1 (ox-LDL R1;
1:100; Santa Cruz Biotech), and anti-human NOGA-A (1:100; Santa Cruz, Biotech).
Cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3%
(v/v) Triton (Triton X-100; Sigma, St. Louis, MO) for 30 minutes to access intracellular antigens. Where the epitope of interest was located on the cell surface (CD34, ox-LDL R1), Triton X-100 was omitted in all steps of the procedure in order to prevent epitope loss.
Furthermore, in instances where the primary antibody was raised against goat (GCP-2, ox-LDL
R1, NOGO-A), 3% (v/v) donkey serum was used in place of goat serum throughout the process.
Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature. The primary antibody solutions were removed, and the cultures
2% (w/v) agarose gel and stained with ethidium bromide (Sigma, St. Louis, MO).
Images were captured using a 667 Universal Twinpack film (VWR International, South Plainfield, NJ) using a focal-length POLAROID camera (VWR International, South Plainfield, NJ).
Table 9-1: Primers used Primer name Primers Oxidized LDL receptor S: 5I-GAGAAATCCAAAGAGCAAATGG-3' (SEQ ID NO: 1) A: 5'-AGAATGGAAAACTGGAATAGG-3' (SEQ ID NO:2) Renin S: 5'-TCTTCGATGCTTCGGATTCC-3' (SEQ ID NO:3) A: 5 ' -GAATTCTCGGAATCTCTGTTG-3 ' (SEQ ID NO : 4 ) Reticulon 5: 5 ' - TTACAAGCAGTGCAGAAAACC-3 ' (SEQ ID NO: 5) A: 5 ' - AGTAAACATTGAAACCACAGCC-3 ' (SEQ ID NO: 6) Interleukin-8 5: 5'- TCTGCAGCTCTGTGTGAAGG-3 ' (SEQ ID NO : 7 ) A: 5 -CTTCAAAAACTTCTCCACAACC- 3' (SEQ ID NO: 8 ) Chemokine (CXC) ligand 3 5: 5'- CCCACGCCACGCTCTCC-3' (SEQ ID NO: 9) A: 5'-TCCTGTCAGTTGGTGCTCC -3' (SEQ ID NO:10) Immunofluoreseence. Cells were fixed with cold 4% (w/v) paraformaldehyde (Sigma-Aldrich, St. Louis, MO) for 10 minutes at room temperature. Placenta-derived cells at passage 0 (PO) (one isolate, directly after isolation) and passage 11 (P11) (two isolates) and fibroblasts (P11) were used. Immunocytochemistry was perfoimed using antibodies directed against the following epitopes: vixnentin (1:500, Sigma, St. Louis, MO), desmin (1:150;
Sigma - raised against rabbit; or 1:300; Chemicon, Temecula, CA ¨ raised against mouse,), alpha-smooth muscle actin (SMA; 1:400; Sigma), cytokeratin 18 (CK18; 1:400; Sigma), von Willebrand Factor (vWF; 1:200; Sigma), and CD34 (human CD34 Class III; 1:100; DAKOCytomation, Carpinteria, CA). In addition, the following markers were tested on passage 11 placenta-derived cells: anti-human GROalpha - PE (1:100; Becton Dickinson, Franklin Lakes, NJ), anti-human (1:100; Santa Cruz Biotech, Santa Cruz, CA), anti-human oxidized LDL receptor 1 (ox-LDL R1;
1:100; Santa Cruz Biotech), and anti-human NOGA-A (1:100; Santa Cruz, Biotech).
Cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3%
(v/v) Triton (Triton X-100; Sigma, St. Louis, MO) for 30 minutes to access intracellular antigens. Where the epitope of interest was located on the cell surface (CD34, ox-LDL R1), Triton X-100 was omitted in all steps of the procedure in order to prevent epitope loss.
Furthermore, in instances where the primary antibody was raised against goat (GCP-2, ox-LDL
R1, NOGO-A), 3% (v/v) donkey serum was used in place of goat serum throughout the process.
Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature. The primary antibody solutions were removed, and the cultures
-77-were washed with PBS prior 'L'o application of secondary antibody solutions (1 hour at room temperature) containing block along with goat anti-mouse IgG ¨ Texas Red (1:250; Molecular Probes, Eugene, OR) and/or goat anti-rabbit IgG - Alexa 488 (1:250; Molecular Probes) or donkey anti-goat IgG FITC (1:150, Santa Cruz Biotech). Cultures were washed and 10 microMolar DAPI (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using an appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
In all cases, positive staining represented fluorescence signal above control staining where the entire procedure outlined above was followed, with the exception of application of a primary antibody solution. Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Preparation of cells for FACS analysis. Adherent cells in flasks were washed in phosphate buffered saline (PBS) (Gibco, Carlsbad, CA) and detached with Trypsin/EDTA
(Gibco, Carlsbad, CA). Cells were harvested, centrifuged, and re-suspended in 3% (v/v) FBS in PBS at a cell concentration of lx107 /milliliter. One hundred microliter aliquots were delivered to conical tubes. Cells stained for intracellular antigens were pernaeabilized with Perm/Wash buffer (BD Pharrningen, San Diego, CA). Antibody was added to aliquots as per manufacturer's specifications and the cells were incubated in the dark for 30 minutes at 4 C.
After incubation, cells were washed with PBS and centrifuged to remove excess antibody. Cells requiring a secondary antibody were resuspended in 100 microliter of 3% FBS. Secondary antibody was added as per manufacturer's specification and the cells were incubated in the dark for 30 minutes at 4 C. After incubation, cells were washed with PBS and centrifuged to remove excess secondary antibody. Washed cells were resuspended in 0.5 milliliter PBS and analyzed by flow cytometry. The following antibodies were used: oxidized LDL receptor 1 (sc-5813; Santa Cruz, Biotech), GROa (555042; BD Pharmingen, Bedford, MA), Mouse IgG1 kappa, (P-4685 and M-5284; Sigma), Donkey against Goat IgG (sc-3743; Santa Cruz, Biotech.).
FACS analysis. Flow cytometry analysis was performed with FACScalibur (Becton Dickinson San Jose, CA).
Results Results of real-time PCR for selected "signature" genes performed on cDNA from cells derived from human placentas, adult and neonatal fibroblasts, and Mesenchymal Stem Cells
Following immunostaining, fluorescence was visualized using an appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
In all cases, positive staining represented fluorescence signal above control staining where the entire procedure outlined above was followed, with the exception of application of a primary antibody solution. Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Preparation of cells for FACS analysis. Adherent cells in flasks were washed in phosphate buffered saline (PBS) (Gibco, Carlsbad, CA) and detached with Trypsin/EDTA
(Gibco, Carlsbad, CA). Cells were harvested, centrifuged, and re-suspended in 3% (v/v) FBS in PBS at a cell concentration of lx107 /milliliter. One hundred microliter aliquots were delivered to conical tubes. Cells stained for intracellular antigens were pernaeabilized with Perm/Wash buffer (BD Pharrningen, San Diego, CA). Antibody was added to aliquots as per manufacturer's specifications and the cells were incubated in the dark for 30 minutes at 4 C.
After incubation, cells were washed with PBS and centrifuged to remove excess antibody. Cells requiring a secondary antibody were resuspended in 100 microliter of 3% FBS. Secondary antibody was added as per manufacturer's specification and the cells were incubated in the dark for 30 minutes at 4 C. After incubation, cells were washed with PBS and centrifuged to remove excess secondary antibody. Washed cells were resuspended in 0.5 milliliter PBS and analyzed by flow cytometry. The following antibodies were used: oxidized LDL receptor 1 (sc-5813; Santa Cruz, Biotech), GROa (555042; BD Pharmingen, Bedford, MA), Mouse IgG1 kappa, (P-4685 and M-5284; Sigma), Donkey against Goat IgG (sc-3743; Santa Cruz, Biotech.).
FACS analysis. Flow cytometry analysis was performed with FACScalibur (Becton Dickinson San Jose, CA).
Results Results of real-time PCR for selected "signature" genes performed on cDNA from cells derived from human placentas, adult and neonatal fibroblasts, and Mesenchymal Stem Cells
- 78 -(MSCs) indicate that both oxidized LDL receptor and renin were expressed at higher level in the placenta-derived cells as compared to other cells. The data obtained from real-time PCR were analyzed by the AACT method and expressed on a logarithmic scale. No significant difference in the expression levels of CXC ligand 3 and GCP-2 were found between placenta-derived cells and controls. CXC ligand 3 was expressed at very low levels. GCP-2 was expressed at levels comparable to human adult and neonatal fibroblasts. The results of real-time PCR were confirmed by conventional PCR. Sequencing of PCR products further validated these observations. No significant difference in the expression level of CXC ligand 3 was found between postpartum cells and controls using conventional PCR CXC ligand 3 primers listed in Table 9-1.
The production of the cytokine IL-8 in placenta-derived cells is elevated in both Growth medium-cultured and serum-starved placenta-derived cells. All real-time PCR
data was validated with conventional PCR and by sequencing PCR products.
When supernatants of cells grown in serum-free medium were examined for the presence of IL-8, high amounts were detected in media derived from certain isolates of placenta cells (Table 9-2). No IL-8 was detected in medium derived from human dermal fibroblasts.
Table 9-2. IL-8 protein production measured by ELISA
Cell type IL-8 Human Fibroblasts ND
Placenta Isolate 1 ND
Placenta Isolate 2 ND
Placenta Isolate3 (normal 02) 17.27+8.63 Placenta Isolate 3 (low02, W/O 264.92+9.88 BME) Results of the ELISA assay for interleuldn-8 (IL-8) performed on placenta-derived cells and human sldn fibroblasts. Values are presented here are picogram/million cells, n=2, sem.
ND: Not Detected Placenta-derived cells were examined for the production of oxidized LDL
receptor, GCP-2, and GROalpha by FACS analysis. Cells tested positive for GCP-2. Oxidized LDL receptor and GROalpha were not detected by this method.
Placenta-derived cells were tested for the production of selected proteins by immunocytochemical analysis. Immediately after isolation (passage 0), cells derived from the human placenta were fixed with 4% paraformaldehyde and exposed to antibodies for six proteins: von Willebrand Factor, CD34, cytokeratin 18, desmin, alpha-smooth muscle actin, and vimentin. Cells stained positive for both alpha-smooth muscle actin and vimentin. This pattern
The production of the cytokine IL-8 in placenta-derived cells is elevated in both Growth medium-cultured and serum-starved placenta-derived cells. All real-time PCR
data was validated with conventional PCR and by sequencing PCR products.
When supernatants of cells grown in serum-free medium were examined for the presence of IL-8, high amounts were detected in media derived from certain isolates of placenta cells (Table 9-2). No IL-8 was detected in medium derived from human dermal fibroblasts.
Table 9-2. IL-8 protein production measured by ELISA
Cell type IL-8 Human Fibroblasts ND
Placenta Isolate 1 ND
Placenta Isolate 2 ND
Placenta Isolate3 (normal 02) 17.27+8.63 Placenta Isolate 3 (low02, W/O 264.92+9.88 BME) Results of the ELISA assay for interleuldn-8 (IL-8) performed on placenta-derived cells and human sldn fibroblasts. Values are presented here are picogram/million cells, n=2, sem.
ND: Not Detected Placenta-derived cells were examined for the production of oxidized LDL
receptor, GCP-2, and GROalpha by FACS analysis. Cells tested positive for GCP-2. Oxidized LDL receptor and GROalpha were not detected by this method.
Placenta-derived cells were tested for the production of selected proteins by immunocytochemical analysis. Immediately after isolation (passage 0), cells derived from the human placenta were fixed with 4% paraformaldehyde and exposed to antibodies for six proteins: von Willebrand Factor, CD34, cytokeratin 18, desmin, alpha-smooth muscle actin, and vimentin. Cells stained positive for both alpha-smooth muscle actin and vimentin. This pattern
- 79 was preserved through passage 11. Only a few cells (<5%) at passage 0 stained positive for cytokeratin 18.
Placenta-derived cells at passage 11 were also investigated by immunocytochemistry for the production of GROalpha and GCP-2. Placenta-derived cells were GCP-2 positive, but GROalpha production was not detected by this method.
Summary. Accordance between gene expression levels measured by microarray and PCR (both real-time and conventional) has been established for four genes:
oxidized LDL
receptor 1, renin, reticulon, and IL-8. The expression of these genes was differentially regulated at the mR_NA level in placenta-derived cells, with IL-8 also differentially regulated at the protein level. The presence of mddi7ed LDL receptor was not detected at the protein level by FACS
analysis in cells derived from the placenta. Differential expression of GCP-2 and CXC ligand 3 was not confirmed at the mRNA level, however, GCP-2 was detected at the protein level by FACS analysis in the placenta-derived cells. Although this result may not be fully consistent with data obtained from the micro array experiment, any inconsistency may simply be due to differences in the sensitivity of the methodologies.
Immediately after isolation (passage 0), cells derived from the human placenta stained positive for both alpha-smooth muscle actin and vimentin. This pattern was also observed in cells at passage 11. These results suggest that vimentin and alpha-smooth muscle actin production is preserved in cells with passaging, for example, in the Growth medium used here.
Immunohistochemical Characterization of PDC Phenotype The phenotypes of cells found within human placental tissue was analyzed by immunohistochemistry.
Materials & Methods Tissue Preparation. Human placenta tissue was harvested and immersion-fixed in 4%
(w/v) paraformaldehyde overnight at 4 C. Immunohistochemistry was performed using antibodies directed against the following epitopes (see Table 10-1): vimentin (1:500; Sigma, St.
Louis, MO), desmin (1:150, raised against rabbit; Sigma; or 1:300, raised against mouse;
Chemicon, Temecula, CA), alpha-smooth muscle actin (SMA; 1:400; Sigma), cytokeratin 18 (CK18; 1:400; Sigma), von Willebrand Factor (vWF; 1:200; Sigma), and CD34 (human CD34 Class III; 1:100; DAKOCytomation, Carpinteria, CA). In addition, the following markers were tested: anti-human GROalpha - PE (1:100; Becton Dickinson, Franklin Lakes, NJ), anti-human
Placenta-derived cells at passage 11 were also investigated by immunocytochemistry for the production of GROalpha and GCP-2. Placenta-derived cells were GCP-2 positive, but GROalpha production was not detected by this method.
Summary. Accordance between gene expression levels measured by microarray and PCR (both real-time and conventional) has been established for four genes:
oxidized LDL
receptor 1, renin, reticulon, and IL-8. The expression of these genes was differentially regulated at the mR_NA level in placenta-derived cells, with IL-8 also differentially regulated at the protein level. The presence of mddi7ed LDL receptor was not detected at the protein level by FACS
analysis in cells derived from the placenta. Differential expression of GCP-2 and CXC ligand 3 was not confirmed at the mRNA level, however, GCP-2 was detected at the protein level by FACS analysis in the placenta-derived cells. Although this result may not be fully consistent with data obtained from the micro array experiment, any inconsistency may simply be due to differences in the sensitivity of the methodologies.
Immediately after isolation (passage 0), cells derived from the human placenta stained positive for both alpha-smooth muscle actin and vimentin. This pattern was also observed in cells at passage 11. These results suggest that vimentin and alpha-smooth muscle actin production is preserved in cells with passaging, for example, in the Growth medium used here.
Immunohistochemical Characterization of PDC Phenotype The phenotypes of cells found within human placental tissue was analyzed by immunohistochemistry.
Materials & Methods Tissue Preparation. Human placenta tissue was harvested and immersion-fixed in 4%
(w/v) paraformaldehyde overnight at 4 C. Immunohistochemistry was performed using antibodies directed against the following epitopes (see Table 10-1): vimentin (1:500; Sigma, St.
Louis, MO), desmin (1:150, raised against rabbit; Sigma; or 1:300, raised against mouse;
Chemicon, Temecula, CA), alpha-smooth muscle actin (SMA; 1:400; Sigma), cytokeratin 18 (CK18; 1:400; Sigma), von Willebrand Factor (vWF; 1:200; Sigma), and CD34 (human CD34 Class III; 1:100; DAKOCytomation, Carpinteria, CA). In addition, the following markers were tested: anti-human GROalpha - PE (1:100; Becton Dickinson, Franklin Lakes, NJ), anti-human
- 80 -GCP-2 (1:100; Santa Cruz Biotech, Santa Cruz, CA), anti-human oxidized LDL
receptor 1 (ox-LDL R1; 1:100; Santa Cruz Biotech), and anti-human NOGO-A (1:100; Santa Cruz Biotech).
Fixed specimens were trimmed with a scalpel and placed within OCT embedding compound (Tissue-Tek OCT; Sakura, Torrance, CA) on a dry ice bath containing ethanol.
Frozen blocks were then sectioned (10 micron thick) using a standard cryostat (Leica Microsystems) and mounted onto glass slides for staining.
Table 10-1: Summary of Primary Antibodies Used Antibody Concentration Vendor Vimentin 1:500 Sigma, St. Louis, MO
Desmin (rb) 1:150 Sigma Desmin (m) 1:300 Chemicon, Temecula, CA
alpha-smooth muscle actin 1:400 Sigma (SMA) Cytokeratin 18 (CK18) 1:400 Sigma von Willebrand factor (vWF) 1:200 Sigma CD34 III 1:100 DakoCytomation, Carpinteria, CA
GROalpha ¨ PE 1:100 BD, Franklin Lakes, NJ
GCP-2 1:100 Santa Cruz Biotech Ox-LDL R1 1:100 Santa Cruz Biotech NOGO-A 1:100 Santa Cruz Biotech Immunohistochemistry. Immunohistochemistry was performed similar to previous studies (e.g., Messina, et al. (2003) Exper. Neurol. 184: 816-829). Tissue sections were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100;
Sigma) for 1 hour to access intracellular antigens. In instances where the epitope of interest would be located on the cell surface (CD34, ox-LDL R1), triton was omitted in all steps of the procedure in order to prevent epitope loss. Furthermore, in instances where the primary antibody was raised against goat (GCP-2, ox-LDL R1, NOGO-A), 3% (v/v) donkey serum was used in place of goat serum throughout the procedure. Primary antibodies, diluted in blocking solution, were then applied to the sections for a period of 4 hours at room temperature.
Primary antibody solutions were removed, and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing block along with goat anti-mouse
receptor 1 (ox-LDL R1; 1:100; Santa Cruz Biotech), and anti-human NOGO-A (1:100; Santa Cruz Biotech).
Fixed specimens were trimmed with a scalpel and placed within OCT embedding compound (Tissue-Tek OCT; Sakura, Torrance, CA) on a dry ice bath containing ethanol.
Frozen blocks were then sectioned (10 micron thick) using a standard cryostat (Leica Microsystems) and mounted onto glass slides for staining.
Table 10-1: Summary of Primary Antibodies Used Antibody Concentration Vendor Vimentin 1:500 Sigma, St. Louis, MO
Desmin (rb) 1:150 Sigma Desmin (m) 1:300 Chemicon, Temecula, CA
alpha-smooth muscle actin 1:400 Sigma (SMA) Cytokeratin 18 (CK18) 1:400 Sigma von Willebrand factor (vWF) 1:200 Sigma CD34 III 1:100 DakoCytomation, Carpinteria, CA
GROalpha ¨ PE 1:100 BD, Franklin Lakes, NJ
GCP-2 1:100 Santa Cruz Biotech Ox-LDL R1 1:100 Santa Cruz Biotech NOGO-A 1:100 Santa Cruz Biotech Immunohistochemistry. Immunohistochemistry was performed similar to previous studies (e.g., Messina, et al. (2003) Exper. Neurol. 184: 816-829). Tissue sections were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100;
Sigma) for 1 hour to access intracellular antigens. In instances where the epitope of interest would be located on the cell surface (CD34, ox-LDL R1), triton was omitted in all steps of the procedure in order to prevent epitope loss. Furthermore, in instances where the primary antibody was raised against goat (GCP-2, ox-LDL R1, NOGO-A), 3% (v/v) donkey serum was used in place of goat serum throughout the procedure. Primary antibodies, diluted in blocking solution, were then applied to the sections for a period of 4 hours at room temperature.
Primary antibody solutions were removed, and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing block along with goat anti-mouse
- 81 -IgG ¨ Texas Red (1:250; Molecular Probes, Eugene, OR) and/or goat anti-rabbit IgG - Alexa 488 (1:250; Molecular Probes) or donkey anti-goat IgG ¨ FITC (1:150; Santa Cruz Biotech).
Cultures were washed, and 10 microMolar DAFT (Molecular Probes) was applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-flUorescent microscope (Olympus, Melville, NY).
Positive staining was represented by fluorescence signal above control staining. Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results Placenta Characterization. Vimentin, desmin, SMA, CK18, vWF, and CD34 were all observed within the placenta and regionally specific.
GROalpha, GCP-2, ox-LDL R1, and NOGO-A Tissue Expression. None of these markers were observed within placental tissue.
Summary. Vimentin, desmin, alpha-smooth muscle actin, cytokeratin 18, von Willebrand Factor, and CD34 are expressed in cells within human placenta.
In Vitro Immunology Postpartum cell lines were evaluated in vitro for their immunological characteristics in an effort to predict the immunological response, if any, these cells would elicit upon in vivo transplantation. Postpartum cell lines were assayed by flow cytometry for the production of HLA-DR, HLA-DP, HLA-DQ, CD80, CD86, and B7-H2. These proteins are expressed by antigen-presenting cells (APC) and are required for the direct stimulation of naïve CD4+ T cells (Abbas & Lichtman, CELLULAR AND MOLECULAR IMMUNOLOGY, 5th Ed. (2003) Saunders, Philadelphia, p. 171). The cell lines were also analyzed by flow cytometry for the production of HLA-G (Abbas & Lichtman, CELLULAR AND MOLECULAR IMMUNOLOGY, 5th Ed. (2003) Saunders, Philadelphia, p. 171), CD 178 (Coumans, et.al., (1999) Journal of Immunological Methods 224, 185-196), and PD-L2 (Abbas & Lichtman, CELLULAR AND MOLECULAR
IMMUNOLOGY, 5th Ed. (2003) Saunders, Philadelphia, p. 171; Brown, et. al.
(2003) The Journal of Immunology 170, 1257-1266). The production of these proteins by cells residing in placental
Cultures were washed, and 10 microMolar DAFT (Molecular Probes) was applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-flUorescent microscope (Olympus, Melville, NY).
Positive staining was represented by fluorescence signal above control staining. Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results Placenta Characterization. Vimentin, desmin, SMA, CK18, vWF, and CD34 were all observed within the placenta and regionally specific.
GROalpha, GCP-2, ox-LDL R1, and NOGO-A Tissue Expression. None of these markers were observed within placental tissue.
Summary. Vimentin, desmin, alpha-smooth muscle actin, cytokeratin 18, von Willebrand Factor, and CD34 are expressed in cells within human placenta.
In Vitro Immunology Postpartum cell lines were evaluated in vitro for their immunological characteristics in an effort to predict the immunological response, if any, these cells would elicit upon in vivo transplantation. Postpartum cell lines were assayed by flow cytometry for the production of HLA-DR, HLA-DP, HLA-DQ, CD80, CD86, and B7-H2. These proteins are expressed by antigen-presenting cells (APC) and are required for the direct stimulation of naïve CD4+ T cells (Abbas & Lichtman, CELLULAR AND MOLECULAR IMMUNOLOGY, 5th Ed. (2003) Saunders, Philadelphia, p. 171). The cell lines were also analyzed by flow cytometry for the production of HLA-G (Abbas & Lichtman, CELLULAR AND MOLECULAR IMMUNOLOGY, 5th Ed. (2003) Saunders, Philadelphia, p. 171), CD 178 (Coumans, et.al., (1999) Journal of Immunological Methods 224, 185-196), and PD-L2 (Abbas & Lichtman, CELLULAR AND MOLECULAR
IMMUNOLOGY, 5th Ed. (2003) Saunders, Philadelphia, p. 171; Brown, et. al.
(2003) The Journal of Immunology 170, 1257-1266). The production of these proteins by cells residing in placental
- 82 -tissues is thought to mediate the immuno-privileged status of placental tissues in utero. To predict the extent to which placenta-derived cell lines elicit an immune response in vivo, the cell lines were tested in a one-way mixed lymphocyte, reaction (MLR).
Materials and Methods Cell culture. Cells were cultured in Growth Medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (PBS); (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)) until confluent in T75 flasks (Coming, Corning, NY) coated with 2% gelatin (Sigma, St. Louis, MO).
Antibody Staining. Cells were washed in phosphate buffered saline (PBS) (Gibco, Carlsbad, CA) and detached with Trypsin/EDTA (Gibco, Carlsbad, CA). Cells were harvested, centrifuged, and re-suspended in 3% (v/v) FBS in PBS at a cell concentration of 1x107 per milliliter. Antibody (Table 11-1) was added to one hundred microliters of cell suspension as per manufacturer's specifications and incubated in the dark for 30 minutes at 4 C.
After incubation, cells were washed with PBS and centrifuged to remove unbound antibody. Cells were re-suspended in five hundred microliters of PBS and analyzed by flow cytometry using a FACSCalibur instrument (Becton Dickinson, San Jose, CA).
Table 11-1. Antibodies Antibody Manufacturer Catalog Number HLA-DRDPDQ BD Pharmingen (San Diego, 555558 CA) CD80 BD Pharmingen (San Diego, 557227 CA) CD86 BD Pharmingen (San Diego, 555665 CA) B7-H2 BD Pharmingen (San Diego, 552502 CA) HLA-G Abcam (Cambridgeshire, UK) ab 7904-100 CD 178 Santa Cruz (San Cruz, CA) sc-19681 PD-L2 BD Pharmingen (San Diego, 557846 CA) Mouse IgG2a Sigma (St. Louis, MO) F-6522 Mouse IgGlkappa Sigma (St. Louis, MO) P-4685 Mixed Lymphocyte Reaction. Cryopreserved vials of passage 11 placenta-derived PDCs labeled as cell line B were sent on dry ice to CTBR (Senneville, Quebec) to conduct a mixed lymphocyte reaction using CTBR SOP no. CAC-031. Peripheral blood mononuclear cells
Materials and Methods Cell culture. Cells were cultured in Growth Medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (PBS); (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)) until confluent in T75 flasks (Coming, Corning, NY) coated with 2% gelatin (Sigma, St. Louis, MO).
Antibody Staining. Cells were washed in phosphate buffered saline (PBS) (Gibco, Carlsbad, CA) and detached with Trypsin/EDTA (Gibco, Carlsbad, CA). Cells were harvested, centrifuged, and re-suspended in 3% (v/v) FBS in PBS at a cell concentration of 1x107 per milliliter. Antibody (Table 11-1) was added to one hundred microliters of cell suspension as per manufacturer's specifications and incubated in the dark for 30 minutes at 4 C.
After incubation, cells were washed with PBS and centrifuged to remove unbound antibody. Cells were re-suspended in five hundred microliters of PBS and analyzed by flow cytometry using a FACSCalibur instrument (Becton Dickinson, San Jose, CA).
Table 11-1. Antibodies Antibody Manufacturer Catalog Number HLA-DRDPDQ BD Pharmingen (San Diego, 555558 CA) CD80 BD Pharmingen (San Diego, 557227 CA) CD86 BD Pharmingen (San Diego, 555665 CA) B7-H2 BD Pharmingen (San Diego, 552502 CA) HLA-G Abcam (Cambridgeshire, UK) ab 7904-100 CD 178 Santa Cruz (San Cruz, CA) sc-19681 PD-L2 BD Pharmingen (San Diego, 557846 CA) Mouse IgG2a Sigma (St. Louis, MO) F-6522 Mouse IgGlkappa Sigma (St. Louis, MO) P-4685 Mixed Lymphocyte Reaction. Cryopreserved vials of passage 11 placenta-derived PDCs labeled as cell line B were sent on dry ice to CTBR (Senneville, Quebec) to conduct a mixed lymphocyte reaction using CTBR SOP no. CAC-031. Peripheral blood mononuclear cells
- 83 -(PBMCs) were collected from multiple male and female volunteer donors.
Stimulator (donor) allogeneic PBMC, autologous PBMC, and placenta-derived cell lines were treated with mitomycin C. Autologous and mitomycin C-treated stimulator cells were added to responder (recipient) PBMCs and cultured for 4 days. After incubation, [31I]thymidine was added to each sample and cultured for 18 hours. Following harvest of the cells, radiolabeled DNA was extracted, and {3111-thymidine incorporation was measured using a scintillation counter.
The stimulation index for the allogeneic donor (SIAD) was calculated as the mean proliferation of the receiver plus mitomycin C-treated allogeneic donor divided by the baseline proliferation of the receiver. The stimulation index of the placenta-derived cell was calculated as the mean proliferation of the receiver plus mitomycin C-treated placenta-derived cell line divided by the baseline proliferation of the receiver.
Results Mixed Lymphocyte Reaction-Placenta. Seven human volunteer blood donors were screened to identify a single allogeneic donor that would exhibit a robust proliferation response in a mixed lymphocyte reaction with the other six blood donors. This donor was selected as the allogeneic positive control donor. The remaining six blood donors were selected as recipients.
The allogeneic positive control donor and placenta cell lines were treated with mitomycin C and cultured in a mixed lymphocyte reaction with the six individual allogeneic receivers. Reactions were performed in triplicate using two cell culture plates with three receivers per plate (Table 11-2). The average stimulation index ranged from 1.3 (plate 2) to 3 (plate 1) and the allogeneic donor positive controls ranged from 46.25 (plate 2) to 279 (plate 1) (Table 11-3).
Stimulator (donor) allogeneic PBMC, autologous PBMC, and placenta-derived cell lines were treated with mitomycin C. Autologous and mitomycin C-treated stimulator cells were added to responder (recipient) PBMCs and cultured for 4 days. After incubation, [31I]thymidine was added to each sample and cultured for 18 hours. Following harvest of the cells, radiolabeled DNA was extracted, and {3111-thymidine incorporation was measured using a scintillation counter.
The stimulation index for the allogeneic donor (SIAD) was calculated as the mean proliferation of the receiver plus mitomycin C-treated allogeneic donor divided by the baseline proliferation of the receiver. The stimulation index of the placenta-derived cell was calculated as the mean proliferation of the receiver plus mitomycin C-treated placenta-derived cell line divided by the baseline proliferation of the receiver.
Results Mixed Lymphocyte Reaction-Placenta. Seven human volunteer blood donors were screened to identify a single allogeneic donor that would exhibit a robust proliferation response in a mixed lymphocyte reaction with the other six blood donors. This donor was selected as the allogeneic positive control donor. The remaining six blood donors were selected as recipients.
The allogeneic positive control donor and placenta cell lines were treated with mitomycin C and cultured in a mixed lymphocyte reaction with the six individual allogeneic receivers. Reactions were performed in triplicate using two cell culture plates with three receivers per plate (Table 11-2). The average stimulation index ranged from 1.3 (plate 2) to 3 (plate 1) and the allogeneic donor positive controls ranged from 46.25 (plate 2) to 279 (plate 1) (Table 11-3).
- 84-Table 11-2. Mixed Lymphocyte Reaction Data - Cell Line B (Placenta) = DPM for Proliferation Assay ___________________________________ . . .
. 1 Plate ID: Platel i i __ I
. I t=-=
, Analytical Culture Replicates number System 1 i 2 i 3 Mean SD CV
Proliferation baseline of receiver 79 I 119 138 112.0 30.12 26.9 Control of autostimulation (Mtornycin C treated autologous cells) 241 ........72 175 229.3 49.54 21.6 MLR allogenic donor IM03-7768 (Mtomycin C treated) 23971 I22352 20921 22414.7 1525.97_ 6.8 . _ MLR with cell line (Mtomycin C treated cell type B) 664 1 559 1090 771.0 -281.21 36.5 SI (donor) 1 I 200 SI (cell line) i 7 Proliferation baseline of receiver 206 1 134 262 200.7 64.17 32.0 IM03-7770 Control of autostimulation (Mtomycin C
treated autologous cells) 1091 1 602 -524 - 739.0 ' 307.33 41.6 MLR allogenic donor 9103-7768 (Mtonvcin C treated) 45005 I 43729 44071 44268.3 660.49 1.5 -...i.
MLR with cell line (Mtomycin C treated cell type E3) 533 I 2582 2376 1830.3 1128.24 61.6 SI (donor) I .
SI (cell line) 1 9 Proliferation baseline of receiver 157 ! 87 1 128 124.0 35.17 28.4 Control of autostimulation (Mtomycin C treated autologous cells) 293 ;
138 1 508 313.0 185.81 59.4 r MLR allogenic donor I1103-7768 (Mtomycin C treated) 24497 i 34348 31388 30077.7 5054.53 16.8 MLR with cell line (tvItornycin C treated cell type B) 601 1 643 a 622.0 29.70 4.8 SI (donor) I i 243 :
SI (cell line) I _______________________________ 15 1 i= , 1 Roliferation baseline of receiver 56 1 98 51 68.3 25.81 37.8 ==, Control of autostimulation (Mtomycin C treated autologous cells) 133 I
120 213 155.3 50.36 32.4 _ MLR allogenic donor I1103-7766 (Mtomycin C treated) - 14222 I 20076 22168 18822.0 4118.75 21.9 i MLR w ith cell line (Mtomycin C treated cell type B) a i a a a a a SI (donor) i I i ! 275 SI (cell line) i I a i .
IM03-7768 Proliferation baseline of receiver 84 I 242 208 178.0 83.16 46.7 (allogenic donor) Control of autostimulation (Mtomycin treated autologous cells) 361 -t 617 304 427.3 166.71 39.0 i I .=== 1 Cell line e B Proliferation baseline of receiver 126 I 124 143 131.0 10.44 8.0 typ Control of autostimulation (Mtomycin treated autologous cells) 822 i 1075 487 794.7 294.95 37.1 .= I I
.=
. .
:
Plate ID: Plate 2 Analytical Culture Replicates number System 1 2 3 Mean SD
CV , Proliferation baieline of receiver 908 181 330 473.0 384.02 81.2 IM03-7773 Control of autostimulation (Mitomycin C
treated autologous cells) 269 405 572 415.3 151.76 36.5 MLR allogenic donor IM03-7768 (Mitomycin C 'treated) 29151 28691 28315 28719.0 418.70 1.5 MLR with cell line (Mitomycin C treated cell type B) 567 732 905 734.7 169.02 23.0 SI (donor) 61 SI (cell line) 2 Proliferation baseline of receiver 893 1376 185 818.0 599.03 73.2 IM03-7774 Control of autostimulation (Mitomycin C
treated autologous cells) 261 381 568 403.3 154.71 38.4 MLR allogenic donor IM03-7768 (Mitomycin C treated) 53101 42839 48283 48074.3 5134.18 10.7 MLR with cell line (Mitomycin C treated cell type B) 515 789 294 532.7 247.97 46.6 SI (donor) 59 SI (cell line) 1 Proliferation baseline of receiver 1272 300 544 705.3 505.69 71.7 IM03-7775 Control of autostimulation (Mitomycin C
treated autologous cells) 232 199 484 305.0 155.89 51.1 MLR allogenic donor IM03-776B (Mitomycin C treated) 23554 10523 28965 21014.0 9479.74 45.1 MLR with cell line (Mitomycin C treated cell type 6) 768 924 563 751.7 181.05 24.1 SI (donor) 30 SI (cell line) 1 Proliferation baseline of receiver 1530 137 1046 904.3 707.22 78.2 IM03-7776 Control of autostimulation (Mitomycin C
treated autologous cells) 420 218 394 344.0 109.89 31.9 MLR allogenic donor IM03-7768 (Mitomycin C treated) 28893 32493 34746 32044.0 2952.22 9.2 MLR with cell line (Mitomycin C treated cell type B) a a a a a a SI (donor) 35 SI (cell line) a I
. 1 Plate ID: Platel i i __ I
. I t=-=
, Analytical Culture Replicates number System 1 i 2 i 3 Mean SD CV
Proliferation baseline of receiver 79 I 119 138 112.0 30.12 26.9 Control of autostimulation (Mtornycin C treated autologous cells) 241 ........72 175 229.3 49.54 21.6 MLR allogenic donor IM03-7768 (Mtomycin C treated) 23971 I22352 20921 22414.7 1525.97_ 6.8 . _ MLR with cell line (Mtomycin C treated cell type B) 664 1 559 1090 771.0 -281.21 36.5 SI (donor) 1 I 200 SI (cell line) i 7 Proliferation baseline of receiver 206 1 134 262 200.7 64.17 32.0 IM03-7770 Control of autostimulation (Mtomycin C
treated autologous cells) 1091 1 602 -524 - 739.0 ' 307.33 41.6 MLR allogenic donor 9103-7768 (Mtonvcin C treated) 45005 I 43729 44071 44268.3 660.49 1.5 -...i.
MLR with cell line (Mtomycin C treated cell type E3) 533 I 2582 2376 1830.3 1128.24 61.6 SI (donor) I .
SI (cell line) 1 9 Proliferation baseline of receiver 157 ! 87 1 128 124.0 35.17 28.4 Control of autostimulation (Mtomycin C treated autologous cells) 293 ;
138 1 508 313.0 185.81 59.4 r MLR allogenic donor I1103-7768 (Mtomycin C treated) 24497 i 34348 31388 30077.7 5054.53 16.8 MLR with cell line (tvItornycin C treated cell type B) 601 1 643 a 622.0 29.70 4.8 SI (donor) I i 243 :
SI (cell line) I _______________________________ 15 1 i= , 1 Roliferation baseline of receiver 56 1 98 51 68.3 25.81 37.8 ==, Control of autostimulation (Mtomycin C treated autologous cells) 133 I
120 213 155.3 50.36 32.4 _ MLR allogenic donor I1103-7766 (Mtomycin C treated) - 14222 I 20076 22168 18822.0 4118.75 21.9 i MLR w ith cell line (Mtomycin C treated cell type B) a i a a a a a SI (donor) i I i ! 275 SI (cell line) i I a i .
IM03-7768 Proliferation baseline of receiver 84 I 242 208 178.0 83.16 46.7 (allogenic donor) Control of autostimulation (Mtomycin treated autologous cells) 361 -t 617 304 427.3 166.71 39.0 i I .=== 1 Cell line e B Proliferation baseline of receiver 126 I 124 143 131.0 10.44 8.0 typ Control of autostimulation (Mtomycin treated autologous cells) 822 i 1075 487 794.7 294.95 37.1 .= I I
.=
. .
:
Plate ID: Plate 2 Analytical Culture Replicates number System 1 2 3 Mean SD
CV , Proliferation baieline of receiver 908 181 330 473.0 384.02 81.2 IM03-7773 Control of autostimulation (Mitomycin C
treated autologous cells) 269 405 572 415.3 151.76 36.5 MLR allogenic donor IM03-7768 (Mitomycin C 'treated) 29151 28691 28315 28719.0 418.70 1.5 MLR with cell line (Mitomycin C treated cell type B) 567 732 905 734.7 169.02 23.0 SI (donor) 61 SI (cell line) 2 Proliferation baseline of receiver 893 1376 185 818.0 599.03 73.2 IM03-7774 Control of autostimulation (Mitomycin C
treated autologous cells) 261 381 568 403.3 154.71 38.4 MLR allogenic donor IM03-7768 (Mitomycin C treated) 53101 42839 48283 48074.3 5134.18 10.7 MLR with cell line (Mitomycin C treated cell type B) 515 789 294 532.7 247.97 46.6 SI (donor) 59 SI (cell line) 1 Proliferation baseline of receiver 1272 300 544 705.3 505.69 71.7 IM03-7775 Control of autostimulation (Mitomycin C
treated autologous cells) 232 199 484 305.0 155.89 51.1 MLR allogenic donor IM03-776B (Mitomycin C treated) 23554 10523 28965 21014.0 9479.74 45.1 MLR with cell line (Mitomycin C treated cell type 6) 768 924 563 751.7 181.05 24.1 SI (donor) 30 SI (cell line) 1 Proliferation baseline of receiver 1530 137 1046 904.3 707.22 78.2 IM03-7776 Control of autostimulation (Mitomycin C
treated autologous cells) 420 218 394 344.0 109.89 31.9 MLR allogenic donor IM03-7768 (Mitomycin C treated) 28893 32493 34746 32044.0 2952.22 9.2 MLR with cell line (Mitomycin C treated cell type B) a a a a a a SI (donor) 35 SI (cell line) a I
-85-Table 11-3. Average stimulation index of placenta cells and an allogeneic donor in a mixed lymphocyte reaction with six individual allogeneic receivers.
Average Stimulation Index Recipient Placenta Plate 1 (receivers 1-3) 279 3 Plate 2 (receivers 4-6) 46.25 1.3 Antigen Presenting Cell Markers - Placenta. Histograms of placenta-derived cells analyzed by flow cytometry show negative for production of HLA-DR, DP, DQ, CD80, CD86, and B7-H2, as noted by fluorescence value consistent with the IgG control, indicating that placental cell lines lack the cell surface molecules required to directly stimulate allogeneic PBMCs (e.g., CD4+ T cells).
Immuno-modulating Markers - Placenta. Histograms of placenta-derived cells analyzed by flow cytometry show positive for production of PD-L2, as noted by the increased value of fluorescence relative to the IgG control, and negative for production of CD178 and HLA-G, as noted by fluorescence value consistent with the IgG control.
Summary. In the mixed lymphocyte reactions conducted with placenta-derived cell lines, the average stimulation index ranged from 1.3 to 3, and that of the allogeneic positive controls ranged from 46.25 to 279. Placenta-derived cell lines were negative for the production of the stimulating proteins HLA-DR, HLA-DP, HLA-DQ, CD80, CD86, and B7-H2, as measured by flow cytometry. Placenta-derived cell lines were negative for the production of immuno-modulating proteins HLA-G and CD178 and positive for the production of PD-L2, as measured by flow cytometry. Allogeneic donor PBMCs contain antigen-presenting cells expressing HLA-DP, DR, DQ, CD80, CD86, and B7-H2, thereby allowing for the stimulation of allogeneic PBMCs (e.g., naive CD4+ T cells). The absence of antigen-presenting cell surface molecules on placenta-derived cells required for the direct stimulation of allogeneic PBMCs (e.g., naive CD4+ T cells) and the presence of PD-L2, an immuno-modulating protein, may account for the low stimulation index exhibited by these cells in a MLR as compared to allogeneic controls.
Secretion of Trophic Factors by Placenta-Derived Cells The secretion of selected trophic factors from PDCs was measured. Factors were selected that have angiogenic activity (i.e., hepatocyte growth factor (HGF) (Rosen et al. (1997)
Average Stimulation Index Recipient Placenta Plate 1 (receivers 1-3) 279 3 Plate 2 (receivers 4-6) 46.25 1.3 Antigen Presenting Cell Markers - Placenta. Histograms of placenta-derived cells analyzed by flow cytometry show negative for production of HLA-DR, DP, DQ, CD80, CD86, and B7-H2, as noted by fluorescence value consistent with the IgG control, indicating that placental cell lines lack the cell surface molecules required to directly stimulate allogeneic PBMCs (e.g., CD4+ T cells).
Immuno-modulating Markers - Placenta. Histograms of placenta-derived cells analyzed by flow cytometry show positive for production of PD-L2, as noted by the increased value of fluorescence relative to the IgG control, and negative for production of CD178 and HLA-G, as noted by fluorescence value consistent with the IgG control.
Summary. In the mixed lymphocyte reactions conducted with placenta-derived cell lines, the average stimulation index ranged from 1.3 to 3, and that of the allogeneic positive controls ranged from 46.25 to 279. Placenta-derived cell lines were negative for the production of the stimulating proteins HLA-DR, HLA-DP, HLA-DQ, CD80, CD86, and B7-H2, as measured by flow cytometry. Placenta-derived cell lines were negative for the production of immuno-modulating proteins HLA-G and CD178 and positive for the production of PD-L2, as measured by flow cytometry. Allogeneic donor PBMCs contain antigen-presenting cells expressing HLA-DP, DR, DQ, CD80, CD86, and B7-H2, thereby allowing for the stimulation of allogeneic PBMCs (e.g., naive CD4+ T cells). The absence of antigen-presenting cell surface molecules on placenta-derived cells required for the direct stimulation of allogeneic PBMCs (e.g., naive CD4+ T cells) and the presence of PD-L2, an immuno-modulating protein, may account for the low stimulation index exhibited by these cells in a MLR as compared to allogeneic controls.
Secretion of Trophic Factors by Placenta-Derived Cells The secretion of selected trophic factors from PDCs was measured. Factors were selected that have angiogenic activity (i.e., hepatocyte growth factor (HGF) (Rosen et al. (1997)
- 86 -Ciba Found. Symp. 212:215-26), monocyte chemotactic protein 1 (MCP-1) (Salcedo et al.
(2000) Blood 96;34-40), interleukin-8 (IL-8) ( Li et al. (2003) J. Immunol.
170:3369-76), keratinocyte growth factor (KGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) (Hughes et al. (2004) Ann. Thorac. Surg. 77:812-8), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), thrombopoietin (TPO), heparin-binding epidermal growth factor (1{B-EGF), stromal-derived factor lalpha (SDF-lalpha)), neurotrophic/neuroprotective activity (brain-derived neurotrophic factor (BDNF) (Cheng et al. (2003) Dev. Biol. 258;319-33), interleukin-6 (IL-6), granulocyte chemotactic protein-2 (GCP-2), transforming growth factor beta2 (TGFbeta2)), or chemokine activity (macrophage inflammatory protein lalpha (MIP1a), macrophage inflammatory protein lbeta (MIP lb), monocyte chemoattractant-1 (MCP-1), Rantes (regulated on activation, normal T cell expressed and secreted), 1309, thymus and activation-regulated chemokine (TARC), Eotaxin, macrophage-derived chemokine (MDC), IL-8).
Methods & Materials Cell culture. PDCs derived from placenta and human fibroblasts derived from human neonatal foreskin were cultured in Growth Medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (SH30070.03; Hyclone, Logan, UT), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) on gelatin-coated T75 flasks.
Cells were cryopreserved at passage 11 and stored in liquid nitrogen. After thawing of the cells, Growth Medium was added to the cells followed by transfer to a 15 milliliter centrifuge tube and centrifugation of the cells at 150 x g for 5 minutes. The supernatant was discarded. The cell pellet was resuspended in 4 milliliters Growth Medium, and cells were counted.
Cells were seeded at 5,000 cells/cm2 on a T75 flask containing 15 milliliters of Growth Medium and cultured for 24 hours. The medium was changed to a serum-free medium (DMEM-low glucose (Gibco), 0.1% (w/v) bovine serum albumin (Sigma), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) for 8 hours. Conditioned serum-free media was collected at the end of incubation by centrifugation at 14,000 x g for 5 minutes and stored at ¨
20 C. To estimate the number of cells in each flask, cells were washed with phosphate-buffered saline (PBS) and detached using 2 milliliters trypsin/EDTA (Gibco). Trypsin activity was inhibited by addition of 8 milliliters Growth Medium. Cells were centrifuged at 150 x g for 5 minutes. Supernatant was removed, and cells were resuspended in 1 milliliter Growth Medium.
Cell number was estimated using a hemocytometer.
(2000) Blood 96;34-40), interleukin-8 (IL-8) ( Li et al. (2003) J. Immunol.
170:3369-76), keratinocyte growth factor (KGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) (Hughes et al. (2004) Ann. Thorac. Surg. 77:812-8), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), thrombopoietin (TPO), heparin-binding epidermal growth factor (1{B-EGF), stromal-derived factor lalpha (SDF-lalpha)), neurotrophic/neuroprotective activity (brain-derived neurotrophic factor (BDNF) (Cheng et al. (2003) Dev. Biol. 258;319-33), interleukin-6 (IL-6), granulocyte chemotactic protein-2 (GCP-2), transforming growth factor beta2 (TGFbeta2)), or chemokine activity (macrophage inflammatory protein lalpha (MIP1a), macrophage inflammatory protein lbeta (MIP lb), monocyte chemoattractant-1 (MCP-1), Rantes (regulated on activation, normal T cell expressed and secreted), 1309, thymus and activation-regulated chemokine (TARC), Eotaxin, macrophage-derived chemokine (MDC), IL-8).
Methods & Materials Cell culture. PDCs derived from placenta and human fibroblasts derived from human neonatal foreskin were cultured in Growth Medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (SH30070.03; Hyclone, Logan, UT), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) on gelatin-coated T75 flasks.
Cells were cryopreserved at passage 11 and stored in liquid nitrogen. After thawing of the cells, Growth Medium was added to the cells followed by transfer to a 15 milliliter centrifuge tube and centrifugation of the cells at 150 x g for 5 minutes. The supernatant was discarded. The cell pellet was resuspended in 4 milliliters Growth Medium, and cells were counted.
Cells were seeded at 5,000 cells/cm2 on a T75 flask containing 15 milliliters of Growth Medium and cultured for 24 hours. The medium was changed to a serum-free medium (DMEM-low glucose (Gibco), 0.1% (w/v) bovine serum albumin (Sigma), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) for 8 hours. Conditioned serum-free media was collected at the end of incubation by centrifugation at 14,000 x g for 5 minutes and stored at ¨
20 C. To estimate the number of cells in each flask, cells were washed with phosphate-buffered saline (PBS) and detached using 2 milliliters trypsin/EDTA (Gibco). Trypsin activity was inhibited by addition of 8 milliliters Growth Medium. Cells were centrifuged at 150 x g for 5 minutes. Supernatant was removed, and cells were resuspended in 1 milliliter Growth Medium.
Cell number was estimated using a hemocytometer.
- 87 -ELISA assay. Cells were grown at 37 C in 5% carbon dioxide and atmospheric oxygen.
PDCs (isolate 3) also were grown in 5% oxygen or beta-mercaptoethanol (BME).
The amount of MCP-1, IL-6, VEGF, SDF-lalpha , GCP-2 , IL-8, and TGF-beta2 produced by each cell sample was measured by an ELISA assay (R&D Systems, Minneapolis, MN). All assays were performed according to the manufacturer's instructions. Values presented are picogram/milliliter/million cells (n=2, sem).
SEARCHLIGHT Multiplexed ELISA assay. Chemokines (MIPla, MIP lb, MCP-1, Rantes, 1309, TARC, Eotaxin, MDC, IL8), BDNF, and angiogenic factors (HGF, KGF, bFGF, VEGF, TIMP1, ANG2, PDGF-bb, TPO, BB-GF were measured using SEARCHLIGHT
Proteome Arrays (Pierce Biotechnology Inc.). The Proteome Arrays are multiplexed sandwich ELISAs for the quantitative measurement of two to 16 proteins per well. The arrays are produced by spotting a 2 x 2, 3 x 3, or 4 x 4 pattern of four to 16 different capture antibodies into each well of a 96-well plate. Following a sandwich ELISA procedure, the entire plate is imaged to capture chemiluminescent signal generated at each spot within each well of the plate.
The amount of signal generated in each spot is proportional to the amount of target protein in the original standard or sample.
' Results ELISA assay. MCP-1 and IL-6 were secreted by placenta-derived PDCs and dermal fibroblasts (Table 12-1). SDF-lalpha was secreted by placenta-derived cells cultured in 5% 02 and by fibroblasts. GCP-2 and IL-8 were secreted by placenta-derived cells cultured in the presence of BME or 5% 02. GCP-2 also was secreted by human fibroblasts. TGF-beta2 was not detectable by ELISA assay.
Table 12-1. ELISA assay results lalpha beta2 Fibroblast 17+1 61+3 29+2 19+1 21+1 ND ND
Placenta ¨ 60+3 41+2 ND ND ND ND ND
isolate 1 Placenta¨ 125+16 10+1 ND ND ND ND ND
isolate 2 Placenta¨ 21+10 67+3 ND ND 44+9 17+9 ND
isolate 3, + BME
Placenta¨ 77+16 339+21 ND 1149+137 54+2 265+10 ND
isolate 3, +5%
02, W/O BME
Key: ND: Not Detected.
PDCs (isolate 3) also were grown in 5% oxygen or beta-mercaptoethanol (BME).
The amount of MCP-1, IL-6, VEGF, SDF-lalpha , GCP-2 , IL-8, and TGF-beta2 produced by each cell sample was measured by an ELISA assay (R&D Systems, Minneapolis, MN). All assays were performed according to the manufacturer's instructions. Values presented are picogram/milliliter/million cells (n=2, sem).
SEARCHLIGHT Multiplexed ELISA assay. Chemokines (MIPla, MIP lb, MCP-1, Rantes, 1309, TARC, Eotaxin, MDC, IL8), BDNF, and angiogenic factors (HGF, KGF, bFGF, VEGF, TIMP1, ANG2, PDGF-bb, TPO, BB-GF were measured using SEARCHLIGHT
Proteome Arrays (Pierce Biotechnology Inc.). The Proteome Arrays are multiplexed sandwich ELISAs for the quantitative measurement of two to 16 proteins per well. The arrays are produced by spotting a 2 x 2, 3 x 3, or 4 x 4 pattern of four to 16 different capture antibodies into each well of a 96-well plate. Following a sandwich ELISA procedure, the entire plate is imaged to capture chemiluminescent signal generated at each spot within each well of the plate.
The amount of signal generated in each spot is proportional to the amount of target protein in the original standard or sample.
' Results ELISA assay. MCP-1 and IL-6 were secreted by placenta-derived PDCs and dermal fibroblasts (Table 12-1). SDF-lalpha was secreted by placenta-derived cells cultured in 5% 02 and by fibroblasts. GCP-2 and IL-8 were secreted by placenta-derived cells cultured in the presence of BME or 5% 02. GCP-2 also was secreted by human fibroblasts. TGF-beta2 was not detectable by ELISA assay.
Table 12-1. ELISA assay results lalpha beta2 Fibroblast 17+1 61+3 29+2 19+1 21+1 ND ND
Placenta ¨ 60+3 41+2 ND ND ND ND ND
isolate 1 Placenta¨ 125+16 10+1 ND ND ND ND ND
isolate 2 Placenta¨ 21+10 67+3 ND ND 44+9 17+9 ND
isolate 3, + BME
Placenta¨ 77+16 339+21 ND 1149+137 54+2 265+10 ND
isolate 3, +5%
02, W/O BME
Key: ND: Not Detected.
- 88 -SEARCHLIGHT Multiplexed ELISA assay. TIMP1, TPO, KGF, HGF, HBEGF, BDNF, MIP la, MCP-1, RANTES, TARC, Eotaxin, and IL-8 were secreted from placenta-derived cells (Tables 12-2 and 12-3). No Ang2, VEGF, or PDGF-bb were detected.
Table 12-2. SEARCHLIGHT Multiplexed ELISA assay results TIMP1 ANG2 PDGFbb TPO KGF HGF FGF VEGF HBEGF BDNF
HFB 19306.3 ND ND 230.5 5.0 ND ND 27.9 1.3 ND
P1 24299.5 ND ND 546.6 8.8 16.4 ND ND
3.8 ND
P3 14176.8 ND ND 568.7 5.2 10.2 ND ND
1.9 33.6 Key: hFB (human fibroblasts), P1 (placenta-derived cells - isolate 1), P3 (placenta-derived cells 0 isolate 3).
ND: Not Detected.
Table 12-3. SEARCHLIGHT Multiplexed ELISA assay results MIPla MIPlb MCP1 RANTES 1309 TARC Eotaxin MDC IL8 HFB ND ND 39.6 ND ND 0.1 ND ND 204.9 P1 79.5 ND 228.4 4.1 ND 3.8 12.2 ND 413.5 P3 ND ND 102.7 ND ND 0.4 ND ND 63.8 Key: hFB (human fibroblasts), P1 (placenta-derived cells - isolate 1), P3 (placenta-derived cells - isolate 3).
ND: Not Detected.
Summary. Placenta-derived cells secreted a number of trophic factors. Some of these trophic factors, such as HGF, MCP-1, and 1L-8, play important roles in angiogenesis. Other trophic factors, such as BDNF and IL-6, have important roles in neural regeneration.
Plasma Clotting Assay Cell therapy may be injected systemically for certain applications where cells are able to target the site of action. It is important that injected cells not cause thrombosis, which may be fatal. Tissue factor, a membrane-bound procoagulant glycoprotein, is the initiator of the extrinsic clotting cascade, which is the predominant coagulation pathway in vivo. Tissue factor also plays an important role in embryonic vessel formation, for example, in the formation of the primitive vascular wall (Brodsky et al. (2002) Exp. Nephrol. 10:299-306). To-deteimine the potential for PPDCs to initiate clotting, placenta-derived PPDCs were evaluated for tissue factor production and their ability to initiate plasma clotting.
Table 12-2. SEARCHLIGHT Multiplexed ELISA assay results TIMP1 ANG2 PDGFbb TPO KGF HGF FGF VEGF HBEGF BDNF
HFB 19306.3 ND ND 230.5 5.0 ND ND 27.9 1.3 ND
P1 24299.5 ND ND 546.6 8.8 16.4 ND ND
3.8 ND
P3 14176.8 ND ND 568.7 5.2 10.2 ND ND
1.9 33.6 Key: hFB (human fibroblasts), P1 (placenta-derived cells - isolate 1), P3 (placenta-derived cells 0 isolate 3).
ND: Not Detected.
Table 12-3. SEARCHLIGHT Multiplexed ELISA assay results MIPla MIPlb MCP1 RANTES 1309 TARC Eotaxin MDC IL8 HFB ND ND 39.6 ND ND 0.1 ND ND 204.9 P1 79.5 ND 228.4 4.1 ND 3.8 12.2 ND 413.5 P3 ND ND 102.7 ND ND 0.4 ND ND 63.8 Key: hFB (human fibroblasts), P1 (placenta-derived cells - isolate 1), P3 (placenta-derived cells - isolate 3).
ND: Not Detected.
Summary. Placenta-derived cells secreted a number of trophic factors. Some of these trophic factors, such as HGF, MCP-1, and 1L-8, play important roles in angiogenesis. Other trophic factors, such as BDNF and IL-6, have important roles in neural regeneration.
Plasma Clotting Assay Cell therapy may be injected systemically for certain applications where cells are able to target the site of action. It is important that injected cells not cause thrombosis, which may be fatal. Tissue factor, a membrane-bound procoagulant glycoprotein, is the initiator of the extrinsic clotting cascade, which is the predominant coagulation pathway in vivo. Tissue factor also plays an important role in embryonic vessel formation, for example, in the formation of the primitive vascular wall (Brodsky et al. (2002) Exp. Nephrol. 10:299-306). To-deteimine the potential for PPDCs to initiate clotting, placenta-derived PPDCs were evaluated for tissue factor production and their ability to initiate plasma clotting.
- 89 -Methods & Materials Human Tissue factor. Human tissue factor SIMPLASTIN (Organon Tekailca Corporation, Durham, NC), was reconstituted with 20 milliliters distilled water. The stock solution was serially diluted (1:2) in eight tubes. Noimal human plasma (George King Bio-Medical, Overland Park, KS) was thawed at 37 C in a water bath and then stored in ice before use. To each well of a 96-well plate was added 100 microliters phosphate buffered saline (PBS), microliters diluted SIMPLAST1N (except a blank well), 30 microliters 0.1 Molar calcium chloride, and 100 microliters of normal human plasma. The plate was immediately placed in a temperature-controlled microplate reader and absorbance measured at 405 nanometer at 40 second intervals for 30 minutes.
J-82 and placenta-derived cells. J-82 cells (ATCC, MD) were grown in Iscove's modified Dulbecco's medium (IMDM; Gibco, Carlsbad, CA) containing 10% (v/v) fetal bovine serum (FBS; Hyclone, Logan UT), 1 milliMolar sodium pyruvate (Sigma Chemical, St. Louis, MO), 2 milliMolar L-Glutamin (Mediatech Herndon, VA), 1 x non-essential amino acids (Mediatech Herndion, VA). At about 70% confluence, cells were transferred to wells of 96-well plate at 100,000, 50,000 and 25,000 cells/well. Placenta-derived cells were cultured in Growth Medium (DMEM-low glucose (Gibco), 15% (v/v) FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco), and 0.001% betamercaptoethanol (Sigma)) in gelatin-coated T75 flasks (Corning, Corning, NY). Placenta-derived cells at passage 5 were transferred to wells at 50,000 cells/well. Culture medium was removed from each well after centrifugation at 150 x g for 5 minutes. Cells were suspended in PBS without calcium and magnesium.
Tissue factor inhibition. Inhibition of the clotting reaction by preincubation of cells with CNTO 859, an antibody to tissue factor, will demonstrate that tissue factor is responsible for the clotting. Cells are incubated with 20 microgram/milliliter CNTO 859 (Centocor, Malvern, PA) for 30 minutes. Calcium chloride (30 microliter) is added to each well.
The plate is immediately placed in a temperature-controlled microplate reader and absorbance measured at 405 nanometer at 40 second intervals for 30 minutes. Cells are washed in PBS
and detached from the flask with Trypsin/EDTA (Gibco Carlsbad, CA). Cells are harvested, centrifuged, and re-suspended 3% (v/v) FBS in PBS at a cell concentration of lx107 per milliliter. Antibody is added to 100 microliter cell suspension as per the manufacturer's specifications, and the cells are incubated in the dark for 30 minutes at 4 C. After incubation, cells are washed with PBS and centrifuged at 150 x g for 5 minutes to remove unbound antibody. Cells are re-suspended in 100 microliter of 3% FBS and secondary antibody added as per the manufacturer's instructions. Cells are incubated in the dark for 30 minutes at 4 C. After incubation, cells are washed with PBS and
J-82 and placenta-derived cells. J-82 cells (ATCC, MD) were grown in Iscove's modified Dulbecco's medium (IMDM; Gibco, Carlsbad, CA) containing 10% (v/v) fetal bovine serum (FBS; Hyclone, Logan UT), 1 milliMolar sodium pyruvate (Sigma Chemical, St. Louis, MO), 2 milliMolar L-Glutamin (Mediatech Herndon, VA), 1 x non-essential amino acids (Mediatech Herndion, VA). At about 70% confluence, cells were transferred to wells of 96-well plate at 100,000, 50,000 and 25,000 cells/well. Placenta-derived cells were cultured in Growth Medium (DMEM-low glucose (Gibco), 15% (v/v) FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco), and 0.001% betamercaptoethanol (Sigma)) in gelatin-coated T75 flasks (Corning, Corning, NY). Placenta-derived cells at passage 5 were transferred to wells at 50,000 cells/well. Culture medium was removed from each well after centrifugation at 150 x g for 5 minutes. Cells were suspended in PBS without calcium and magnesium.
Tissue factor inhibition. Inhibition of the clotting reaction by preincubation of cells with CNTO 859, an antibody to tissue factor, will demonstrate that tissue factor is responsible for the clotting. Cells are incubated with 20 microgram/milliliter CNTO 859 (Centocor, Malvern, PA) for 30 minutes. Calcium chloride (30 microliter) is added to each well.
The plate is immediately placed in a temperature-controlled microplate reader and absorbance measured at 405 nanometer at 40 second intervals for 30 minutes. Cells are washed in PBS
and detached from the flask with Trypsin/EDTA (Gibco Carlsbad, CA). Cells are harvested, centrifuged, and re-suspended 3% (v/v) FBS in PBS at a cell concentration of lx107 per milliliter. Antibody is added to 100 microliter cell suspension as per the manufacturer's specifications, and the cells are incubated in the dark for 30 minutes at 4 C. After incubation, cells are washed with PBS and centrifuged at 150 x g for 5 minutes to remove unbound antibody. Cells are re-suspended in 100 microliter of 3% FBS and secondary antibody added as per the manufacturer's instructions. Cells are incubated in the dark for 30 minutes at 4 C. After incubation, cells are washed with PBS and
- 90 -centntuged to remove unbound secondary antibody. Washed cells are re-suspended in 500 microliter of PBS and analyzed by flow cytometry.
Results Flow cytometry analysis revealed that placenta-derived postpartum cells express tissue factor. Placenta-derived cells increased the clotting rate as indicated by the time to half maximal absorbance (T 1/2 to max; Table 13-1). The T 1/2 to max is inversely proportional to the number of J82 cells.
Table 13-1. The effect of human tissue factor (SIMPLAST1N) and placenta-derived cells (Pla) on plasma clotting was evaluated. The time to half maximal absorbance (T 1/2 to max) at the plateau in seconds was used as a measurement unit.
S1MPLASTIN Dilution T 1/2 to max (seconds) 1:2 61 1:4 107 1:8 147 1:16 174 1:32 266 1:64 317 1:128 378 0 (negative control) 1188 J-82 cells 100,000 122 50,000 172 25,000 275 Pla P5 50,000 757 Summary. Placenta-derived cells express tissue factor. Tissue factor is normally found on cells in a conformation that is inactive but is activated by mechanical or chemical (e.g., LPS) stress (Sakariassen et al. (2001) Thromb. Res. 104:149-74; Engstad et al.
(2002) Int.
Immunopharmacol. 2:1585-97). Thus, minimization of stress during the preparation process of PDCs may prevent activation of tissue factor. In addition to the thrombogenic activity, tissue factor has been associated with angiogenic activity. Thus, tissue factor activity may be beneficial when placenta-derived cells are transplanted in tissue but should be inhibited when PDCs are injected intravenously.
Results Flow cytometry analysis revealed that placenta-derived postpartum cells express tissue factor. Placenta-derived cells increased the clotting rate as indicated by the time to half maximal absorbance (T 1/2 to max; Table 13-1). The T 1/2 to max is inversely proportional to the number of J82 cells.
Table 13-1. The effect of human tissue factor (SIMPLAST1N) and placenta-derived cells (Pla) on plasma clotting was evaluated. The time to half maximal absorbance (T 1/2 to max) at the plateau in seconds was used as a measurement unit.
S1MPLASTIN Dilution T 1/2 to max (seconds) 1:2 61 1:4 107 1:8 147 1:16 174 1:32 266 1:64 317 1:128 378 0 (negative control) 1188 J-82 cells 100,000 122 50,000 172 25,000 275 Pla P5 50,000 757 Summary. Placenta-derived cells express tissue factor. Tissue factor is normally found on cells in a conformation that is inactive but is activated by mechanical or chemical (e.g., LPS) stress (Sakariassen et al. (2001) Thromb. Res. 104:149-74; Engstad et al.
(2002) Int.
Immunopharmacol. 2:1585-97). Thus, minimization of stress during the preparation process of PDCs may prevent activation of tissue factor. In addition to the thrombogenic activity, tissue factor has been associated with angiogenic activity. Thus, tissue factor activity may be beneficial when placenta-derived cells are transplanted in tissue but should be inhibited when PDCs are injected intravenously.
- 91 -Example 14 Differentiation of Placenta-Derived Cells into Ilepatocytes A variety of conditions were examined to determine a suitable combination of basic media and growth factors for the differentiation of placenta-derived cells into hepatocytes. HNF-lalpha, a hepatocyte-specific transcription factor, cytoplasmic inteimediate filament proteins such as keratin 19 (K19), keratin 8 (K8), and cytokeratin 18 (CK18), which are markers of epithelial cells and two liver-specific secreted proteins, alpha-fetoprotein (alphaFP), and albumin were selected as markers for hepatocyte differentiation (Schwartz et al.
(2002) Clin. Invest.
109(10):1291-1302; Okumoto et al. (2003) Biochern. Biophys. Res. Commun.
304(4):691-695;
Chagraoui et al. (2003) Blood 101(8): 2973-2982).
Methods & Materials Placenta-derived cells isolated according to the method described in Example 1, as well as neonatal or adult Noimal Human Dermal Fibroblasts (NHDF) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (Cat.
#SH30070.03;
Hyclone, Logan UT), 0.001% (v/v) beta-mercaptoethanol (Sigma, St. Louis, MO), Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)), in a gelatin-coated T75 flask. Basic Fibroblast Growth Factor (bFGF), Oncostatin M, Hepatocyte Growth Factor (HGF), Stem Cell Factor (SCF), and Fibroblast Growth Factor 4 (FGF 4) were from PeproTech Inc.
(Rocky Hill, NJ). Platelet Derived Growth Factor BB (PDGF-BB) was from R&D
Systems (Minneapolis, MN).
The following conditions were tested:
Method 1 Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), neonatal and adult Normal Human Dermal Fibroblasts (NHDF). Cells were plated at 22.5 x 103 cells/cm2 on 1% MATRIGEL (BD Discovery Labware, Bedford, MA) (Becton-Dickinson and Co., Franklin Lakes, NJ) in serum-free medium (60% (v/v) low glucose DMEM) (DMEM-LG;
Gibco, Carlsbad, CA), 40% (v/v) MCDB-201 (Sigma, St. Louis, MO), supplemented with lx insulin/transferrin/selenium, 4.7 microgram/milliliter linoleic acid, 1 milligram/milliliter bovine serum albumin, 10 nanoMolar Dexamethasone, 100 microMolar ascorbic acid phosphate (all from Sigma), 100 Units/milliliter penicillin, 100 Units/milliliter streptomycin (Gibco), 2% (v/v) FCS (Hyclone Laboratories, Logan, UT), and 10 nanogram/milliliter each EGF and PDGF-BB).
After 8 to 12 hours, medium was removed, cells were washed twice with PBS
(Gibco) and cultured in the above-described medium without EGF and PDGF-BB but supplemented with 20
(2002) Clin. Invest.
109(10):1291-1302; Okumoto et al. (2003) Biochern. Biophys. Res. Commun.
304(4):691-695;
Chagraoui et al. (2003) Blood 101(8): 2973-2982).
Methods & Materials Placenta-derived cells isolated according to the method described in Example 1, as well as neonatal or adult Noimal Human Dermal Fibroblasts (NHDF) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (Cat.
#SH30070.03;
Hyclone, Logan UT), 0.001% (v/v) beta-mercaptoethanol (Sigma, St. Louis, MO), Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)), in a gelatin-coated T75 flask. Basic Fibroblast Growth Factor (bFGF), Oncostatin M, Hepatocyte Growth Factor (HGF), Stem Cell Factor (SCF), and Fibroblast Growth Factor 4 (FGF 4) were from PeproTech Inc.
(Rocky Hill, NJ). Platelet Derived Growth Factor BB (PDGF-BB) was from R&D
Systems (Minneapolis, MN).
The following conditions were tested:
Method 1 Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), neonatal and adult Normal Human Dermal Fibroblasts (NHDF). Cells were plated at 22.5 x 103 cells/cm2 on 1% MATRIGEL (BD Discovery Labware, Bedford, MA) (Becton-Dickinson and Co., Franklin Lakes, NJ) in serum-free medium (60% (v/v) low glucose DMEM) (DMEM-LG;
Gibco, Carlsbad, CA), 40% (v/v) MCDB-201 (Sigma, St. Louis, MO), supplemented with lx insulin/transferrin/selenium, 4.7 microgram/milliliter linoleic acid, 1 milligram/milliliter bovine serum albumin, 10 nanoMolar Dexamethasone, 100 microMolar ascorbic acid phosphate (all from Sigma), 100 Units/milliliter penicillin, 100 Units/milliliter streptomycin (Gibco), 2% (v/v) FCS (Hyclone Laboratories, Logan, UT), and 10 nanogram/milliliter each EGF and PDGF-BB).
After 8 to 12 hours, medium was removed, cells were washed twice with PBS
(Gibco) and cultured in the above-described medium without EGF and PDGF-BB but supplemented with 20
- 92 -I
nanogram/milliliter HGF and/or 10 nanogram/milliliter FGF-4 (Schwartz et al.
(2002)J. Clin.
Invest. 109(10):1291-1302). Cells were cultured in standard air with 5% CO2 at 37 C.
Method 2 Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), neonatal and adult NHDF. Cells were seeded at 22,500 cells/cm2 in 24-well plates coated with gelatin and grown as described above.
Method 3 Placenta-derived cells (P10), adult NHDF, Placenta-derived cells (P3). Cells were seeded at high density (50,000 cells/cm2) in 24-well TCP plates and grown in DMEM (Gibco), B27 Supplement (Gibco), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 20 nanograms/milliliter HGF and/or 10 nanograms/milliliter FGF-4. Cells were grown in these conditions for 4 weeks.
Method 4 Placenta-derived cells (P3), Placenta-derived cells (P15), Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), Placenta-derived cells (P5) (predominately neonatal as analyzed by karyotyping), Placenta-derived cells (P5) (predominately maternal as analyzed by karyotyping), neonatal and adult NHDF.
Cells were seeded at a density of 5,000 cells/cm2 in T25 flasks in Chang C medium (Irvine Scientific, Santa Ana, CA) on either fibronectin (PeproTech, Rocky Hill, NJ) or gelatin (Sigma) and grown for two passages until confluence. Cells were then seeded at 1,000 cells/cm2 in 24-well TCPS plates and grown as described above until they reached about 40-60% confluence.
Method 5 Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), and adult NHDF. Cells were plated in 24-well plates on gelatin in Growth medium supplemented with either 1 nanogram/milliliter or 10 nanogram/milliliter oncostatin M
(Chagaoui et al. (2003) Blood 101(8): 2973-2982). Cells were grown in these conditions for 4 weeks.
Method 6 Placenta-derived cells (P2)(predominately neonatal as analyzed by karyotyping), and adult NIIDF. Cells were plated in 24-well plates on gelatin in Growth medium supplemented with 10 nanogram/milliliter bFGF, 10 nanogram/milliliter HGF, 10 nanogram/milliliter SCF.
Cells were grown in these conditions for 4 weeks (Okumoto et al. (2003) Biochem. Biophys. Res.
Comn2un. 304(4):691-695.).
Total RNA isolation and quantitative RT-PCR. RNA was extracted from placenta-derived cells and fibroblasts grown as described in each protocol. Cells were lysed with 350
nanogram/milliliter HGF and/or 10 nanogram/milliliter FGF-4 (Schwartz et al.
(2002)J. Clin.
Invest. 109(10):1291-1302). Cells were cultured in standard air with 5% CO2 at 37 C.
Method 2 Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), neonatal and adult NHDF. Cells were seeded at 22,500 cells/cm2 in 24-well plates coated with gelatin and grown as described above.
Method 3 Placenta-derived cells (P10), adult NHDF, Placenta-derived cells (P3). Cells were seeded at high density (50,000 cells/cm2) in 24-well TCP plates and grown in DMEM (Gibco), B27 Supplement (Gibco), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 20 nanograms/milliliter HGF and/or 10 nanograms/milliliter FGF-4. Cells were grown in these conditions for 4 weeks.
Method 4 Placenta-derived cells (P3), Placenta-derived cells (P15), Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), Placenta-derived cells (P5) (predominately neonatal as analyzed by karyotyping), Placenta-derived cells (P5) (predominately maternal as analyzed by karyotyping), neonatal and adult NHDF.
Cells were seeded at a density of 5,000 cells/cm2 in T25 flasks in Chang C medium (Irvine Scientific, Santa Ana, CA) on either fibronectin (PeproTech, Rocky Hill, NJ) or gelatin (Sigma) and grown for two passages until confluence. Cells were then seeded at 1,000 cells/cm2 in 24-well TCPS plates and grown as described above until they reached about 40-60% confluence.
Method 5 Placenta-derived cells (P2) (predominately neonatal as analyzed by karyotyping), and adult NHDF. Cells were plated in 24-well plates on gelatin in Growth medium supplemented with either 1 nanogram/milliliter or 10 nanogram/milliliter oncostatin M
(Chagaoui et al. (2003) Blood 101(8): 2973-2982). Cells were grown in these conditions for 4 weeks.
Method 6 Placenta-derived cells (P2)(predominately neonatal as analyzed by karyotyping), and adult NIIDF. Cells were plated in 24-well plates on gelatin in Growth medium supplemented with 10 nanogram/milliliter bFGF, 10 nanogram/milliliter HGF, 10 nanogram/milliliter SCF.
Cells were grown in these conditions for 4 weeks (Okumoto et al. (2003) Biochem. Biophys. Res.
Comn2un. 304(4):691-695.).
Total RNA isolation and quantitative RT-PCR. RNA was extracted from placenta-derived cells and fibroblasts grown as described in each protocol. Cells were lysed with 350
- 93 -microliter buffer RLT containing beta-mercaptoethanol (Sigma St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini Kit, Qiagen, Valencia, CA) and RNA
extracted according to the manufacturer's instructions (RNeasy Mini Kit, Qiagen, Valencia, CA) with a 2.7 Units/sample DNase treatment (Sigma). RNA was eluted with 50 microliter DEPC-treated water and stored at ¨80 C. RNA was reverse transcribed using random hexamers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
Real-time PCR. PCR was performed on cDNA samples using ASSSAYS-ON-DEMAND gene expression products for albumin (Hs00609411), cytochrome p450 2B6 (Hs00167937), GAPDH (Applied Biosystems, Foster City, CA) and TaqMan Universal PCR
master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 C for 2 min and 95 C
for 10 minute followed by 40 cycles of 95 C for 15 seconds and 60 C for 1 minute. PCR data were analyzed according to manufacturer's specifications (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System).
Immunofluorescence. Cell cultures were fixed with cold 4% (w/v) paraformaldehyde for a period of 10 minutes at room temperature. Immunocytochemistry was perfoimed using antibodies directed against the following epitopes: keratin 8 (K8;1:400;
Chemicon, Temecula, CA), keratin 19 (K19; 1:400; Chemicon), cytokeratin 18 (CK18; 1:400; Sigma, St. Louis, MO), vimentin (1:500; Sigma), desmin (1:150; Sigma), albumin (1:200; Sigma), c-met (1:400; Santa Cruz Biotech, Santa Cruz, CA), and HNF-lalpha (1:400; Santa Cruz Biotech). In general, cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100, Sigma) for 30 minutes to access intracellular antigens. In instances where the epitope of interest would be located on the cell surface (c-met), triton was omitted in all steps of the procedure in order to prevent epitope loss. Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature.
Next, primary antibody solutions were removed and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨ Texas Red (1:250; Molecular Probes, Eugene, OR) for K8, K19, CK18, vimentin, and albumin, goat anti-rabbit IgG - Alexa 488 (1:250;
Molecular Probes) for desmin and c-met, or donkey anti-goat IgG ¨ FITC (1:150; Santa Cruz Biotech) for HNF-1alpha
extracted according to the manufacturer's instructions (RNeasy Mini Kit, Qiagen, Valencia, CA) with a 2.7 Units/sample DNase treatment (Sigma). RNA was eluted with 50 microliter DEPC-treated water and stored at ¨80 C. RNA was reverse transcribed using random hexamers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
Real-time PCR. PCR was performed on cDNA samples using ASSSAYS-ON-DEMAND gene expression products for albumin (Hs00609411), cytochrome p450 2B6 (Hs00167937), GAPDH (Applied Biosystems, Foster City, CA) and TaqMan Universal PCR
master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 C for 2 min and 95 C
for 10 minute followed by 40 cycles of 95 C for 15 seconds and 60 C for 1 minute. PCR data were analyzed according to manufacturer's specifications (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System).
Immunofluorescence. Cell cultures were fixed with cold 4% (w/v) paraformaldehyde for a period of 10 minutes at room temperature. Immunocytochemistry was perfoimed using antibodies directed against the following epitopes: keratin 8 (K8;1:400;
Chemicon, Temecula, CA), keratin 19 (K19; 1:400; Chemicon), cytokeratin 18 (CK18; 1:400; Sigma, St. Louis, MO), vimentin (1:500; Sigma), desmin (1:150; Sigma), albumin (1:200; Sigma), c-met (1:400; Santa Cruz Biotech, Santa Cruz, CA), and HNF-lalpha (1:400; Santa Cruz Biotech). In general, cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100, Sigma) for 30 minutes to access intracellular antigens. In instances where the epitope of interest would be located on the cell surface (c-met), triton was omitted in all steps of the procedure in order to prevent epitope loss. Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature.
Next, primary antibody solutions were removed and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨ Texas Red (1:250; Molecular Probes, Eugene, OR) for K8, K19, CK18, vimentin, and albumin, goat anti-rabbit IgG - Alexa 488 (1:250;
Molecular Probes) for desmin and c-met, or donkey anti-goat IgG ¨ FITC (1:150; Santa Cruz Biotech) for HNF-1alpha
- 94 -staining. Cultures were washed and 10 microMolar DAPI (Molecular Probes) was applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results In order to determine whether placenta-derived cells could express epithelial markers, cells were cultured in Chang C medium. Placenta-derived cells (P4), (P3), and (P8) were grown in Chang C medium for 11 days. Placenta-derived cells stained positive for cytokeratin 18 by immunocytochemistry analysis. None of the samples stained positive for keratin 8. Samples grown in Growth medium were negative for both markers.
The effect of early and late passages as well as gelatin and fibronectin substrata was investigated. Cells were grown in Chang C medium for 11 days. RNA and protein expression of epithelial/hepatocyte-specific proteins were analyzed. Immunocytochemistry staining for cytokeratin18, keratin 8, keratin 19, c-met, albumin, desmin, and HNF-1alpha were negative in all conditions. Cells stained positive for vimentin. Expression of both albumin and cytochrome p450 2B6 at levels lower than that of human HepG2 cells was detected with assay-on-demand primers. Albumin and cytochrome p450 2B6 expression also were detected in cells grown in Growth medium.
Placenta-derived cells were treated as described in method 1 according to a protocol developed by Schwartz etal. (002) 1 ain. Invest. 109(10):1291-1302.). Both albumin and cytochrome p450 2B6 were detected with assay-on-demand primers at levels lower than HepG2 positive control. No clear pattern emerged between conditions applied and gene expression levels, i.e., albumin and cytochrome p450 2B6 expression was also detected in control samples.
Some expression of albumin and cytochrome p450 2B6 was detected with ASSAY-ON-DEMAND primers however the levels were significantly lower than those observed in human HepG2 cells.
Oncostatin M at low concentration of 1 nanogram/milliliter increased expression levels of cytochrome p450 2B6 in placenta-derived cells grown in Growth medium on gelatin-coated
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results In order to determine whether placenta-derived cells could express epithelial markers, cells were cultured in Chang C medium. Placenta-derived cells (P4), (P3), and (P8) were grown in Chang C medium for 11 days. Placenta-derived cells stained positive for cytokeratin 18 by immunocytochemistry analysis. None of the samples stained positive for keratin 8. Samples grown in Growth medium were negative for both markers.
The effect of early and late passages as well as gelatin and fibronectin substrata was investigated. Cells were grown in Chang C medium for 11 days. RNA and protein expression of epithelial/hepatocyte-specific proteins were analyzed. Immunocytochemistry staining for cytokeratin18, keratin 8, keratin 19, c-met, albumin, desmin, and HNF-1alpha were negative in all conditions. Cells stained positive for vimentin. Expression of both albumin and cytochrome p450 2B6 at levels lower than that of human HepG2 cells was detected with assay-on-demand primers. Albumin and cytochrome p450 2B6 expression also were detected in cells grown in Growth medium.
Placenta-derived cells were treated as described in method 1 according to a protocol developed by Schwartz etal. (002) 1 ain. Invest. 109(10):1291-1302.). Both albumin and cytochrome p450 2B6 were detected with assay-on-demand primers at levels lower than HepG2 positive control. No clear pattern emerged between conditions applied and gene expression levels, i.e., albumin and cytochrome p450 2B6 expression was also detected in control samples.
Some expression of albumin and cytochrome p450 2B6 was detected with ASSAY-ON-DEMAND primers however the levels were significantly lower than those observed in human HepG2 cells.
Oncostatin M at low concentration of 1 nanogram/milliliter increased expression levels of cytochrome p450 2B6 in placenta-derived cells grown in Growth medium on gelatin-coated
- 95 -flasks. FGF-4 and HGF treatment had little effect and may have reduced the expression of albumin and cytochrome p450 2B6.
Summary. Several differentiation protocols were tested for ability to induce differentiation of placenta-derived cells to hepatocyte phenotype. Expression of hepatocyte-specific markers such as albumiri and cytochrome p450 2B6 was detected, thereby indicating that the cells underwent some differentiation into hepatocytes. Placenta-derived cells cultured in Chang C medium expressed cytokeratin 18, a marker of epithelial cells in the lower or pancreatic ducts.
' EXAMPLE 15 Differentiation of Placenta-Derived Cells to an Osteogenic Phenotype Mesenchymal stem cells (MSCs) derived from bone marrow have been demonstrated to reproducibly differentiate into osteoblast-like cells that mineralize and express alkaline phosphatase. Additional markers expressed by osteoblasts, such as osteocalcin and bone sialoprotein, have been used to demonstrate differentiation into an osteoblast-like cell. The ability of placenta-derived cells to differentiate into an osteogenic phenotype was evaluated by culturing in an osteogenic medium and addition of bone morphogenic proteins (BMP) ¨2 (Rickard et al. (1994) Dev. Biol. 161,:218-228) or ¨4 and transforming growth factor betal.
Methods & Materials Culture of cells. Prior to initiation of osteogenesis, Mesenchymal Stem Cells (MSC) were grown in Mesenchymal Stem Cell Growth Medium Bullet kit (MSCGM, Cambrex, Walkerville, MD). Other cells were cultured in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (SH30070.03; Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) in a gelatin-coated T75 flask and were washed with phosphate buffered saline (PBS).
Osteoblasts (9F1721; Cambrex) were grown in osteoblast growth medium (Cambrex) and RNA was extracted as described below.
Osteogenesis Protocol 1. Placenta-derived cells (P3) and (P4) (previously karyotyped and shown to be predominantly neonatal-derived cells) and MSCs (P3) were seeded at 5 x 103 cells/cm2 in 24-well plates and 6-well dishes in Growth medium and incubated overnight. The medium was removed and replaced with Osteogenic medium (DMEM-low glucose, 10% (v/v) fetal bovine
Summary. Several differentiation protocols were tested for ability to induce differentiation of placenta-derived cells to hepatocyte phenotype. Expression of hepatocyte-specific markers such as albumiri and cytochrome p450 2B6 was detected, thereby indicating that the cells underwent some differentiation into hepatocytes. Placenta-derived cells cultured in Chang C medium expressed cytokeratin 18, a marker of epithelial cells in the lower or pancreatic ducts.
' EXAMPLE 15 Differentiation of Placenta-Derived Cells to an Osteogenic Phenotype Mesenchymal stem cells (MSCs) derived from bone marrow have been demonstrated to reproducibly differentiate into osteoblast-like cells that mineralize and express alkaline phosphatase. Additional markers expressed by osteoblasts, such as osteocalcin and bone sialoprotein, have been used to demonstrate differentiation into an osteoblast-like cell. The ability of placenta-derived cells to differentiate into an osteogenic phenotype was evaluated by culturing in an osteogenic medium and addition of bone morphogenic proteins (BMP) ¨2 (Rickard et al. (1994) Dev. Biol. 161,:218-228) or ¨4 and transforming growth factor betal.
Methods & Materials Culture of cells. Prior to initiation of osteogenesis, Mesenchymal Stem Cells (MSC) were grown in Mesenchymal Stem Cell Growth Medium Bullet kit (MSCGM, Cambrex, Walkerville, MD). Other cells were cultured in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (SH30070.03; Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) in a gelatin-coated T75 flask and were washed with phosphate buffered saline (PBS).
Osteoblasts (9F1721; Cambrex) were grown in osteoblast growth medium (Cambrex) and RNA was extracted as described below.
Osteogenesis Protocol 1. Placenta-derived cells (P3) and (P4) (previously karyotyped and shown to be predominantly neonatal-derived cells) and MSCs (P3) were seeded at 5 x 103 cells/cm2 in 24-well plates and 6-well dishes in Growth medium and incubated overnight. The medium was removed and replaced with Osteogenic medium (DMEM-low glucose, 10% (v/v) fetal bovine
- 96 -serum, 10 milliMolar betaglycerophosphate (Sigma), 100 nanoMolar dexamethasone (Sigma, St.
Louis, MO), 50 microMolar ascorbate phosphate salt (Sigma), fungizone (Gibco), Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)).
Osteogenic medium was supplemented with 20 nanogram/milliliter TGF-betal (Sigma), 40 nanogram/milliliter hrBMP-2 (Sigma) or 40 nanogram/milliliter hrBMP-4 (Sigma). Cultures were treated for a total of 14, 21, and 28 days, with media changes every 3-4 days.
Protocol 2. Placenta-derived cells were tested for the ability to differentiate into an osteogenic phenotype. Placenta-derived cells (P4) were seeded at 30,000 cells/well of a 6-well plate (gelatin-coated) in Growth medium. Mesenchyrnal stem cells (MSC) (P3 and P4), fibroblasts (P11), and iliac crest bone marrow cells (P3; International PCT
Publication No.
W003/025149) were seeded at 30,000 cells/well of a 6 well plate (gelatin-coated) in mesenchymal stem cell growth medium (MSCGM, Cambrex) and Growth medium, respectively.
Osteogenic induction was initiated by removing the initial seeding media (24 h) and replacing it with osteogenic induction medium: DMEM-low glucose, 10% fetal bovine serum, 10 millimolar betaglycerophosphate (Sigma), 100 nanoMolar dexamethasone (Sigma), rnicroMolar ascorbate phosphate salt (Sigma), 50 Units/milliliter penicillin, microgram/milliliter streptomycin (Gibco). In some conditions, osteogenic medium was supplemented with human recombinant (hr) BMP-2 (20 nanogram/milliliter) (Sigma,) or hrBMP-4 or with both hrBMP-2 (20 nanogram/milliliter) and hrBMP-4 (20 nanogram/milliliter) (Sigma). Cultures were treated for a total of 28 days with media changes every 3-4 days.
RNA extraction and Reverse Transcription. Cells were lysed with 350 microliter buffer RLT containing betamercaptoethanol (Sigma, St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) and stored at ¨80 C. Cell lysates were thawed and RNA extracted according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) with a 2.7 Unit/sample DNase treatment (Sigma St. Louis, MO).
RNA was elated with 50 micoliter DEPC-treated water and stored at ¨80 C. RNA
was reverse transcribed using random hexamers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND gene expression products bone sialoprotein (Hs00173720), osteocalcin (Hs00609452), GAPDH
(Applied Biosystems, Foster City, CA), and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA).
Louis, MO), 50 microMolar ascorbate phosphate salt (Sigma), fungizone (Gibco), Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)).
Osteogenic medium was supplemented with 20 nanogram/milliliter TGF-betal (Sigma), 40 nanogram/milliliter hrBMP-2 (Sigma) or 40 nanogram/milliliter hrBMP-4 (Sigma). Cultures were treated for a total of 14, 21, and 28 days, with media changes every 3-4 days.
Protocol 2. Placenta-derived cells were tested for the ability to differentiate into an osteogenic phenotype. Placenta-derived cells (P4) were seeded at 30,000 cells/well of a 6-well plate (gelatin-coated) in Growth medium. Mesenchyrnal stem cells (MSC) (P3 and P4), fibroblasts (P11), and iliac crest bone marrow cells (P3; International PCT
Publication No.
W003/025149) were seeded at 30,000 cells/well of a 6 well plate (gelatin-coated) in mesenchymal stem cell growth medium (MSCGM, Cambrex) and Growth medium, respectively.
Osteogenic induction was initiated by removing the initial seeding media (24 h) and replacing it with osteogenic induction medium: DMEM-low glucose, 10% fetal bovine serum, 10 millimolar betaglycerophosphate (Sigma), 100 nanoMolar dexamethasone (Sigma), rnicroMolar ascorbate phosphate salt (Sigma), 50 Units/milliliter penicillin, microgram/milliliter streptomycin (Gibco). In some conditions, osteogenic medium was supplemented with human recombinant (hr) BMP-2 (20 nanogram/milliliter) (Sigma,) or hrBMP-4 or with both hrBMP-2 (20 nanogram/milliliter) and hrBMP-4 (20 nanogram/milliliter) (Sigma). Cultures were treated for a total of 28 days with media changes every 3-4 days.
RNA extraction and Reverse Transcription. Cells were lysed with 350 microliter buffer RLT containing betamercaptoethanol (Sigma, St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) and stored at ¨80 C. Cell lysates were thawed and RNA extracted according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) with a 2.7 Unit/sample DNase treatment (Sigma St. Louis, MO).
RNA was elated with 50 micoliter DEPC-treated water and stored at ¨80 C. RNA
was reverse transcribed using random hexamers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND gene expression products bone sialoprotein (Hs00173720), osteocalcin (Hs00609452), GAPDH
(Applied Biosystems, Foster City, CA), and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA).
-97-Thermal cycle conditions were initially 50 C for 2 minutes and 95 C for 10 minutes followed by 40 cycles of 95 C for 15 seconds and 60 C for 1 minute.
von Kossa Staining. Cells were fixed with 10% (v/v) neutral buffered fonnalin (Richard-Allan, Kalamazoo, MI). After fixation, the cells were washed in deionized water and incubated in 5% (w/v) silver nitrate (Aldrich Chemical Company Milwaukee, WI) for one hour in direct sunlight. Cells were washed in deionized water and incubated in 5%
(w/v) sodium thiosulfate (EM Sciences, Gibbstown, NJ) for five minutes. Cells were then washed in distilled water and examined by light microscopy.
Results Protocol 1. RNA extracted from osteoblasts was used as a positive control for the real-time gene expression of osteocalcin and bone sialoprotein. Osteoblast expression levels of osteocalcin and BSP relative to placenta-derived cells grown in growth medium were 2.5- and 8000-fold, respectively. MSCs grown in the osteogenic medium mineralized and gave positive von Kossa staining. MSC expression of osteocalcin and BSP was significantly increased in osteogenic medium at 21 days . The addition of BMP-2 and ¨4 enhanced BSP
expression but had no effect on osteocalcin expression . TGF-betal did not augment the effect of osteogenesis medium. Extensive mineralization was observed with one placenta sample (P4) that had predominantly neonatal-derived cells. Placenta-derived cells (P3) showed induction of BSP
expression levels in osteogenic media and low levels of osteocalcin induction.
BMP-4 and TGF-betal increased osteocalcin expression by placenta-derived cells (P3).
Protocol 2. Osteogenic differentiation, as shown by positive von Kossa staining for mineralization, was observed with placenta-derived cells (P4) and ICBM (P3) incubated with osteogenic medium supplemented with BMP2 or 4, and MSCs (P3) incubated with osteogenic medium supplemented with BMP 4 (Table 15-1). None of the other cells differentiated into the osteogenic phenotype and stained by von Kossa. To ensure that von Kossa staining was related to the cell and not extracellular matrix, cells were counterstained with nuclear fast red. This stain demonstrated large lipid droplets in some MSCs consistent with an adipocyte phenotype. This suggests that MSCs do not differentiate specifically into an osteogenic phenotype in these conditions. Furthermore, the level of adipogenesis was seen to increase when MSCs were incubated in osteogenic medium supplemented with either BM.P2 or BMP4 .
Table 15-1: Results of osteogenic differentiation using von Kossa staining for Protocol 2. Placenta-derived cells (Pla), mesenchymal stem cells (MSC), fibroblasts (Fib), and iliac crest bone marrow cells (ICBM) cells were cultured in
von Kossa Staining. Cells were fixed with 10% (v/v) neutral buffered fonnalin (Richard-Allan, Kalamazoo, MI). After fixation, the cells were washed in deionized water and incubated in 5% (w/v) silver nitrate (Aldrich Chemical Company Milwaukee, WI) for one hour in direct sunlight. Cells were washed in deionized water and incubated in 5%
(w/v) sodium thiosulfate (EM Sciences, Gibbstown, NJ) for five minutes. Cells were then washed in distilled water and examined by light microscopy.
Results Protocol 1. RNA extracted from osteoblasts was used as a positive control for the real-time gene expression of osteocalcin and bone sialoprotein. Osteoblast expression levels of osteocalcin and BSP relative to placenta-derived cells grown in growth medium were 2.5- and 8000-fold, respectively. MSCs grown in the osteogenic medium mineralized and gave positive von Kossa staining. MSC expression of osteocalcin and BSP was significantly increased in osteogenic medium at 21 days . The addition of BMP-2 and ¨4 enhanced BSP
expression but had no effect on osteocalcin expression . TGF-betal did not augment the effect of osteogenesis medium. Extensive mineralization was observed with one placenta sample (P4) that had predominantly neonatal-derived cells. Placenta-derived cells (P3) showed induction of BSP
expression levels in osteogenic media and low levels of osteocalcin induction.
BMP-4 and TGF-betal increased osteocalcin expression by placenta-derived cells (P3).
Protocol 2. Osteogenic differentiation, as shown by positive von Kossa staining for mineralization, was observed with placenta-derived cells (P4) and ICBM (P3) incubated with osteogenic medium supplemented with BMP2 or 4, and MSCs (P3) incubated with osteogenic medium supplemented with BMP 4 (Table 15-1). None of the other cells differentiated into the osteogenic phenotype and stained by von Kossa. To ensure that von Kossa staining was related to the cell and not extracellular matrix, cells were counterstained with nuclear fast red. This stain demonstrated large lipid droplets in some MSCs consistent with an adipocyte phenotype. This suggests that MSCs do not differentiate specifically into an osteogenic phenotype in these conditions. Furthermore, the level of adipogenesis was seen to increase when MSCs were incubated in osteogenic medium supplemented with either BM.P2 or BMP4 .
Table 15-1: Results of osteogenic differentiation using von Kossa staining for Protocol 2. Placenta-derived cells (Pla), mesenchymal stem cells (MSC), fibroblasts (Fib), and iliac crest bone marrow cells (ICBM) cells were cultured in
- 98 -osteogenic medium (OM) alone or supplemented with BMP2 or BMP2 and BMP4.
Number Cell Line Conditions Von Kossa Comments 1 ICBM P3 Osteogenic Neg Normal 02 medium (OM) 2 ICBM P3 OM, BMP2 Pos Normal 03 3 ICBM P3 OM, BMP4 Pos Normal 04 4 MSC Osteogenic Neg lots of fat medium (OM) MSC OM, BMP2 Neg lots of fat 6 MSC OM, BMP4 Pos lots of fat 7 Pla P4 Osteogenic Neg medium (OM) 8 Pla P4 OM, BMP2 Pos 9 Pla P4 OM, BMP4 Pos MSC P4 Osteogenic Neg Fat medium (OM) 11 MSC P4 OM, BMP2 Neg Fat 12 MSC P4 OM, BMP2, Neg Fat 13 Pla P4 Osteogenic Neg medium (OM) 14 Pla P4 OM, BMP2 Neg Pla P4 OM, BMP2, Neg 16 Fib 1F1853 P1 1 Osteogenic Neg medium (OM) 17 Fib 1F1853 P1 1 OM, BMP2 Neg 18 Fib 1F1853 P1 1 OM, BMP2, Neg Summary. Bone marrow-derived MSCs (Kadiyala et al. (1997) Cell Transplant.6:125-34) as well as cells derived from other tissue such as adipose (Halvorsen et al. (2001) Tissue Eng. 7:729-41) have been shown to differentiate into an osteoblast-like cell.
MSCs have also been shown to differentiate into adipocytes or osteoblasts in response to BMPs (Chen et al.
(1998) J. Cell Biol. 142:295-305) due to differential roles for bone morphogenic protein (BMP) receptor type 1B and IA. Placenta-derived cells are also capable of expressing an osteoblast-like phenotype as previously observed with bone marrow-derived mesenchymal stein cells (MSCs) when placed in osteogenic medium containing dexamethasone, B-glycerophosphate, and ascorbic acid. Several experiments were conducted with different isolates to determine whether there was mineralization of the cultured cells by von Kossa staining and expression of bone sialoprotein (BSP) and osteocalcin, which are expressed in osteoblasts.
Following induction of osteogenesis, MSCs were demonstrated to mineralize and stain with von Kossa and also have
Number Cell Line Conditions Von Kossa Comments 1 ICBM P3 Osteogenic Neg Normal 02 medium (OM) 2 ICBM P3 OM, BMP2 Pos Normal 03 3 ICBM P3 OM, BMP4 Pos Normal 04 4 MSC Osteogenic Neg lots of fat medium (OM) MSC OM, BMP2 Neg lots of fat 6 MSC OM, BMP4 Pos lots of fat 7 Pla P4 Osteogenic Neg medium (OM) 8 Pla P4 OM, BMP2 Pos 9 Pla P4 OM, BMP4 Pos MSC P4 Osteogenic Neg Fat medium (OM) 11 MSC P4 OM, BMP2 Neg Fat 12 MSC P4 OM, BMP2, Neg Fat 13 Pla P4 Osteogenic Neg medium (OM) 14 Pla P4 OM, BMP2 Neg Pla P4 OM, BMP2, Neg 16 Fib 1F1853 P1 1 Osteogenic Neg medium (OM) 17 Fib 1F1853 P1 1 OM, BMP2 Neg 18 Fib 1F1853 P1 1 OM, BMP2, Neg Summary. Bone marrow-derived MSCs (Kadiyala et al. (1997) Cell Transplant.6:125-34) as well as cells derived from other tissue such as adipose (Halvorsen et al. (2001) Tissue Eng. 7:729-41) have been shown to differentiate into an osteoblast-like cell.
MSCs have also been shown to differentiate into adipocytes or osteoblasts in response to BMPs (Chen et al.
(1998) J. Cell Biol. 142:295-305) due to differential roles for bone morphogenic protein (BMP) receptor type 1B and IA. Placenta-derived cells are also capable of expressing an osteoblast-like phenotype as previously observed with bone marrow-derived mesenchymal stein cells (MSCs) when placed in osteogenic medium containing dexamethasone, B-glycerophosphate, and ascorbic acid. Several experiments were conducted with different isolates to determine whether there was mineralization of the cultured cells by von Kossa staining and expression of bone sialoprotein (BSP) and osteocalcin, which are expressed in osteoblasts.
Following induction of osteogenesis, MSCs were demonstrated to mineralize and stain with von Kossa and also have
- 99 -increased mRNA levels of bone sialoprotein and osteocalcin expression using real-time relative quantitation. Numerous MSCs also formed lipid droplets in the cytoplasm similar to adipocytes.
Placenta-derived cells (predominantly neonatal cells) showed extensive mineralization and induction of BSP and osteocalcin in osteogenic medium, which was enhanced at 21 days with BMP-2 or ¨4.
Chondrogenic Differentiation of Placenta-Derived Cells Placenta-derived cells were tested for their ability to differentiate into chondrocytes in vitro in two different assay systems: the pellet assay culture system and collagen gel cultures.
The pellet culture system has been used successfully with selected lots of human mesenchymal stem cells (MSC). MSC grown in this assay and treated with transforming growth factor-beta3 have been shown to differentiate into chondrocytes (Johnstone, et al. (1998) Exp. Cell Res.
238:265-272). The collagen gel system has been used to culture chondrocytes in vitro (Gosiewska, et al. (2001) Tissue Eng. 7:267-277.). Chondrocytes grown under these conditions form a cartilage-like structure.
Materials and Methods Cell Culture Human placentas were received and cells were isolated as described (Example 1). Cells were cultured in Growth medium (Dulbecco's Modified Essential Media (DMEM), 15% (v/v) fetal bovine serum (Hyclone, Logan UT), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen, Carlsbad, CA), 0.001% (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO)) on gelatin-coated tissue culture plastic flasks. The cultures were incubated at 37 C with 5 % CO2. For use in experiments, cells were between passages 4 and 12.
Human articular chondrocytes were purchased from Cambrex (Walkersville, MD) and cultured in the same media as the placenta-derived cells. Twenty-four hours before the experiment, the culture media was changed to a media containing 1% FBS.
Human mesenchymal stem cells (MSCs) were purchased from Cambrex (Walkersville, MD) and cultured in MSCGM (Cambrex). Cells used for experiments were between passages 2 and 4.
Collagen gel assays. Cultured cells were trypsinized to remove from culture plate. Cells were washed with centrifugation twice at 300 x g for 5 mm in DMEM without serum and counted. Cells were mixed with the following components at the final concentrations listed: rat tail collagen (1 milligram/milliliter, , BD DiscoveryLabware, Bedford, MA), 0.01 Normal NaOH,
Placenta-derived cells (predominantly neonatal cells) showed extensive mineralization and induction of BSP and osteocalcin in osteogenic medium, which was enhanced at 21 days with BMP-2 or ¨4.
Chondrogenic Differentiation of Placenta-Derived Cells Placenta-derived cells were tested for their ability to differentiate into chondrocytes in vitro in two different assay systems: the pellet assay culture system and collagen gel cultures.
The pellet culture system has been used successfully with selected lots of human mesenchymal stem cells (MSC). MSC grown in this assay and treated with transforming growth factor-beta3 have been shown to differentiate into chondrocytes (Johnstone, et al. (1998) Exp. Cell Res.
238:265-272). The collagen gel system has been used to culture chondrocytes in vitro (Gosiewska, et al. (2001) Tissue Eng. 7:267-277.). Chondrocytes grown under these conditions form a cartilage-like structure.
Materials and Methods Cell Culture Human placentas were received and cells were isolated as described (Example 1). Cells were cultured in Growth medium (Dulbecco's Modified Essential Media (DMEM), 15% (v/v) fetal bovine serum (Hyclone, Logan UT), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen, Carlsbad, CA), 0.001% (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO)) on gelatin-coated tissue culture plastic flasks. The cultures were incubated at 37 C with 5 % CO2. For use in experiments, cells were between passages 4 and 12.
Human articular chondrocytes were purchased from Cambrex (Walkersville, MD) and cultured in the same media as the placenta-derived cells. Twenty-four hours before the experiment, the culture media was changed to a media containing 1% FBS.
Human mesenchymal stem cells (MSCs) were purchased from Cambrex (Walkersville, MD) and cultured in MSCGM (Cambrex). Cells used for experiments were between passages 2 and 4.
Collagen gel assays. Cultured cells were trypsinized to remove from culture plate. Cells were washed with centrifugation twice at 300 x g for 5 mm in DMEM without serum and counted. Cells were mixed with the following components at the final concentrations listed: rat tail collagen (1 milligram/milliliter, , BD DiscoveryLabware, Bedford, MA), 0.01 Normal NaOH,
- 100 -and Chondrogenic medium (DMEM, 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 2 millimolar L-Glutamine, 1 millimolar Sodium Pyruvate, 0.35 millimolar L-Proline, 100 nanoMolar dexamethasone, 0.17 millimolar L-Ascorbic Acid, 1 %
(v/v) ITS
(insulin, transferrin, selenium) (all components from Sigma Chemical Company)). The cells were gently mixed with the medium, and the samples were aliquoted into individual wells of a 24-well ultra-low cluster plate (Coming, Corning, NY) at a concentration of either 2 x 105 per well or 5 x 105 per well. Cultures were placed in an incubator and left undisturbed for 24 to 48 hours. Medium was replaced with fresh chondrogenic medium supplemented with appropriate growth factor every 24-48 hours. Samples were allowed to culture for up to 28 days at which time they were removed and fixed in 10% (v/v) formalin (VWR Scientific, West Chester, PA) and processed for histological examination. Samples were stained with Safranin 0 or hematoxylin/eosin for evaluation.
Pellet culture assays. Cultured cells were trypsinized to remove from the culture plate.
Cells were washed with centrifugation twice at 300 x g for 5 minutes in DMEM
without serum and counted. Cells were resuspended in fresh chondrogenic medium (described above) at a concentration of 5 x 105 cells per milliliter. Cells were aliquoted into new polypropylene tubes at 2.5 x 105 cells per tube. The appropriate samples were then treated with either TGF-beta3 (10 nanogram/milliliter, Sigma) or GDF-5 (100 nanogram/milliliter; R&D Systems, Minneapolis, MN) as growth factor. Cells were then centrifuged at 150 x g for 3 minutes.
Tubes were then transferred to the incubator and left undisturbed for 24 to 48 hours in standard atmosphere with 5 % CO2 at 37 C and. Media was replaced with fresh chondrocyte cell media and growth factor, where appropriate, every 2 to 3 days. Samples were allowed to culture for up to 28 days at which time they were removed and fixed and stained as described above.
Results Safranin 0 stains of cell pellets of placenta-derived cells treated with TGF-beta3 and GDF-5 showed positive Safranin 0 staining as compared to control cells, indicating glycosoaminoglycan. Placenta-derived cells also showed some chondrocyte-like morphology.
Summary. The results of the present study show that the placenta-derived cells partially differentiated into chondrocytes in vitro in the pellet culture and the collagen gel assay systems, as evidenced by glycosaminoglycan expression and similarity of cell morphology to cartilage tissue.
Evaluation of Chondrogenic Potential of Placenta-Derived Cells
(v/v) ITS
(insulin, transferrin, selenium) (all components from Sigma Chemical Company)). The cells were gently mixed with the medium, and the samples were aliquoted into individual wells of a 24-well ultra-low cluster plate (Coming, Corning, NY) at a concentration of either 2 x 105 per well or 5 x 105 per well. Cultures were placed in an incubator and left undisturbed for 24 to 48 hours. Medium was replaced with fresh chondrogenic medium supplemented with appropriate growth factor every 24-48 hours. Samples were allowed to culture for up to 28 days at which time they were removed and fixed in 10% (v/v) formalin (VWR Scientific, West Chester, PA) and processed for histological examination. Samples were stained with Safranin 0 or hematoxylin/eosin for evaluation.
Pellet culture assays. Cultured cells were trypsinized to remove from the culture plate.
Cells were washed with centrifugation twice at 300 x g for 5 minutes in DMEM
without serum and counted. Cells were resuspended in fresh chondrogenic medium (described above) at a concentration of 5 x 105 cells per milliliter. Cells were aliquoted into new polypropylene tubes at 2.5 x 105 cells per tube. The appropriate samples were then treated with either TGF-beta3 (10 nanogram/milliliter, Sigma) or GDF-5 (100 nanogram/milliliter; R&D Systems, Minneapolis, MN) as growth factor. Cells were then centrifuged at 150 x g for 3 minutes.
Tubes were then transferred to the incubator and left undisturbed for 24 to 48 hours in standard atmosphere with 5 % CO2 at 37 C and. Media was replaced with fresh chondrocyte cell media and growth factor, where appropriate, every 2 to 3 days. Samples were allowed to culture for up to 28 days at which time they were removed and fixed and stained as described above.
Results Safranin 0 stains of cell pellets of placenta-derived cells treated with TGF-beta3 and GDF-5 showed positive Safranin 0 staining as compared to control cells, indicating glycosoaminoglycan. Placenta-derived cells also showed some chondrocyte-like morphology.
Summary. The results of the present study show that the placenta-derived cells partially differentiated into chondrocytes in vitro in the pellet culture and the collagen gel assay systems, as evidenced by glycosaminoglycan expression and similarity of cell morphology to cartilage tissue.
Evaluation of Chondrogenic Potential of Placenta-Derived Cells
- 101 -. .
in an In Vitro Pellet Culture Based Assay This example describes evaluation of the chondrogenic potential of cells derived from placental tissue using in vitro pellet culture based assays. Cells derived from placenta at early passage (P3) and late passage (P12) were used. The chondrogenic potential of the cells was assessed in pellet culture assays, under chondrogenic induction conditions, in medium supplemented with transforming growth factor beta-3 (TGF beta -3), rhGDF-5 (recombinant human growth and differentiation factor 5) or a combination of both.
Materials & Methods Reagents. Dulbecco's Modified Essential Media (DMEM), Penicillin and Streptomycin, were obtained from Invitrogen, Carlsbad, CA. Fetal calf serum (FCS) was obtained from HyClone (Logan, UT). Mesenchymal stem cell growth medium (MSCGM) and hMSC
chondrogenic differentiation bullet kit were obtained from Biowhittaker, Walkersville, MD.
TGF beta -3 was obtained from Oncogene research products, San Diego, CA. rhGDF-5 was obtained from Biophami, Heidelberg, Germany (W09601316 Al, US5994094 A).
Cells. Human mesenchymal stem cells (Lot# 2F1656) were obtained from Biowhittaker, Walkersville, MD and were cultured in MSCGM according to manufacturer's instructions. This lot has been tested previously, and was shown to be positive in the chondrogenesis assays.
Human adult and neonatal fibroblasts were obtained from American Type Culture Collection (ATCC), Manassas, VA and cultured in growth medium (Dulbecco's Modified Essential supplemented with 15% (v/v) fetal bovine serum, 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin and 0.001 % (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO) on gelatin-coated tissue culture plastic flasks. Placenta-derived cells (Lot#
071003Plac) were utilized. Cells were cultured in Growth medium similar to fibroblasts. The cell cultures were incubated at 37 C with 5 % CO2. Cells used for experiments were at passages 3 and 12.
Pellet culture assay. For pellet cultures, 0.25x106 cells were placed in a 15 milliliter conical tube and centrifuged at 150xg for 5 minutes at room temperature to form a spherical pellet according to protocol for chondrogenic assay from Biowhittaker. Pellets were cultured in chondrogenic induction, medium containing TGF beta -3 (10 nanogram/milliliter), rhGDF-5 (500 nanogram/milliliter), or a combination of TGF beta -3 (10 nanogram/milliliter), and rhGDF-(500 nanogram/milliliter) for three weeks. Untreated controls were cultured in growth medium. During culture, pellets were re-fed with fresh medium every other day.
Treatment groups included the following:
in an In Vitro Pellet Culture Based Assay This example describes evaluation of the chondrogenic potential of cells derived from placental tissue using in vitro pellet culture based assays. Cells derived from placenta at early passage (P3) and late passage (P12) were used. The chondrogenic potential of the cells was assessed in pellet culture assays, under chondrogenic induction conditions, in medium supplemented with transforming growth factor beta-3 (TGF beta -3), rhGDF-5 (recombinant human growth and differentiation factor 5) or a combination of both.
Materials & Methods Reagents. Dulbecco's Modified Essential Media (DMEM), Penicillin and Streptomycin, were obtained from Invitrogen, Carlsbad, CA. Fetal calf serum (FCS) was obtained from HyClone (Logan, UT). Mesenchymal stem cell growth medium (MSCGM) and hMSC
chondrogenic differentiation bullet kit were obtained from Biowhittaker, Walkersville, MD.
TGF beta -3 was obtained from Oncogene research products, San Diego, CA. rhGDF-5 was obtained from Biophami, Heidelberg, Germany (W09601316 Al, US5994094 A).
Cells. Human mesenchymal stem cells (Lot# 2F1656) were obtained from Biowhittaker, Walkersville, MD and were cultured in MSCGM according to manufacturer's instructions. This lot has been tested previously, and was shown to be positive in the chondrogenesis assays.
Human adult and neonatal fibroblasts were obtained from American Type Culture Collection (ATCC), Manassas, VA and cultured in growth medium (Dulbecco's Modified Essential supplemented with 15% (v/v) fetal bovine serum, 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin and 0.001 % (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO) on gelatin-coated tissue culture plastic flasks. Placenta-derived cells (Lot#
071003Plac) were utilized. Cells were cultured in Growth medium similar to fibroblasts. The cell cultures were incubated at 37 C with 5 % CO2. Cells used for experiments were at passages 3 and 12.
Pellet culture assay. For pellet cultures, 0.25x106 cells were placed in a 15 milliliter conical tube and centrifuged at 150xg for 5 minutes at room temperature to form a spherical pellet according to protocol for chondrogenic assay from Biowhittaker. Pellets were cultured in chondrogenic induction, medium containing TGF beta -3 (10 nanogram/milliliter), rhGDF-5 (500 nanogram/milliliter), or a combination of TGF beta -3 (10 nanogram/milliliter), and rhGDF-(500 nanogram/milliliter) for three weeks. Untreated controls were cultured in growth medium. During culture, pellets were re-fed with fresh medium every other day.
Treatment groups included the following:
- 102 -Treatment Group A. Placenta-derived cells early passage (P EP) + rhGDF-5 B. Placenta-derived cells late passage (P LP) + rhGDF-5 C. Human Mesenchymal Stem cells (HMSC) + rhGDF-5 D. Human adult fibroblast cells (HAF) + rhGDF-5 E. Placenta-derived cells early passage (P EP) + TGF beta -3 F. Placenta-derived cells late passage (P LP) + TGF beta -3 G. Human Mesenchymal Stem cells (HMSC) + TGF beta -3 J. Human adult fibroblast cells (HAF) + TGF beta -3 I. Placenta-derived cells early passage (P EP) + rhGDF-5+ TGF beta -3, n=1 J. Placenta-derived cells late passage (P LP) + rhGDF-5+ TGF beta -3 K. Human Mesenchymal Stem cells (HMSC) + rhGDF-5+ TGF beta -3 L. Human adult fibroblast cells (HAF) + rhGDF-5+ TGF beta -3 M. Human neonatal fibroblast cells (HNF) + rhGDF-5+ TGF beta -3 N. Placenta-derived cells early passage (P EP) 0. Placenta-derived cells late passage (P LP) P. Human Mesenchymal Stem cells (HMSC) Q. Human adult fibroblast cells (HAF) Histology of in vitro samples. At the end of the culture period pellets were fixed in 10%
buffered formalin and sent to MPI Research (Mattawan, MI) for paraffin embedding, sectioning, and staining with Hematoxylin /Eosin (H/E) and Safranin 0 (SO) staining.
Results Placenta-derived cells, MSCs and fibroblasts formed cell pellets in chondrogenic induction medium with the different growth factors. The size of the pellets at the end of culture period varied among the different cell types. Pellets fowled with the placental cells were similar in size, or slightly larger than, those formed by MSCs and fibroblasts.
Pellets formed with all cell types and cultured in control medium were smaller than pellets cultured in chondrogenic induction medium.
Examination of cross sections of pellets stained with H/E and Safranin-0 provided some indication that placenta-derived cells at early and late passage may have the potential to undergo chondrogenic differentiation. Chondrogenesis as assessed by cell condensation, cell morphology
buffered formalin and sent to MPI Research (Mattawan, MI) for paraffin embedding, sectioning, and staining with Hematoxylin /Eosin (H/E) and Safranin 0 (SO) staining.
Results Placenta-derived cells, MSCs and fibroblasts formed cell pellets in chondrogenic induction medium with the different growth factors. The size of the pellets at the end of culture period varied among the different cell types. Pellets fowled with the placental cells were similar in size, or slightly larger than, those formed by MSCs and fibroblasts.
Pellets formed with all cell types and cultured in control medium were smaller than pellets cultured in chondrogenic induction medium.
Examination of cross sections of pellets stained with H/E and Safranin-0 provided some indication that placenta-derived cells at early and late passage may have the potential to undergo chondrogenic differentiation. Chondrogenesis as assessed by cell condensation, cell morphology
- 103 -and Safranin 0 positive staining of matrix was indistinct in the placenta-derived cells cultured in chondrogenic induction medium supplemented with TGF beta -3, rhGDF-5, or both.
However, this may be due to the fact that chondrogenic induction conditions were optimized for MSCs, not for postpartum-derived cells, and it should be noted that control pellets cultured in growth medium showed no evidence of chondrogenesis. Moreover, distinct cell populations were observed in placenta-derived cells at both passages located apically or centrally. Some cell condensation was observed with fibroblast, but it was not associated with Safi-anin 0 staining.
Adipogenic Differentiation of Placenta-Derived Cells Stromal populations of stem cells have been demonstrated to differentiate into an adipogenic phenotype (Janderova et al. (2003) Obes. Res. 11(1):65-74; Zangani et al. (1999) Differentiation 64(2):91-101; Liu et al. .(2003) Curr. Ma Med. 3(4):325-40).
The potential of placenta-derived cells to differentiate into an adipogenic phenotype was examined.
Methods & Materials Adipose differentiation. Placenta-derived cells (P3) were,seeded at 200,000 cells per well on 6-well tissue culture-treated plates in growth medium ((DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15 percent (v/v) defined bovine serum (Hyclone, Logan, UT;
Lot#AND18475), 0.001 percent 2-mercaptoethanol (Sigma, St. Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B;
Invitrogen, Carlsbad, CA). Mesenchymal stem cells (P3, IF2155), osteoblasts (P5, CC2538;
Cambrex, Walkerville, MD), omental cells (P6) (isolated from omental tissue from NDRI, following protocol used for placenta-derived cell isolation in Example 1), adipose-derived cells (U.S. Patent No. 6,555,374 B1) (P6), and fibroblasts (P6, CC2509) (Cambrex, Walkerville, MD) were also seeded under the same conditions. Prior to initiation of osteogenesis, Mesenchymal Stem Cells were grown in a Mesenchymal Stem Cell Growth Medium Bullet kit (Cambrex, Walkerville, MD). After 2 days, spent medium was aspirated off and cells were washed with phosphate buffered saline (PBS). At this point, medium was switched to Dulbecco's minimal essential medium-high glucose (DMEM-Hg; Invitrogen, Carlsbad, CA) containing 10 percent FBS (v/v, Hyclone, Logan UT), 0.02 milligrams per milliliter insulin (Sigma, St. Louis, MO), and 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B; Invitrogen, Carlsbad, CA). Once the cells had reached confluence, spent medium was aspirated off. Cells were then cultured in an adipose differentiation medium
However, this may be due to the fact that chondrogenic induction conditions were optimized for MSCs, not for postpartum-derived cells, and it should be noted that control pellets cultured in growth medium showed no evidence of chondrogenesis. Moreover, distinct cell populations were observed in placenta-derived cells at both passages located apically or centrally. Some cell condensation was observed with fibroblast, but it was not associated with Safi-anin 0 staining.
Adipogenic Differentiation of Placenta-Derived Cells Stromal populations of stem cells have been demonstrated to differentiate into an adipogenic phenotype (Janderova et al. (2003) Obes. Res. 11(1):65-74; Zangani et al. (1999) Differentiation 64(2):91-101; Liu et al. .(2003) Curr. Ma Med. 3(4):325-40).
The potential of placenta-derived cells to differentiate into an adipogenic phenotype was examined.
Methods & Materials Adipose differentiation. Placenta-derived cells (P3) were,seeded at 200,000 cells per well on 6-well tissue culture-treated plates in growth medium ((DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15 percent (v/v) defined bovine serum (Hyclone, Logan, UT;
Lot#AND18475), 0.001 percent 2-mercaptoethanol (Sigma, St. Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B;
Invitrogen, Carlsbad, CA). Mesenchymal stem cells (P3, IF2155), osteoblasts (P5, CC2538;
Cambrex, Walkerville, MD), omental cells (P6) (isolated from omental tissue from NDRI, following protocol used for placenta-derived cell isolation in Example 1), adipose-derived cells (U.S. Patent No. 6,555,374 B1) (P6), and fibroblasts (P6, CC2509) (Cambrex, Walkerville, MD) were also seeded under the same conditions. Prior to initiation of osteogenesis, Mesenchymal Stem Cells were grown in a Mesenchymal Stem Cell Growth Medium Bullet kit (Cambrex, Walkerville, MD). After 2 days, spent medium was aspirated off and cells were washed with phosphate buffered saline (PBS). At this point, medium was switched to Dulbecco's minimal essential medium-high glucose (DMEM-Hg; Invitrogen, Carlsbad, CA) containing 10 percent FBS (v/v, Hyclone, Logan UT), 0.02 milligrams per milliliter insulin (Sigma, St. Louis, MO), and 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B; Invitrogen, Carlsbad, CA). Once the cells had reached confluence, spent medium was aspirated off. Cells were then cultured in an adipose differentiation medium
- 104 -(DMEM-Hg (Invitrogen, Carlsbad, CA), containing 10 percent defined fetal bovine serum ((v/v), Hyclone, Logan, UT), 0.02 milligrams per milliliter insulin (Sigma, St. Louis, MO) and 100 Units/milliliter penicillin, 100 micrograms/milliliter streptomycin, and 0.25 micrograms/milliliter amphotericin, 5 micromolar isobutylmethylxanthine (Sigma, St. Louis, MO), 100 micromolar dexamethasone (Sigma, St. Louis, MO), and 2.5 micromolar indomethacin (Sigma, St. Louis, MO) for up to 4 weeks. Cells were stained with Oil-Red-0 to determine the presence of lipid droplet formation.
Oil Red 0 Staining. Cells were fixed with 10 percent (v/v) neutral buffered formalin (Richard-Allan Kalamazoo, MI). After fixation, the cells were washed in deionized water and incubated for two minutes in propylene glycol (absolute; Poly Scientific, Bay Shore, NY).
Propylene glycol was removed by aspiration, and samples were incubated in Oil Red 0 (Poly Scientific, Bay Shore, NY) for one hour. Staining solution was removed by aspiration and stained samples were then incubated in 85 percent (v/v) propylene glycol solution (Poly Scientific, Bay Shore, NY) for one minute. Finally stained samples were washed with two changes of de-ionized water. Stained samples were counter-stained with Mayer's Hematoxylin (Poly Scientific Bay Shore, NY) and examined by light microscopy. Images were taken at magnification of 20 X.
Leptin Assay. Adipose-derived cells and placenta-derived cells were seeded at 200,000 cells/well in 6-well tissue culture-treated plates. Cells were initially seeded in growth medium ((DMEM:Lg; Invitrogen, Carlsbad, CA), 15 % FBS (defined bovine serum Lot#A1ND18475;
Hyclone, Logan, UT), 0.001% 2-mercaptoethanol (Sigma, St. Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B;
Invitrogen, Carlsbad, CA)), which was changed to an adipogenic differentiation medium (DMEM-Hg medium (Gibco, Carlsbad, CA) containing 1 micromolar dexamethasone (Sigma, St. Louis, MO), 0.2 millimolar indomethasone (Sigma, St. Louis, MO), 0.01 milligrams per microliter insulin (Sigma, St. Louis, MO), 0.5 millimolar isobutylmethylxanthine (Sigma, St.
Louis, MO), 10 percent (v/v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, UT), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin (Gibco, Carlsbad CA)). At the end of the assay, the conditioned medium was collected and leptin levels were measured using an ELISA kit (Quantikine, R&D Systems, Minneapolis, MN).
Results Adipose differentiation. Morphologically, MSCs and Adipose-derived cells (Artecel;
U.S. Patent NO. 6,555,374) demonstrated lipid formation as early as 5 days in this assay. Large
Oil Red 0 Staining. Cells were fixed with 10 percent (v/v) neutral buffered formalin (Richard-Allan Kalamazoo, MI). After fixation, the cells were washed in deionized water and incubated for two minutes in propylene glycol (absolute; Poly Scientific, Bay Shore, NY).
Propylene glycol was removed by aspiration, and samples were incubated in Oil Red 0 (Poly Scientific, Bay Shore, NY) for one hour. Staining solution was removed by aspiration and stained samples were then incubated in 85 percent (v/v) propylene glycol solution (Poly Scientific, Bay Shore, NY) for one minute. Finally stained samples were washed with two changes of de-ionized water. Stained samples were counter-stained with Mayer's Hematoxylin (Poly Scientific Bay Shore, NY) and examined by light microscopy. Images were taken at magnification of 20 X.
Leptin Assay. Adipose-derived cells and placenta-derived cells were seeded at 200,000 cells/well in 6-well tissue culture-treated plates. Cells were initially seeded in growth medium ((DMEM:Lg; Invitrogen, Carlsbad, CA), 15 % FBS (defined bovine serum Lot#A1ND18475;
Hyclone, Logan, UT), 0.001% 2-mercaptoethanol (Sigma, St. Louis, MO), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B;
Invitrogen, Carlsbad, CA)), which was changed to an adipogenic differentiation medium (DMEM-Hg medium (Gibco, Carlsbad, CA) containing 1 micromolar dexamethasone (Sigma, St. Louis, MO), 0.2 millimolar indomethasone (Sigma, St. Louis, MO), 0.01 milligrams per microliter insulin (Sigma, St. Louis, MO), 0.5 millimolar isobutylmethylxanthine (Sigma, St.
Louis, MO), 10 percent (v/v) fetal bovine serum (Cat. #SH30070.03; Hyclone, Logan, UT), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin (Gibco, Carlsbad CA)). At the end of the assay, the conditioned medium was collected and leptin levels were measured using an ELISA kit (Quantikine, R&D Systems, Minneapolis, MN).
Results Adipose differentiation. Morphologically, MSCs and Adipose-derived cells (Artecel;
U.S. Patent NO. 6,555,374) demonstrated lipid formation as early as 5 days in this assay. Large
- 105 -amounts of lipid droplet formation were observed in both these cultures by 15 days of culture.
Cultures of osteoblasts also deposited large amounts of lipid under these conditions after 10 days in culture and extensively at 15 days. Lipid droplet formation was observed in placenta-derived and mental cell cultures after 15 days of culture. Low level lipid droplet fonnation was observed in the fibroblast cultures after 20 days in adipogenic-inducing conditions.
Leptin. Leptin was not detected by ELISA in placenta-derived cell conditioned medium.
Summary. The potential of placenta-derived cells to differentiate into an adipose phenotype was examined. The data demonstrate that placenta-derived cells undergo a low level of adipose differentiation when compared to cultures of mesenchymal stem cells, adipose-derived cells, or osteoblasts. No leptin was detected in placenta-derived cells by ELISA
following the adipogenic differentiation protocol used.
Differentiation of Placenta-Derived Cells to Beta Cells The pancreas contains endocrine cells, organized in islets of Langerhans, which produce insulin, glucagon, somatostatin, and pancreatic polypeptide (PP). The ability of placenta-derived cells to differentiate towards cells with an insulin-producing phenotype was tested under eight different induction protocols.
Methods & Materials Placenta-derived cells as well as neonatal or adult Normal Human Detinal Fibroblasts (NHDF) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03, Hyclone; Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)) in a gelatin-coated T75 flask as well as in different beta-cell promoting differentiation conditions. Flasks were coated with 2% (w/v) gelatin solution (Sigma, St. Louis, MO) for 20 minutes at room temperature. Gelatin solution was aspirated off, and flasks were washed with PBS. Basic Fibroblast Growth Factor (bFGF), Epidermal Growth Factor (EGF), Transfolining Growth Factor beta (TGFbeta) and Fibroblast Growth Factor 10 (FGF-10) were purchased from PeproTech Inc. (Rocky Hill, NJ). GLP-1 was purchased from Sigma (St. Louis, MO) Protocol 1: Placenta-derived cells (isolate I; P2), adipose-derived cells (US.
Patent No. 6,555,374), placenta-derived cells (isolate 2; P4) (predominately neonatal as analyzed by karyotyping ¨ data not shown), and adult Normal Human Dermal Fibroblasts (NHDF) (PI0).
Cultures of osteoblasts also deposited large amounts of lipid under these conditions after 10 days in culture and extensively at 15 days. Lipid droplet formation was observed in placenta-derived and mental cell cultures after 15 days of culture. Low level lipid droplet fonnation was observed in the fibroblast cultures after 20 days in adipogenic-inducing conditions.
Leptin. Leptin was not detected by ELISA in placenta-derived cell conditioned medium.
Summary. The potential of placenta-derived cells to differentiate into an adipose phenotype was examined. The data demonstrate that placenta-derived cells undergo a low level of adipose differentiation when compared to cultures of mesenchymal stem cells, adipose-derived cells, or osteoblasts. No leptin was detected in placenta-derived cells by ELISA
following the adipogenic differentiation protocol used.
Differentiation of Placenta-Derived Cells to Beta Cells The pancreas contains endocrine cells, organized in islets of Langerhans, which produce insulin, glucagon, somatostatin, and pancreatic polypeptide (PP). The ability of placenta-derived cells to differentiate towards cells with an insulin-producing phenotype was tested under eight different induction protocols.
Methods & Materials Placenta-derived cells as well as neonatal or adult Normal Human Detinal Fibroblasts (NHDF) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad, CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03, Hyclone; Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad, CA)) in a gelatin-coated T75 flask as well as in different beta-cell promoting differentiation conditions. Flasks were coated with 2% (w/v) gelatin solution (Sigma, St. Louis, MO) for 20 minutes at room temperature. Gelatin solution was aspirated off, and flasks were washed with PBS. Basic Fibroblast Growth Factor (bFGF), Epidermal Growth Factor (EGF), Transfolining Growth Factor beta (TGFbeta) and Fibroblast Growth Factor 10 (FGF-10) were purchased from PeproTech Inc. (Rocky Hill, NJ). GLP-1 was purchased from Sigma (St. Louis, MO) Protocol 1: Placenta-derived cells (isolate I; P2), adipose-derived cells (US.
Patent No. 6,555,374), placenta-derived cells (isolate 2; P4) (predominately neonatal as analyzed by karyotyping ¨ data not shown), and adult Normal Human Dermal Fibroblasts (NHDF) (PI0).
- 106 -Cells were maintained under either noimal or 5% 02 conditions. Cells were seeded at low density (5,000 cells/cm2) in gelatin-coated T75 flasks on gelatin and grown in Ham's F12 medium (Clonetics, Santa Rosa, CA), 2% (v/v) FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 10 nanograms/milliliter EGF, and 20 nanograms/milliliter bFGF until confluence. Confluent cells were trypsinized and plated at 50,000 cells/cm2 in 24-well Tissue Culture Polystyrene (TCPS; BD Biosciences, Bedford, MA) plates with or without gelatin or collagen coating. Cells were grown in Ham's F12 medium, 2% FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF, and 15 nanoMolar GLP-1 (7-37 isoform) for up to 3 weeks.
Protocol 2: Placenta-derived cells (isolate 3; P3) and placenta-derived cells (isolate 2;
P3) (predominately neonatal as identified by karyotyping analysis). Cells were seeded at low density (5,000 cells/cm2) in T75 flasks on gelatin and grown in Ham's F12 medium, 2% FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF until confluence. Confluent cells were trypsinized and plated at 50,000 cells/cm2 in 24-well TCPS plates with or without gelatin coating. Cells were grown in Ham's F12 medium, 2% FBS, P/S, 15 nanoMolar GLP-1 (7-37 isoform) for up to 3 weeks.
Protocol 3: Placenta-derived cells (isolate 1, P10), adult NHDF P10, and placenta-derived cells (isolate 2; P3). Cells were seeded at high density (50,000 cells/cm2) in 24-well TCPS plates and grown in DMEM:Ham's F12 (1:1) medium, B-27 supplement (Gibco, Carlsbad, CA), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 20 nanograms/milliliter EGF, 40 nanograms/milliliter bFGF. Spherical clusters were generated within about 4-6 days. Following that period, the spherical clusters were collected, centrifuged, and replated onto laminin-coated, 24-well plates (BD Biosciences, Bedford, MA), and cultured up to 3 weeks in B-27-supplemented medium containing 10 nanoMolar GLP-1 (7-37) with no other growth factors (i.e., no bFGF and no EGF).
Protocol 4: Placenta-derived cells (isolate I; P10), adult NHDF (P10), placenta-derived cells (isolate 2; P3). Cells were set up at high density (50,000 cells/cm2) in 24-well TCPS plates and grown in DMEM:Ham's F12 (1:1) medium, B-27 supplement, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 20 nanograms/milliliter EGF, 40 nanograms/milliliter bFGF. Spherical clusters were generated, usually in about 4-6 days. Following that period, the spherical clusters were collected, centrifuged, and replated onto larninin-coated, 24-well plates and cultured up to 3 weeks in B-27-supplemented medium containing 10 nanoMolar GLP-1 (1-37 isoform) but no other growth factors (i.e., no bFGF and no EGF).
Protocol 2: Placenta-derived cells (isolate 3; P3) and placenta-derived cells (isolate 2;
P3) (predominately neonatal as identified by karyotyping analysis). Cells were seeded at low density (5,000 cells/cm2) in T75 flasks on gelatin and grown in Ham's F12 medium, 2% FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF until confluence. Confluent cells were trypsinized and plated at 50,000 cells/cm2 in 24-well TCPS plates with or without gelatin coating. Cells were grown in Ham's F12 medium, 2% FBS, P/S, 15 nanoMolar GLP-1 (7-37 isoform) for up to 3 weeks.
Protocol 3: Placenta-derived cells (isolate 1, P10), adult NHDF P10, and placenta-derived cells (isolate 2; P3). Cells were seeded at high density (50,000 cells/cm2) in 24-well TCPS plates and grown in DMEM:Ham's F12 (1:1) medium, B-27 supplement (Gibco, Carlsbad, CA), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 20 nanograms/milliliter EGF, 40 nanograms/milliliter bFGF. Spherical clusters were generated within about 4-6 days. Following that period, the spherical clusters were collected, centrifuged, and replated onto laminin-coated, 24-well plates (BD Biosciences, Bedford, MA), and cultured up to 3 weeks in B-27-supplemented medium containing 10 nanoMolar GLP-1 (7-37) with no other growth factors (i.e., no bFGF and no EGF).
Protocol 4: Placenta-derived cells (isolate I; P10), adult NHDF (P10), placenta-derived cells (isolate 2; P3). Cells were set up at high density (50,000 cells/cm2) in 24-well TCPS plates and grown in DMEM:Ham's F12 (1:1) medium, B-27 supplement, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 20 nanograms/milliliter EGF, 40 nanograms/milliliter bFGF. Spherical clusters were generated, usually in about 4-6 days. Following that period, the spherical clusters were collected, centrifuged, and replated onto larninin-coated, 24-well plates and cultured up to 3 weeks in B-27-supplemented medium containing 10 nanoMolar GLP-1 (1-37 isoform) but no other growth factors (i.e., no bFGF and no EGF).
- 107 -Protocol 5: Adult NHDF (P15) and placenta-derived cells (isolate 1; P15).
Cells were seeded at high density (50,000 cells/cm2) in 24-well TCPS gelatin-coated plates and grown in DMEM:Ham's F12 (1:1) medium, B-27 supplement, 50 Units/milliliter penicillin, microgram/milliliter streptomycin, 10 nanograms/milliliter FOF-10, and/or 40 nanograms/milliliter TGFbeta for > two weeks.
Protocol 6: Adult NHDF and placenta-derived cells (isolate 1; P15). Cells were seeded at high density (50,000 cells/cm2) in 24-well TCPS gelatin-coated plates and grown in EBM-2 medium, 10 nanograms/milliliter FGF-10, and/or 40 nanograms/milliliter TGFbeta for > two weeks.
Protocol 7: Placenta-derived cells (isolate 3; P3) were seeded at low density (5,000 cells/cm2) in T75 flasks on gelatin and grown either in Growth medium or in Ham's F12 medium, 2% FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF until confluence.
Confluent cells were trypsinized and plated at 50,000 cells/cm2 in 24-well TCPS plates, with or without gelatin coating. Three types of basic media were used for up to 3 weeks:
betaI medium: Ham's F12 medium, 2% FBS, 10 millimolar nicotinamide, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 25 milliMolar glucose betall medium: Equal parts of DMEM/Ham's F12 media, 2% FBS, 10 millimolar nicotinamide, 25 milliMolar glucose Endothelial Cell Basal Medium (EBM), (Clonetics, Santa Rosa, CA).
The following growth factors were added to each of the media: 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF, 10 nanoMolar GLP-1 (7-37 isoform).
Protocol 8: Placenta-derived cells (isolate 2; P2) (predominately neonatal as identified by karyotyping analysis), placenta-derived cells (isolate 2; P1), clone #22.
Cells were seeded at low density (5,000 cells/cm2) in T25 TCPS flasks and grown in DMEM, 20% FBS, Units/milliliter penicillin, 50 microgram/milliliter streptomycin until confluence.
Total RNA isolation and quantitative RT-PCR. RNA was extracted from placenta-derived cells and fibroblasts grown as described in each protocol. Cells were lysed with 350 microliter buffer RLT containing beta-mercaptoethanol (Sigma St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) and RNA
extracted according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) with a 2.7 Units/sample DNase treatment (Sigma St. Louis, MO). RNA was eluted with 50 microliter DEPC-treated water and stored at ¨80 C. RNA was reverse transcribed using random hexamers
Cells were seeded at high density (50,000 cells/cm2) in 24-well TCPS gelatin-coated plates and grown in DMEM:Ham's F12 (1:1) medium, B-27 supplement, 50 Units/milliliter penicillin, microgram/milliliter streptomycin, 10 nanograms/milliliter FOF-10, and/or 40 nanograms/milliliter TGFbeta for > two weeks.
Protocol 6: Adult NHDF and placenta-derived cells (isolate 1; P15). Cells were seeded at high density (50,000 cells/cm2) in 24-well TCPS gelatin-coated plates and grown in EBM-2 medium, 10 nanograms/milliliter FGF-10, and/or 40 nanograms/milliliter TGFbeta for > two weeks.
Protocol 7: Placenta-derived cells (isolate 3; P3) were seeded at low density (5,000 cells/cm2) in T75 flasks on gelatin and grown either in Growth medium or in Ham's F12 medium, 2% FBS, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF until confluence.
Confluent cells were trypsinized and plated at 50,000 cells/cm2 in 24-well TCPS plates, with or without gelatin coating. Three types of basic media were used for up to 3 weeks:
betaI medium: Ham's F12 medium, 2% FBS, 10 millimolar nicotinamide, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 25 milliMolar glucose betall medium: Equal parts of DMEM/Ham's F12 media, 2% FBS, 10 millimolar nicotinamide, 25 milliMolar glucose Endothelial Cell Basal Medium (EBM), (Clonetics, Santa Rosa, CA).
The following growth factors were added to each of the media: 10 nanograms/milliliter EGF, 20 nanograms/milliliter bFGF, 10 nanoMolar GLP-1 (7-37 isoform).
Protocol 8: Placenta-derived cells (isolate 2; P2) (predominately neonatal as identified by karyotyping analysis), placenta-derived cells (isolate 2; P1), clone #22.
Cells were seeded at low density (5,000 cells/cm2) in T25 TCPS flasks and grown in DMEM, 20% FBS, Units/milliliter penicillin, 50 microgram/milliliter streptomycin until confluence.
Total RNA isolation and quantitative RT-PCR. RNA was extracted from placenta-derived cells and fibroblasts grown as described in each protocol. Cells were lysed with 350 microliter buffer RLT containing beta-mercaptoethanol (Sigma St. Louis, MO) according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) and RNA
extracted according to the manufacturer's instructions (RNeasy Mini kit, Qiagen, Valencia, CA) with a 2.7 Units/sample DNase treatment (Sigma St. Louis, MO). RNA was eluted with 50 microliter DEPC-treated water and stored at ¨80 C. RNA was reverse transcribed using random hexamers
- 108 -with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C
for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
Real-time PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND
gene expression products PDX-1 (lls00426216), pro-insulin (11s00355773), Ngn-3 (11s003 60700), Glut-2 (Hs00165775), GAPDH (Applied Biosystems, Foster City, CA) and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI
prism 7000 SDS
software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 C
for 2 minutes and 95 C for 10 minutes followed by 40 cycles of 95 C for 15 seconds and 60 C
for 1 minute. In addition another set of primers designed in-house for PDX-1 and Ngn-3 was tested. Table 19-1 contains primers' sequences. PCR using these primers was performed as described above. Pancreas total RNA (Ambion, Austin, TX) was used as control.
PCR data was analyzed according to the AACT method recommended by Applied Biosystems (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System).
Table 19-1 Primers - Primer name Sequence PDX-1 Forward primer 5'-CTGGATTGGCGTTGTTTGTG-3' (SEQ
ID NO:11) PDX-1 Reverse primer 5'-TCCCAAGGTGGAGTGCTGTAG-3' (SEQ ID NO:12) PDX-1-TaqMan probe 5'-CTGTTGCGCACATCCCTGCCC-3' (SEQ ID NO:13) Ngn-3 Forward primer 5'-GGCAGTCTGGCTTTCTCAGATT-3' (SEQ ID NO:14) Ngn-3 Reverse primer 5'-CCCTCT000TTACCCTTAGCA-3' (SEQ ID NO:15) Ngn-3 TaqMan probe 5'-CTGTGAAAGGACCTGTCTGTCGC-3' (SEQ ID NO:16) Results For placenta-derived cells treated according to protocols 1-8, expression of pancreas-specific marker was not detected using real-time PCR and the assay-on-demand primers, with the exception that low levels of Ngn-3 were detected in cells from protocol 7. The same primers produced positive results with cDNA derived from pancreatic tissue RNA.
Results of real-time PCR for PDX-1 and Ngn-3 performed on cDNA samples derived from human placenta were compared to results for adipose-derived cells grown according to protocol 1.
PCR was also performed using in-house designed primers (Table 19-1). Results of real-time PCR using these primers for PDX-1 and Ngn-3 performed on cDNA samples derived from human placenta were compared to results from adipose-derived cells. Data obtained from real-time PCR was analyzed
for 10 minutes, 37 C for 60 minutes, and 95 C for 10 minutes. Samples were stored at -20 C.
Real-time PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND
gene expression products PDX-1 (lls00426216), pro-insulin (11s00355773), Ngn-3 (11s003 60700), Glut-2 (Hs00165775), GAPDH (Applied Biosystems, Foster City, CA) and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) using a 7000 sequence detection system with ABI
prism 7000 SDS
software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 C
for 2 minutes and 95 C for 10 minutes followed by 40 cycles of 95 C for 15 seconds and 60 C
for 1 minute. In addition another set of primers designed in-house for PDX-1 and Ngn-3 was tested. Table 19-1 contains primers' sequences. PCR using these primers was performed as described above. Pancreas total RNA (Ambion, Austin, TX) was used as control.
PCR data was analyzed according to the AACT method recommended by Applied Biosystems (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System).
Table 19-1 Primers - Primer name Sequence PDX-1 Forward primer 5'-CTGGATTGGCGTTGTTTGTG-3' (SEQ
ID NO:11) PDX-1 Reverse primer 5'-TCCCAAGGTGGAGTGCTGTAG-3' (SEQ ID NO:12) PDX-1-TaqMan probe 5'-CTGTTGCGCACATCCCTGCCC-3' (SEQ ID NO:13) Ngn-3 Forward primer 5'-GGCAGTCTGGCTTTCTCAGATT-3' (SEQ ID NO:14) Ngn-3 Reverse primer 5'-CCCTCT000TTACCCTTAGCA-3' (SEQ ID NO:15) Ngn-3 TaqMan probe 5'-CTGTGAAAGGACCTGTCTGTCGC-3' (SEQ ID NO:16) Results For placenta-derived cells treated according to protocols 1-8, expression of pancreas-specific marker was not detected using real-time PCR and the assay-on-demand primers, with the exception that low levels of Ngn-3 were detected in cells from protocol 7. The same primers produced positive results with cDNA derived from pancreatic tissue RNA.
Results of real-time PCR for PDX-1 and Ngn-3 performed on cDNA samples derived from human placenta were compared to results for adipose-derived cells grown according to protocol 1.
PCR was also performed using in-house designed primers (Table 19-1). Results of real-time PCR using these primers for PDX-1 and Ngn-3 performed on cDNA samples derived from human placenta were compared to results from adipose-derived cells. Data obtained from real-time PCR was analyzed
- 109 -by the AACT method (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System) and expressed on a logarithmic scale.
Experimental conditions in Protocols 3 and 8 applied to placenta-derived cells, but not fibroblasts, produced structures resembling the cellular assembly of pancreatic epithelial cells into islets. These structures emerged about 3-5 days after the implementation of the protocol.
Expression of pancreatic markers PDX-1, Ngn3, Glut-2 and pro-insulin were not detected by real-time PCR.
Summary. Limited expression of PDX-1 and Ngn-3 was observed in placenta-derived cells treated with a variety of experimental protocols. There were differences in results between in-house designed and commercially available primers. For example, while protocol number 1 gave positive data for PDX-1 and Ngn-3 using in-house designed primers, ASSAYS-ON-DEMAND primers for the same genes produced negative data. The results were not directly verified by immunological techniques. Notwithstanding such differences, expression of several pancreatic markers has been accomplished, suggesting the potential of placenta-derived cells to differentiate towards the pancreatic phenotypes.
Differentiation of Placenta-Derived Cells to the Cardiomyocyte Phenotype There is a tremendous need for therapy that will slow the progression of and/or cure heart disease, such as ischemic heart disease and congestive heart failure. Cells that can differentiate into cardiomyocytes that can fully integrate into the patient's cardiac muscle without arrhythmias are highly desirable. Rodent mesenchymal stem cells treated with 5-azacytidine have been shown to express markers of cardiomyocytes (Fukuda et al. (2002) C. R. Biol.
325:1027-38).
This has not been shown for adult human stem cells. Additional factors have been used to improve stem cell differentiation including low oxygen (Storch (1990) Biochim.
Biophys. Acta 1055:126-9), retinoic acid (Wobus et al. (1997) J. Mol. Cell Cardiol. 29:1525-39), DMSO (Xu et al. (2002) Circ. Res. 91:501-8), and chelerythrine chloride (International PCT
Publication No.
W003/025149), which effects the translocation of PKC from the cytosol to plasma membrane 4 and is an inhibitor of PKC activity. In this example, placenta-derived cells were treated with 5-azacytidine either alone or in combination with DMSO or chelerythrine chloride and markers of cardiomyocytes measured by real-time PCR.
Methods & Materials
Experimental conditions in Protocols 3 and 8 applied to placenta-derived cells, but not fibroblasts, produced structures resembling the cellular assembly of pancreatic epithelial cells into islets. These structures emerged about 3-5 days after the implementation of the protocol.
Expression of pancreatic markers PDX-1, Ngn3, Glut-2 and pro-insulin were not detected by real-time PCR.
Summary. Limited expression of PDX-1 and Ngn-3 was observed in placenta-derived cells treated with a variety of experimental protocols. There were differences in results between in-house designed and commercially available primers. For example, while protocol number 1 gave positive data for PDX-1 and Ngn-3 using in-house designed primers, ASSAYS-ON-DEMAND primers for the same genes produced negative data. The results were not directly verified by immunological techniques. Notwithstanding such differences, expression of several pancreatic markers has been accomplished, suggesting the potential of placenta-derived cells to differentiate towards the pancreatic phenotypes.
Differentiation of Placenta-Derived Cells to the Cardiomyocyte Phenotype There is a tremendous need for therapy that will slow the progression of and/or cure heart disease, such as ischemic heart disease and congestive heart failure. Cells that can differentiate into cardiomyocytes that can fully integrate into the patient's cardiac muscle without arrhythmias are highly desirable. Rodent mesenchymal stem cells treated with 5-azacytidine have been shown to express markers of cardiomyocytes (Fukuda et al. (2002) C. R. Biol.
325:1027-38).
This has not been shown for adult human stem cells. Additional factors have been used to improve stem cell differentiation including low oxygen (Storch (1990) Biochim.
Biophys. Acta 1055:126-9), retinoic acid (Wobus et al. (1997) J. Mol. Cell Cardiol. 29:1525-39), DMSO (Xu et al. (2002) Circ. Res. 91:501-8), and chelerythrine chloride (International PCT
Publication No.
W003/025149), which effects the translocation of PKC from the cytosol to plasma membrane 4 and is an inhibitor of PKC activity. In this example, placenta-derived cells were treated with 5-azacytidine either alone or in combination with DMSO or chelerythrine chloride and markers of cardiomyocytes measured by real-time PCR.
Methods & Materials
- 110 -Cells. Cryopreserved placenta-derived cells (P24) were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat.
#SH30070.03, Hyclone, Logan UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)), in a gelatin-coated flask. Cells were seeded at 5 x 104 cells/well in 96-well plates in Growth medium for 24 hours.
The medium was changed to 0, 3, 10 and 30 uM 5-azacytidine (Sigma, St. Louis, MO) alone or with 5 microMolar chelerythrine chloride (Sigma), 1% (v/v) dimethylsulfoxide (DMSO) (Sigma), or 1 microMolar retinoic acid (Sigma) in MEM-alpha (Sigma), insulin, transferrin, and selenium (ITS; Sigma), 10% (v/v) fetal bovine serum, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, and cells incubated at 37 C, 5 % (v/v) 02 for 48 or 72 hours.
Media was then changed to MEM-alpha, insulin, transferrin, and selenium, 10 %
(v/v) fetal bovine serum, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, and cells incubated at 37 C, 5 % (v/v) 02 for 14 days.
RNA extraction and Reverse Transcription. Cells were lysed with 150 microliter buffer RLT containing beta-mercaptoethanol (Sigma St. Louis, MO) according to the manufacturer's instructions (RNeasy 96 kit, Qiagen, Valencia, CA) and stored at ¨80 C. Cell lysates were thawed and RNA extracted according to the manufacturer's instructions (RNeasy 96 kit, Qiagen, Valencia, CA) with a 2.7 Units/sample DNase treatment (Sigma St.
Louis, MO).
RNA was eluted with 50 microliter DEPC-treated water and stored at ¨80 C. RNA
was reverse transcribed using random hexamers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes and 95 C for 10 minutes. Samples were stored at -20 C.
PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND gene expression products cardiac myosin (Hs00165276 ml), skeletal myosin (Hs00428600), GATA 4 (11s00171403 ml), GAPDH (Applied Biosystems, Foster City, CA), and TaqMan Universal PCR
master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) ' using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 C for 2 minutes and 95 C for 10 minutes followed by 40 cycles of 95 C for 15 seconds and 60 C for 1 minute. cDNA
from heart and skeletal muscle (Ambion Austin TX) were used as a control.
Results Control RNA from cardiac muscle showed expression of cardiac myosin and GATA
4, skeletal muscle RNA showed skeletal myosin and cardiac myosin but no GATA 4 expression.
#SH30070.03, Hyclone, Logan UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)), in a gelatin-coated flask. Cells were seeded at 5 x 104 cells/well in 96-well plates in Growth medium for 24 hours.
The medium was changed to 0, 3, 10 and 30 uM 5-azacytidine (Sigma, St. Louis, MO) alone or with 5 microMolar chelerythrine chloride (Sigma), 1% (v/v) dimethylsulfoxide (DMSO) (Sigma), or 1 microMolar retinoic acid (Sigma) in MEM-alpha (Sigma), insulin, transferrin, and selenium (ITS; Sigma), 10% (v/v) fetal bovine serum, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, and cells incubated at 37 C, 5 % (v/v) 02 for 48 or 72 hours.
Media was then changed to MEM-alpha, insulin, transferrin, and selenium, 10 %
(v/v) fetal bovine serum, 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, and cells incubated at 37 C, 5 % (v/v) 02 for 14 days.
RNA extraction and Reverse Transcription. Cells were lysed with 150 microliter buffer RLT containing beta-mercaptoethanol (Sigma St. Louis, MO) according to the manufacturer's instructions (RNeasy 96 kit, Qiagen, Valencia, CA) and stored at ¨80 C. Cell lysates were thawed and RNA extracted according to the manufacturer's instructions (RNeasy 96 kit, Qiagen, Valencia, CA) with a 2.7 Units/sample DNase treatment (Sigma St.
Louis, MO).
RNA was eluted with 50 microliter DEPC-treated water and stored at ¨80 C. RNA
was reverse transcribed using random hexamers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA) at 25 C for 10 minutes, 37 C for 60 minutes and 95 C for 10 minutes. Samples were stored at -20 C.
PCR. PCR was performed on cDNA samples using ASSAYS-ON-DEMAND gene expression products cardiac myosin (Hs00165276 ml), skeletal myosin (Hs00428600), GATA 4 (11s00171403 ml), GAPDH (Applied Biosystems, Foster City, CA), and TaqMan Universal PCR
master mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA) ' using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50 C for 2 minutes and 95 C for 10 minutes followed by 40 cycles of 95 C for 15 seconds and 60 C for 1 minute. cDNA
from heart and skeletal muscle (Ambion Austin TX) were used as a control.
Results Control RNA from cardiac muscle showed expression of cardiac myosin and GATA
4, skeletal muscle RNA showed skeletal myosin and cardiac myosin but no GATA 4 expression.
-111 -Placenta-derived cells (P24) treated for 72 h with factors and grown for an additionall4 days expressed GATA 4, but no skeletal myosin or cardiac myosin. Additional samples from placenta that were analyzed showed expression of GATA 4.
Summary. Untreated placenta-derived cells constitutively express GATA 4, a nuclear transcription factor in cardiomyocytes, sertoli cells, and hepatocytes.
Treatment of Placenta-Derived Cells with Progesterone and cAMP
Placenta comprises both neonatal and maternal cells. The maternal cells are derived from the uterine wall during the process of implantation. Endometrial cells of the uterus undergo a process called decidualization after conception that is driven by steroid hormones and embryonic signals that changes the cell's morphology, phenotype and function. The morphology of the cells changes from fibroblastic to polygonal. Expression of alpha-smooth muscle actin is reduced, and cells begin to express desmin, prolactin, and insulin growth factor binding protein-1 (IGFBP-1) (Fazleabas and Strakova (2002) Mol. Cellular. Endo. 186:143-147). In the present study the effects of progesterone and 8-bromoadenosine 3',5'-cyclicmonophosphate, a cAMP
analogue, were investigated. It has been previously shown that these compounds promote endometritun decidualization in vitro (Gellersen and Brosens (2003) J.
Endocrinol. 178:357-372). Fibroblasts, mesenchymal stem cells (MSC), and placenta-derived cells were treated with progesterone and a cAMP analogue for 3 and 6 days and stained for desmin, a marker of decidualization, and vimentin for mesenchymal stromal cells.
Methods & Materials Mesenchymal stem cells (P3) (Cambrex, Walkersville, MD), placenta-derived cells (P3) (maternal karyotype), and dermal fibroblasts (P10) (Cambrex,) were seeded onto gelatin-coated LabTek II chamber slides (Nalgene, Rochester, NY) at 10,000 cells/well in Growth medium (DMEM-low glucose (Gibco Carlsbad CA), 15% (v/v) fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St Loins, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)). Cells became confluent in 4 days and the medium was changed to either 1) control basal medium (DMEM-low glucose (Gibco), 10%
(v/v) fetal bovine serum charcoal/dextran-treated (Hyclone), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco), Fungizone (Gibco)) or 2) basal medium containing 63.5 microMolar progesterone (Sigma) and 0.76 milliMolar 8-bromoadenosine 3'5'-cyclicmonophosphate (Sigma). Cells were incubated for 3 or 6 days with media changed at 3
Summary. Untreated placenta-derived cells constitutively express GATA 4, a nuclear transcription factor in cardiomyocytes, sertoli cells, and hepatocytes.
Treatment of Placenta-Derived Cells with Progesterone and cAMP
Placenta comprises both neonatal and maternal cells. The maternal cells are derived from the uterine wall during the process of implantation. Endometrial cells of the uterus undergo a process called decidualization after conception that is driven by steroid hormones and embryonic signals that changes the cell's morphology, phenotype and function. The morphology of the cells changes from fibroblastic to polygonal. Expression of alpha-smooth muscle actin is reduced, and cells begin to express desmin, prolactin, and insulin growth factor binding protein-1 (IGFBP-1) (Fazleabas and Strakova (2002) Mol. Cellular. Endo. 186:143-147). In the present study the effects of progesterone and 8-bromoadenosine 3',5'-cyclicmonophosphate, a cAMP
analogue, were investigated. It has been previously shown that these compounds promote endometritun decidualization in vitro (Gellersen and Brosens (2003) J.
Endocrinol. 178:357-372). Fibroblasts, mesenchymal stem cells (MSC), and placenta-derived cells were treated with progesterone and a cAMP analogue for 3 and 6 days and stained for desmin, a marker of decidualization, and vimentin for mesenchymal stromal cells.
Methods & Materials Mesenchymal stem cells (P3) (Cambrex, Walkersville, MD), placenta-derived cells (P3) (maternal karyotype), and dermal fibroblasts (P10) (Cambrex,) were seeded onto gelatin-coated LabTek II chamber slides (Nalgene, Rochester, NY) at 10,000 cells/well in Growth medium (DMEM-low glucose (Gibco Carlsbad CA), 15% (v/v) fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St Loins, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)). Cells became confluent in 4 days and the medium was changed to either 1) control basal medium (DMEM-low glucose (Gibco), 10%
(v/v) fetal bovine serum charcoal/dextran-treated (Hyclone), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco), Fungizone (Gibco)) or 2) basal medium containing 63.5 microMolar progesterone (Sigma) and 0.76 milliMolar 8-bromoadenosine 3'5'-cyclicmonophosphate (Sigma). Cells were incubated for 3 or 6 days with media changed at 3
- 112 -days. Cells were washed with PBS (Gibco) and fixed with 4% (w/v) paraformaldehyde (Sigma) for 20 minutes and stored at 4 C in phosphate buffered saline.
Immunocytochemistry was performed to evaluate expression of vimentin (1:500, Sigma,) and desmin (1:150, Sigma). Briefly, fixed cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% goat serum (Chemicon, Temecula, CA), and 0.3% Triton (Triton X-100, Sigma) for 30 minutes. Primary antibody solutions were then applied to the samples containing blocking solution plus vimentin antibody (1:500) and desmin (1:150) for a period of 1 hour at room temperature. Next, primary antibody solutions were removed and samples washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨ Texas Red (1:250) and goat anti-rabbit IgG - Alexa 488 (1:250; Molecular Probes, Eugene, OR). Samples were washed and 10 microMolar DAPI (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope.
Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results All cells, with the exception of MSCs, in the control medium showed no vimentin or desmin staining at day 3 or 6. Maternal placenta-derived cells at 3 and 6 days showed a change in morphology when treated with progesterone and 8-bromoadenosine 3'5'-cyclicmonophosphate. Placenta-derived cells became phase bright and had a significantly reduced proliferation rate resulting in a lower density culture. Placenta-derived cells were the only cells to stain strongly for vimentin when treated with progesterone and 8-bromoadenosine 3'5'-cyclicmonophosphate for 3 or 6 days. MSCs showed weakly positive staining for vimentin under both conditions at 3 and 6 days.
Summary. Placenta-derived cells and fibroblasts grown in DMEM-low glucose with 10% fetal bovine serum normally express vimentin. In the present analysis, there was no staining for vimentin when cells were grown in 10% charcoal/dextran-treated fetal calf serum for as little as 3 days. Maternal placenta-derived cells showed a change in morphology and vimentin
Immunocytochemistry was performed to evaluate expression of vimentin (1:500, Sigma,) and desmin (1:150, Sigma). Briefly, fixed cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% goat serum (Chemicon, Temecula, CA), and 0.3% Triton (Triton X-100, Sigma) for 30 minutes. Primary antibody solutions were then applied to the samples containing blocking solution plus vimentin antibody (1:500) and desmin (1:150) for a period of 1 hour at room temperature. Next, primary antibody solutions were removed and samples washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨ Texas Red (1:250) and goat anti-rabbit IgG - Alexa 488 (1:250; Molecular Probes, Eugene, OR). Samples were washed and 10 microMolar DAPI (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope.
Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results All cells, with the exception of MSCs, in the control medium showed no vimentin or desmin staining at day 3 or 6. Maternal placenta-derived cells at 3 and 6 days showed a change in morphology when treated with progesterone and 8-bromoadenosine 3'5'-cyclicmonophosphate. Placenta-derived cells became phase bright and had a significantly reduced proliferation rate resulting in a lower density culture. Placenta-derived cells were the only cells to stain strongly for vimentin when treated with progesterone and 8-bromoadenosine 3'5'-cyclicmonophosphate for 3 or 6 days. MSCs showed weakly positive staining for vimentin under both conditions at 3 and 6 days.
Summary. Placenta-derived cells and fibroblasts grown in DMEM-low glucose with 10% fetal bovine serum normally express vimentin. In the present analysis, there was no staining for vimentin when cells were grown in 10% charcoal/dextran-treated fetal calf serum for as little as 3 days. Maternal placenta-derived cells showed a change in morphology and vimentin
- 113 -expression with progesterone and 8-bromoadenosine 3'5'-cyclicmonophosphate treatment.
Expression of desmin was not detected.
Gene chip analysis revealed that there is little or no expression of the progesterone receptor in the cells tested. Expression of a putative steroid receptor, progesterone membrane components 1 and 2 (Gerdes et al. (1998) Biol. Chem.379:907-11) was detected.
Short-Term Neural Differentiation of Placenta-Derived Cells The ability of placenta-derived cells to differentiate into neural lineage cells was examined.
Materials & Methods Isolation and Expansion of Placenta-derived Cells. Placenta-derived cells were isolated and expanded as described in Example 1.
Modified Woodbury-Black Protocol. (A) This assay was adapted from an assay originally performed to test the neural induction potential of bone marrow stromal cells (1).
Placenta-derived cells (P3) were thawed and expanded in Growth Medium at 5,000 cells/cm2 until sub-confluence (75%) was reached. Cells were then trypsinized and seeded at 6,000 cells per well of a Titretek II glass slide (VWR International, Bristol, CT). As controls, mesenchymal stem cells (P3; 1F2155; Cambrex, Walkersville, MD), osteoblasts (P5; CC2538;
Cambrex), omental cells (P6; (041003)), Artecel cells (US6555374 B1) (P6; Donor 2) and neonatal human dermal fibroblasts (P6; CC2509; Cambrex) were also seeded under the same conditions.
All cells were initially expanded for 4 days in DMEM/F12 medium (Invitrogen, Carlsbad, CA) containing 15% (v/v) fetal bovine serum (FBS; Hyclone, Logan, UT), basic fibroblast growth factor (bFGF; 20 nanogram/milliliter; Peprotech, Rocky Hill, NJ), epidermal growth factor (EGF; 20 nanogram/milliliter; Peprotech) and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen). After 4 days, cells were rinsed in phosphate-buffered saline (PBS; Invitrogen) and were subsequently cultured in DMEM/F12 medium + 20%
(v/v) FBS + 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin for 24 hours.
After 24 hours, cells were rinsed with PBS. Cells were then cultured for 1 to 6 hours in an induction medium which was comprised of DMEM/F12 (serum-free) containing 200 milliMolar butylated hydroxyanisole, 10 nanoMolax potassium chloride, 5 milligram/milliliter insulin, 10 nanoMolarforskolin, 4 nanoMolarvalproic acid, and 2 nanoMolayhydrocortisone (all chemicals from Sigma, St. Louis, MO). Cells were then fixed in -20 C 100% methanol and
Expression of desmin was not detected.
Gene chip analysis revealed that there is little or no expression of the progesterone receptor in the cells tested. Expression of a putative steroid receptor, progesterone membrane components 1 and 2 (Gerdes et al. (1998) Biol. Chem.379:907-11) was detected.
Short-Term Neural Differentiation of Placenta-Derived Cells The ability of placenta-derived cells to differentiate into neural lineage cells was examined.
Materials & Methods Isolation and Expansion of Placenta-derived Cells. Placenta-derived cells were isolated and expanded as described in Example 1.
Modified Woodbury-Black Protocol. (A) This assay was adapted from an assay originally performed to test the neural induction potential of bone marrow stromal cells (1).
Placenta-derived cells (P3) were thawed and expanded in Growth Medium at 5,000 cells/cm2 until sub-confluence (75%) was reached. Cells were then trypsinized and seeded at 6,000 cells per well of a Titretek II glass slide (VWR International, Bristol, CT). As controls, mesenchymal stem cells (P3; 1F2155; Cambrex, Walkersville, MD), osteoblasts (P5; CC2538;
Cambrex), omental cells (P6; (041003)), Artecel cells (US6555374 B1) (P6; Donor 2) and neonatal human dermal fibroblasts (P6; CC2509; Cambrex) were also seeded under the same conditions.
All cells were initially expanded for 4 days in DMEM/F12 medium (Invitrogen, Carlsbad, CA) containing 15% (v/v) fetal bovine serum (FBS; Hyclone, Logan, UT), basic fibroblast growth factor (bFGF; 20 nanogram/milliliter; Peprotech, Rocky Hill, NJ), epidermal growth factor (EGF; 20 nanogram/milliliter; Peprotech) and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen). After 4 days, cells were rinsed in phosphate-buffered saline (PBS; Invitrogen) and were subsequently cultured in DMEM/F12 medium + 20%
(v/v) FBS + 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin for 24 hours.
After 24 hours, cells were rinsed with PBS. Cells were then cultured for 1 to 6 hours in an induction medium which was comprised of DMEM/F12 (serum-free) containing 200 milliMolar butylated hydroxyanisole, 10 nanoMolax potassium chloride, 5 milligram/milliliter insulin, 10 nanoMolarforskolin, 4 nanoMolarvalproic acid, and 2 nanoMolayhydrocortisone (all chemicals from Sigma, St. Louis, MO). Cells were then fixed in -20 C 100% methanol and
-114-immunocytochemistry was performed (see methods below) to assess human nestin protein expression.
(B) Placenta-derived cells (P11) and adult human denn al fibroblasts (1F1853, P11) were thawed and culture expanded in Growth Medium at 5,000 cells/cm2 until sub-confluence (75%) was reached. Cells were then trypsinized and seeded at similar density as in (A), but onto (1) 24 well tissue culture-treated plates (TCP, Falcon brand, VWR International), (2) TCP wells + 2%
(w/v) gelatin adsorbed for 1 hour at room temperature, or (3) TCP wells + 20 nanogram/milliliter adsorbed mouse laminin (adsorbed for a minimum of 2 hours at 37 C;
Invitrogen).
Exactly as in (A), cells were initially expanded and media switched at the aforementioned timeframes. One set of cultures was fixed, as before, at 5 days and six hours, this time with 4 C
4% (w/v) parafounaldehyde (Sigma) for 10 minutes at room temperature. In the second set of cultures, media was removed and switched to Neural Progenitor Expansion medium (NPE) consisting of Neurobasal-A medium (Invitrogen) containing B27 (B27 supplement;
Invitrogen), L-glutamine (4 milliMolar), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen). NPE medium was further supplemented with retinoic acid (RA; 1 micromolar; Sigma). This medium was removed 4 days later and cultures were fixed with 4 C
4% (w/v) parafoimaldehyde (Sigma) for 10 minutes at room temperature, and stained for nestin, GFAP, and Tull protein expression (see Table 22-1).
Table 22-1 Summary of Primary Antibodies Used Antibody Concentration Vendor Rat 401 (nestin) 1:200 Chemicon, Temecula, CA
Human Nestin 1:100 Chemicon TuJ1 (Bill Tubulin) 1:500 Sigma, St. Louis, MO
GFAP 1:2000 DakoCytomation, Carpinteria, CA
Tyrosine hydroxylase 1:1000 Chemicon (TH) GABA 1:400 Chemicon Desmin (mouse) 1:300 Chemicon alpha - smooth muscle 1:400 Sigma actin Human nuclear protein 1:150 Chemicon
(B) Placenta-derived cells (P11) and adult human denn al fibroblasts (1F1853, P11) were thawed and culture expanded in Growth Medium at 5,000 cells/cm2 until sub-confluence (75%) was reached. Cells were then trypsinized and seeded at similar density as in (A), but onto (1) 24 well tissue culture-treated plates (TCP, Falcon brand, VWR International), (2) TCP wells + 2%
(w/v) gelatin adsorbed for 1 hour at room temperature, or (3) TCP wells + 20 nanogram/milliliter adsorbed mouse laminin (adsorbed for a minimum of 2 hours at 37 C;
Invitrogen).
Exactly as in (A), cells were initially expanded and media switched at the aforementioned timeframes. One set of cultures was fixed, as before, at 5 days and six hours, this time with 4 C
4% (w/v) parafounaldehyde (Sigma) for 10 minutes at room temperature. In the second set of cultures, media was removed and switched to Neural Progenitor Expansion medium (NPE) consisting of Neurobasal-A medium (Invitrogen) containing B27 (B27 supplement;
Invitrogen), L-glutamine (4 milliMolar), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen). NPE medium was further supplemented with retinoic acid (RA; 1 micromolar; Sigma). This medium was removed 4 days later and cultures were fixed with 4 C
4% (w/v) parafoimaldehyde (Sigma) for 10 minutes at room temperature, and stained for nestin, GFAP, and Tull protein expression (see Table 22-1).
Table 22-1 Summary of Primary Antibodies Used Antibody Concentration Vendor Rat 401 (nestin) 1:200 Chemicon, Temecula, CA
Human Nestin 1:100 Chemicon TuJ1 (Bill Tubulin) 1:500 Sigma, St. Louis, MO
GFAP 1:2000 DakoCytomation, Carpinteria, CA
Tyrosine hydroxylase 1:1000 Chemicon (TH) GABA 1:400 Chemicon Desmin (mouse) 1:300 Chemicon alpha - smooth muscle 1:400 Sigma actin Human nuclear protein 1:150 Chemicon
- 115 -(hNuc) Two Stage Differentiation Protocol. Placenta-derived cells (P11), adult human dermal fibroblasts (P11; 1F1853; Cambrex) were thawed and culture expanded in Growth Medium at 5,000 cells/cm2 until sub-confluence (75%) was reached. Cells were then trypsinized and seeded at 2,000 cells/cm2, but onto 24 well plates coated with laminin (BD
Biosciences, Franklin Lakes, NJ) in the presence of NPE media supplemented with bFGF (20 nanogram/milliliter; Peprotech, Rocky Hill, NJ) and EGF (20 nanogram/milliliter; Peprotech) [whole media composition further referred to as NPE + F + E]. At the same time, adult rat neural progenitors isolated from hippocampus (P4; (062603); see Example 23)) were also plated onto 24 well laminin-coated plates in NPE + F + E media. All cultures were maintained in such conditions for a period of 6 days (cells were fed once during that time) at which time media was switched to the differentiation conditions listed in Table 22-2 for an additional period of 7 days. Cultures were fixed with ice-cold 4% (w/v) paraformaldehyde (Sigma) for 10 minutes at room temperature, and stained for human or rat nestin, GFAP, and TuJ1 protein expression.
Table 22-2. Summary of Conditions for Two-Stage Differentiation Protocol A
COND. # PRE-DIFFERENTIATION 2" STAGE DIFF
1 NPE+F+E NPE + SHH (200 nanogram/milliliter) + F8 (100 nanogram/milliliter) 2 NPE+F+E NPE + SIM (200 nanogram/milliliter) + F8 (100 nanogram/milliliter) + RA (1 micromolar) 3 NPE+F+E NPE + RA (1 micromolar) 4 NPE+F+E NPE + F (20 nanogram/milliliter) +
E (20 nanogram/milliliter) NPE+F+E Growth Medium 6 NPE+F+E Condition 1B + rhGDF-5 (20 nanogram/milliliter) 7 NPE+F+E Condition 1B + BMP7 (20 nanogram/milliliter) 8 NPE+F+E Condition 1B + GDNF (20 nanogram/milliliter) 9 NPE+F+E Condition 2B + rhGDF-5 (20 nanogram/milliliter) NPE+F+E Condition 2B + BM1P7 (20 nanogram/milliliter) 11 NPE+F +E Condition 2B + GDNF (20
Biosciences, Franklin Lakes, NJ) in the presence of NPE media supplemented with bFGF (20 nanogram/milliliter; Peprotech, Rocky Hill, NJ) and EGF (20 nanogram/milliliter; Peprotech) [whole media composition further referred to as NPE + F + E]. At the same time, adult rat neural progenitors isolated from hippocampus (P4; (062603); see Example 23)) were also plated onto 24 well laminin-coated plates in NPE + F + E media. All cultures were maintained in such conditions for a period of 6 days (cells were fed once during that time) at which time media was switched to the differentiation conditions listed in Table 22-2 for an additional period of 7 days. Cultures were fixed with ice-cold 4% (w/v) paraformaldehyde (Sigma) for 10 minutes at room temperature, and stained for human or rat nestin, GFAP, and TuJ1 protein expression.
Table 22-2. Summary of Conditions for Two-Stage Differentiation Protocol A
COND. # PRE-DIFFERENTIATION 2" STAGE DIFF
1 NPE+F+E NPE + SHH (200 nanogram/milliliter) + F8 (100 nanogram/milliliter) 2 NPE+F+E NPE + SIM (200 nanogram/milliliter) + F8 (100 nanogram/milliliter) + RA (1 micromolar) 3 NPE+F+E NPE + RA (1 micromolar) 4 NPE+F+E NPE + F (20 nanogram/milliliter) +
E (20 nanogram/milliliter) NPE+F+E Growth Medium 6 NPE+F+E Condition 1B + rhGDF-5 (20 nanogram/milliliter) 7 NPE+F+E Condition 1B + BMP7 (20 nanogram/milliliter) 8 NPE+F+E Condition 1B + GDNF (20 nanogram/milliliter) 9 NPE+F+E Condition 2B + rhGDF-5 (20 nanogram/milliliter) NPE+F+E Condition 2B + BM1P7 (20 nanogram/milliliter) 11 NPE+F +E Condition 2B + GDNF (20
- 116 -nanogram/milliliter) 12 NPE + F + E Condition 3B + rhGDF-5 (20 nanogram/milliliter) 13 NPE + F + E Condition 3B + BMP7 (20 nanogram/milliliter) 14 NPE + F + E Condition 3B + GDNF (20 nanogram/milliliter) 15 NPE + F + E NPE + rhGDF-5 (20 nanogram/milliliter) 16 NPE + F + E NPE + BMP7 (20 nanogram/milliliter) 17 NPE + F + E NPE + GDNF (20 nanogram/milliliter) Neural Progenitor Co-Culture Protocol. Adult rat hippocampal progenitors (062603) were plated as neurospheres or single cells (10,000 cells/well) onto laminin-coated 24 well dishes (BD Biosciences) in NPE + F (20 nanogram/milliliter) + E (20 nanogram/milliliter).
Separately, placenta-derived cells (022803) Pll were thawed and culture expanded in NPE + F (20 nanogram/milliliter) + E (20 nanogram/milliliter) at 5,000 cells/cm2 for a period of 48 hours. Cells were then trypsinized and seeded at 2,500 cells/well onto existing cultures of neural progenitors. At that time, existing medium was exchanged for fresh medium. Four days later, cultures were fixed with ice-cold 4% (w/v) paraformaldehyde (Sigma) for 10 minutes at room temperature, and stained for human nuclear protein (hNuc; Chemicon) (Table 221-1 above) to identify PPDCs.
Immunocytochemistry. Immunocytochemistry was performed using the antibodies listed in Table 22-1. Cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100; Sigma) for 30 minutes to access, intracellular antigens.
Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature. Next, primary antibody solutions were removed and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨
Texas Red (1:250;
Molecular Probes, Eugene, OR) and goat anti-rabbit IgG - Alexa 488 (1:250;
Molecular Probes).
Cultures were then washed and 10 micromolar DAPI (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
In all cases, positive staining represented fluorescence signal above control staining where the
Separately, placenta-derived cells (022803) Pll were thawed and culture expanded in NPE + F (20 nanogram/milliliter) + E (20 nanogram/milliliter) at 5,000 cells/cm2 for a period of 48 hours. Cells were then trypsinized and seeded at 2,500 cells/well onto existing cultures of neural progenitors. At that time, existing medium was exchanged for fresh medium. Four days later, cultures were fixed with ice-cold 4% (w/v) paraformaldehyde (Sigma) for 10 minutes at room temperature, and stained for human nuclear protein (hNuc; Chemicon) (Table 221-1 above) to identify PPDCs.
Immunocytochemistry. Immunocytochemistry was performed using the antibodies listed in Table 22-1. Cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100; Sigma) for 30 minutes to access, intracellular antigens.
Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature. Next, primary antibody solutions were removed and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨
Texas Red (1:250;
Molecular Probes, Eugene, OR) and goat anti-rabbit IgG - Alexa 488 (1:250;
Molecular Probes).
Cultures were then washed and 10 micromolar DAPI (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
In all cases, positive staining represented fluorescence signal above control staining where the
- 117 -entire procedure outlined above was followed with the exception of application of a primary antibody solution. Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Results Woodbury-Black Protocol. (A) Upon incubation in this neural induction composition, all cell types transformed into cells with bipolar morphologies and extended processes. Other larger non-bipolar morphologies were also observed. Furthermore, the induced cell populations stained positively for nestin, a nCUrker of multipotent neural stem and progenitor cells.
(B) When repeated on tissue culture plastic (TCP) dishes, nestin expression was not observed unless laminin was pre-adsorbed to the culture surface. To further assess whether nestin-expressing cells could then go on to generate mature neurons, PPDCs and fibroblasts were exposed to NPE + RA (lmicroMolar), a media composition known to induce the differentiation of neural stem and progenitor cells into such cells (2,3,4). Cells were stained for TuJ1, a marker for immature and mature neurons, GFAP, a marker of astrocytes, and nestin, a marker for neural progenitors. Under no conditions was TuJ1 expression turned on nor were cells with neuronal morphology observed, suggesting that neurons were not generated in the short term.
Furthermore, nestin and GFAP expression were no longer expressed by PDCs, as determined by immunocytochemistry.
Two Stage Differentiation Results. Placenta derived cells (as well as human fibroblasts and rodent neural progenitors as negative and positive control cell types, respectively) were plated on laminin (neural promoting)-coated dishes and exposed to 13 different growth conditions (and two control conditions) known to promote differentiation of neural progenitors into neurons and astrocytes. In addition, two conditions were added to examine the influence of GDF5, and BMP7 on PPDC differentiation. Generally, a two-step differentiation approach was taken, where the cells were first placed in neural progenitor expansion conditions for a period of 6 days followed by full differentiation conditions for 7 days.
Morphologically, placenta-derived cells exhibited fundamental changes in cell morphology throughout the time-course of this procedure. However, in no cases were neuronal or astrocytic-shaped cells observed except for in control, neural progenitor-plated conditions. Immunocytochemistry, negative for human nestin, Tull, and GFAP confirmed these morphological observations.
Results Woodbury-Black Protocol. (A) Upon incubation in this neural induction composition, all cell types transformed into cells with bipolar morphologies and extended processes. Other larger non-bipolar morphologies were also observed. Furthermore, the induced cell populations stained positively for nestin, a nCUrker of multipotent neural stem and progenitor cells.
(B) When repeated on tissue culture plastic (TCP) dishes, nestin expression was not observed unless laminin was pre-adsorbed to the culture surface. To further assess whether nestin-expressing cells could then go on to generate mature neurons, PPDCs and fibroblasts were exposed to NPE + RA (lmicroMolar), a media composition known to induce the differentiation of neural stem and progenitor cells into such cells (2,3,4). Cells were stained for TuJ1, a marker for immature and mature neurons, GFAP, a marker of astrocytes, and nestin, a marker for neural progenitors. Under no conditions was TuJ1 expression turned on nor were cells with neuronal morphology observed, suggesting that neurons were not generated in the short term.
Furthermore, nestin and GFAP expression were no longer expressed by PDCs, as determined by immunocytochemistry.
Two Stage Differentiation Results. Placenta derived cells (as well as human fibroblasts and rodent neural progenitors as negative and positive control cell types, respectively) were plated on laminin (neural promoting)-coated dishes and exposed to 13 different growth conditions (and two control conditions) known to promote differentiation of neural progenitors into neurons and astrocytes. In addition, two conditions were added to examine the influence of GDF5, and BMP7 on PPDC differentiation. Generally, a two-step differentiation approach was taken, where the cells were first placed in neural progenitor expansion conditions for a period of 6 days followed by full differentiation conditions for 7 days.
Morphologically, placenta-derived cells exhibited fundamental changes in cell morphology throughout the time-course of this procedure. However, in no cases were neuronal or astrocytic-shaped cells observed except for in control, neural progenitor-plated conditions. Immunocytochemistry, negative for human nestin, Tull, and GFAP confirmed these morphological observations.
- 118 -Neural Progenitor and PDC Co-culture Procedures. Placenta-derived cells were plated onto cultures of rat neural progenitors seeded two days earlier in neural expansion conditions (NPE + F + E). While visual confirmation of plated placenta-derived cells proved that these cells were plated as single cells, human-specific nuclear staining (hNuc) 4 days post-plating (6 days total length of exposure) showed that they tended to ball up and avoid contact with the neural progenitors. Furthermore, where placental cells attached, these cells spread out and appeared to be innervated by differentiated neurons that were of rat origin suggesting that the placental cells may have differentiated into muscle cells. This observation was based upon morphology under phase contrast microscopy. Another observation was that typically large cell bodies (larger than neural progenitors) possessed morphologies resembling neural progenitors, with thin processes spanning out in multiple directions. HNuc staining (found in one half of the cell's nucleus) suggested that in some cases these human cells may have fused with rat progenitors and assumed their phenotype. Controls wells containing neural progenitors only had fewer total progenitors and apparent differentiated cells than did co-culture wells containing placental cells, further indicating that placenta-derived cells influenced the differentiation and behavior of neural progenitors either by release of chemokines and cytokines, or by contact-mediated effects.
Summary. Multiple protocols were conducted to determine the short term potential of placenta-derived PPDCs to differentiate into neural lineage cells. These included phase contrast imaging of morphology in combination with immunocytochemistry for nestin, TuJ1, and GFAP, proteins associated with multipotent neural stem and progenitor cells, immature and mature neurons, and astrocytes, respectively. Evidence was observed to suggest that neural i differentiation occurred in certain instances in these short-term protocols.
Several notable observations were made in co-cultures of PPDCs with neural progenitors.
This approach, using human PPDCs along with a xenogeneic cell type allowed for absolute determination of the origin of each cell in these cultures. First, some cells were observed in these cultures where the cell cytoplasm was enlarged, with neurite-like processes extending away from the cell body, yet only half of the body labeled with hNuc protein. Those cells may be human PPDCs that have differentiated into neural lineage cells or they may be PPDCs that have fused with neural progenitors of rat origin. Second, it appeared that neural progenitors extended neurites to PPDCs in a way that indicates the progenitors differentiated into neurons and innervated the PPDCs. Third, cultures of neural progenitors and PPDCs had more cells of rat origin and larger amounts of differentiation than control cultures of neural progenitors alone,
Summary. Multiple protocols were conducted to determine the short term potential of placenta-derived PPDCs to differentiate into neural lineage cells. These included phase contrast imaging of morphology in combination with immunocytochemistry for nestin, TuJ1, and GFAP, proteins associated with multipotent neural stem and progenitor cells, immature and mature neurons, and astrocytes, respectively. Evidence was observed to suggest that neural i differentiation occurred in certain instances in these short-term protocols.
Several notable observations were made in co-cultures of PPDCs with neural progenitors.
This approach, using human PPDCs along with a xenogeneic cell type allowed for absolute determination of the origin of each cell in these cultures. First, some cells were observed in these cultures where the cell cytoplasm was enlarged, with neurite-like processes extending away from the cell body, yet only half of the body labeled with hNuc protein. Those cells may be human PPDCs that have differentiated into neural lineage cells or they may be PPDCs that have fused with neural progenitors of rat origin. Second, it appeared that neural progenitors extended neurites to PPDCs in a way that indicates the progenitors differentiated into neurons and innervated the PPDCs. Third, cultures of neural progenitors and PPDCs had more cells of rat origin and larger amounts of differentiation than control cultures of neural progenitors alone,
- 119 -further indicating that plated PPDCs provided soluble factors and or contact-dependent mechanisms that stimulated neural progenitor survival, proliferation, and/or differentiation.
References for Example 22 (1) Woodbury, D. et al. (2000). J Neurosci. Research. 61(4): 364-70.
(2) Jang, Y.K. et al. (2004). J. Neurosci. Research. 75(4): 573-84.
(3) Jones-Villeneuve, E.M. et al. (1983). Mol Gel Biol. 3(12): 2271-9.
(4) Mayer-Proschel, M. et al. (1997). Neuron. 19(4): 773-85.
Placenta-Derived Cellular Trophic Factors for Neural Progenitor Support The influence of placenta-derived cells on adult neural stem and progenitor cell survival and differentiation through non-contact dependent (trophic) mechanisms was examined.
Materials & Methods Adult Neural Stem and Progenitor Cell Isolation. Fisher 344 adult rats were sacrificed by CO2 asphyxiation followed by cervical dislocation. Whole brains were removed intact using bone rongeurs and hippocampus tissue dissected based on coronal incisions posterior to the motor and somatosensory regions of the brain (1). Tissue was washed in Neurobasal-A medium (Invitrogen, Carlsbad, CA) containing B27 (B27 supplement; Invitrogen), L-glutamine (4 milliMolar; Invitrogen), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen), the combination of which is herein referred to as Neural Progenitor Expansion (NPE) medium. NPE medium was further supplemented with bFGF (20 nanogram/milliliter, Peprotech, Rocky Hill, NJ) and EGF (20 nanogram/milliliter, Peprotech, Rocky Hill, NJ), herein referred to as NPE + bFGF + EGF.
Following wash, the overlying meninges were removed, and the tissue minced with a scalpel. Minced tissue was collected and trypsin/EDTA (Invitrogen) added as 75% of the total volume. DNAse (100 microliter per 8 milliliters total volume, Sigma, St.
Louis, MO) was also added. Next, the tissue/media was sequentially passed through an 18 gauge needle, 20 gauge needle, and finally a 25 gauge needle one time each (all needles from Becton Dickinson, Franklin Lakes, NJ). The mixture was centrifuged for 3 minutes at 250 x g.
Supernatant was removed, fresh NPE + bFGF + EGF was added and the pellet resuspended. The resultant cell suspension was passed through a 40 micron cell strainer (BD Biosciences), plated on laminin-
References for Example 22 (1) Woodbury, D. et al. (2000). J Neurosci. Research. 61(4): 364-70.
(2) Jang, Y.K. et al. (2004). J. Neurosci. Research. 75(4): 573-84.
(3) Jones-Villeneuve, E.M. et al. (1983). Mol Gel Biol. 3(12): 2271-9.
(4) Mayer-Proschel, M. et al. (1997). Neuron. 19(4): 773-85.
Placenta-Derived Cellular Trophic Factors for Neural Progenitor Support The influence of placenta-derived cells on adult neural stem and progenitor cell survival and differentiation through non-contact dependent (trophic) mechanisms was examined.
Materials & Methods Adult Neural Stem and Progenitor Cell Isolation. Fisher 344 adult rats were sacrificed by CO2 asphyxiation followed by cervical dislocation. Whole brains were removed intact using bone rongeurs and hippocampus tissue dissected based on coronal incisions posterior to the motor and somatosensory regions of the brain (1). Tissue was washed in Neurobasal-A medium (Invitrogen, Carlsbad, CA) containing B27 (B27 supplement; Invitrogen), L-glutamine (4 milliMolar; Invitrogen), and 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Invitrogen), the combination of which is herein referred to as Neural Progenitor Expansion (NPE) medium. NPE medium was further supplemented with bFGF (20 nanogram/milliliter, Peprotech, Rocky Hill, NJ) and EGF (20 nanogram/milliliter, Peprotech, Rocky Hill, NJ), herein referred to as NPE + bFGF + EGF.
Following wash, the overlying meninges were removed, and the tissue minced with a scalpel. Minced tissue was collected and trypsin/EDTA (Invitrogen) added as 75% of the total volume. DNAse (100 microliter per 8 milliliters total volume, Sigma, St.
Louis, MO) was also added. Next, the tissue/media was sequentially passed through an 18 gauge needle, 20 gauge needle, and finally a 25 gauge needle one time each (all needles from Becton Dickinson, Franklin Lakes, NJ). The mixture was centrifuged for 3 minutes at 250 x g.
Supernatant was removed, fresh NPE + bFGF + EGF was added and the pellet resuspended. The resultant cell suspension was passed through a 40 micron cell strainer (BD Biosciences), plated on laminin-
- 120 -, coated T-75 flasks (Becton Dickinson) or low cluster 24-well plates (Becton Dickinson), and grown in NPE + bFGF + EGF media until sufficient cell numbers were obtained for the studies outlined.
Placenta-Derived Cell Plating. Placenta-derived cells (P12) previously grown in Growth medium were plated at 5,000 cells / transwell insert (sized for 24 well plate) and grown for a period of one week in Growth medium in inserts to achieve confluence.
Adult Neural Progenitor Plating. Neural progenitors, grown as neurospheres or as single cells, were seeded onto laminin-coated 24 well plates at an approximate density of 2,000 cells / well in NPE + bFGF + EGF for a period of one day to promote cellular attachment. One day later, transwell inserts containing placenta-derived cells were added according to the following scheme:
(1) Transwell (placenta in Growth medium, 200 microliter) + neural progenitors (NPE + bFGF + EGF, 1 milliliter) (2) Transwell (adult human dermal fibroblasts [1F1853; Cambrex, Walkersville, MD]
P12 in Growth medium, 200 microliter) + neural progenitors (NPE + bFGF + EGF, 1 milliliter) (3) Control: neural progenitors alone (NPE + bFGF + EGF, 1 milliliter) (4) Control: neural progenitors alone (NPE only, 1 milliliter) Immunocytochemistry. After 7 days in co-culture, all conditions were fixed with cold 4% (w/v) parafonnaldehyde (Sigma) for a period of 10 minutes at room temperature.
Immunocytochemistry was performed using antibodies directed against the epitopes listed in Table 23-1. Briefly, cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100; Sigma) for 30 minutes to access intracellular antigens.
Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature. Next, primary antibodies solutions were removed and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨
Texas Red (1:250;
Molecular Probes, Eugene, OR) and goat anti-rabbit IgG - Alexa 488 (1:250;
Molecular Probes).
Cultures were then washed and 10 microMolar DAN (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
In all cases, positive staining represented fluorescence signal above control staining where the
Placenta-Derived Cell Plating. Placenta-derived cells (P12) previously grown in Growth medium were plated at 5,000 cells / transwell insert (sized for 24 well plate) and grown for a period of one week in Growth medium in inserts to achieve confluence.
Adult Neural Progenitor Plating. Neural progenitors, grown as neurospheres or as single cells, were seeded onto laminin-coated 24 well plates at an approximate density of 2,000 cells / well in NPE + bFGF + EGF for a period of one day to promote cellular attachment. One day later, transwell inserts containing placenta-derived cells were added according to the following scheme:
(1) Transwell (placenta in Growth medium, 200 microliter) + neural progenitors (NPE + bFGF + EGF, 1 milliliter) (2) Transwell (adult human dermal fibroblasts [1F1853; Cambrex, Walkersville, MD]
P12 in Growth medium, 200 microliter) + neural progenitors (NPE + bFGF + EGF, 1 milliliter) (3) Control: neural progenitors alone (NPE + bFGF + EGF, 1 milliliter) (4) Control: neural progenitors alone (NPE only, 1 milliliter) Immunocytochemistry. After 7 days in co-culture, all conditions were fixed with cold 4% (w/v) parafonnaldehyde (Sigma) for a period of 10 minutes at room temperature.
Immunocytochemistry was performed using antibodies directed against the epitopes listed in Table 23-1. Briefly, cultures were washed with phosphate-buffered saline (PBS) and exposed to a protein blocking solution containing PBS, 4% (v/v) goat serum (Chemicon, Temecula, CA), and 0.3% (v/v) Triton (Triton X-100; Sigma) for 30 minutes to access intracellular antigens.
Primary antibodies, diluted in blocking solution, were then applied to the cultures for a period of 1 hour at room temperature. Next, primary antibodies solutions were removed and cultures washed with PBS prior to application of secondary antibody solutions (1 hour at room temperature) containing blocking solution along with goat anti-mouse IgG ¨
Texas Red (1:250;
Molecular Probes, Eugene, OR) and goat anti-rabbit IgG - Alexa 488 (1:250;
Molecular Probes).
Cultures were then washed and 10 microMolar DAN (Molecular Probes) applied for 10 minutes to visualize cell nuclei.
Following immunostaining, fluorescence was visualized using the appropriate fluorescence filter on an Olympus inverted epi-fluorescent microscope (Olympus, Melville, NY).
In all cases, positive staining represented fluorescence signal above control staining where the
- 121 -entire procedure outlined above was followed with the exception of application of a primary antibody solution. Representative images were captured using a digital color videocamera and ImagePro software (Media Cybernetics, Carlsbad, CA). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, CA).
Table 23-1. Summary of Primary Antibodies Used Antibody Concentration Vendor Rat 401 (nestin) 1:200 Chemicon, Temecula, CA
Tun (Bill Tubulin) 1:500 Sigma, St. Louis, MO
Tyrosine hydroxylase 1:1000 Chemicon (TH) GABA 1:400 Chemicon GFAP 1:2000 DakoCytomation, Carpinteria, CA
Myelin Basic Protein 1:400 Chemicon (MBP) Quantitative Analysis of Neural Progenitor Differentiation. Quantification of hippocampal neural progenitor differentiation was examined. A minimum of 1000 cells were counted per condition or if less, the total number of cells observed in that condition. The percentage of cells positive for a given stain was assessed by dividing the number of positive cells by the total number of cells as determined by DAPI (nuclear) staining.
Mass Spectrometry Analysis & 2D Gel Electrophoresis. In order to identify unique, secreted factors as a result of co-culture, conditioned media samples taken prior to culture fixation were frozen down at -80 C overnight. Samples were then applied to ultrafiltration spin devices (MW cutoff 301(D). Retentate was applied to immunoaffinity chromatography (anti-Hu-albumin; IgY) (immunoaffinity did not remove albumin from the samples).
Filtrate was analyzed by MALDI. The pass through was applied to Cibachron Blue affinity chromatography.
Samples were analyzed by SDS-PAGE and 2D gel electrophoresis.
Results Placenta-derived cell co-culture stimulates adult neural progenitor differentiation.
Following culture with placenta-derived cells, co-cultured neural progenitor cells derived from adult rat hippocampus exhibited differentiation along all three major lineages in the central nervous system. This effect was clearly observed after five days in co-culture, with numerous cells elaborating complex processes and losing their phase bright features characteristic of
Table 23-1. Summary of Primary Antibodies Used Antibody Concentration Vendor Rat 401 (nestin) 1:200 Chemicon, Temecula, CA
Tun (Bill Tubulin) 1:500 Sigma, St. Louis, MO
Tyrosine hydroxylase 1:1000 Chemicon (TH) GABA 1:400 Chemicon GFAP 1:2000 DakoCytomation, Carpinteria, CA
Myelin Basic Protein 1:400 Chemicon (MBP) Quantitative Analysis of Neural Progenitor Differentiation. Quantification of hippocampal neural progenitor differentiation was examined. A minimum of 1000 cells were counted per condition or if less, the total number of cells observed in that condition. The percentage of cells positive for a given stain was assessed by dividing the number of positive cells by the total number of cells as determined by DAPI (nuclear) staining.
Mass Spectrometry Analysis & 2D Gel Electrophoresis. In order to identify unique, secreted factors as a result of co-culture, conditioned media samples taken prior to culture fixation were frozen down at -80 C overnight. Samples were then applied to ultrafiltration spin devices (MW cutoff 301(D). Retentate was applied to immunoaffinity chromatography (anti-Hu-albumin; IgY) (immunoaffinity did not remove albumin from the samples).
Filtrate was analyzed by MALDI. The pass through was applied to Cibachron Blue affinity chromatography.
Samples were analyzed by SDS-PAGE and 2D gel electrophoresis.
Results Placenta-derived cell co-culture stimulates adult neural progenitor differentiation.
Following culture with placenta-derived cells, co-cultured neural progenitor cells derived from adult rat hippocampus exhibited differentiation along all three major lineages in the central nervous system. This effect was clearly observed after five days in co-culture, with numerous cells elaborating complex processes and losing their phase bright features characteristic of
- 122 -=
dividing progenitor cells. Conversely, neural progenitors grown alone in the absence of bFGF
and EGF appeared unhealthy and survival was limited.
After completion of the procedure, cultures were stained for markers indicative of undifferentiated stern and progenitor cells (nestin), immature and mature neurons (TuJ1), astrocytes (GFAP), and mature oligodendrocytes (MBP). Differentiation along all three lineages was confirmed while control conditions did not exhibit significant differentiation as evidenced by retention of nestin-positive staining amongst the majority of cells. Though differentiation also appeared to be influenced by adult human fibroblasts, such cells were not able to promote the differentiation of mature oligodendrocytes nor were they able to generate an appreciable quantity of neurons. Though not quantified, fibroblasts did, however, appear to enhance the survival of neural progenitors and their progeny similar to findings for placenta-derived postpartum cells.
Identification of Unique Compounds. Conditioned media from placental test conditions along with the appropriate controls (NPE media 1.7 % serum, media from co-culture with fibroblasts) were examined for differences. Potentially unique compounds were ' identified and excised from their respective 2D gels.
Summary. Co-culture of adult neural progenitor cells with placenta-derived postpartum cells results in differentiation of those cells. In view of the lack of contact between the PPDCs and the neural progenitors, this result appears to be a function of soluble factors released from the PPDCs (trophic effect).
Several other observations were made. First, there were very few cells in the control condition where EGF and bFGF were removed. Most cells died and on average, there were about 100 cells or fewer per well. Second, it is to be expected that there would be very little differentiation in the control condition where EGF and bFGF was retained in the medium throughout, since this is normally an expansion medium. While approximately 70% of the cells were observed to retain their progenitor status (nestin-t-), about 30% were GFAP+ (indicative of astrocytes). This may be due to the fact that such significant expansion occurred throughout the course of the procedure that contact between progenitors induced this differentiation. Similar findings have been reported in the literature (2).
References for Example 23 (1) Paxinos, G. & Watson, C. (1997). THE RAT BRAIN IN STEREOTAXIC
COORDINATES.
(2) Song, H. et al. (2002). Nature. 417(6884): 39-44.
dividing progenitor cells. Conversely, neural progenitors grown alone in the absence of bFGF
and EGF appeared unhealthy and survival was limited.
After completion of the procedure, cultures were stained for markers indicative of undifferentiated stern and progenitor cells (nestin), immature and mature neurons (TuJ1), astrocytes (GFAP), and mature oligodendrocytes (MBP). Differentiation along all three lineages was confirmed while control conditions did not exhibit significant differentiation as evidenced by retention of nestin-positive staining amongst the majority of cells. Though differentiation also appeared to be influenced by adult human fibroblasts, such cells were not able to promote the differentiation of mature oligodendrocytes nor were they able to generate an appreciable quantity of neurons. Though not quantified, fibroblasts did, however, appear to enhance the survival of neural progenitors and their progeny similar to findings for placenta-derived postpartum cells.
Identification of Unique Compounds. Conditioned media from placental test conditions along with the appropriate controls (NPE media 1.7 % serum, media from co-culture with fibroblasts) were examined for differences. Potentially unique compounds were ' identified and excised from their respective 2D gels.
Summary. Co-culture of adult neural progenitor cells with placenta-derived postpartum cells results in differentiation of those cells. In view of the lack of contact between the PPDCs and the neural progenitors, this result appears to be a function of soluble factors released from the PPDCs (trophic effect).
Several other observations were made. First, there were very few cells in the control condition where EGF and bFGF were removed. Most cells died and on average, there were about 100 cells or fewer per well. Second, it is to be expected that there would be very little differentiation in the control condition where EGF and bFGF was retained in the medium throughout, since this is normally an expansion medium. While approximately 70% of the cells were observed to retain their progenitor status (nestin-t-), about 30% were GFAP+ (indicative of astrocytes). This may be due to the fact that such significant expansion occurred throughout the course of the procedure that contact between progenitors induced this differentiation. Similar findings have been reported in the literature (2).
References for Example 23 (1) Paxinos, G. & Watson, C. (1997). THE RAT BRAIN IN STEREOTAXIC
COORDINATES.
(2) Song, H. et al. (2002). Nature. 417(6884): 39-44.
- 123 -Endothelial Network Formation Assay Angiogenesis, or the formation of new vasculature, is necessary for the growth of new tissue. Induction of angiogenesis is an important therapeutic goal in many pathological conditions. The present study was aimed at identifying potential angiogenic activity of the placenta-derived cells in in vitro assays. The study followed a well-established method of seeding endothelial cells onto a culture plate coated with MATRIGEL (BD
Discovery Labware, Bedford, MA), a basement membrane extract (Nicosia and Ottinetti (1990) In Vitro Cell Dev.
Biol. 26(2):119-28). Treating endothelial cells on MATRIGEL (BD Discovery Labware, Bedford, MA) with angiogenic factors will stimulate the cells to form a network that is similar to capillaries. This is a common in vitro assay for testing stimulators and inhibitors of blood vessel formation (Ito et al. (1996) Int. J. Cancer 67(1):148-52). The protocols utilized in this example made use of a co-culture system with the placenta-derived cells seeded onto culture well inserts.
These permeable inserts allow for the passive exchange of media components between the endothelial and the placenta-derived culture media.
Material & Methods Cell Culture.
Placenta-derived cells. Human placentas were received and cells were isolated as previously described (Example 1). Cells were cultured in Growth medium (Dulbecco's Modified Essential Media (DMEM; Invitrogen, Carlsbad, CA), 15% (v/v) fetal bovine serum (Hyclone, Logan UT), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin Invitrogen), 0.001 % (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO)) on gelatin-coated tissue culture plastic flasks. The cultures were incubated at 37 C with 5 % CO2.
Cells used for experiments were between passages 4 and 12.
Actively growing placenta-derived cells were trypsinized, counted, and seeded onto COSTAR TRANS WELL 6.5 millimeter diameter tissue culture inserts (Corning, Corning, NY) at 15,000 cells per insert. Cells were cultured on the inserts for 48 to 72 hours in growth media in standard air with 5 % CO2 at 37 C.
Human mesenchymal stein cells (hMSC). hMSCs were purchased from Cambrex (Walkersville, MD) and cultured in MSCGM (Cambrex). The cultures were incubated in standard air with 5 % CO2 at 37 C.
Discovery Labware, Bedford, MA), a basement membrane extract (Nicosia and Ottinetti (1990) In Vitro Cell Dev.
Biol. 26(2):119-28). Treating endothelial cells on MATRIGEL (BD Discovery Labware, Bedford, MA) with angiogenic factors will stimulate the cells to form a network that is similar to capillaries. This is a common in vitro assay for testing stimulators and inhibitors of blood vessel formation (Ito et al. (1996) Int. J. Cancer 67(1):148-52). The protocols utilized in this example made use of a co-culture system with the placenta-derived cells seeded onto culture well inserts.
These permeable inserts allow for the passive exchange of media components between the endothelial and the placenta-derived culture media.
Material & Methods Cell Culture.
Placenta-derived cells. Human placentas were received and cells were isolated as previously described (Example 1). Cells were cultured in Growth medium (Dulbecco's Modified Essential Media (DMEM; Invitrogen, Carlsbad, CA), 15% (v/v) fetal bovine serum (Hyclone, Logan UT), 100 Units/milliliter penicillin, 100 microgram/milliliter streptomycin Invitrogen), 0.001 % (v/v) 2-mercaptoethanol (Sigma, St. Louis, MO)) on gelatin-coated tissue culture plastic flasks. The cultures were incubated at 37 C with 5 % CO2.
Cells used for experiments were between passages 4 and 12.
Actively growing placenta-derived cells were trypsinized, counted, and seeded onto COSTAR TRANS WELL 6.5 millimeter diameter tissue culture inserts (Corning, Corning, NY) at 15,000 cells per insert. Cells were cultured on the inserts for 48 to 72 hours in growth media in standard air with 5 % CO2 at 37 C.
Human mesenchymal stein cells (hMSC). hMSCs were purchased from Cambrex (Walkersville, MD) and cultured in MSCGM (Cambrex). The cultures were incubated in standard air with 5 % CO2 at 37 C.
- 124 -Actively growing MSCs were trypsinized and counted and seeded onto Costar Transwell 6.5 millimeter diameter tissue culture inserts (Corning, Corning, NY) at 15,000 cells per insert. Cells were cultured on the inserts for 48 to 72 hours in growth media in standard air with 5 % CO2 at 37 C.
Human umbilical vein endothelial cells (HUVEC). HUVEC were obtained from Cambrex (Walkersville, MD). Cells were grown in separate cultures in either EBM or EGM
endothelial cell media (Cambrex). Cells were grown on standard tissue cultured plastic in standard air with % CO2 at 37 C. Cells used in the assay were between passages 4 and 10.
Human coronary artery endothelial cells (HCAEC). HCAEC were purchased from Cambrex Incorporated (Walkersville, MD). These cells were also maintained in separate cultures in either the EBM or EGM media formulations. Cells were grown on standard tissue cultured plastic in standard air with 5 % CO2 at 37 C. Cells used for experiments were between passages 4 and 8.
Endothelial Network Formation (MATRIGEL) assays. Culture plates were coated with MATRIGEL (BD Discovery Labware, Bedford, MA) according to manufacturer's specifications. Briefly, MATRIGEL (BD Discovery Labware, Bedford, MA) was thawed at 4 C
and approximately 250 microliter was aliquoted and distributed evenly onto each well of a chilled 24-well culture plate (Corning). The plate was then incubated at 37 C
for 30 minutes to allow the material to solidify. Actively growing endothelial cell cultures were trypsinized and counted. Cells were washed twice in Growth media with 2% FBS, followed by centrifugation, resuspension, and aspiration of the supernatant. Cells were seeded onto the coated wells 20,000 cells per well in approximately 0.5 milliliter Growth medium with 2% (v/v) FBS. Cells were then incubated for approximately 30 minutes to allow cells to settle.
Endothelial cell cultures were then treated with either 10 nanoMolar human bFGF
(Peprotech, Rocky Hill, NJ) or 10 nanoMolar human VEGF (Peprotech, Rocky Hill, NJ) to serve as a positive control for endothelial cell response. Transwell inserts seeded with placenta-derived cells were added to appropriate wells with Growth medium with 2% FBS
in the insert chamber. Cultures were incubated in standard air with 5 % CO2 at 37 Cfor approximately 24 hours. The well plate was removed from the incubator, and images of the endothelial cell cultures were collected with an Olympus inverted microscope (Olympus, Melville, NY).
Results In a co-culture system with placenta-derived cells, HUVEC form cell networks.
HUVEC
cells form limited cell networks in co-culture experiments with hMSC and with 10 nanoMolar
Human umbilical vein endothelial cells (HUVEC). HUVEC were obtained from Cambrex (Walkersville, MD). Cells were grown in separate cultures in either EBM or EGM
endothelial cell media (Cambrex). Cells were grown on standard tissue cultured plastic in standard air with % CO2 at 37 C. Cells used in the assay were between passages 4 and 10.
Human coronary artery endothelial cells (HCAEC). HCAEC were purchased from Cambrex Incorporated (Walkersville, MD). These cells were also maintained in separate cultures in either the EBM or EGM media formulations. Cells were grown on standard tissue cultured plastic in standard air with 5 % CO2 at 37 C. Cells used for experiments were between passages 4 and 8.
Endothelial Network Formation (MATRIGEL) assays. Culture plates were coated with MATRIGEL (BD Discovery Labware, Bedford, MA) according to manufacturer's specifications. Briefly, MATRIGEL (BD Discovery Labware, Bedford, MA) was thawed at 4 C
and approximately 250 microliter was aliquoted and distributed evenly onto each well of a chilled 24-well culture plate (Corning). The plate was then incubated at 37 C
for 30 minutes to allow the material to solidify. Actively growing endothelial cell cultures were trypsinized and counted. Cells were washed twice in Growth media with 2% FBS, followed by centrifugation, resuspension, and aspiration of the supernatant. Cells were seeded onto the coated wells 20,000 cells per well in approximately 0.5 milliliter Growth medium with 2% (v/v) FBS. Cells were then incubated for approximately 30 minutes to allow cells to settle.
Endothelial cell cultures were then treated with either 10 nanoMolar human bFGF
(Peprotech, Rocky Hill, NJ) or 10 nanoMolar human VEGF (Peprotech, Rocky Hill, NJ) to serve as a positive control for endothelial cell response. Transwell inserts seeded with placenta-derived cells were added to appropriate wells with Growth medium with 2% FBS
in the insert chamber. Cultures were incubated in standard air with 5 % CO2 at 37 Cfor approximately 24 hours. The well plate was removed from the incubator, and images of the endothelial cell cultures were collected with an Olympus inverted microscope (Olympus, Melville, NY).
Results In a co-culture system with placenta-derived cells, HUVEC form cell networks.
HUVEC
cells form limited cell networks in co-culture experiments with hMSC and with 10 nanoMolar
- 125 -bFGF. HUVEC cells without any treatment showed very little or no network formation. These results suggest that the placenta-derived cells release angiogenic factors that stimulate the HUVEC.
In a co-culture system with placenta-derived cells, CAECs form cell networks.
Table 24-1 shows levels of known angiogenic factors released by PDCs in Growth medium. Placenta-derived cells were seeded onto inserts as described above.
The cells were cultured at 37 C in atmospheric oxygen for 48 hours on the inserts and then switched to a 2%
PBS medium and returned at 37 C for 24 hours. Media was removed, immediately frozen and stored at ¨80 C, and analyzed by the SEARCHLIGHT multiplex ELISA assay (Pierce Chemical Company, Rockford, IL). Results shown are the averages of duplicate measurements. The results show that the placenta-derived cells do not release detectable levels of platelet-derived growth factor-bb (PDGF-bb) or heparin-binding epidermal growth factor (HBEGF).
The cells do release measurable quantities of tissue inhibitor of metalloprotease-1 (TIMP-1), angiopoietin 2 (ANG2), thrombopoietin (TPO), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF).
Table 24-1. Potential angiogenic factors released from placenta-derived cells.
Cells were cultured in 24 hours in media with 2% FBS in atmospheric oxygen.
Media was removed and assayed by the SEARCHLIGHT multiplex ELISA assay (Pierce). Results are the means of a duplicate analysis. Values are concentrations in the media reported in picograms per milliliter of culture media.
PDGF- HB-(pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/m1) (pg/ml) (pg/ml) (pg/ml) (pg/m1) Plac (P4) 91655.3 175.5 <2.0 275.5 3.0 58.3 7.5 644.6 <1.2 Plac 159283 (P11) 2.4 28.1 <2.0 1273.1 193.3 5960.3 34.8 12361.1 1.7 Media alone <9.8 25.1 <2.0 <6.4 <2.0 <3.2 <5.4 <4.0 <1.2 Table 24-2 shows levels of known angiogenic factors released by PDCs. PDCs were seeded onto inserts as described above. The cells were cultured in Growth medium at 5%
oxygen for 48 hours on the inserts and then switched to a 2% PBS medium and returned to 5%
02 incubation for 24 hours. Media was removed, immediately frozen, and stored at ¨80 C, and analyzed by the SEARCHLIGHT multiplex ELISA assay (Pierce Chemical Company, Rockford,
In a co-culture system with placenta-derived cells, CAECs form cell networks.
Table 24-1 shows levels of known angiogenic factors released by PDCs in Growth medium. Placenta-derived cells were seeded onto inserts as described above.
The cells were cultured at 37 C in atmospheric oxygen for 48 hours on the inserts and then switched to a 2%
PBS medium and returned at 37 C for 24 hours. Media was removed, immediately frozen and stored at ¨80 C, and analyzed by the SEARCHLIGHT multiplex ELISA assay (Pierce Chemical Company, Rockford, IL). Results shown are the averages of duplicate measurements. The results show that the placenta-derived cells do not release detectable levels of platelet-derived growth factor-bb (PDGF-bb) or heparin-binding epidermal growth factor (HBEGF).
The cells do release measurable quantities of tissue inhibitor of metalloprotease-1 (TIMP-1), angiopoietin 2 (ANG2), thrombopoietin (TPO), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF).
Table 24-1. Potential angiogenic factors released from placenta-derived cells.
Cells were cultured in 24 hours in media with 2% FBS in atmospheric oxygen.
Media was removed and assayed by the SEARCHLIGHT multiplex ELISA assay (Pierce). Results are the means of a duplicate analysis. Values are concentrations in the media reported in picograms per milliliter of culture media.
PDGF- HB-(pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/m1) (pg/ml) (pg/ml) (pg/ml) (pg/m1) Plac (P4) 91655.3 175.5 <2.0 275.5 3.0 58.3 7.5 644.6 <1.2 Plac 159283 (P11) 2.4 28.1 <2.0 1273.1 193.3 5960.3 34.8 12361.1 1.7 Media alone <9.8 25.1 <2.0 <6.4 <2.0 <3.2 <5.4 <4.0 <1.2 Table 24-2 shows levels of known angiogenic factors released by PDCs. PDCs were seeded onto inserts as described above. The cells were cultured in Growth medium at 5%
oxygen for 48 hours on the inserts and then switched to a 2% PBS medium and returned to 5%
02 incubation for 24 hours. Media was removed, immediately frozen, and stored at ¨80 C, and analyzed by the SEARCHLIGHT multiplex ELISA assay (Pierce Chemical Company, Rockford,
- 126 -IL). Results shown are the averages of duplicate measurements. The results show that the placenta-derived cells do not release detectable levels of platelet-derived growth factor-bb (PDGF-BB), or heparin-binding epidermal growth factor (HBEGF). The cells do release measurable quantities of tissue inhibitor of metallinoprotease-1 (TIMP-1), angiopoietin 2 (ANG2), thrombopoietin (TPO), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF).
Table 24-2. Potential angiogenic factors released from placenta-derived cells.
Cells were cultured in 24 hours in media with 2% FBS in 5% oxygen. Media was removed and assayed by the SEARCHLIGHT multiplex ELISA assay (Pierce).
Results are the means of a duplicate analysis. Values are concentrations in the media reported in picograms per milliter of culture media.
PDGF- HB-Trmpl ANG2 BB TPO i(GF HGF FGF VEGF EGF
(pg/m1) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) Plac (P4) 72972.5 253.6 <2.0 743.1 2.5 30.2 15.1 1495.1 <1.2 Plac (P11) 458023.1 55.1 <2.0 2562.2 114.2 2138.0 295.1 7521.3 1.8 Media alone <9.8 25.1 <2.0 <6.4 <2.0 <3.2 <5.4 <4.0 <1.2 Summary. The results show that placenta-derived cells can stimulate both human umbilical vein and coronary artery endothelial cells to form networks in an in vitro MATRIGEL
(BD Discovery Labware, Bedford, MA) assay. This effect is similar to that seen with known angiogenic factors in this assay system. These results suggest that PDCs are useful for stimulating angiogenesis in vivo.
Transplantation of Placenta-Derived Cells under the Kidney Capsule Transplantation of pancreatic islets to the kidney capsule is routinely performed to evaluate transplantation methodologies for the treatment of diabetes (Refaie et al. (1998) Trans.
Proc. 30:400-403). In addition to pancreatic islets, other cells may be differentiated into insulin-secreting cells capable of blood glucose homeostasis. The purpose of this study was to determine whether cells derived from human placenta could survive when implanted under the kidney capsule in immune-deficient mice. In addition, placenta-derived cells were mixed with GM-CSF
Table 24-2. Potential angiogenic factors released from placenta-derived cells.
Cells were cultured in 24 hours in media with 2% FBS in 5% oxygen. Media was removed and assayed by the SEARCHLIGHT multiplex ELISA assay (Pierce).
Results are the means of a duplicate analysis. Values are concentrations in the media reported in picograms per milliter of culture media.
PDGF- HB-Trmpl ANG2 BB TPO i(GF HGF FGF VEGF EGF
(pg/m1) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) Plac (P4) 72972.5 253.6 <2.0 743.1 2.5 30.2 15.1 1495.1 <1.2 Plac (P11) 458023.1 55.1 <2.0 2562.2 114.2 2138.0 295.1 7521.3 1.8 Media alone <9.8 25.1 <2.0 <6.4 <2.0 <3.2 <5.4 <4.0 <1.2 Summary. The results show that placenta-derived cells can stimulate both human umbilical vein and coronary artery endothelial cells to form networks in an in vitro MATRIGEL
(BD Discovery Labware, Bedford, MA) assay. This effect is similar to that seen with known angiogenic factors in this assay system. These results suggest that PDCs are useful for stimulating angiogenesis in vivo.
Transplantation of Placenta-Derived Cells under the Kidney Capsule Transplantation of pancreatic islets to the kidney capsule is routinely performed to evaluate transplantation methodologies for the treatment of diabetes (Refaie et al. (1998) Trans.
Proc. 30:400-403). In addition to pancreatic islets, other cells may be differentiated into insulin-secreting cells capable of blood glucose homeostasis. The purpose of this study was to determine whether cells derived from human placenta could survive when implanted under the kidney capsule in immune-deficient mice. In addition, placenta-derived cells were mixed with GM-CSF
- 127 -mobilized CD34+ cells to determine whether these cells could promote vascularization and survival of the placenta-derived cells.
Methods & Materials Cell Culture. Cryopreserved placenta-derived cells (isolate 1, P10) were removed from liquid nitrogen storage and grown in Growth medium (DMEM-low glucose (Gibco Carlsbad CA), 15% (v/v) fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) on gelatin (Sigma)-coated T225 (Coming, Coming, NY) flasks until confluent.
Cells from two flasks were washed with Phosphate buffered saline (PBS) and a single cell suspension was obtained by using Trypsin/EDTA,(Gibco). Cryopreserved GM-CSF
mobilized CD34+ cells were purchased from Cambrex, Walkersville, MD (lot 1F0174 donor 7956). CD34+ cells were thawed and washed in DMEM medium.
The cell suspension was washed twice in DMEM. Cell number and viability was estimated after trypan blue (Sigma) staining using a hemocytometer. Aliquots of the cell suspension containing ¨300,000 viable cells were centrifuged at 150 x g, and the cells were resuspended in approximately 6 microliter of DMEM and drawn into a 20 microliter pipette tip connected to a 1 milliliter syringe. The tip of the pipette tip containing the cells was clamped using a small Ligaclip (Ethicon Endosurgery, Cincinnati OH).
Animal preparation.
Mice (Mus Musculus)/Fox Chase SCID/Male (Harlan Sprague Dawley, Inc., Indianapolis, Indiana), 8 weeks of age. All handling of the SCID mice took place under a hood.
The mice were individually weighed and anesthetized with an intraperitoneal injection of a mixture of 60 milligrams/kilogram KETASET (ketamine hydrochloride, Aveco Co., Inc., Fort Dodge, Iowa) and 10 milligrams/kilogram ROMPUN (xylazine, Mobay Corp., Shawnee, Kansas) and saline. After induction of anesthesia, the entire back of the animal from the dorsal cervical area to the dorsal lumbosacral area was clipped free of hair using electric animal clippers. The area was scrubbed with chlorhexidine diacetate, rinsed with alcohol, dried, and painted with an aqueous iodophor solution of 1% available iodine. Ophthalmic ointment was applied to the eyes to prevent drying of the tissue during the anesthetic period. The anesthetized and surgically prepared animal was placed in the desired recumbent position. A
transverse incision was made on the left abdominal side approximately 2 cm caudal to the rib cage of animal. The kidney was exposed and the capsule pierced with a 26-gauge needle.
A capsule lance (modified glass pipette tip) was used to create a space beneath the kidney capsule into
Methods & Materials Cell Culture. Cryopreserved placenta-derived cells (isolate 1, P10) were removed from liquid nitrogen storage and grown in Growth medium (DMEM-low glucose (Gibco Carlsbad CA), 15% (v/v) fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) on gelatin (Sigma)-coated T225 (Coming, Coming, NY) flasks until confluent.
Cells from two flasks were washed with Phosphate buffered saline (PBS) and a single cell suspension was obtained by using Trypsin/EDTA,(Gibco). Cryopreserved GM-CSF
mobilized CD34+ cells were purchased from Cambrex, Walkersville, MD (lot 1F0174 donor 7956). CD34+ cells were thawed and washed in DMEM medium.
The cell suspension was washed twice in DMEM. Cell number and viability was estimated after trypan blue (Sigma) staining using a hemocytometer. Aliquots of the cell suspension containing ¨300,000 viable cells were centrifuged at 150 x g, and the cells were resuspended in approximately 6 microliter of DMEM and drawn into a 20 microliter pipette tip connected to a 1 milliliter syringe. The tip of the pipette tip containing the cells was clamped using a small Ligaclip (Ethicon Endosurgery, Cincinnati OH).
Animal preparation.
Mice (Mus Musculus)/Fox Chase SCID/Male (Harlan Sprague Dawley, Inc., Indianapolis, Indiana), 8 weeks of age. All handling of the SCID mice took place under a hood.
The mice were individually weighed and anesthetized with an intraperitoneal injection of a mixture of 60 milligrams/kilogram KETASET (ketamine hydrochloride, Aveco Co., Inc., Fort Dodge, Iowa) and 10 milligrams/kilogram ROMPUN (xylazine, Mobay Corp., Shawnee, Kansas) and saline. After induction of anesthesia, the entire back of the animal from the dorsal cervical area to the dorsal lumbosacral area was clipped free of hair using electric animal clippers. The area was scrubbed with chlorhexidine diacetate, rinsed with alcohol, dried, and painted with an aqueous iodophor solution of 1% available iodine. Ophthalmic ointment was applied to the eyes to prevent drying of the tissue during the anesthetic period. The anesthetized and surgically prepared animal was placed in the desired recumbent position. A
transverse incision was made on the left abdominal side approximately 2 cm caudal to the rib cage of animal. The kidney was exposed and the capsule pierced with a 26-gauge needle.
A capsule lance (modified glass pipette tip) was used to create a space beneath the kidney capsule into
- 128 -which the cells were introduced. The cells were injected via a syringe with a micropipette tip attached. The pocket was closed by passing an ophthalmic cautery pen (Aaron medical Industries, St. Petersburg, Florida) over the opening (not touching the kidney). The kidney was placed back in the correct anatomical position and the muscle layer sutured closed. The skin was closed with wound clips.
The experimental design comprised one transplantation of cells per mouse (Table 25-1);
four treatments with n-value of 4 per treatment; and three time-points (1, 14, and 30 days).
Mice were euthanized at their designated intervals by carbon dioxide inhalation. The kidney implantation sites were excised and frozen for histology.
Immunohistochemistry. Frozen kidney implantation sites were embedded on edge in O.C.T. Compound (Sakura, Torrance, CA). The kidney tissue was trimmed by cryosectioning to yield a five-micron section of the implantation site and adjacent tissue.
Yielded sections were fixed in freshly prepared 4% paraformaldehyde (EM Sciences Gibbstown, NJ) in phosphate buffered saline (Gibco) for 15 minutes. Sections were washed in PBS and incubated in 3% goat serum in PBS blocking solution for one hour. Blocking solution was removed by gentle aspiration. Sections were incubated in anti-human nuclei antibody (Chemicon International, Temecula, CA) diluted 1:100 in blocking solution for one hour. Sections were washed with PBS
and incubated in fluorescent labeled goat anti-mouse IgG antibody (Molecular Probes Eugene, OR) diluted 1:200 in blocking solution for 30 minutes in absence of light.
Sections were washed in PBS and incubated in 10 microMolar DAPI (Molecular Probes Eugene, OR) for five minutes.
Sections were washed in PBS and examined by fluorescent microscopy.
Tr-Chrome Staining. Frozen kidney implantation sites were embedded on edge in O.C.T. Compound (Sakura Torrance, CA). The kidney tissue was trimmed by cryosectioning to yield a five-micron section of the implantation site and adjacent tissue.
Yielded sections were fixed in 10% neutral buffered formalin (Richard-Allan Scientific Kalamazoo, MI) for 15 minutes. Sections were stained tri-chrome (Poly Scientific Bay Shore, NY) using manufacturer's methods.
Table 25-1. SCID Mouse Kidney Capsule Cell Transplantation Scheme Animal (#) Post-Transplantation Days Kidney Capsule (left)
The experimental design comprised one transplantation of cells per mouse (Table 25-1);
four treatments with n-value of 4 per treatment; and three time-points (1, 14, and 30 days).
Mice were euthanized at their designated intervals by carbon dioxide inhalation. The kidney implantation sites were excised and frozen for histology.
Immunohistochemistry. Frozen kidney implantation sites were embedded on edge in O.C.T. Compound (Sakura, Torrance, CA). The kidney tissue was trimmed by cryosectioning to yield a five-micron section of the implantation site and adjacent tissue.
Yielded sections were fixed in freshly prepared 4% paraformaldehyde (EM Sciences Gibbstown, NJ) in phosphate buffered saline (Gibco) for 15 minutes. Sections were washed in PBS and incubated in 3% goat serum in PBS blocking solution for one hour. Blocking solution was removed by gentle aspiration. Sections were incubated in anti-human nuclei antibody (Chemicon International, Temecula, CA) diluted 1:100 in blocking solution for one hour. Sections were washed with PBS
and incubated in fluorescent labeled goat anti-mouse IgG antibody (Molecular Probes Eugene, OR) diluted 1:200 in blocking solution for 30 minutes in absence of light.
Sections were washed in PBS and incubated in 10 microMolar DAPI (Molecular Probes Eugene, OR) for five minutes.
Sections were washed in PBS and examined by fluorescent microscopy.
Tr-Chrome Staining. Frozen kidney implantation sites were embedded on edge in O.C.T. Compound (Sakura Torrance, CA). The kidney tissue was trimmed by cryosectioning to yield a five-micron section of the implantation site and adjacent tissue.
Yielded sections were fixed in 10% neutral buffered formalin (Richard-Allan Scientific Kalamazoo, MI) for 15 minutes. Sections were stained tri-chrome (Poly Scientific Bay Shore, NY) using manufacturer's methods.
Table 25-1. SCID Mouse Kidney Capsule Cell Transplantation Scheme Animal (#) Post-Transplantation Days Kidney Capsule (left)
- 129 -Treatments:
1. 3 x 103 cells from placenta 2. 3 x 103 cells from placenta + 3 x 103 CD34+cells Added animal # 25-27 as control (No cells) Results The viability of the placenta-derived cells was ¨75% and the CD34+ cells was 95%.
Initial attempts to transplant 1 x 106 viable cells were unsuccessful due to inadequate size of the kidney capsule to accommodate the cells. Cells were transplanted within 3 hours of trypsinization. The localization of placenta-derived cells under the kidney capsule was observed microscopically. There were no apparent differences in the number and distribution of placenta-
1. 3 x 103 cells from placenta 2. 3 x 103 cells from placenta + 3 x 103 CD34+cells Added animal # 25-27 as control (No cells) Results The viability of the placenta-derived cells was ¨75% and the CD34+ cells was 95%.
Initial attempts to transplant 1 x 106 viable cells were unsuccessful due to inadequate size of the kidney capsule to accommodate the cells. Cells were transplanted within 3 hours of trypsinization. The localization of placenta-derived cells under the kidney capsule was observed microscopically. There were no apparent differences in the number and distribution of placenta-
- 130 -derived cells with or without CD34+ cells at each time point. There was an apparent decrease in cell numbers over time.
Staining of cells under the kidney capsule showed the retention of transplanted cells.
Human cells were detected using the human nuclear antigen. All cells (human and mouse) were detected using DAPI.
Summary. Transplantation of cells into the renal capsule was successful.
Undifferentiated placenta-derived cells (3 x 103) pre-treated with growth factors with or without 3 x 103 GM-CSF mobilized CD34+ cells were transplanted beneath the capsule of the kidney.
Animals were sacrificed at 1, 14, and 30 days following cell transplantation.
Cells survived at 1, 14, and 30 days with a reduction in apparent cell numbers at 30 days. The presence of GM-CSF
mobilized CD34+ cells did not effect the survival of placenta-derived cells.
This study demonstrates that placenta-derived cells can be transplanted to the kidney capsule.
Example 26 Transplantation of Placenta-Derived Cells Cells derived from the postpartum placenta are useful for regenerative therapies. The tissue produced by placenta-derived cells transplanted into SC ID mice with a biodegradable material was evaluated. The materials evaluated were VICRYL nonwoven, 35/65 PCL/PGA
foam, and RAID 16 self-assembling peptide hydrogel.
Methods & Materials Cell Culture. Placenta-derived cells were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03;
Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) in a gelatin-coated flasks.
Matrix Preparation. A nonwoven scaffold was prepared using a traditional needle punching technique as described below. Fibers, comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA), sold under the tradename VICRYL were obtained from Ethicon, Inc. (Somerville, NJ). The fibers were filaments of approximately 20 microns in diameter. The fibers were then cut and crimped into uniform 2-inch lengths to form 2-inch staple fiber. A dry lay needle-punched nonwoven matrix was then prepared utilizing the VICRYL staple fibers. The staple fibers were opened and carded on standard nonwoven machinery. The resulting mat was in the fon-n of webbed staple fibers. The webbed staple fibers were needle-punched to form the dry lay needle-punched nonwoven scaffold. The nonwoven
Staining of cells under the kidney capsule showed the retention of transplanted cells.
Human cells were detected using the human nuclear antigen. All cells (human and mouse) were detected using DAPI.
Summary. Transplantation of cells into the renal capsule was successful.
Undifferentiated placenta-derived cells (3 x 103) pre-treated with growth factors with or without 3 x 103 GM-CSF mobilized CD34+ cells were transplanted beneath the capsule of the kidney.
Animals were sacrificed at 1, 14, and 30 days following cell transplantation.
Cells survived at 1, 14, and 30 days with a reduction in apparent cell numbers at 30 days. The presence of GM-CSF
mobilized CD34+ cells did not effect the survival of placenta-derived cells.
This study demonstrates that placenta-derived cells can be transplanted to the kidney capsule.
Example 26 Transplantation of Placenta-Derived Cells Cells derived from the postpartum placenta are useful for regenerative therapies. The tissue produced by placenta-derived cells transplanted into SC ID mice with a biodegradable material was evaluated. The materials evaluated were VICRYL nonwoven, 35/65 PCL/PGA
foam, and RAID 16 self-assembling peptide hydrogel.
Methods & Materials Cell Culture. Placenta-derived cells were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03;
Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco)) in a gelatin-coated flasks.
Matrix Preparation. A nonwoven scaffold was prepared using a traditional needle punching technique as described below. Fibers, comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA), sold under the tradename VICRYL were obtained from Ethicon, Inc. (Somerville, NJ). The fibers were filaments of approximately 20 microns in diameter. The fibers were then cut and crimped into uniform 2-inch lengths to form 2-inch staple fiber. A dry lay needle-punched nonwoven matrix was then prepared utilizing the VICRYL staple fibers. The staple fibers were opened and carded on standard nonwoven machinery. The resulting mat was in the fon-n of webbed staple fibers. The webbed staple fibers were needle-punched to form the dry lay needle-punched nonwoven scaffold. The nonwoven
- 131 -scaffold was rinsed in water followed by another incubation in ethanol to remove any residual chemicals or processing aids used during the manufacturing process.
Foams, composed of 35/65 poly(epsilon-caprolactone)/poly(glycolic acid) (35/65 PCL/PGA) copolymer, werer formed by the process of lyophilized, as discussed in U.S. Patent No. 6,355,699.
Sample Preparation. One million viable cells were seeded in 15 microliter Growth medium onto 5 millimeter diameter, 2.25 millimeter thick nonwoven scaffolds (64.33 milligram/cubic centimeters) or 5 millimeter diameter 35/65 PCL/PGA foam disks. Cells were allowed to attach for two hours before adding more Growth medium to cover the scaffolds. Cells were grown on scaffolds overnight. Scaffolds without cells were also incubated in medium.
RAD16 self-assembling peptides (3D Matrix, Cambridge, MA under a material transfer agreement) was obtained as a sterile 1 % (w/v) solution in water, which was mixed 1:1 with 1 x 106 cells in 10% (w/v) sucrose (Sigma, St Louis, MO), 10 millimolar HEPES in Dulbecco's modified medium (DMEM; Gibco) immediately before use. The final concentration of cells in RAD16 hydrogel was 1 x 106 cells/100 microliter.
TEST MATERIAL (N=4/Rx) 1. VICRYL nonwoven + 1 x 106 placenta-derived cells 2. 35/65 PCL/PGA foam + 1 x 106 placenta-derived cells 3. RAD 16 self-assembling peptide + 1 x 106 placenta-derived cells 4. 35/65 PCL/PGA foam 5. VICRYL nonwoven Animal Preparation. The animals utilized in this study were handled and maintained in accordance with the current requirements of the Animal Welfare Act. Compliance with the above Public Laws were accomplished by adhering to the Animal Welfare regulations (9 CFR) and conforming to the current standards promulgated in the Guide for the Care and Use of Laboratory Animals, 7th edition.
Mice (Mus Musculus)/Fox Chase SCID/Male (Harlan Sprague Dawley, Inc., Indianapolis, Indiana), 5 weeks of age. All handling of the SCID mice took place under a hood.
The mice were individually weighed and anesthetized with an intraperitoneal injection of a mixture of 60 milligram/kilogram KETASET (ketamine hydrochloride, Aveco Co., Inc., Fort Dodge, Iowa) and 10 milligram/kilogram ROMPUN (xylazine, Mobay Corp., Shawnee, Kansas) and saline. After induction of anesthesia, the entire back of the animal from the dorsal cervical
Foams, composed of 35/65 poly(epsilon-caprolactone)/poly(glycolic acid) (35/65 PCL/PGA) copolymer, werer formed by the process of lyophilized, as discussed in U.S. Patent No. 6,355,699.
Sample Preparation. One million viable cells were seeded in 15 microliter Growth medium onto 5 millimeter diameter, 2.25 millimeter thick nonwoven scaffolds (64.33 milligram/cubic centimeters) or 5 millimeter diameter 35/65 PCL/PGA foam disks. Cells were allowed to attach for two hours before adding more Growth medium to cover the scaffolds. Cells were grown on scaffolds overnight. Scaffolds without cells were also incubated in medium.
RAD16 self-assembling peptides (3D Matrix, Cambridge, MA under a material transfer agreement) was obtained as a sterile 1 % (w/v) solution in water, which was mixed 1:1 with 1 x 106 cells in 10% (w/v) sucrose (Sigma, St Louis, MO), 10 millimolar HEPES in Dulbecco's modified medium (DMEM; Gibco) immediately before use. The final concentration of cells in RAD16 hydrogel was 1 x 106 cells/100 microliter.
TEST MATERIAL (N=4/Rx) 1. VICRYL nonwoven + 1 x 106 placenta-derived cells 2. 35/65 PCL/PGA foam + 1 x 106 placenta-derived cells 3. RAD 16 self-assembling peptide + 1 x 106 placenta-derived cells 4. 35/65 PCL/PGA foam 5. VICRYL nonwoven Animal Preparation. The animals utilized in this study were handled and maintained in accordance with the current requirements of the Animal Welfare Act. Compliance with the above Public Laws were accomplished by adhering to the Animal Welfare regulations (9 CFR) and conforming to the current standards promulgated in the Guide for the Care and Use of Laboratory Animals, 7th edition.
Mice (Mus Musculus)/Fox Chase SCID/Male (Harlan Sprague Dawley, Inc., Indianapolis, Indiana), 5 weeks of age. All handling of the SCID mice took place under a hood.
The mice were individually weighed and anesthetized with an intraperitoneal injection of a mixture of 60 milligram/kilogram KETASET (ketamine hydrochloride, Aveco Co., Inc., Fort Dodge, Iowa) and 10 milligram/kilogram ROMPUN (xylazine, Mobay Corp., Shawnee, Kansas) and saline. After induction of anesthesia, the entire back of the animal from the dorsal cervical
- 132 -area to the dorsal lumbosacral area was clipped free of hair using electric animal clippers. The area was then scrubbed with chlorhexidine diacetate, rinsed with alcohol, dried, and painted with an aqueous iodophor solution of 1% available iodine. Ophthalmic ointment was applied to the eyes to prevent drying of the tissue during the anesthetic period.
Subcutaneous Implantation Technique. Four skin incisions, each approximately 1.0 cm in length, were made on the dorsum of the mice. Two cranial sites were located transversely over the dorsal lateral thoracic region, about 5-millimeter caudal to the palpated inferior edge of the scapula, with one to the left and one to the right of the vertebral column. Another two were placed transversely over the gluteal muscle area at the caudal sacro-lumbar level, about 5-mm caudal to the palpated iliac crest, with one on either side of the midline.
Implants were randomly placed in these sites. The skin was separated from the underlying connective tissue to make a small pocket and the implant placed (or injected for RAD16) about 1-cm caudal to the incision.
The appropriate test material was implanted into the subcutaneous space. The skin incision was closed with metal clips.
Animal Housing. Mice were individually housed in microisolator cages throughout the course of the study within a temperature range of 64 F - 79 F and relative humidity of 30% to 70% and were maintained on an approximate 12 hour light/12 hour dark cycle.
The temperature and relative humidity were maintained within the stated ranges to the greatest extent possible.
Diet consisted of Irradiated Pico Mouse Chow 5058 (Purina Co.) and water fed ad libitum.
Mice were euthanized at their designated intervals by carbon dioxide inhalation. The subcutaneous implantation sites with their overlying skin were excised and frozen for histology.
Histology. Excised skin with implant was fixed with 10% neutral buffered formalin (Richard-Allan Kalamazoo, MI). Samples with overlying and adjacent tissue were centrally bisected, paraffin-processed, and embedded on cut surface using routine methods. Five-micron tissue sections were obtained by microtome and stained with hematoxylin and eosin (Poly Scientific Bay Shore, NY) using routine methods.
Results There was minimal ingrowth of tissue into foams implanted subcutaneously in SCID
mice after 30 day. In contrast there was extensive tissue fill in foams implanted with placenta-derived cells.
There was some tissue in growth in VICRYL nonwoven scaffolds. Nonwoven scaffolds seeded with placenta-derived cells showed increased matrix deposition and mature blood vessels.
It was not possible to identify the point of injection of RAD16 and cells.
Subcutaneous Implantation Technique. Four skin incisions, each approximately 1.0 cm in length, were made on the dorsum of the mice. Two cranial sites were located transversely over the dorsal lateral thoracic region, about 5-millimeter caudal to the palpated inferior edge of the scapula, with one to the left and one to the right of the vertebral column. Another two were placed transversely over the gluteal muscle area at the caudal sacro-lumbar level, about 5-mm caudal to the palpated iliac crest, with one on either side of the midline.
Implants were randomly placed in these sites. The skin was separated from the underlying connective tissue to make a small pocket and the implant placed (or injected for RAD16) about 1-cm caudal to the incision.
The appropriate test material was implanted into the subcutaneous space. The skin incision was closed with metal clips.
Animal Housing. Mice were individually housed in microisolator cages throughout the course of the study within a temperature range of 64 F - 79 F and relative humidity of 30% to 70% and were maintained on an approximate 12 hour light/12 hour dark cycle.
The temperature and relative humidity were maintained within the stated ranges to the greatest extent possible.
Diet consisted of Irradiated Pico Mouse Chow 5058 (Purina Co.) and water fed ad libitum.
Mice were euthanized at their designated intervals by carbon dioxide inhalation. The subcutaneous implantation sites with their overlying skin were excised and frozen for histology.
Histology. Excised skin with implant was fixed with 10% neutral buffered formalin (Richard-Allan Kalamazoo, MI). Samples with overlying and adjacent tissue were centrally bisected, paraffin-processed, and embedded on cut surface using routine methods. Five-micron tissue sections were obtained by microtome and stained with hematoxylin and eosin (Poly Scientific Bay Shore, NY) using routine methods.
Results There was minimal ingrowth of tissue into foams implanted subcutaneously in SCID
mice after 30 day. In contrast there was extensive tissue fill in foams implanted with placenta-derived cells.
There was some tissue in growth in VICRYL nonwoven scaffolds. Nonwoven scaffolds seeded with placenta-derived cells showed increased matrix deposition and mature blood vessels.
It was not possible to identify the point of injection of RAD16 and cells.
- 133 -Summary. The purpose of this study was to determine the type of tissue formed by cells derived from human placenta in scaffolds in immune deficient mice. Synthetic absorbable nonwoven/foam discs (5.0 millimeter diameter x 1.0 millimeter thick) or self-assembling peptide hydrogel were seeded with cells derived from human placenta and implanted subcutaneously bilaterally in the dorsal spine region Of SCID mice. It has been demonstrated that placenta-derived cells can dramatically increase good quality tissue formation in biodegradable scaffolds.
Assessment of Placenta-Derived Cells for Cardiovascular Therapy in a Rodent Coronary Ligation Model The efficacy of intracardiac human placenta-derived cell treatment when administered 15 minutes post-coronary artery occlusion was evaluated in a rodent model of myocardial ischemia/infarction.
Methods & Materials The Charles River Worcester, MA test facility is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) and registered with the United States Department of Agriculture to conduct research in laboratory animals. All the conditions of testing will confoini to the Animal Welfare Act (9 CFR) and its amendments. The protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the Test Facility for compliance with regulations prior to study initiation.
The animals having characteristics identified in Table 27-1 were individually housed in micro-isolator cages on autoclaved bedding. The cages conform to standards set forth in The Guide for the Care and Use of Laboratory Animals.
Table 27-1. Animal characteristics Species: Rattus norvegicus Strain: Rnu Source: Charles River Laboratories Age at Dosing: 6-8 weeks Weight at Dosing: ¨200-250 grams Number of Males (including spares): 40 + 10 Purina Certified Diet (irradiated) was provided to the animals ad libitum.
This diet was routinely analyzed by the manufacturer for nutritional components and environmental
Assessment of Placenta-Derived Cells for Cardiovascular Therapy in a Rodent Coronary Ligation Model The efficacy of intracardiac human placenta-derived cell treatment when administered 15 minutes post-coronary artery occlusion was evaluated in a rodent model of myocardial ischemia/infarction.
Methods & Materials The Charles River Worcester, MA test facility is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) and registered with the United States Department of Agriculture to conduct research in laboratory animals. All the conditions of testing will confoini to the Animal Welfare Act (9 CFR) and its amendments. The protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the Test Facility for compliance with regulations prior to study initiation.
The animals having characteristics identified in Table 27-1 were individually housed in micro-isolator cages on autoclaved bedding. The cages conform to standards set forth in The Guide for the Care and Use of Laboratory Animals.
Table 27-1. Animal characteristics Species: Rattus norvegicus Strain: Rnu Source: Charles River Laboratories Age at Dosing: 6-8 weeks Weight at Dosing: ¨200-250 grams Number of Males (including spares): 40 + 10 Purina Certified Diet (irradiated) was provided to the animals ad libitum.
This diet was routinely analyzed by the manufacturer for nutritional components and environmental
- 134 -contaminants. Results of the manufacturer's analyses are Oh file at the Test Facility. Autoclaved Filtered tap water, was provided ad libitum. Samples of the filtered water were analyzed for total dissolved solids, hardness, specified microbiological content, and selected environmental contaminants. Results of these analyses are on file at the Test Facility.
Environmental controls were set to maintain temperatures of 18 to 26 C (64 to 79 F) with a relative humidity of 30% to 70%. A 12:12 hour light:dark cycle was maintained. Ten or greater air changes per hour were maintained in the animal rooms. Upon receipt and prior to use on the study, the animals were held for a minimum of four days for conditioning according to the Test Facility Vendor Management Program as described in the Test Facility Standard Operating Procedure, Receipt, Conditioning, and Quarantine of Laboratory Animals.
Each animal was identified by a unique number and this number was indicated by an ear punch. Animals were randomly assigned to groups by a weight-ordered distribution such that individual body weights did not exceed 20% of mean weight.
The animals were anesthetized with sodium pentobarbital (40 milligram/kilogram) and buprenorphine(0.05 milligram/kilogram) as a single cocktail given intramuscularly (IM).
Following the establishment of anesthesia, animals were intubated using an 18-16 gauge, 2-inch length angiocath, or appropriate sized angiocath, and maintained on room air respiration (supplemented with oxygen) and a positive pressure ventilator throughout the surgical procedure.
Additional anesthesia was given incrementally as needed. Preoperative antibiotic therapy was also administered, Benzathine/Procaine penicillin G, 40,000 Units/kilogram, IM. Additional antibiotic therapy was administered every 48 hours.
Electrode pads were placed around the appropriate paws of the animals to receive a useable electrocardiogram (ECG) signal. Animals were positioned on a heating pad to help maintain body temperature throughout the procedure. A rectal temperature probe was inserted into the animal to monitor body temperature. Ophthalmic ointment was administered to each eye. The surgical sites (thoracic area) were prepared for aseptic surgery by removing any excess fur, and gently wiping the area with sponges that have been soaked in 70%
isopropyl alcohol, which was allowed to dry. Medi SeppsTM or similar solution was then applied to the area and also allowed to dry. The area was appropriately draped for strict aseptic surgery.
A surgical incision was made on the skin over the fourth intercostal space.
Blunt dissection through the muscle layers was used to access the thoracic cavity. A
retractor was carefully inserted into the fourth intercostal space and opened to allow access to the interior cavity. The pericardium was carefully opened via gentle teasing with cotton swabs dampened in sterile saline solution. A damp cotton swab was used to gently push the apex of the heart into the
Environmental controls were set to maintain temperatures of 18 to 26 C (64 to 79 F) with a relative humidity of 30% to 70%. A 12:12 hour light:dark cycle was maintained. Ten or greater air changes per hour were maintained in the animal rooms. Upon receipt and prior to use on the study, the animals were held for a minimum of four days for conditioning according to the Test Facility Vendor Management Program as described in the Test Facility Standard Operating Procedure, Receipt, Conditioning, and Quarantine of Laboratory Animals.
Each animal was identified by a unique number and this number was indicated by an ear punch. Animals were randomly assigned to groups by a weight-ordered distribution such that individual body weights did not exceed 20% of mean weight.
The animals were anesthetized with sodium pentobarbital (40 milligram/kilogram) and buprenorphine(0.05 milligram/kilogram) as a single cocktail given intramuscularly (IM).
Following the establishment of anesthesia, animals were intubated using an 18-16 gauge, 2-inch length angiocath, or appropriate sized angiocath, and maintained on room air respiration (supplemented with oxygen) and a positive pressure ventilator throughout the surgical procedure.
Additional anesthesia was given incrementally as needed. Preoperative antibiotic therapy was also administered, Benzathine/Procaine penicillin G, 40,000 Units/kilogram, IM. Additional antibiotic therapy was administered every 48 hours.
Electrode pads were placed around the appropriate paws of the animals to receive a useable electrocardiogram (ECG) signal. Animals were positioned on a heating pad to help maintain body temperature throughout the procedure. A rectal temperature probe was inserted into the animal to monitor body temperature. Ophthalmic ointment was administered to each eye. The surgical sites (thoracic area) were prepared for aseptic surgery by removing any excess fur, and gently wiping the area with sponges that have been soaked in 70%
isopropyl alcohol, which was allowed to dry. Medi SeppsTM or similar solution was then applied to the area and also allowed to dry. The area was appropriately draped for strict aseptic surgery.
A surgical incision was made on the skin over the fourth intercostal space.
Blunt dissection through the muscle layers was used to access the thoracic cavity. A
retractor was carefully inserted into the fourth intercostal space and opened to allow access to the interior cavity. The pericardium was carefully opened via gentle teasing with cotton swabs dampened in sterile saline solution. A damp cotton swab was used to gently push the apex of the heart into the
- 135 -opening where a length of 6-0 silk suture was attached into the myocardium for manipulation of the heart. After a pause to allow the heart to recover, the suture placed in the apex was used to ease the heart out of the chest cavity and to place sufficient tension on the heart to allow access , to the upper heart and the left anterior descending coronary artery (LAD). Another length of 6-0 silk suture was placed into the myocardium so as to surround the LAD. The pressure on the apical suture was released and the heart allowed to return to the interior of the chest cavity.
Once the heart rate and ECG returned to baseline values, the ligatures around the LAD
were tied off to occlude the LAD. This was a permanent occlusion with the suture tied off and the ends trimmed. Once the ligature was tied, the surgeon looked for the following indications of successful occlusion: change in color of the area of the heart directly below the ligature to a white/grayish white as a result of the termination of blood flow to the area and a significant change in the ECG corresponding to occlusion of the LAD. Arrhythmias may have developed within the first 10 minutes of the occlusion. The rat was monitored closely during this time period in the event that resuscitation was necessary. In the event of severe arrhythmia and failure of the rat to convert to normal sinus rhythm without assistance, aid was rendered via cardiac massage. Approximately 15 minutes following the initiation of the LAD
occlusion, the area of left ventricle made ischemic was treated with either vehicle or test article by direct injection into the ischemic myocardium. Treatment consisted of three to ten intramyocardial injections (100 microliter/injection) into the ischemic zone of myocardium.
Human cells were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03, Hyclone, Logan UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad CA), in a gelatin-coated T300 flasks. Cells were washed with phosphate buffered saline (PBS, Gibco, Carlsbad CA) and trypsinized using Trypsin/EDTA (Gibco, Carlsbad CA). The trypsinization was stopped by adding Growth medium. The cells were centrifuged at 150 x g, supernatant removed, and the cell pellet was resuspended in approximately 1 milliliter Growth medium per million cells. An aliquot of cells was removed and added to trypan blue (Sigma, St. Louis, MO). The viable cell number was estimated using a hemocytometer. The cell suspension was centrifuged and resuspended in 1 milliliter Growth containing 10% (v/v) DMSO (Hybrimax, Sigma, St. Louis, MO) per 5 million cells and transferred into Cryovials (Nalgene). The cells were cooled at approximately 1 C/minute overnight in a -80 C freezer using a "Mr Frosty" freezing container (Nalgene, Rochester, NY). Vials of cells were transferred into liquid nitrogen. Vials were shipped from CBAT, Somerville, NJ to Charles River, Worcester, MA on dry ice and stored at -80 C.
Once the heart rate and ECG returned to baseline values, the ligatures around the LAD
were tied off to occlude the LAD. This was a permanent occlusion with the suture tied off and the ends trimmed. Once the ligature was tied, the surgeon looked for the following indications of successful occlusion: change in color of the area of the heart directly below the ligature to a white/grayish white as a result of the termination of blood flow to the area and a significant change in the ECG corresponding to occlusion of the LAD. Arrhythmias may have developed within the first 10 minutes of the occlusion. The rat was monitored closely during this time period in the event that resuscitation was necessary. In the event of severe arrhythmia and failure of the rat to convert to normal sinus rhythm without assistance, aid was rendered via cardiac massage. Approximately 15 minutes following the initiation of the LAD
occlusion, the area of left ventricle made ischemic was treated with either vehicle or test article by direct injection into the ischemic myocardium. Treatment consisted of three to ten intramyocardial injections (100 microliter/injection) into the ischemic zone of myocardium.
Human cells were grown in Growth medium (DMEM-low glucose (Gibco, Carlsbad CA), 15% (v/v) fetal bovine serum (Cat. #SH30070.03, Hyclone, Logan UT), 0.001% (v/v) betamercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin (Gibco, Carlsbad CA), in a gelatin-coated T300 flasks. Cells were washed with phosphate buffered saline (PBS, Gibco, Carlsbad CA) and trypsinized using Trypsin/EDTA (Gibco, Carlsbad CA). The trypsinization was stopped by adding Growth medium. The cells were centrifuged at 150 x g, supernatant removed, and the cell pellet was resuspended in approximately 1 milliliter Growth medium per million cells. An aliquot of cells was removed and added to trypan blue (Sigma, St. Louis, MO). The viable cell number was estimated using a hemocytometer. The cell suspension was centrifuged and resuspended in 1 milliliter Growth containing 10% (v/v) DMSO (Hybrimax, Sigma, St. Louis, MO) per 5 million cells and transferred into Cryovials (Nalgene). The cells were cooled at approximately 1 C/minute overnight in a -80 C freezer using a "Mr Frosty" freezing container (Nalgene, Rochester, NY). Vials of cells were transferred into liquid nitrogen. Vials were shipped from CBAT, Somerville, NJ to Charles River, Worcester, MA on dry ice and stored at -80 C.
- 136 -Approximately 1-2 hours before injection of cells into the animal, a vial of cells was thawed rapidly in a 37 C water bath. Under aseptic conditions in a BSL2 biosafety cabinet, cells were added to 40 Milliliters PBS with magnesium and calcium (Sigma St. Louis, MO) and centrifuged at 150 x g for 5 minutes before resuspending the cell pellet in 10 milliliters PBS. The cell number and viability was estimated as described above. The cells were centrifuged at 150 x g for minutes and resuspended in PBS at a final concentration of 106 viable cells /100 microliter.
The cell suspension was loaded into 1 milliliter syringes with a 30G needle and kept on ice.
Viability was assessed again up to 5 hours on ice.
Following the administration of treatment (Table 27-2) and stabilization of the heart, the surgeon began closing the surgical incision. The retractor was removed. The lungs were over-inflated for 3 ¨4 breaths and visually inspected as much as possible to ensure that they were fully re-inflated. This created a negative pressure necessary to prevent pneumothorax post-recovery. To evacuate fluid and excess air from the thoracic cavity after closing the cavity, an intravenous catheter (i.e., 20 gauge, 2 millimeter in length) was placed through the skin and muscle layers so that the tip remains in the thoracic cavity. Care was taken so that the tip did not pierce the lung or heart. The separated ribs and associated muscle was sutured together with appropriate suture. The upper layers of muscle was sutured using a simple continuous pattern.
The skin was closed with 4-0 silk using a horizontal mattress pattern. A 10 milliliter syringe was attached to the intravenous catheter that had been previously placed in the thoracic cavity and the plunger slowly pulled back to withdraw fluids and air from the cavity. At the same time, the catheter was slowly withdrawn from the entry site, thereby allowing the surrounding muscle mass and skin to seal the puncture. The surgical drape was removed and fluids (i.e., lactated Ringers solution, 25 milliliter/kilogram subcutaneously [SC] or intraperitoneally [IP]) were given.
Table 27-2 Treatment regimens
The cell suspension was loaded into 1 milliliter syringes with a 30G needle and kept on ice.
Viability was assessed again up to 5 hours on ice.
Following the administration of treatment (Table 27-2) and stabilization of the heart, the surgeon began closing the surgical incision. The retractor was removed. The lungs were over-inflated for 3 ¨4 breaths and visually inspected as much as possible to ensure that they were fully re-inflated. This created a negative pressure necessary to prevent pneumothorax post-recovery. To evacuate fluid and excess air from the thoracic cavity after closing the cavity, an intravenous catheter (i.e., 20 gauge, 2 millimeter in length) was placed through the skin and muscle layers so that the tip remains in the thoracic cavity. Care was taken so that the tip did not pierce the lung or heart. The separated ribs and associated muscle was sutured together with appropriate suture. The upper layers of muscle was sutured using a simple continuous pattern.
The skin was closed with 4-0 silk using a horizontal mattress pattern. A 10 milliliter syringe was attached to the intravenous catheter that had been previously placed in the thoracic cavity and the plunger slowly pulled back to withdraw fluids and air from the cavity. At the same time, the catheter was slowly withdrawn from the entry site, thereby allowing the surrounding muscle mass and skin to seal the puncture. The surgical drape was removed and fluids (i.e., lactated Ringers solution, 25 milliliter/kilogram subcutaneously [SC] or intraperitoneally [IP]) were given.
Table 27-2 Treatment regimens
- 137 -Dosage Time of Cr. No. ofDose Conc. Route / Dose Necropsy Test Article Level Treatment No. Males (cells/mL) Regimen Day (cells/animal) Administration 1 8 Vehicle 0 0Direct injection(s) into the ischemic 2 8 Placenta #4 (P10) region of the left (A) ventricle of the 15 minutes Day 28 heart, consisting after coronary ( 1 3 8 Placenta #3 (P10) 1 million 10 million of 3 to 10 artery ligation Day) (C) intramyocardial injections of Human 100 microliters 4 8 fibroblasts total.
1F1853 (P10) (D) Gr. = Group; No. = Number; Conc. = Concentration Immediately after each rat had undergone treatment with test article and the incision sutured, the animal underwent an echocardiography (ECG) examination.
Anesthesia was maintained throughout the completion of the echo examination. Upon the completion of the echo examination, ventilation was discontinued, arid the rat was returned to the recovery area to recover in a heated, oxygenated recovery cage.
A second echo examination of each surviving animal was completed at the end of the study (approximately 28 days post-treatment), prior to termination. During the second examination, the animals were anesthetized as described previously.
For each echo examination, the left thoracic area was shaved, and wanned, ultrasonic gel was applied to the skin to enhance contact with the transducer. Electrode pads were placed around the ,appropriate extremities to receive an ECG signal.
Echocardiographic images included short axis and long axis views to allow for the determination of ventricular cavity dimensions, contractility, blood flow through vasculature, and wall thickness.
These images were saved on optical disk for further analysis. After examination, the gel medium was removed from the skin with gauze or paper towel. The rat was removed from the ventilator and placed in a warmed recovery cage until mobile.
At the conclusion of the surgical procedures, respiratory ventilation was turned off. The animals were observed for pedal reflex. The rectal probe and ECG electrodes subsequently were removed, and the animal was extubated and placed in a warmed oxygenated recovery cage.
After complete recovery from anesthesia, the animals were given buprenorphine (0.05 milligram/kilogram, SC). Observations were made regularly until the animals showed full mobility and an interest in food and water. The animals then were placed in a clean housing
1F1853 (P10) (D) Gr. = Group; No. = Number; Conc. = Concentration Immediately after each rat had undergone treatment with test article and the incision sutured, the animal underwent an echocardiography (ECG) examination.
Anesthesia was maintained throughout the completion of the echo examination. Upon the completion of the echo examination, ventilation was discontinued, arid the rat was returned to the recovery area to recover in a heated, oxygenated recovery cage.
A second echo examination of each surviving animal was completed at the end of the study (approximately 28 days post-treatment), prior to termination. During the second examination, the animals were anesthetized as described previously.
For each echo examination, the left thoracic area was shaved, and wanned, ultrasonic gel was applied to the skin to enhance contact with the transducer. Electrode pads were placed around the ,appropriate extremities to receive an ECG signal.
Echocardiographic images included short axis and long axis views to allow for the determination of ventricular cavity dimensions, contractility, blood flow through vasculature, and wall thickness.
These images were saved on optical disk for further analysis. After examination, the gel medium was removed from the skin with gauze or paper towel. The rat was removed from the ventilator and placed in a warmed recovery cage until mobile.
At the conclusion of the surgical procedures, respiratory ventilation was turned off. The animals were observed for pedal reflex. The rectal probe and ECG electrodes subsequently were removed, and the animal was extubated and placed in a warmed oxygenated recovery cage.
After complete recovery from anesthesia, the animals were given buprenorphine (0.05 milligram/kilogram, SC). Observations were made regularly until the animals showed full mobility and an interest in food and water. The animals then were placed in a clean housing
- 138 -cage and returned to the animal housing room. Animals were monitored for surgical incision integrity twice daily post-surgery.
Analgesics (i.e., Buprenorphine, 0.05 milligram/kilogram SC) were given twice daily for 4 days post-operatively and thereafter as needed. Visual indications of post-operative pain include lack of normal body postures and movement (e.g., animal remains in hunched position), antipathy, lack of eating/drinking, lack of grooming, etc.
Body weight was recorded for each animal prior to initial treatment, weekly thereafter, and on the day of necropsy. Animals found dead were weighed and necropsied.
In order for the heart to be harvested, each rat was anesthetized as was done for surgery.
The jugular vein was cannulated. The heart was arrested in diastole with potassium chloride infused via the jugular cannula. The heart was then removed from the thoracic cavity. A limited necropsy was then performed on the heart after which the heart was placed in 10% neutral buffered fatmalin. The remainder of each carcass was then discarded with no further evaluation.
Hearts of all animals that were found dead or euthanized moribund were placed in 4%
paraformaldehyde until evaluated. The remainder of each carcass was then discarded with no further evaluation.
Histology and Image Analysis. Fixed tissues sectioned with a stainless steel coronal heart matrix (Harvard Apparatus Holliston, MA) yielded four two-millimeter thick serial tissue sections. Sections were processed and serially embedded in paraffin using routine methods.
Five-micron sections were obtained by microtome and stained Masson's Tr-chrome for Connective Tissue (Poly Scientific Bay Shore, NY) using manufacturer's methods. Electronic photomicrographs were captured and analyzed using image analysis methods developed by Phase 3 Imaging System (Glen Mills, PA). Photomicrographs of the tri-chrome stained sections were color-metrically analyzed electronically to determine the overall area of the ventricle and free wall and the area of the differential staining.
Results There was no loss in the initial viability of cells over 5 hours in the vehicle when kept on ice. Cells were injected into the infarct with one to three needle entry points and multiple changes in direction of needle orientation.
Echocardiography measurements were taken from the infarct-treated rats.
Fractional shortening of the vehicle-treated animals had a significant decrease from 47.7% J 8.3% at Day 0 to 23.5% 30.2% at Day 28 (p<0.05). The animals that were treated with placenta-derived cells showed small, non-significant differences between the fractional shortening between Day 0 and
Analgesics (i.e., Buprenorphine, 0.05 milligram/kilogram SC) were given twice daily for 4 days post-operatively and thereafter as needed. Visual indications of post-operative pain include lack of normal body postures and movement (e.g., animal remains in hunched position), antipathy, lack of eating/drinking, lack of grooming, etc.
Body weight was recorded for each animal prior to initial treatment, weekly thereafter, and on the day of necropsy. Animals found dead were weighed and necropsied.
In order for the heart to be harvested, each rat was anesthetized as was done for surgery.
The jugular vein was cannulated. The heart was arrested in diastole with potassium chloride infused via the jugular cannula. The heart was then removed from the thoracic cavity. A limited necropsy was then performed on the heart after which the heart was placed in 10% neutral buffered fatmalin. The remainder of each carcass was then discarded with no further evaluation.
Hearts of all animals that were found dead or euthanized moribund were placed in 4%
paraformaldehyde until evaluated. The remainder of each carcass was then discarded with no further evaluation.
Histology and Image Analysis. Fixed tissues sectioned with a stainless steel coronal heart matrix (Harvard Apparatus Holliston, MA) yielded four two-millimeter thick serial tissue sections. Sections were processed and serially embedded in paraffin using routine methods.
Five-micron sections were obtained by microtome and stained Masson's Tr-chrome for Connective Tissue (Poly Scientific Bay Shore, NY) using manufacturer's methods. Electronic photomicrographs were captured and analyzed using image analysis methods developed by Phase 3 Imaging System (Glen Mills, PA). Photomicrographs of the tri-chrome stained sections were color-metrically analyzed electronically to determine the overall area of the ventricle and free wall and the area of the differential staining.
Results There was no loss in the initial viability of cells over 5 hours in the vehicle when kept on ice. Cells were injected into the infarct with one to three needle entry points and multiple changes in direction of needle orientation.
Echocardiography measurements were taken from the infarct-treated rats.
Fractional shortening of the vehicle-treated animals had a significant decrease from 47.7% J 8.3% at Day 0 to 23.5% 30.2% at Day 28 (p<0.05). The animals that were treated with placenta-derived cells showed small, non-significant differences between the fractional shortening between Day 0 and
- 139 -28. There was no significant difference between the fractional shortening between the groups at Day 0. Each group had eight animals at the start but some did not survive the experiment. The fibroblast-treated animals experienced greater mortality than those treated with PDCs.
Hearts collected at the study termination were subjected to histological analysis. The hearts were arrested in diastole and fixed. The results were calculated from an algorithm to estimate the percentage of total heart area that comprises the infarct. The infarct size in the vehicle-treated animals was 22.9% 6.7% of heart area, while the infarct size in hearts treated with two different isolates of placenta-derived cells was 13.9% 3.7% and 12.9% 3.4%, respectively, and with fibroblasts was 19.3% 8.0%. The difference of infarct size of cell-treated animals relative to vehicle-treated animals was not statistically significant, as determined by t-test/ANOVA.
Summary. The results of the present study suggest that the placenta-derived cells have some benefit in reducing the damage of a surgically induced myocardial infarction in rats. The vehicle-treated animals showed a significant reduction in cardiac function at day 28 as compared to day 0, as measured by fractional shortening, while the placenta-derived cell-treated animals showed minimal change over the 28-day study. The fibroblast-treated animals showed minimal change but only two animals survived the study. Evaluation of infarct size suggested that there may be some modest, but not statistically significant, reduction in the infarct size in the placenta-derived cell-treated animals as compared to the vehicle controls at Day 28.
Taken together, these data support efficacy of the placenta-derived cells in reducing damage from a myocardial infarction.
Use of Placenta-Derived Cells in the Treatment of Retinitis Pigmentosa Currently no real treatment exists for blinding disorders that stem from the degeneration of cells in the retina. Loss of photoreceptors as a result of apoptosis or secondary degeneration lead to progressive deterioration of vision, and ultimately to blindness.
Diseases in which this occurs include age-related macular degeneration (AMD) and retinitis pigmentosa (RP). RP is most commonly associated with a single gene mutation, which contributes to photoreceptor cell death.
The retinal photoreceptors and adjacent retinal pigment epithelium form a functional unit.
The Royal College of Surgeons (RCS) rat presents with a tyrosine receptor kinase (Merkt) defect affecting outer segment phagocytosis, leading to photoreceptor cell death (D'Cruz et al. (2000) Hum. Mol. Genet. 9(4):645-51).
=
Hearts collected at the study termination were subjected to histological analysis. The hearts were arrested in diastole and fixed. The results were calculated from an algorithm to estimate the percentage of total heart area that comprises the infarct. The infarct size in the vehicle-treated animals was 22.9% 6.7% of heart area, while the infarct size in hearts treated with two different isolates of placenta-derived cells was 13.9% 3.7% and 12.9% 3.4%, respectively, and with fibroblasts was 19.3% 8.0%. The difference of infarct size of cell-treated animals relative to vehicle-treated animals was not statistically significant, as determined by t-test/ANOVA.
Summary. The results of the present study suggest that the placenta-derived cells have some benefit in reducing the damage of a surgically induced myocardial infarction in rats. The vehicle-treated animals showed a significant reduction in cardiac function at day 28 as compared to day 0, as measured by fractional shortening, while the placenta-derived cell-treated animals showed minimal change over the 28-day study. The fibroblast-treated animals showed minimal change but only two animals survived the study. Evaluation of infarct size suggested that there may be some modest, but not statistically significant, reduction in the infarct size in the placenta-derived cell-treated animals as compared to the vehicle controls at Day 28.
Taken together, these data support efficacy of the placenta-derived cells in reducing damage from a myocardial infarction.
Use of Placenta-Derived Cells in the Treatment of Retinitis Pigmentosa Currently no real treatment exists for blinding disorders that stem from the degeneration of cells in the retina. Loss of photoreceptors as a result of apoptosis or secondary degeneration lead to progressive deterioration of vision, and ultimately to blindness.
Diseases in which this occurs include age-related macular degeneration (AMD) and retinitis pigmentosa (RP). RP is most commonly associated with a single gene mutation, which contributes to photoreceptor cell death.
The retinal photoreceptors and adjacent retinal pigment epithelium form a functional unit.
The Royal College of Surgeons (RCS) rat presents with a tyrosine receptor kinase (Merkt) defect affecting outer segment phagocytosis, leading to photoreceptor cell death (D'Cruz et al. (2000) Hum. Mol. Genet. 9(4):645-51).
=
- 140 -Transplantation of retinal pigment epithelial (RPE) cells into the subretinal space of RCS
rats was found to limit the progress of photoreceptor loss and preserve visual function (Li and Turner (1988) Exp Eye Res. 47(6):911-7). In this example, it is demonstrated that placenta-derived cells can be used to promote photoreceptor rescue in a RCS model.
Methods & Materials Cell transplants. Cultures of human placental and adult fibroblast cells (passage 10) were expanded for 1 passage. All cells were initially seeded at 5,000 cells/cm2 on gelatin-coated T75 flasks in growth medium ((DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15 % (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001% 2-mercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B; Invitrogen, Carlsbad, CA)). For subsequent passages, all cells were treated as follows. After trypsinization, viable cells were counted after trypan Blue staining. Briefly, 50 microliter of cell suspension was combined with 50 microliter of 0.04% w/v trypan Blue (Sigma, St. Louis MO) and the viable cell number, was estimated using a heamocytometer. Cells were trypsinized and washed three times in supplement free-DMEM:Low glucose medium (Invitrogen, Carlsbad, CA). Cultures of human placental and fibroblast cells at passage 11 were trypsinized and washed twice in Leibovitz's L-15 medium (Invitrogen, Carlsbad, CA). For the transplantation procedure, dystrophic RCS
rats were anesthetized with xylazine-ketamine (1 milligram/kilogram intraperitoneal (i.p.) of the following mixture: 2.5 milliliters xylazine at 20 milligram/milliliter, 5 milliliters ketamine at 100 milligram/milliliter, and 0.5 milliliter distilled water) and their heads secured by a nose bar.
Cells devoid of serum were resuspended (2 X 105 cells per injection) in 2 microliter of Leibovitz, L-15 medium (Invitrogen, Carlsbad, CA) and transplanted using a fine glass pipette (internal diameter 75 to 150 microliter) trans-scerally. Cells were delivered into the dorso-temporal subretinal space of anesthetized 3 week old dystrophic-pigmented RCS rats (total N=10/cell type).
Cells were injected unilaterally into the right eye, while the left eye was injected with carrier medium alone (Sham control; Leibovitz's L-15 medium). Viability of residual transplant cells remained at greater than 95% as assessed by trypan blue exclusion at the end of the transplant session. After cell injections were performed, animals were injected with dexamethasone (2 milligram/kilogram) for 10 days post transplantation. For the duration of the study, animals were maintained on oral cyclosporine A (210 milligram/liter of drinking water;
resulting blood concentration: 250-300 microgram/liter) (Bedford Labs, Bedford, Ohio) from 2
rats was found to limit the progress of photoreceptor loss and preserve visual function (Li and Turner (1988) Exp Eye Res. 47(6):911-7). In this example, it is demonstrated that placenta-derived cells can be used to promote photoreceptor rescue in a RCS model.
Methods & Materials Cell transplants. Cultures of human placental and adult fibroblast cells (passage 10) were expanded for 1 passage. All cells were initially seeded at 5,000 cells/cm2 on gelatin-coated T75 flasks in growth medium ((DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15 % (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001% 2-mercaptoethanol (Sigma, St. Louis, MO), 50 Units/milliliter penicillin, 50 microgram/milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B; Invitrogen, Carlsbad, CA)). For subsequent passages, all cells were treated as follows. After trypsinization, viable cells were counted after trypan Blue staining. Briefly, 50 microliter of cell suspension was combined with 50 microliter of 0.04% w/v trypan Blue (Sigma, St. Louis MO) and the viable cell number, was estimated using a heamocytometer. Cells were trypsinized and washed three times in supplement free-DMEM:Low glucose medium (Invitrogen, Carlsbad, CA). Cultures of human placental and fibroblast cells at passage 11 were trypsinized and washed twice in Leibovitz's L-15 medium (Invitrogen, Carlsbad, CA). For the transplantation procedure, dystrophic RCS
rats were anesthetized with xylazine-ketamine (1 milligram/kilogram intraperitoneal (i.p.) of the following mixture: 2.5 milliliters xylazine at 20 milligram/milliliter, 5 milliliters ketamine at 100 milligram/milliliter, and 0.5 milliliter distilled water) and their heads secured by a nose bar.
Cells devoid of serum were resuspended (2 X 105 cells per injection) in 2 microliter of Leibovitz, L-15 medium (Invitrogen, Carlsbad, CA) and transplanted using a fine glass pipette (internal diameter 75 to 150 microliter) trans-scerally. Cells were delivered into the dorso-temporal subretinal space of anesthetized 3 week old dystrophic-pigmented RCS rats (total N=10/cell type).
Cells were injected unilaterally into the right eye, while the left eye was injected with carrier medium alone (Sham control; Leibovitz's L-15 medium). Viability of residual transplant cells remained at greater than 95% as assessed by trypan blue exclusion at the end of the transplant session. After cell injections were performed, animals were injected with dexamethasone (2 milligram/kilogram) for 10 days post transplantation. For the duration of the study, animals were maintained on oral cyclosporine A (210 milligram/liter of drinking water;
resulting blood concentration: 250-300 microgram/liter) (Bedford Labs, Bedford, Ohio) from 2
- 141 -days pre-transplantation until end of the study. Food and water were available ad libitum.
Animals were sacrificed at 60 or 90 days postoperatively, with some animals being sacrificed at earlier timepoints for histological assessment of short-term changes associated with cell transplantation.
ERG recordings. Following overnight dark adaptation, animals were prepared for ERG
recording under dim red light, as previously described (Sauve et a/.(2004) Vision Res.
Jan;44(1):9-18). In brief, under anesthesia (with a mixture of 150 milligram/kilogram i.p ketamine, and 10 milligram/kilogram i.p. xylazine), the head was secured with a stereotaxic head holder and the body temperature monitored through a rectal thermometer and maintained at 38 C
using a homeothermic blanket. Pupils were dilated using equal parts of topical 2.5 %
phenylephrine and 1 % tropicamide. Topical anesthesia with 0.75 % bupivacaine was used to prevent any corneal reflexes and a drop of 0.9 % saline was frequently applied on the cornea to prevent its dehydration and allow electrical contact with the recording electrode (gold wire loop).
A 25-gauge needle inserted under the scalp, between the two eyes, served as the reference electrode. Amplification (at 1-1000 Hz bandpass, without notch filtering), stimulus presentation, and data acquisition were provided by the UTAS-3000 system from LKC
Technologies (Gaithersburg, MD). ERGs were recorded at 60 days.
Mixed a- and b-wave recording. For the quantification of dark-adapted b-waves, recordings consisted of single flash presentations (10 microseconds duration), repeated 3 to 5 times to verify the response reliability and improve the signal-to-noise ratio, if required. Stimuli were presented at six increasing intensities in one log unit steps varying from ¨3.6 to 1.4 log candila/m2 in luminance. To minimize the potential bleaching of rods, inter-stimulus intervals were increased as the stimulus luminance was elevated from 10 sec at lowest stimulus intensity to 2 minutes at highest stimulus intensity. The maximum b-wave amplitude was defined as that obtained from the flash intensity series, regardless of the stimulus intensity. The true Vmax from fitting the data with a Naka-Rushton curve was not used because ERG responses were often erratic at higher luminance levels in dystrophic animals and showed tendencies for depressed responses around 0.4 and 1.4 log candila/m2. In order to determine the age at which ERG
components were obtained or lost, criterion amplitudes were used: 20 microVolt for a- and b-waves, and 10 microVolt for STR-like responses. The amplitude of the b-wave was measured from the a-wave negative peak up to the b-wave positive apex, and not up to the peak of oscillations, which can exceed the b-wave apex (Nusinowitz et al. (1999) Invest Ophthalmol Vis Sci. 40(12):2848-58).
=
Animals were sacrificed at 60 or 90 days postoperatively, with some animals being sacrificed at earlier timepoints for histological assessment of short-term changes associated with cell transplantation.
ERG recordings. Following overnight dark adaptation, animals were prepared for ERG
recording under dim red light, as previously described (Sauve et a/.(2004) Vision Res.
Jan;44(1):9-18). In brief, under anesthesia (with a mixture of 150 milligram/kilogram i.p ketamine, and 10 milligram/kilogram i.p. xylazine), the head was secured with a stereotaxic head holder and the body temperature monitored through a rectal thermometer and maintained at 38 C
using a homeothermic blanket. Pupils were dilated using equal parts of topical 2.5 %
phenylephrine and 1 % tropicamide. Topical anesthesia with 0.75 % bupivacaine was used to prevent any corneal reflexes and a drop of 0.9 % saline was frequently applied on the cornea to prevent its dehydration and allow electrical contact with the recording electrode (gold wire loop).
A 25-gauge needle inserted under the scalp, between the two eyes, served as the reference electrode. Amplification (at 1-1000 Hz bandpass, without notch filtering), stimulus presentation, and data acquisition were provided by the UTAS-3000 system from LKC
Technologies (Gaithersburg, MD). ERGs were recorded at 60 days.
Mixed a- and b-wave recording. For the quantification of dark-adapted b-waves, recordings consisted of single flash presentations (10 microseconds duration), repeated 3 to 5 times to verify the response reliability and improve the signal-to-noise ratio, if required. Stimuli were presented at six increasing intensities in one log unit steps varying from ¨3.6 to 1.4 log candila/m2 in luminance. To minimize the potential bleaching of rods, inter-stimulus intervals were increased as the stimulus luminance was elevated from 10 sec at lowest stimulus intensity to 2 minutes at highest stimulus intensity. The maximum b-wave amplitude was defined as that obtained from the flash intensity series, regardless of the stimulus intensity. The true Vmax from fitting the data with a Naka-Rushton curve was not used because ERG responses were often erratic at higher luminance levels in dystrophic animals and showed tendencies for depressed responses around 0.4 and 1.4 log candila/m2. In order to determine the age at which ERG
components were obtained or lost, criterion amplitudes were used: 20 microVolt for a- and b-waves, and 10 microVolt for STR-like responses. The amplitude of the b-wave was measured from the a-wave negative peak up to the b-wave positive apex, and not up to the peak of oscillations, which can exceed the b-wave apex (Nusinowitz et al. (1999) Invest Ophthalmol Vis Sci. 40(12):2848-58).
=
- 142 -Isolation of rod and cone responses. The double flash protocol was used to determine the isolation of rod and cone responses (Nixon et al. (2001) Clin. Experiment Ophthalmol.
29(3):193-6). A probe flash was presented 1 sec after a conditioning flash, using a specific feature of the UTAS-3000 system (LKC Technologies) with calibrated ganzfeld;
assuring complete recharge of the stimulator under the conditions used. The role of the conditioning flash in the procedure was to transiently saturate rods so that they were rendered unresponsive to the probe flash. Response to the probe flash was taken as reflecting cone-driven activity. A rod-driven b-wave was obtained by subtracting the cone-driven response from the mixed response (obtained following presentation of a probe flash alone, i.e., not preceded by any conditioning flash).
Histology. Animals were sacrificed with an overdose of urethane (12.5 gram/kilogram).
The orientation of the eye was maintained by placing a 6.0 suture through the superior rectus muscle prior to enucleation. After making a corneal incision, the eyes were fixed with 2.5 %
parafomaldehyde, 2.5 % glutaraldehyde, 0.01 % picric acid in 0.1 M cacodylate buffer (pH 7.4).
After fixation, the cornea and lens were removed by cutting around the cilliary body. A small nick was made in the periphery of the dorsal retina prior to removal of the superior rectus to assist in maintaining orientation. The retinas were then post-fixed in 1 %
osmium tetroxide for 1 hour. After dehydration through a series of alcohols to epoxypropane, the retinas were embedded in TAAB embedding resin (TAAB Laboratories, Aldemarston, UK). Semi-thin sections were stained with 1% toluidine Blue in 1% borate buffer and the ultra thin sections were contrasted with uranyl acetate and lead citrate.
For Nissl staining, sections were stained with 0.75% cresyl violet (Sigma, St.
Louis, MO) after which they were dehydrated through graded alcohols at 70, 95 and 100 %
twice. They were then placed in xylene (Sigma, St. Louis, MO), rinsed with PBS (pH 7.4) (Invitrogen, Carlsbad, CA), coverslipped and mounted with DPX mountant (Sigma, St. Louis, MO).
Results ERG Recordings. At 60 days post-transplant, animals that received placenta-derived cell injections (n=4) showed no improvement in a-wave (20 20) versus sham controls (0), but showed improvement in mixed b-wave (81 72) versus sham controls (1.5 2), and good improvement in cone-b-wave (50 19) versus sham controls (7 7), and in rod contribution (30 %) versus sham controls (0). These results indicated improvement in visual responsiveness when compared to sham controls. In contrast to transplantation of placenta-derived cells, fibroblast transplantations showed no improvement in any of the parameters tested.
29(3):193-6). A probe flash was presented 1 sec after a conditioning flash, using a specific feature of the UTAS-3000 system (LKC Technologies) with calibrated ganzfeld;
assuring complete recharge of the stimulator under the conditions used. The role of the conditioning flash in the procedure was to transiently saturate rods so that they were rendered unresponsive to the probe flash. Response to the probe flash was taken as reflecting cone-driven activity. A rod-driven b-wave was obtained by subtracting the cone-driven response from the mixed response (obtained following presentation of a probe flash alone, i.e., not preceded by any conditioning flash).
Histology. Animals were sacrificed with an overdose of urethane (12.5 gram/kilogram).
The orientation of the eye was maintained by placing a 6.0 suture through the superior rectus muscle prior to enucleation. After making a corneal incision, the eyes were fixed with 2.5 %
parafomaldehyde, 2.5 % glutaraldehyde, 0.01 % picric acid in 0.1 M cacodylate buffer (pH 7.4).
After fixation, the cornea and lens were removed by cutting around the cilliary body. A small nick was made in the periphery of the dorsal retina prior to removal of the superior rectus to assist in maintaining orientation. The retinas were then post-fixed in 1 %
osmium tetroxide for 1 hour. After dehydration through a series of alcohols to epoxypropane, the retinas were embedded in TAAB embedding resin (TAAB Laboratories, Aldemarston, UK). Semi-thin sections were stained with 1% toluidine Blue in 1% borate buffer and the ultra thin sections were contrasted with uranyl acetate and lead citrate.
For Nissl staining, sections were stained with 0.75% cresyl violet (Sigma, St.
Louis, MO) after which they were dehydrated through graded alcohols at 70, 95 and 100 %
twice. They were then placed in xylene (Sigma, St. Louis, MO), rinsed with PBS (pH 7.4) (Invitrogen, Carlsbad, CA), coverslipped and mounted with DPX mountant (Sigma, St. Louis, MO).
Results ERG Recordings. At 60 days post-transplant, animals that received placenta-derived cell injections (n=4) showed no improvement in a-wave (20 20) versus sham controls (0), but showed improvement in mixed b-wave (81 72) versus sham controls (1.5 2), and good improvement in cone-b-wave (50 19) versus sham controls (7 7), and in rod contribution (30 %) versus sham controls (0). These results indicated improvement in visual responsiveness when compared to sham controls. In contrast to transplantation of placenta-derived cells, fibroblast transplantations showed no improvement in any of the parameters tested.
- 143 -Table 28-1: ERG data Group a-wave mixed b-wave cone b-wave % rod contribution Untreated Treated Untreated Treated Untreated Treated Untreated Treated Sham 0 0 7 + 9 0 23 + 5 12 N/A N/A
days 0 20 1.5 + 2 81 7 + 7 50 N/A 30 (n=4) 20 72 19 days N.B. Sham = control (medium only), P = Placental cell transplant Histology. Following transplantation, there was no histological evidence of an inflammatory reaction and infiltrating immune cells were not observed in Nissl-stained sections in the placental cell groups. However, fibroblast implantations resulted in animal death (n=7) and indications of early stage inflammatory responses.
References Lund et al. (2001) Proc Natl Acad Sci U.S.A. 98(17):9942-7.
Chondrogenic Potential of Postpartum-Derived Cells on Implantation in SCID
mice The chondrogenic potential of cells derived from umbilical cord or placenta tissue was evaluated following seeding on bioresorbable growth factor-loaded scaffolds and implantation into SCID mice.
Materials & Methods Reagents. Dulbecco's Modified Essential Media (DMEM), Penicillin and Streptomycin, were obtained from Invitrogen, Carlsbad, CA. Fetal calf serum (FCS) was obtained from HyClone (Logan, UT). Mesenchymal stem cell growth medium (MSCGM) was obtained from Biowhittaker, Walkersville, MD. TGFbeta-3 was obtained from Oncogene research products, San Diego, CA. GDF-5 was obtained from Biopharm, Heidelberg, Germany (International PCT
Publication No. W096/01316 Al, U.S. Patent No. 5,994,094A). Chondrocyte growth medium comprised DMEM-High glucose supplemented with 10% fetal calf serum (FCS), 10 milliMolar BEPES, 0.1 milliMolar nonessential amino acids, 20 microgram/milliliter L-proline, 50 microgram/milliliter ascorbic acid, 100 Unit/milliliter penicillin, 100 microgram/milliliter
days 0 20 1.5 + 2 81 7 + 7 50 N/A 30 (n=4) 20 72 19 days N.B. Sham = control (medium only), P = Placental cell transplant Histology. Following transplantation, there was no histological evidence of an inflammatory reaction and infiltrating immune cells were not observed in Nissl-stained sections in the placental cell groups. However, fibroblast implantations resulted in animal death (n=7) and indications of early stage inflammatory responses.
References Lund et al. (2001) Proc Natl Acad Sci U.S.A. 98(17):9942-7.
Chondrogenic Potential of Postpartum-Derived Cells on Implantation in SCID
mice The chondrogenic potential of cells derived from umbilical cord or placenta tissue was evaluated following seeding on bioresorbable growth factor-loaded scaffolds and implantation into SCID mice.
Materials & Methods Reagents. Dulbecco's Modified Essential Media (DMEM), Penicillin and Streptomycin, were obtained from Invitrogen, Carlsbad, CA. Fetal calf serum (FCS) was obtained from HyClone (Logan, UT). Mesenchymal stem cell growth medium (MSCGM) was obtained from Biowhittaker, Walkersville, MD. TGFbeta-3 was obtained from Oncogene research products, San Diego, CA. GDF-5 was obtained from Biopharm, Heidelberg, Germany (International PCT
Publication No. W096/01316 Al, U.S. Patent No. 5,994,094A). Chondrocyte growth medium comprised DMEM-High glucose supplemented with 10% fetal calf serum (FCS), 10 milliMolar BEPES, 0.1 milliMolar nonessential amino acids, 20 microgram/milliliter L-proline, 50 microgram/milliliter ascorbic acid, 100 Unit/milliliter penicillin, 100 microgram/milliliter
-144-streptomycin, and 0.25 microgram/milliliter amphotericin B. Bovine fibrinogen was obtained from Calbiochem.
Cells. Human mesenchymal stem cells (hMSC, Lot# 2F1656) were obtained from Biowhittaker, Walkersville, MD and were cultured in MSCGM according to the manufacturer's instructions. This lot was tested in the laboratory previously in in vitro experiments and was shown to be positive in the chondrogenesis assays. Human adult fibroblasts were obtained from American Type Culture Collection (ATCC), Manassas, VA and cultured in Growth Medium on gelatin-coated tissue culture plastic flasks. Postpartum-derived cells isolated from human umbilical cords (Lot# 022703Umb) and placenta (Lot# 071003Plac) were prepared as previously described (Example 1). Cells were cultured in Growth Medium on gelatin-coated tissue culture plastic flasks. The cell cultures were incubated in standard growth conditions. Cells used for experiments were at passages 5 and 14.
Scaffold. 65/35 Polyglycolic acid (PGA)/ Polycaprolactone (PCL) foam scaffolds [4x5 centimeters, lmillimeter thick, Ethylene Oxide (ETO) sterilized] reinforced with Polydioxanone (PDS) mesh (PGA/PCL foam-PDS mesh) were obtained from Center for Biomaterials and Advanced Technologies (CBAT, Somerville, NJ). Punches (3.5 millimeters) made from scaffolds were loaded with either GDF-5 (3.4 micrograms/scaffold), TGFbeta-3 (10 nanograms/scaffold), a combination of GDF-5 and TGFbeta-3, or control medium, and lyophilized.
Cell seeding on scaffolds. Placenta- and umbilical cord-derived cells were treated with trypsin, and cell number and viability was determined. 0.75x106 cells were resuspended in 15 microliters of Growth Medium and seeded onto 3.5 millimeter scaffold punches in a cell culture dish. The cell-seeded scaffold was incubated in a cell culture incubator in standard air with 5%
CO2 at 37 C for 2 hours after which they were placed within cartilage explant rings.
Bovine Cartilage Explants. Cartilage explants 5 millimeter in diameter were made from cartilage obtained from young bovine shoulder. Punches (3 millimeter) were excised from the center of the explant and replaced with cells seeded 3.5 millimeter resorbable scaffold. Scaffolds with cells were retained within the explants using fibrin glue (60 microliter of bovine fibrinogen, 3 milligram/milliliter). Samples were maintained in chondrocyte growth medium overnight, rinsed in Phosphate Buffered Saline the following day, and implanted into SCID
mice.
Animals. SCID mice ((Mus musculus)IFox Chase SCID/Male), 5 weeks of age, were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, Indiana) and Charles River Laboratories (Portage, Michigan). Animals used in the study were selected without any apparent systematic bias. A tag was placed on each individual animal cage listing the accession number, =
Cells. Human mesenchymal stem cells (hMSC, Lot# 2F1656) were obtained from Biowhittaker, Walkersville, MD and were cultured in MSCGM according to the manufacturer's instructions. This lot was tested in the laboratory previously in in vitro experiments and was shown to be positive in the chondrogenesis assays. Human adult fibroblasts were obtained from American Type Culture Collection (ATCC), Manassas, VA and cultured in Growth Medium on gelatin-coated tissue culture plastic flasks. Postpartum-derived cells isolated from human umbilical cords (Lot# 022703Umb) and placenta (Lot# 071003Plac) were prepared as previously described (Example 1). Cells were cultured in Growth Medium on gelatin-coated tissue culture plastic flasks. The cell cultures were incubated in standard growth conditions. Cells used for experiments were at passages 5 and 14.
Scaffold. 65/35 Polyglycolic acid (PGA)/ Polycaprolactone (PCL) foam scaffolds [4x5 centimeters, lmillimeter thick, Ethylene Oxide (ETO) sterilized] reinforced with Polydioxanone (PDS) mesh (PGA/PCL foam-PDS mesh) were obtained from Center for Biomaterials and Advanced Technologies (CBAT, Somerville, NJ). Punches (3.5 millimeters) made from scaffolds were loaded with either GDF-5 (3.4 micrograms/scaffold), TGFbeta-3 (10 nanograms/scaffold), a combination of GDF-5 and TGFbeta-3, or control medium, and lyophilized.
Cell seeding on scaffolds. Placenta- and umbilical cord-derived cells were treated with trypsin, and cell number and viability was determined. 0.75x106 cells were resuspended in 15 microliters of Growth Medium and seeded onto 3.5 millimeter scaffold punches in a cell culture dish. The cell-seeded scaffold was incubated in a cell culture incubator in standard air with 5%
CO2 at 37 C for 2 hours after which they were placed within cartilage explant rings.
Bovine Cartilage Explants. Cartilage explants 5 millimeter in diameter were made from cartilage obtained from young bovine shoulder. Punches (3 millimeter) were excised from the center of the explant and replaced with cells seeded 3.5 millimeter resorbable scaffold. Scaffolds with cells were retained within the explants using fibrin glue (60 microliter of bovine fibrinogen, 3 milligram/milliliter). Samples were maintained in chondrocyte growth medium overnight, rinsed in Phosphate Buffered Saline the following day, and implanted into SCID
mice.
Animals. SCID mice ((Mus musculus)IFox Chase SCID/Male), 5 weeks of age, were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, Indiana) and Charles River Laboratories (Portage, Michigan). Animals used in the study were selected without any apparent systematic bias. A tag was placed on each individual animal cage listing the accession number, =
- 145 -implantation technique, animal number, species/strain, surgery date, in vivo period, and date of euthanasia. The animals were identified by sequential numbers marked on the ear with an indelible ink marker.
Experimental Design. A total of 42 mice were tested. Two scaffolds were implanted subcutaneously in each mouse as described below; 42 mice for subcutaneous implantation; 28 treatments with n-value of 3 per treatment. The study corresponds to IACUC
Approval Number:
Skillman IACUC 01-037. The study lasted six weeks.
SCID Implantation.
A. Body Weights Each animal was weighed prior to being anesthetized and at necropsy.
B. Anesthesia and Surgical Preparation:
All handling of the SClD mice occurred under a hood. The mice were individually weighed and anesthetized with an intraperitoneal injection of a mixture of KETASET (ketamine hydrochloride [60 milligram/kilogram]), ROMPUN (xylazine [10 milligram/kilogram]), and saline.
After induction of anesthesia, the entire back of the animal from the dorsal cervical area to the dorsal lumbosacral area was clipped free of hair using electric animal clippers. The area was scrubbed with chlorhexidine diacetate, rinsed with alcohol, dried, and painted with an aqueous iodophor solution of 1% available iodine. Ophthalmic ointment was applied to the eyes to prevent drying of the tissue during the anesthetic period. The anesthetized and surgically prepared animal was placed in the desired recumbent position.
C. Subcutaneous Implantation Technique:
An approximate 2-cm skin incision was made just lateral to the thoracic spine parallel to the vertebral column. The skin was separated from the underlying connective tissue via blunt dissection. Each SOD mouse received 2 treatments that were placed in subcutaneous pockets created by blunt dissection in each hemithorax through one skin incision.
Tacking sutures of 5-0 ETHIBOND EXCEL (polyester) were used to tack the skin to musculature around each scaffold to prevent subcutaneous migration. Scaffolds were implanted for 6 weeks and then harvested.
The experimental design is outlined in Table 29-1.
Table 29-1. Experimental Design:Treatment (N=3 per treatment) A. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, EP, TGFbeta3 B. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, EP, rhGDF-5 =
Experimental Design. A total of 42 mice were tested. Two scaffolds were implanted subcutaneously in each mouse as described below; 42 mice for subcutaneous implantation; 28 treatments with n-value of 3 per treatment. The study corresponds to IACUC
Approval Number:
Skillman IACUC 01-037. The study lasted six weeks.
SCID Implantation.
A. Body Weights Each animal was weighed prior to being anesthetized and at necropsy.
B. Anesthesia and Surgical Preparation:
All handling of the SClD mice occurred under a hood. The mice were individually weighed and anesthetized with an intraperitoneal injection of a mixture of KETASET (ketamine hydrochloride [60 milligram/kilogram]), ROMPUN (xylazine [10 milligram/kilogram]), and saline.
After induction of anesthesia, the entire back of the animal from the dorsal cervical area to the dorsal lumbosacral area was clipped free of hair using electric animal clippers. The area was scrubbed with chlorhexidine diacetate, rinsed with alcohol, dried, and painted with an aqueous iodophor solution of 1% available iodine. Ophthalmic ointment was applied to the eyes to prevent drying of the tissue during the anesthetic period. The anesthetized and surgically prepared animal was placed in the desired recumbent position.
C. Subcutaneous Implantation Technique:
An approximate 2-cm skin incision was made just lateral to the thoracic spine parallel to the vertebral column. The skin was separated from the underlying connective tissue via blunt dissection. Each SOD mouse received 2 treatments that were placed in subcutaneous pockets created by blunt dissection in each hemithorax through one skin incision.
Tacking sutures of 5-0 ETHIBOND EXCEL (polyester) were used to tack the skin to musculature around each scaffold to prevent subcutaneous migration. Scaffolds were implanted for 6 weeks and then harvested.
The experimental design is outlined in Table 29-1.
Table 29-1. Experimental Design:Treatment (N=3 per treatment) A. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, EP, TGFbeta3 B. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, EP, rhGDF-5 =
- 146 -C. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, EP, rhGDF-5+TGFbeta3 D. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, EP, control E. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, LP, TGFbeta3 F. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, LP, rhGDF-5 G. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, LP, rhGDF-5+TGFbeta3 H. 65/35 PGA/PCL Foam + PDS mesh cultured with Placenta-derived cells, LP, control I. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, EP, TGFbeta3 J. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, EP, rhGDF-5 K. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, EP, rhGDF-5+TGFbeta3 L. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, EP, control M. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, LP, TGFbeta3 N. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, LP, rhGDF-5 0. 65/35 PGA/PCL Foam + PDS mesh cultured with Umbilical cord-derived cells, LP, rhGDF-5+TGFbeta3 P. 65/35 PGAJPCL Foam + PDS mesh cultured with Umbilical cord-derived cells, LP, control Q. 65/35 PGA/PCL Foam + PDS mesh cultured with hMSC, TGFbeta3 R. 65/35 PGAJPCL Foam + PDS mesh cultured with hMSC, rhGDF-5 S. 65/35 PGA/PCL Foam + PDS mesh cultured with hMSC, rhGDF-5+TGFbeta3 T. 65/35 PGA/PCL Foam + PDS mesh cultured with hMSC, control U. 65/35 PGA/PCL Foam + PDS mesh cultured with fibroblasts, Adult TGFbeta3 V. 65/35 PGA/PCL Foam + PDS mesh cultured with fibroblasts, Adult rhGDF-5 W. 65/35 PGA/PCL Foam + PDS mesh cultured with fibroblasts, Adult rhGDF-5+TGFbeta3 X. 65/35 PGA/PCL Foam + PDS mesh cultured with fibroblasts, Adult control Y. 65/35 PGA/PCL Foam + PDS mesh, TGFbeta3 Z. 65/35 PGA/PCL Foam + PDS mesh, rhGDF-5 AA. 65/35 PGA/PCL Foam + PDS mesh, rhGDF-5+TGFbeta3 BB. 65/35 PGA/PCL Foam + PDS mesh, control D. Necropsy and Histologic Preparation Gross examination was performed on any animals that died during the course of the study or were euthanized in moribund condition. Selected tissues were saved at the discretion of the study director and/or pathologist.
- 147 -Mice were euthanized by CO2 inhalation at their designated intervals. Gross observations of the implanted sites were recorded. Samples of the subcutaneous implantation sites with their overlying skin were excised and fixed in 10% buffered formalin. Each implant was bisected into halves, and one half was sent to MPI Research (Mattawan, MI) for paraffin embedding, sectioning, and staining with Hematoxylin & Eosin (H&E) and Safranin 0 (SO).
The data obtained from this study were not statistically analyzed.
Results New cartilage and bone formation was observed in the majority of the samples including growth factor-loaded, cell-seeded scaffolds, cell-seeded control scaffolds, and scaffolds loaded with growth factor alone. The extent of new cartilage and bone formation varied within the treatment and control groups.
Early and Late passage placenta-derived cell seeded scaffolds showed new cartilage and bone formation within the scaffolds. No obvious differences in new cartilage and bone formation was observed between the different growth factor-loaded, cell-seeded scaffolds and scaffolds seeded with cells alone. Compared to control scaffolds (without growth factors and without cells), it appeared that there was greater extent of new cartilage formation in cell-seeded scaffolds both with and without growth factors and in growth factor-loaded scaffolds alone.
New cartilage formation with placenta-derived cell-seeded scaffolds was similar to MSC- and fibroblast-seeded scaffolds.
In growth factor-treated and control scaffolds seeded with umbilical cord-derived cells at early and late passage, new cartilage and bone formation were observed. The extent of cartilage formation appeared to be less than that seen with placenta-derived cells. No one sample showed extensive cartilage formation as seen with the placenta-derived cells. Bone formation appeared to be higher in scaffolds seeded with umbilical cord-derived cells on scaffolds containing both TGFbeta-3 and rhGDF-5.
hMSC-loaded scaffolds also showed new cartilage and bone formation. The extent of new cartilage and bone formation was similar for all the hMSC treatment groups. Human adult fibroblast seeded scaffolds also demonstrated new cartilage and bone formation. Results were similar to those obtained with placenta-derived cells and hMSCs In the control group, in which growth factor-loaded scaffolds or scaffold alone were placed in cartilage rings and implanted, new cartilage and bone formation were also observed.
Not surprisingly, the extent of new cartilage formation was greater in scaffolds with growth =
The data obtained from this study were not statistically analyzed.
Results New cartilage and bone formation was observed in the majority of the samples including growth factor-loaded, cell-seeded scaffolds, cell-seeded control scaffolds, and scaffolds loaded with growth factor alone. The extent of new cartilage and bone formation varied within the treatment and control groups.
Early and Late passage placenta-derived cell seeded scaffolds showed new cartilage and bone formation within the scaffolds. No obvious differences in new cartilage and bone formation was observed between the different growth factor-loaded, cell-seeded scaffolds and scaffolds seeded with cells alone. Compared to control scaffolds (without growth factors and without cells), it appeared that there was greater extent of new cartilage formation in cell-seeded scaffolds both with and without growth factors and in growth factor-loaded scaffolds alone.
New cartilage formation with placenta-derived cell-seeded scaffolds was similar to MSC- and fibroblast-seeded scaffolds.
In growth factor-treated and control scaffolds seeded with umbilical cord-derived cells at early and late passage, new cartilage and bone formation were observed. The extent of cartilage formation appeared to be less than that seen with placenta-derived cells. No one sample showed extensive cartilage formation as seen with the placenta-derived cells. Bone formation appeared to be higher in scaffolds seeded with umbilical cord-derived cells on scaffolds containing both TGFbeta-3 and rhGDF-5.
hMSC-loaded scaffolds also showed new cartilage and bone formation. The extent of new cartilage and bone formation was similar for all the hMSC treatment groups. Human adult fibroblast seeded scaffolds also demonstrated new cartilage and bone formation. Results were similar to those obtained with placenta-derived cells and hMSCs In the control group, in which growth factor-loaded scaffolds or scaffold alone were placed in cartilage rings and implanted, new cartilage and bone formation were also observed.
Not surprisingly, the extent of new cartilage formation was greater in scaffolds with growth =
- 148 -factor than in scaffolds without growth factor. Increased bone formation was present in the control with the combination of the two tested growth factors.
New cartilage formation was observed adjacent to the cartilage explant rings as well as within the scaffolds. New cartilage formation within the scaffolds adjacent to the cartilage rings could be a result of chondrocyte migration. Cartilage formation seen as islands within the scaffolds may be a result of either migration of chondrocytes within the scaffolds, differentiation of seeded cells or differentiation of endogenous mouse progenitor cells. This observation stems from the fact that in control growth factor-loaded scaffolds with no seeded cells, islands of chondrogenic differentiation were observed. New bone formation was observed within the scaffolds independently and also associated with chondrocytes. Bone formation may have arisen from osteoblast differentiation as well as endochondral ossification.
It is difficult to separate new cartilage and bone formation associated with chondrocytes that migrated versus that from any chondrogenic and osteogenic differentiation of seeded cells that may have occurred. Staining of sections with specific human antibodies may distinguish the contribution of the seeded cells to the observed chondrogenesis and osteogenesis. It is also possible that placenta-derived cells and umbilical cord-derived cells stimulated chondrocyte migration.
Abundant new blood vessels were observed with the scaffolds loaded with placenta-derived cells and umbilical cord-derived cells. Blood vessels were abundant in areas of bone formation. New blood vessels were also observed within the hMSC- and fibroblast-seeded scaffolds associated with new bone formation.
Systemic effects of the adjacent scaffold (with growth factor (GF)) on the control scaffolds (no OF, no cells) on promoting new cartilage and bone formation cannot be ruled out.
Analysis of new cartilage and bone formation in scaffolds, taking into consideration the scaffolds implanted adjacent to it in SCID mice, showed no clear pattern of systemic effect of growth factor from the adjacent scaffold.
Summary. Results showed that new cartilage and bone formation were observed in growth factor and control scaffolds seeded with placenta- and umbilical cord-derived cells.
Results with placenta-derived cells were similar to that seen with human mesenchymal stem cells, while the extent of new cartilage like tissue formation was slightly less pronounced in umbilical cord-derived cells. Growth factor-loaded scaffolds implanted without cells also demonstrated new cartilage and bone formation. These data indicate that new cartilage formation within the scaffolds may arise from chondrocytes that migrated from the bovine =
New cartilage formation was observed adjacent to the cartilage explant rings as well as within the scaffolds. New cartilage formation within the scaffolds adjacent to the cartilage rings could be a result of chondrocyte migration. Cartilage formation seen as islands within the scaffolds may be a result of either migration of chondrocytes within the scaffolds, differentiation of seeded cells or differentiation of endogenous mouse progenitor cells. This observation stems from the fact that in control growth factor-loaded scaffolds with no seeded cells, islands of chondrogenic differentiation were observed. New bone formation was observed within the scaffolds independently and also associated with chondrocytes. Bone formation may have arisen from osteoblast differentiation as well as endochondral ossification.
It is difficult to separate new cartilage and bone formation associated with chondrocytes that migrated versus that from any chondrogenic and osteogenic differentiation of seeded cells that may have occurred. Staining of sections with specific human antibodies may distinguish the contribution of the seeded cells to the observed chondrogenesis and osteogenesis. It is also possible that placenta-derived cells and umbilical cord-derived cells stimulated chondrocyte migration.
Abundant new blood vessels were observed with the scaffolds loaded with placenta-derived cells and umbilical cord-derived cells. Blood vessels were abundant in areas of bone formation. New blood vessels were also observed within the hMSC- and fibroblast-seeded scaffolds associated with new bone formation.
Systemic effects of the adjacent scaffold (with growth factor (GF)) on the control scaffolds (no OF, no cells) on promoting new cartilage and bone formation cannot be ruled out.
Analysis of new cartilage and bone formation in scaffolds, taking into consideration the scaffolds implanted adjacent to it in SCID mice, showed no clear pattern of systemic effect of growth factor from the adjacent scaffold.
Summary. Results showed that new cartilage and bone formation were observed in growth factor and control scaffolds seeded with placenta- and umbilical cord-derived cells.
Results with placenta-derived cells were similar to that seen with human mesenchymal stem cells, while the extent of new cartilage like tissue formation was slightly less pronounced in umbilical cord-derived cells. Growth factor-loaded scaffolds implanted without cells also demonstrated new cartilage and bone formation. These data indicate that new cartilage formation within the scaffolds may arise from chondrocytes that migrated from the bovine =
- 149 -explants, from chondrogenic differentiation of endogenous progenitor cells, and from chondrogenic differentiation of seeded cells.
These results suggest that placenta- and umbilical cord-derived cells undergo chondrogenic and osteogenic differentiation. These results also suggest that placenta- and umbilical cord-derived cells may promote migration of chondrocytes from the cartilage explant into the scaffolds. Abundant new blood vessels were also observed in the scaffolds especially associated with new bone formation.
Use of Postpartum-Derived Cells in Nerve Repair Retinal ganglion cell (RGC) lesions have been extensively used as models for various repair strategies in the adult mammalian CNS. It has been demonstrated that retrobulbar section of adult rodent RGC axons results in abortive sprouting (Zeng et al., 1995) and progressive death of the parent cell population (Villegas-Perez et al., 1993). Numerous studies have demonstrated the stimulatory effects of various exogenous and endogenous factors on the survival of axotomized RUC's and regeneration of their axons (Yip and So, 2000; Fischer et al., 2001).
Furthermore, other studies have demonstrated that cell transplants can be used to promote regeneration of severed nerve axons (Li et al., 2003; Ramon-Cueto et al., 2000). Thus, these and other studies have demonstrated that cell based therapy can be utilized for the treatment of neural disorders that affect the spinal cord, peripheral nerves, pudendal nerves, optic nerves or other diseases/trauma due to injury in which nervous damage can occur.
Self-assembling peptides (PuraMatrixTM, U.S. Patent Nos. 5,670,483, 5,955,343, U.S.
Published Application No. 2002/0160471, International Patent Publication No.
WO 02/062969) have been developed to act as a scaffold for cell-attachment to encapsulate cells in 3-D, plate cells in 2-D coatings, or as microcarriers in suspension cultures. Three-dimensional cell culture has required either animal-derived materials (mouse sarcoma extract), with their inherent reproducibility and cell signaling issues, or much larger synthetic scaffolds, which fail to approximate the physical nanometer-scale and chemical attributes of native ECM. RAD 16 (NH2-RADARADARADA-COOH) and KLD (NH2-KLDLKLDLKLDL-COOH) are synthesized in small (RAD16 is 5 nanometers) oligopeptide fragments that self-assemble into nanofibers on a scale similar to the in vivo extracellular matrix (ECM) (3D
Matrix, Inc Cambridge, MA). The self-assembly is initiated by mono- or di-valent cations found in culture media or the physiological environment. In the protocols described in this example, RAD 16 was used as a microcarrier for the implantation of postpartum cells into the ocular defect. In this
These results suggest that placenta- and umbilical cord-derived cells undergo chondrogenic and osteogenic differentiation. These results also suggest that placenta- and umbilical cord-derived cells may promote migration of chondrocytes from the cartilage explant into the scaffolds. Abundant new blood vessels were also observed in the scaffolds especially associated with new bone formation.
Use of Postpartum-Derived Cells in Nerve Repair Retinal ganglion cell (RGC) lesions have been extensively used as models for various repair strategies in the adult mammalian CNS. It has been demonstrated that retrobulbar section of adult rodent RGC axons results in abortive sprouting (Zeng et al., 1995) and progressive death of the parent cell population (Villegas-Perez et al., 1993). Numerous studies have demonstrated the stimulatory effects of various exogenous and endogenous factors on the survival of axotomized RUC's and regeneration of their axons (Yip and So, 2000; Fischer et al., 2001).
Furthermore, other studies have demonstrated that cell transplants can be used to promote regeneration of severed nerve axons (Li et al., 2003; Ramon-Cueto et al., 2000). Thus, these and other studies have demonstrated that cell based therapy can be utilized for the treatment of neural disorders that affect the spinal cord, peripheral nerves, pudendal nerves, optic nerves or other diseases/trauma due to injury in which nervous damage can occur.
Self-assembling peptides (PuraMatrixTM, U.S. Patent Nos. 5,670,483, 5,955,343, U.S.
Published Application No. 2002/0160471, International Patent Publication No.
WO 02/062969) have been developed to act as a scaffold for cell-attachment to encapsulate cells in 3-D, plate cells in 2-D coatings, or as microcarriers in suspension cultures. Three-dimensional cell culture has required either animal-derived materials (mouse sarcoma extract), with their inherent reproducibility and cell signaling issues, or much larger synthetic scaffolds, which fail to approximate the physical nanometer-scale and chemical attributes of native ECM. RAD 16 (NH2-RADARADARADA-COOH) and KLD (NH2-KLDLKLDLKLDL-COOH) are synthesized in small (RAD16 is 5 nanometers) oligopeptide fragments that self-assemble into nanofibers on a scale similar to the in vivo extracellular matrix (ECM) (3D
Matrix, Inc Cambridge, MA). The self-assembly is initiated by mono- or di-valent cations found in culture media or the physiological environment. In the protocols described in this example, RAD 16 was used as a microcarrier for the implantation of postpartum cells into the ocular defect. In this
- 150 -example, it is demonstrated that transplants of postpartum-derived cells PPDCs) can provide efficacy in an adult rat optic nerve axonal regeneration model.
Methods & Materials Cells. Cultures of human adult PPDCs (umbilical cord and placenta) and fibroblast cells (passage 10) were expanded for 1 passage. All cells were initially seeded at 5,000 cells/cm2 on gelatin-coated T75 flasks in Growth Medium ((DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15 % (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001% 2-mercaptoethanol (Sigma, St. Louis, MO), 100 Units per milliliter penicillin, 100 micrograms per milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B;
Invitrogen, Carlsbad, CA). At passage 11 cells were trypsinized and viability was determined using trypan blue staining. Briefly, 50 microlitres of cell suspension was combined with 50 microlitres of 0.04%
w/v trypan blue (Sigma, St. Louis MO) and the viable cell number, was estimated using a hemocytometer. Cells were then washed three times in supplement free-Leibovitz's L-15 medium (Invitrogen, Carlsbad, CA). Cells were then suspended at a concentration of 200,000 cells in 25 microliters of RAD-16 (3DM Inc., Cambridge, MA) which was buffered and made isotonic as per manufacturer's recommendations. One hundred microliters of supplement free Leibovitz's L-15 medium was added above the cell/matrix suspension to keep it wet till use.
These cell/matrix cultures were maintained under standard atmospheric conditions until transplantation occurred. At the point of transplantation the excess medium was removed.
Animals and Surgery. Long Evans female rats (220-240 gram body weight) were used.
Under intraperitoneal tribromoethanol anesthesia (20 milligram/100 grams body weight), the optic nerve was exposed, and the optic sheath was incised intraorbitally at approximately 2 millimeter from the optic disc, the nerve was lifted from the sheath to allow complete transsection with fine scissors (Li et al., 2003). The completeness of transection was confirmed by visually observing complete separation of the proximal and distal stumps.
The control group consisted of lesioned rats without transplants. In transplant rats cultured postpartum cells seeded in RAD-16 were inserted between the proximal and distal stumps using a pair of microforceps.
Approximately 75,000 cells in RAD-16 were implanted into the severed optic nerve. Cell/matrix was smeared into the severed cut using a pair of fine microforceps. The severed optic nerve sheath was closed with 10/0 black monofilament nylon (ETRICON, Edinburgh, UK).
Thus, the gap was closed by drawing the cut proximal and distal ends of the nerve in proximity with each other.
Methods & Materials Cells. Cultures of human adult PPDCs (umbilical cord and placenta) and fibroblast cells (passage 10) were expanded for 1 passage. All cells were initially seeded at 5,000 cells/cm2 on gelatin-coated T75 flasks in Growth Medium ((DMEM:Low glucose (Invitrogen, Carlsbad, CA), 15 % (v/v) defined bovine serum (Hyclone, Logan, UT; Lot#AND18475), 0.001% 2-mercaptoethanol (Sigma, St. Louis, MO), 100 Units per milliliter penicillin, 100 micrograms per milliliter streptomycin, 0.25 micrograms per milliliter amphotericin B;
Invitrogen, Carlsbad, CA). At passage 11 cells were trypsinized and viability was determined using trypan blue staining. Briefly, 50 microlitres of cell suspension was combined with 50 microlitres of 0.04%
w/v trypan blue (Sigma, St. Louis MO) and the viable cell number, was estimated using a hemocytometer. Cells were then washed three times in supplement free-Leibovitz's L-15 medium (Invitrogen, Carlsbad, CA). Cells were then suspended at a concentration of 200,000 cells in 25 microliters of RAD-16 (3DM Inc., Cambridge, MA) which was buffered and made isotonic as per manufacturer's recommendations. One hundred microliters of supplement free Leibovitz's L-15 medium was added above the cell/matrix suspension to keep it wet till use.
These cell/matrix cultures were maintained under standard atmospheric conditions until transplantation occurred. At the point of transplantation the excess medium was removed.
Animals and Surgery. Long Evans female rats (220-240 gram body weight) were used.
Under intraperitoneal tribromoethanol anesthesia (20 milligram/100 grams body weight), the optic nerve was exposed, and the optic sheath was incised intraorbitally at approximately 2 millimeter from the optic disc, the nerve was lifted from the sheath to allow complete transsection with fine scissors (Li et al., 2003). The completeness of transection was confirmed by visually observing complete separation of the proximal and distal stumps.
The control group consisted of lesioned rats without transplants. In transplant rats cultured postpartum cells seeded in RAD-16 were inserted between the proximal and distal stumps using a pair of microforceps.
Approximately 75,000 cells in RAD-16 were implanted into the severed optic nerve. Cell/matrix was smeared into the severed cut using a pair of fine microforceps. The severed optic nerve sheath was closed with 10/0 black monofilament nylon (ETRICON, Edinburgh, UK).
Thus, the gap was closed by drawing the cut proximal and distal ends of the nerve in proximity with each other.
- 151 -After cell injections were performed, animals were injected with dexamethasone (2 milligrams/kilogram) for 10 days post transplantation. For the duration of the study, animals were maintained on oral cyclosporine A (210 milligrams/liter of drinking water; resulting blood concentration: 250-300 micrograms/liter) (Bedford Labs, Bedford, Ohio) from 2 days pre-transplantation until end of the study. Food and water were available ad libitum. Animals were sacrificed at either 30 or 60 days posttransplantation.
CTB Application. Three days before animals were sacrificed, under anesthesia, a glass micropipette with a 30-50 millimeter tip was inserted tangentially through the sclera behind the lens, and two 4-5 microliter aliquots of a 1% retrograde tracer-cholera toxin B (CTB) aqueous solution (List Biologic, Campbell, CA) was injected into the vitreous. Animals were perfused with fixative and optic nerves were collected in the same fixative for 1 hour.
The optic nerves were transferred into sucrose overnight. Twenty micrometer cryostat sections were incubated in 0.1molar glycine for 30 minutes and blocked in a PBS solution containing 2.5%
bovine serum albumin (BSA) (Boeringer Mannheim, Mannheim, Germany) and 0.5% triton X-100 (Sigma, St.
Louis, MO), followed by a solution containing goat anti-CTB antibody (List Biologic, Campbell, CA) diluted 1:4000 in a PBS containing 2% normal rabbit serum (NRS) (Invitrogen, Carlsbad, CA), 2.5% BSA, and 2% Triton X-100 (Sigma, St. Louis, MO) in PBS, and incubated in biotinylated rabbit anti-goat IgG antibody (Vector Laboratories, Burlinghame, CA) diluted 1:200 in 2% Triton-X100 in PBS for 2 hours at room temperature. This was followed by staining in 1:200 streptavadin-green (Alexa Flour 438;Molecular Probes, Eugene, OR) in PBS
for 2 hours at room temperature. Stained sections were then washed in PBS and counterstained with propidium iodide for confocal microscopy.
Histology Preparation. Briefly, 5 days after CTB injection, rats were perfused with 4%
paraformaldehyde. Rats were given 4 cubic centimeters of urethane and were then perfused with PBS (0.1 molar) then with 4% Paraformaldehyde. The spinal cord was cut and the bone removed from the head to expose the colliculus. The colliculus was then removed and placed in 4%
Paraformaldehyde. The eye was removed by cutting around the outside of the eye and going as far back as possible. Care was given not to cut the optic nerve that lies on the underside of the eye. The eye was removed and the muscles were cut exposing the optic nerve this was then placed in 4% Paraformaldehyde.
Results Lesions alone. One month after retrotubular section of the optic nerve, a number of CTB-labeled axons were identified in the nerve segment attached to the retina.
In the 200 =
CTB Application. Three days before animals were sacrificed, under anesthesia, a glass micropipette with a 30-50 millimeter tip was inserted tangentially through the sclera behind the lens, and two 4-5 microliter aliquots of a 1% retrograde tracer-cholera toxin B (CTB) aqueous solution (List Biologic, Campbell, CA) was injected into the vitreous. Animals were perfused with fixative and optic nerves were collected in the same fixative for 1 hour.
The optic nerves were transferred into sucrose overnight. Twenty micrometer cryostat sections were incubated in 0.1molar glycine for 30 minutes and blocked in a PBS solution containing 2.5%
bovine serum albumin (BSA) (Boeringer Mannheim, Mannheim, Germany) and 0.5% triton X-100 (Sigma, St.
Louis, MO), followed by a solution containing goat anti-CTB antibody (List Biologic, Campbell, CA) diluted 1:4000 in a PBS containing 2% normal rabbit serum (NRS) (Invitrogen, Carlsbad, CA), 2.5% BSA, and 2% Triton X-100 (Sigma, St. Louis, MO) in PBS, and incubated in biotinylated rabbit anti-goat IgG antibody (Vector Laboratories, Burlinghame, CA) diluted 1:200 in 2% Triton-X100 in PBS for 2 hours at room temperature. This was followed by staining in 1:200 streptavadin-green (Alexa Flour 438;Molecular Probes, Eugene, OR) in PBS
for 2 hours at room temperature. Stained sections were then washed in PBS and counterstained with propidium iodide for confocal microscopy.
Histology Preparation. Briefly, 5 days after CTB injection, rats were perfused with 4%
paraformaldehyde. Rats were given 4 cubic centimeters of urethane and were then perfused with PBS (0.1 molar) then with 4% Paraformaldehyde. The spinal cord was cut and the bone removed from the head to expose the colliculus. The colliculus was then removed and placed in 4%
Paraformaldehyde. The eye was removed by cutting around the outside of the eye and going as far back as possible. Care was given not to cut the optic nerve that lies on the underside of the eye. The eye was removed and the muscles were cut exposing the optic nerve this was then placed in 4% Paraformaldehyde.
Results Lesions alone. One month after retrotubular section of the optic nerve, a number of CTB-labeled axons were identified in the nerve segment attached to the retina.
In the 200 =
- 152 -micrometers nearest the cut, axons were seen to emit a number of collaterals at right angles to the main axis and terminate as a neuromatous tangle at the cut surface. In this cut between the proximal and distal stumps, the gap was observed to be progressively bridged by a 2-3 millimeter segment of vascularized connective tissue; however, no axons were seen to advance into this bridged area. Thus, in animals that received lesion alone no axonal growth was observed to reach the distal stump.
RAD-16 transplantation. Following transplantation of RAD-16 into the cut, visible ingrowth of vascularized connective tissue was observed. However, no axonal in growth was observed between the proximal and distal stumps. The results demonstrate that application of RAD-16 alone is not sufficient for inducing axonal regeneration in this situation.
Transplantation of postpartum-derived cells. Transplantation of postpartum-derived cells into the severed optic nerve stimulated optic nerve regrowth. Some regrowth was also observed in conditions in which fibroblast cells were implanted, although this was minimal as compared with the regrowth observed with the transplanted placenta-derived cells. Optic nerve regrowth was observed in 4/5 animals transplanted with placenta-derived cells, 3/6 animals transplanted with adult dermal fibroblasts, and in 1/4 animals transplanted with umbilical cord-derived cells. In situations where regrowth was observed, CTB labeling confirmed regeneration of retinal ganglion cell axons, which were demonstrated to penetrate through the transplant area.
GFAP labeling was also performed to determine the level of glial scarring. The GFAP
expression was intensified at the proximal stump with some immunostaining being observed through the reinervated graft.
Summary. These results demonstrate that transplanted human adult postpartum-derived cells are able to stimulate and guide regeneration of cut retinal ganglion cell axons.
References 1) Zeng BY, Anderson PN, Campbell G, Lieberman AR. 1995. J. Anat.186:495-508.
2) Villegas-Perez MP, Vidal-Sanz M, Bray GM, Aguayo AJ. 1988. J Neurosci.8:265-80.
3) Yip HK, So KF. 2000. Prog Retin Eye Res. 19: 559-75.
4) Fischer D, Heiduschka P, Thanos S. 2001. Exp Neurol. 172: 257-72.
5) Ramon-Cueto A, Cordero MI, Santos-Benito FP, Avila J. 2000. Neuron 25: 425-35.
While the present invention has been particularly shown and described with reference to the presently preferred embodiments, it is understood that the invention is not limited to the embodiments specifically disclosed and exemplified herein. Numerous changes and
RAD-16 transplantation. Following transplantation of RAD-16 into the cut, visible ingrowth of vascularized connective tissue was observed. However, no axonal in growth was observed between the proximal and distal stumps. The results demonstrate that application of RAD-16 alone is not sufficient for inducing axonal regeneration in this situation.
Transplantation of postpartum-derived cells. Transplantation of postpartum-derived cells into the severed optic nerve stimulated optic nerve regrowth. Some regrowth was also observed in conditions in which fibroblast cells were implanted, although this was minimal as compared with the regrowth observed with the transplanted placenta-derived cells. Optic nerve regrowth was observed in 4/5 animals transplanted with placenta-derived cells, 3/6 animals transplanted with adult dermal fibroblasts, and in 1/4 animals transplanted with umbilical cord-derived cells. In situations where regrowth was observed, CTB labeling confirmed regeneration of retinal ganglion cell axons, which were demonstrated to penetrate through the transplant area.
GFAP labeling was also performed to determine the level of glial scarring. The GFAP
expression was intensified at the proximal stump with some immunostaining being observed through the reinervated graft.
Summary. These results demonstrate that transplanted human adult postpartum-derived cells are able to stimulate and guide regeneration of cut retinal ganglion cell axons.
References 1) Zeng BY, Anderson PN, Campbell G, Lieberman AR. 1995. J. Anat.186:495-508.
2) Villegas-Perez MP, Vidal-Sanz M, Bray GM, Aguayo AJ. 1988. J Neurosci.8:265-80.
3) Yip HK, So KF. 2000. Prog Retin Eye Res. 19: 559-75.
4) Fischer D, Heiduschka P, Thanos S. 2001. Exp Neurol. 172: 257-72.
5) Ramon-Cueto A, Cordero MI, Santos-Benito FP, Avila J. 2000. Neuron 25: 425-35.
While the present invention has been particularly shown and described with reference to the presently preferred embodiments, it is understood that the invention is not limited to the embodiments specifically disclosed and exemplified herein. Numerous changes and
- 153 -modifications may be made to the preferred embodiment of the invention as would be apparent to a person skilled in the art.
-154-SEQUENCE LISTING
<110> Ethicon, Incorporated Kihm, Anthony J.
Harris, Ian Ross Mistry, Sanjay Harmon, Alexander M.
Messina, Darin J.
Seyda, Agnieszka Yi, Chin-Feng Gosiewska, Anna <120> POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF
MAKING AND USING THE SAME
<130> CBAT-0171 <150> PCT/US2004/020816 <151> 2004-06-25 <150> US 60/483,264 <151> 2003-06-27 <160> 16 <170> PatentIn version 3.3 <210> 1 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 1 gagaaatcca aagagcaaat gg 22 <210> 2 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 2 agaatggaaa actggaatag g 21 <210> 3 <211> 20 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 3 tcttcgatgc ttcggattcc 20 <210> 4 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 4 gaattctcgg aatctctgtt g 21 <210> 5 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 5 ttacaagcag tgcagaaaac c 21 <210> 6 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 6 agtaaacatt gaaaccacag cc 22 <210> 7 <211> 20 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 7 tctgcagctc tgtgtgaagg 20 <210> 8 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 8 cttcaaaaac ttctccacaa cc 22 <210> 9 <211> 17 <212> DNA
<213> Artificial =
<220>
<223> Synthetic Construct <400> 9 cccacgccac gctctcc 17 <210> 10 <211> 19 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 10 tcctgtcagt tggtgctcc 19 <210> 11 <211> 20 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 11 ctggattggc gttgtttgtg 20 <210> 12 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 12 tcccaaggtg gagtgctgta g 21 <210> 13 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 13 ctgttgcgca catccctgcc c 21 <210> 14 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 14 ggcagtctgg ctttctcaga tt 22 <210> 15 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 15 ccctctccct tacccttagc a 21 <210> 16 <211> 23 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 16 ctgtgaaagg acctgtctgt cgc 23
<110> Ethicon, Incorporated Kihm, Anthony J.
Harris, Ian Ross Mistry, Sanjay Harmon, Alexander M.
Messina, Darin J.
Seyda, Agnieszka Yi, Chin-Feng Gosiewska, Anna <120> POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF
MAKING AND USING THE SAME
<130> CBAT-0171 <150> PCT/US2004/020816 <151> 2004-06-25 <150> US 60/483,264 <151> 2003-06-27 <160> 16 <170> PatentIn version 3.3 <210> 1 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 1 gagaaatcca aagagcaaat gg 22 <210> 2 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 2 agaatggaaa actggaatag g 21 <210> 3 <211> 20 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 3 tcttcgatgc ttcggattcc 20 <210> 4 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 4 gaattctcgg aatctctgtt g 21 <210> 5 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 5 ttacaagcag tgcagaaaac c 21 <210> 6 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 6 agtaaacatt gaaaccacag cc 22 <210> 7 <211> 20 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 7 tctgcagctc tgtgtgaagg 20 <210> 8 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 8 cttcaaaaac ttctccacaa cc 22 <210> 9 <211> 17 <212> DNA
<213> Artificial =
<220>
<223> Synthetic Construct <400> 9 cccacgccac gctctcc 17 <210> 10 <211> 19 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 10 tcctgtcagt tggtgctcc 19 <210> 11 <211> 20 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 11 ctggattggc gttgtttgtg 20 <210> 12 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 12 tcccaaggtg gagtgctgta g 21 <210> 13 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 13 ctgttgcgca catccctgcc c 21 <210> 14 <211> 22 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 14 ggcagtctgg ctttctcaga tt 22 <210> 15 <211> 21 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 15 ccctctccct tacccttagc a 21 <210> 16 <211> 23 <212> DNA
<213> Artificial <220>
<223> Synthetic Construct <400> 16 ctgtgaaagg acctgtctgt cgc 23
Claims (28)
1. An isolated substantially homogenous placenta-derived cell population, wherein said cell population is obtained from human postpartum placenta substantially free of blood, wherein said cell population self-renews and expands in culture; is multipotent; and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C, (b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA.
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C, (b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein lalpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA.
2. The cell population of claim 1, wherein said cell population lacks production of GRO-alpha and oxidized low density lipoprotein receptor 1, as detected by flow cytometry.
3. The cell population of claim 1 further comprising reduced expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, for: short stature homeobox 2; heat shock 27kDa protein 2;
chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin;
mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative;
cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7; collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5; hephaestin; integrin, beta 8;
synaptic vesicle glycoprotein 2; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, alpha 7; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2; early growth response 3; distal-less homeobox 5; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1;
BCL2/adenovirus E1B 19kDa interacting protein 3-like; AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1; neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa.
chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin;
mesenchyme homeobox 2; sine oculis homeobox homolog 1; crystallin, alpha B;
dishevelled associated activator of morphogenesis 2; tetranectin; src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative;
cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7; collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5; hephaestin; integrin, beta 8;
synaptic vesicle glycoprotein 2; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, alpha 7; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2; early growth response 3; distal-less homeobox 5; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1;
BCL2/adenovirus E1B 19kDa interacting protein 3-like; AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1; neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa.
4. An isolated substantially homogenous placenta-derived cell population comprising a cell derived from human postpartum placenta tissue substantially free of blood, wherein said cell population self-renews and expands in culture; is multipotent;
requires L-valine for growth; cell grows in about 5% to about 20% oxygen; and further comprises the following characteristics:
(a) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(b) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lacks production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(d) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, downregulated in ovarian cancer 1;
(e) expresses at a reduced level relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell: short stature homeobox 2;
heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin; mesenchyme homeobox 2; sine oculis homeobox homolog 1;
crystallin, alpha B; dishevelled associated activator of morphogenesis 2;
tetranectin;
src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7;
collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5;
hephaestin;
integrin, beta 8; synaptic vesicle glycoprotein 2; cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis horneobox homolog 2; early growth response 3; distal-less homeobox 5;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus E1B 19kDa interacting protein 3-like; AE
binding protein 1; cytochrome c oxidase subunit VIla polypeptide 1; neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa;
(f) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (1L-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1 alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(g) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA; and (h) has the ability to undergo at least 40 population doublings in culture.
requires L-valine for growth; cell grows in about 5% to about 20% oxygen; and further comprises the following characteristics:
(a) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry;
(b) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lacks production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(d) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of C-type lectin superfamily member A2, Wilms tumor 1, aldehyde dehydrogenase 1 family member A2, renin, oxidized low density lipoprotein receptor 1, protein kinase C zeta, downregulated in ovarian cancer 1;
(e) expresses at a reduced level relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell: short stature homeobox 2;
heat shock 27kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin; mesenchyme homeobox 2; sine oculis homeobox homolog 1;
crystallin, alpha B; dishevelled associated activator of morphogenesis 2;
tetranectin;
src homology three (SH3) and cysteine rich domain; B-cell translocation gene 1, anti-proliferative; cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7;
collagen, type VIII, alpha 1; tenascin C; iroquois homeobox protein 5;
hephaestin;
integrin, beta 8; synaptic vesicle glycoprotein 2; cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, alpha 7; transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis horneobox homolog 2; early growth response 3; distal-less homeobox 5;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; fibronectin 1; proenkephalin; integrin, beta-like 1 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
vesicle-associated membrane protein 5; EGF-containing fibulin-like extracellular matrix protein 1; BCL2/adenovirus E1B 19kDa interacting protein 3-like; AE
binding protein 1; cytochrome c oxidase subunit VIla polypeptide 1; neuroblastoma, suppression of tumorigenicity 1; and insulin-like growth factor binding protein 2, 36kDa;
(f) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (1L-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1 alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin;
(g) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA; and (h) has the ability to undergo at least 40 population doublings in culture.
5. The placenta-derived cell population of any one of claims 1 to 4, which has been isolated from a post-partum placenta or fragment thereof by enzymatic dissociation.
6. The placenta-derived cell population of claim 5, wherein said cell is isolated by enzymatic dissociation with a matrix metalloprotease, a neutral protease, and a mucolytic enzyme that digests hyaluronic acid.
7. The placenta-derived cell population of claim 6, wherein said matrix metalloprotease is collagenase.
8. The placenta-derived cell population of claim 6, wherein said mucolytic enzyme is hyaluronidase.
9. The placenta-derived cell population of any one of claims 1 to 4, wherein said cell is passaged 0 to 25 times.
10. The placenta-derived cell population of any one of claims 1 to 4, wherein said cell is of a neonatal lineage.
11. The placenta-derived cell population of any one of claims 1 to 4, wherein said cell is of a maternal lineage.
12. The cell population of any one of claims 1 to 4, wherein said cell grows in protein-free culture medium.
13. The cell population of any one of claims 1 to 4, wherein said cell grows in serum-free culture medium.
14. A pharmaceutical composition comprising the cell population of any one of claims 1 to 4 and a pharmaceutically acceptable carrier or excipient.
15. The pharmaceutical composition of claim 14, further comprising at least one additional stem cell or progenitor cell having the ability to differentiate into a mesodermal, ectodermal, or endodermal phenotype.
16. The pharmaceutical composition of claim 14 or 15 further comprising at least one growth factor of platelet derived growth factor-bb, epidermal growth factor, vascular endothelial growth factor, fibroblast growth factor, or leukemia inhibitory factor.
17. A cell culture comprising the isolated cell population of any one of claims 1 to 4.
18. The cell culture of claim 17, further comprising at least one growth factor of platelet derived growth factor-bb, epidermal growth factor, vascular endothelial growth factor, fibroblast growth factor, or leukemia inhibitory factor.
19. The culture of claim 17 that can undergo at least 40 population doublings in culture.
20. A kit comprising the isolated placenta-derived cell population of any one of claims 1 to 4 and at least one additional component of a scaffold, a hydrating agent, a cell culture substrate, and cell culture media.
21. The kit of claim 20, wherein said cell population is cryopreserved.
22. The kit of claim 20, wherein said cell population is seeded on said scaffold.
23. The cell population of any one of claims 1 to 4 that is genetically engineered to produce a protein of interest.
24. The pharmaceutical composition of any of claims 14 to 16, further comprising a matrix.
25. The pharmaceutical composition of claim 24, wherein the cell population is seeded on the matrix.
26. An isolated homogenous placenta-derived cell population, wherein said cell population is obtained from human postpartum placenta substantially free of blood, wherein said cell population self-renews and expands in culture; is multipotent;
and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein said cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6074.
and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein said cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6074.
27. An isolated homogenous placenta-derived cell population, wherein said cell population is obtained from human postpartum placenta substantially free of blood, wherein said cell population self-renews and expands in culture; is multipotent;
and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C, (b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein said cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6075.
and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C, (b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein said cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6075.
28. An isolated homogenous placenta-derived cell population, wherein said cell population is obtained from human postpartum placenta substantially free of blood, wherein said cell population self-renews and expands in culture; is multipotent;
and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein said cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6079.
and has the following characteristics:
(a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DP, DQ, DR, as detected by flow cytometry;
(c) expresses, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 mRNA, renin mRNA, Wilms tumor 1 mRNA and protein kinase C zeta;
(d) secretes monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), stromal-derived factor 1alpha (SDF-1alpha), interleukin 8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and (e) lacks secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), 1309, and macrophage-derived chemokine (MDC), as detected by ELISA, wherein said cell population has been deposited with the ATCC under ATCC
Accession No. PTA-6079.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48326403P | 2003-06-27 | 2003-06-27 | |
US60/483,264 | 2003-06-27 | ||
PCT/US2004/020816 WO2005001076A2 (en) | 2003-06-27 | 2004-06-25 | Postpartum cells derived from placental tissue, and methods of making and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2530416A1 CA2530416A1 (en) | 2005-01-06 |
CA2530416C true CA2530416C (en) | 2015-08-25 |
Family
ID=38456561
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2530533A Expired - Fee Related CA2530533C (en) | 2003-06-27 | 2004-06-25 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
CA2530412A Expired - Fee Related CA2530412C (en) | 2003-06-27 | 2004-06-25 | Cartilage and bone repair and regeneration using postpartum-derived cells |
CA2530416A Expired - Fee Related CA2530416C (en) | 2003-06-27 | 2004-06-25 | Postpartum cells derived from placental tissue, and methods of making and using the same |
CA2530421A Expired - Fee Related CA2530421C (en) | 2003-06-27 | 2004-06-25 | Repair and regeneration of ocular tissue using postpartum-derived cells |
CA2530422A Expired - Fee Related CA2530422C (en) | 2003-06-27 | 2004-06-25 | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
CA2530732A Expired - Fee Related CA2530732C (en) | 2003-06-27 | 2004-06-25 | Regeneration and repair of neural tissue using postpartum-derived cells |
CA2530255A Expired - Fee Related CA2530255C (en) | 2003-06-27 | 2004-06-25 | Soft tissue repair and regeneration using postpartum-derived cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2530533A Expired - Fee Related CA2530533C (en) | 2003-06-27 | 2004-06-25 | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
CA2530412A Expired - Fee Related CA2530412C (en) | 2003-06-27 | 2004-06-25 | Cartilage and bone repair and regeneration using postpartum-derived cells |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2530421A Expired - Fee Related CA2530421C (en) | 2003-06-27 | 2004-06-25 | Repair and regeneration of ocular tissue using postpartum-derived cells |
CA2530422A Expired - Fee Related CA2530422C (en) | 2003-06-27 | 2004-06-25 | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
CA2530732A Expired - Fee Related CA2530732C (en) | 2003-06-27 | 2004-06-25 | Regeneration and repair of neural tissue using postpartum-derived cells |
CA2530255A Expired - Fee Related CA2530255C (en) | 2003-06-27 | 2004-06-25 | Soft tissue repair and regeneration using postpartum-derived cells |
Country Status (8)
Country | Link |
---|---|
US (28) | US7413734B2 (en) |
EP (14) | EP1641918B1 (en) |
JP (7) | JP4950661B2 (en) |
AU (7) | AU2004252567B2 (en) |
CA (7) | CA2530533C (en) |
ES (14) | ES2582342T3 (en) |
PL (14) | PL1641914T3 (en) |
WO (7) | WO2005038012A2 (en) |
Families Citing this family (537)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080077251A1 (en) * | 1999-06-07 | 2008-03-27 | Chen Silvia S | Cleaning and devitalization of cartilage |
US8563232B2 (en) | 2000-09-12 | 2013-10-22 | Lifenet Health | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US6179840B1 (en) | 1999-07-23 | 2001-01-30 | Ethicon, Inc. | Graft fixation device and method |
US20020095157A1 (en) * | 1999-07-23 | 2002-07-18 | Bowman Steven M. | Graft fixation device combination |
US8147824B2 (en) | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
ES2522890T3 (en) * | 2000-12-06 | 2014-11-19 | Anthrogenesis Corporation | Method to collect placental stem cells |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
IL157350A0 (en) * | 2001-02-14 | 2004-02-19 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
WO2002063962A1 (en) * | 2001-02-14 | 2002-08-22 | Hariri Robert J | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
WO2003008535A2 (en) * | 2001-07-20 | 2003-01-30 | Technion Research And Development Foundation Ltd. | Methods of generating human cardiac cells and tissues and uses thereof |
US7677565B2 (en) | 2001-09-28 | 2010-03-16 | Shuffle Master, Inc | Card shuffler with card rank and value reading capability |
US7736892B2 (en) * | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
US20080299090A1 (en) * | 2002-02-25 | 2008-12-04 | Kansas State University Research Foundation | Use Of Umbilical Cord Matrix Cells |
US20080003258A1 (en) * | 2002-10-16 | 2008-01-03 | Marcum Frank D | Composition and Method for Treating Rheumatoid Arthritis |
US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
KR101042448B1 (en) * | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
US7807458B2 (en) | 2003-01-30 | 2010-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs | Multilineage-inducible cells and uses thereof |
JP4790592B2 (en) | 2003-02-11 | 2011-10-12 | ダビース,ジヨン・イー | Progenitor cells from Wharton's jelly of human umbilical cord |
AU2004212009B2 (en) * | 2003-02-13 | 2010-07-29 | Celularity Inc. | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
US8197837B2 (en) | 2003-03-07 | 2012-06-12 | Depuy Mitek, Inc. | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
CN100377165C (en) * | 2003-04-24 | 2008-03-26 | 皇家飞利浦电子股份有限公司 | Non-invasive left ventricular volume determination |
US8790637B2 (en) * | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
AU2004252567B2 (en) * | 2003-06-27 | 2011-10-06 | Ethicon, Incorporated | Repair and regeneration of ocular tissue using postpartum-derived cells |
US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US8226715B2 (en) | 2003-06-30 | 2012-07-24 | Depuy Mitek, Inc. | Scaffold for connective tissue repair |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
JP4920412B2 (en) * | 2003-08-12 | 2012-04-18 | ティゲニクス・ナムローゼ・フエンノートシャップ | Use of CXCL6 chemokine in the prevention or recovery of cartilage tissue defects |
US8043614B2 (en) | 2004-03-09 | 2011-10-25 | Ahlfors Jan-Eric W | Autogenic living scaffolds and living tissue matrices: methods and uses thereof |
GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
CN101966183A (en) * | 2003-12-02 | 2011-02-09 | 细胞基因公司 | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US7901461B2 (en) * | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
JP2005168360A (en) * | 2003-12-09 | 2005-06-30 | Olympus Corp | Method for examining biological tissue-supplying material, device, cell culture container and method for examining culturing state |
US20050176139A1 (en) * | 2004-01-12 | 2005-08-11 | Yao-Chang Chen | Placental stem cell and methods thereof |
WO2005071066A1 (en) * | 2004-01-23 | 2005-08-04 | Board Of Regents, The University Of Texas System | Methods and compositions for preparing pancreatic insulin secreting cells |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
WO2005093044A1 (en) * | 2004-03-22 | 2005-10-06 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
US8221780B2 (en) * | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8137686B2 (en) | 2004-04-20 | 2012-03-20 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US7670596B2 (en) * | 2004-04-23 | 2010-03-02 | Bioe, Inc. | Multi-lineage progenitor cells |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
WO2005107807A2 (en) * | 2004-05-06 | 2005-11-17 | University Of South Florida | Cerebral intraventricular transplantation as method of treating amyotrophic lateral sclerosis |
US20060083732A1 (en) * | 2004-06-30 | 2006-04-20 | Arlene Gwon | Hyaluronic acid in the enhancement of lens regeneration |
US8802651B2 (en) * | 2004-06-30 | 2014-08-12 | Abbott Medical Optics Inc. | Hyaluronic acid in the enhancement of lens regeneration |
CA2577447C (en) | 2004-08-16 | 2017-08-01 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
US8039258B2 (en) * | 2004-09-28 | 2011-10-18 | Ethicon, Inc. | Tissue-engineering scaffolds containing self-assembled-peptide hydrogels |
US20060069008A1 (en) * | 2004-09-28 | 2006-03-30 | Sanjay Mistry | Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US7842304B2 (en) * | 2004-10-29 | 2010-11-30 | Nexeon Medsystems, Inc. | Methods and apparatus for treating an injured nerve pathway |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
US8017395B2 (en) * | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
US20060171930A1 (en) * | 2004-12-21 | 2006-08-03 | Agnieszka Seyda | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
WO2006083394A2 (en) * | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
EP1831355A2 (en) * | 2004-12-23 | 2007-09-12 | Ethicon, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
CA2589041C (en) | 2004-12-23 | 2019-08-20 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
WO2006071773A2 (en) * | 2004-12-23 | 2006-07-06 | Ethicon Incoporated | Treatment of osteochondral diseases using postpartum-derived cells and products thereof |
JP5425399B2 (en) | 2004-12-23 | 2014-02-26 | エシコン・インコーポレイテッド | Treatment of Parkinson's disease and related disorders using postpartum-derived cells |
WO2006088867A2 (en) * | 2005-02-15 | 2006-08-24 | Medistem Laboratories, Incorporated | Method for expansion of stem cells |
EP2295541B1 (en) * | 2005-03-04 | 2016-04-27 | Kyoto University | Pluripotent stem cell derived from cardiac tissue |
US8153430B2 (en) * | 2005-03-31 | 2012-04-10 | Stemnion, Inc. | Methods related to surgery |
CN103356707B (en) | 2005-03-31 | 2016-07-06 | 斯丹姆涅恩有限公司 | Prepare in order to treat wound or the ulcer of diabetic neuropathy initiation, or the method for the medicine of prevention postoperative hernia formation |
US20060222634A1 (en) | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
US8999706B2 (en) * | 2005-04-12 | 2015-04-07 | The Trustees Of The University Of Pennsylvania | Methods for preparation of human hair-follicle derived multipotent adult stem cells |
WO2006113731A2 (en) * | 2005-04-20 | 2006-10-26 | University Of Florida Research Foundation, Inc. | Bone marrow-derived neurogenic cells and uses thereof |
US20100087546A1 (en) * | 2005-04-20 | 2010-04-08 | Biogenic Innovations, Llc | Use of dimethyl sulfone (msm) to reduce homocysteine levels |
WO2006116524A1 (en) * | 2005-04-25 | 2006-11-02 | Massachusetts Institute Of Technology | Compositions and methods for promoting hemostasis and other physiological activities |
AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
PL1888123T3 (en) | 2005-06-08 | 2013-06-28 | Janssen Biotech Inc | A cellular therapy for ocular degeneration |
GB0511723D0 (en) * | 2005-06-09 | 2005-07-13 | Smith & Nephew | Placental stem cells |
WO2006135899A2 (en) * | 2005-06-13 | 2006-12-21 | The Johns Hopkins University | Survival, differentiation and structural intergration of human neural stem cells grafted into the adult spinal cord |
US7838503B2 (en) * | 2005-06-15 | 2010-11-23 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
US20140336514A1 (en) * | 2005-08-05 | 2014-11-13 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
US20150119794A1 (en) * | 2005-08-05 | 2015-04-30 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
WO2007033180A1 (en) | 2005-09-12 | 2007-03-22 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds |
US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
AU2006291134C1 (en) | 2005-09-12 | 2013-08-15 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
JP2007106760A (en) * | 2005-09-16 | 2007-04-26 | Kenji Yoshida | Hematopoietic stem cell proliferator |
EP1933852B1 (en) | 2005-09-27 | 2018-12-19 | TissueTech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
ZA200803929B (en) * | 2005-10-13 | 2009-08-26 | Anthrogenesis Corp | Production of oligodendrocytes from placenta-derived stem cells |
EP1957633B1 (en) | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
JP4921767B2 (en) * | 2005-10-14 | 2012-04-25 | 株式会社カネカ | Cell differentiation induction method |
US11000546B2 (en) | 2005-11-09 | 2021-05-11 | Athersys, Inc. | Immunomodulatory properties of MAPCs and uses thereof |
US10117900B2 (en) * | 2005-11-09 | 2018-11-06 | Athersys, Inc. | MAPC treatment of brain injuries and diseases |
EP1945794A2 (en) * | 2005-11-09 | 2008-07-23 | Chemimage Corporation | System and method for cytological analysis by raman spectroscopic imaging |
US20090170059A1 (en) * | 2005-11-14 | 2009-07-02 | Hans Klingemann | Methods for Preparing Cord Matrix Stem Cells (CMSC) for Long Term Storage and for Preparing a Segment of umbilical cord for cryopreservation |
CA2630077C (en) * | 2005-11-17 | 2014-07-15 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
JP5289970B2 (en) * | 2005-12-16 | 2013-09-11 | エシコン・インコーポレイテッド | Compositions and methods for inhibiting reverse immune responses in histocompatible incompatible transplants |
WO2007073552A1 (en) * | 2005-12-19 | 2007-06-28 | Ethicon, Inc. | In vitro expansion of postpartum derived cells in roller bottles |
KR20140146220A (en) | 2005-12-22 | 2014-12-24 | 제인 에니스 | Viable cells from frozen umbilical cord tissue |
CN105106239A (en) * | 2005-12-28 | 2015-12-02 | 伊西康公司 | Treatment of peripheral vascular disease using postpartum-derived cells |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US20070160588A1 (en) * | 2005-12-28 | 2007-07-12 | Ethicon, Incorporated | Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells |
CA2633980A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
KR20080081088A (en) | 2005-12-29 | 2008-09-05 | 안트로제네시스 코포레이션 | Co-culture of placental stem cells and stem cells from a second source |
CN103146640B (en) | 2005-12-29 | 2015-09-09 | 人类起源公司 | Placental stem cell populations |
US8343762B2 (en) | 2006-01-11 | 2013-01-01 | Technion Research & Development Foundation Ltd. | Human embryonic stem cell-derived connective tissue progenitors for tissue engineering |
US20080286249A1 (en) * | 2006-01-12 | 2008-11-20 | Varney Timothy R | Use of mesenchymal stem cells for treating genetic diseases and disorders |
US20070253931A1 (en) * | 2006-01-12 | 2007-11-01 | Osiris Therapeutics, Inc. | Use of mesenchymal stem cells for treating genetic diseases and disorders |
US8871198B2 (en) * | 2006-03-29 | 2014-10-28 | Stemnion, Inc. | Methods related to wound healing |
GB0600972D0 (en) * | 2006-01-18 | 2006-03-01 | Univ Leeds | Enrichment of cells |
US9944900B2 (en) * | 2006-01-18 | 2018-04-17 | Hemacell Perfusion | Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells |
US7875451B2 (en) * | 2006-01-19 | 2011-01-25 | The University Of Washington | Formulation to improve survival of transplanted cells |
CN104027359A (en) | 2006-01-23 | 2014-09-10 | 阿特西斯公司 | MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment |
CA2640185A1 (en) * | 2006-01-24 | 2007-08-02 | Christopher J. Centeno | Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting |
FR2896511B1 (en) * | 2006-01-26 | 2012-10-26 | Centre Nat Rech Scient | PROCESS FOR CULTIVATION OF CELLS FROM ADIPOSE TISSUE AND THEIR APPLICATIONS |
EP2311505B1 (en) * | 2006-02-09 | 2013-11-06 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
EP1996698A1 (en) * | 2006-03-01 | 2008-12-03 | Cartela R&D AB | Expansion and differentiation of mesenchymal stem cells |
US20090280093A1 (en) * | 2006-03-01 | 2009-11-12 | The Regenerative Medicine Institute | Compositions and populations of cells obtained from the umbilical cord and methods of producing the same |
US20110171182A1 (en) * | 2006-03-23 | 2011-07-14 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2626417B1 (en) * | 2006-03-23 | 2015-09-02 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2019858B1 (en) * | 2006-04-17 | 2012-06-13 | BioE LLC | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
US20090208466A1 (en) * | 2006-04-21 | 2009-08-20 | James Yoo | Ink-jet printing of tissues |
WO2007127873A2 (en) | 2006-04-27 | 2007-11-08 | Advanced Medical Optics, Inc. | Enhancement of lens regeneration using materials comprising polysiloxane polymers |
US9456979B2 (en) * | 2006-04-27 | 2016-10-04 | Sri International | Adminstration of intact mammalian cells to the brain by the intranasal route |
US8741643B2 (en) * | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
PL2029149T3 (en) | 2006-05-05 | 2017-12-29 | John E. Davies | Immune privileged and modulatory progenitor cells |
EP4094578A1 (en) | 2006-05-11 | 2022-11-30 | Celularity Inc. | Methods for collecting and using placenta cord blood stem cells |
WO2007146106A2 (en) * | 2006-06-05 | 2007-12-21 | Cryo- Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
KR20090031895A (en) * | 2006-06-09 | 2009-03-30 | 안트로제네시스 코포레이션 | Placental niche and use thereof to culture stem cells |
WO2007145889A1 (en) * | 2006-06-14 | 2007-12-21 | Stemnion, Inc. | Methods of treating spinal cord injury and minimizing scarring |
US8475788B2 (en) | 2006-06-14 | 2013-07-02 | Stemnion, Inc. | Methods of treating spinal cord injury and minimizing scarring |
US20070292401A1 (en) * | 2006-06-20 | 2007-12-20 | Harmon Alexander M | Soft tissue repair and regeneration using stem cell products |
RU2009102643A (en) * | 2006-06-28 | 2010-08-10 | Дзе Юниверсити Оф Канзас (Us) | DIFFERENTIATION OF STEM CELLS FROM THE URBINE MATRIX TO CELLS OF THE HEPATOCYTES LINE |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
AU2007269712B2 (en) | 2006-06-30 | 2013-02-07 | Biomimetic Therapeutics, Llc | PDGF-biomatrix compositions and methods for treating rotator cuff injuries |
EP2049043B1 (en) * | 2006-07-24 | 2018-10-10 | International Stem Cell Corporation | Synthetic cornea from retinal stem cells |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
US8822030B2 (en) | 2006-08-11 | 2014-09-02 | Aqua Resources Corporation | Nanoplatelet metal hydroxides and methods of preparing same |
US20080171203A1 (en) * | 2006-08-11 | 2008-07-17 | Aqua Resources Corporation | Nanoplatelet nickel hydroxides and methods of preparing same |
US7671014B2 (en) * | 2006-08-14 | 2010-03-02 | Warsaw Orthopedic, Inc. | Flowable carrier matrix and methods for delivering to a patient |
US8372437B2 (en) | 2006-08-17 | 2013-02-12 | Mimedx Group, Inc. | Placental tissue grafts |
WO2008023829A1 (en) * | 2006-08-22 | 2008-02-28 | National University Corporation Tokyo Medical And Dental University | Application of synovium-derived mesenchymal stem cells (mscs) for cartilage or meniscus regeneration |
US20080082170A1 (en) * | 2006-09-29 | 2008-04-03 | Peterman Marc M | Apparatus and methods for surgical repair |
US20080078412A1 (en) * | 2006-10-03 | 2008-04-03 | Restore Medical, Inc. | Tongue implant |
US20080078411A1 (en) * | 2006-10-03 | 2008-04-03 | Restore Medical, Inc. | Tongue implant for sleep apnea |
EP2078073B1 (en) | 2006-10-12 | 2013-07-24 | Ethicon, Inc. | Kidney-derived cells and methods of use in tissue repair and regeneration |
EP1913869A3 (en) * | 2006-10-19 | 2008-12-10 | Esaote S.p.A. | Diagnostic imaging method and apparatus for the anatomical region of the pelvic floor |
CN101631852A (en) * | 2006-10-23 | 2010-01-20 | 人类起源公司 | Methods and compositions for treatment of bone defects with placental cell populations |
US8106008B2 (en) * | 2006-11-03 | 2012-01-31 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures |
US9102915B2 (en) * | 2006-11-13 | 2015-08-11 | DePuy Synthes Products, Inc. | In vitro expansion of postpartum-derived cells using microcarriers |
US20080132803A1 (en) * | 2006-11-30 | 2008-06-05 | Hyman Friedlander | Method and system for doing business by mining the placental-chord complex |
WO2008073331A2 (en) * | 2006-12-07 | 2008-06-19 | Teva Pharmaceutical Industries Ltd. | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
WO2008082525A1 (en) * | 2006-12-19 | 2008-07-10 | National Stem Cell Inc | Umbilical cord stem cell secreted product derived topical compositions and methods of use thereof |
WO2008083223A1 (en) * | 2006-12-28 | 2008-07-10 | Isolagen Technologies, Inc. | Methods for culturing dermal cells for treatment of skin injuries such as burns |
US7980000B2 (en) * | 2006-12-29 | 2011-07-19 | Applied Materials, Inc. | Vapor dryer having hydrophilic end effector |
ES2623141T3 (en) * | 2007-01-17 | 2017-07-10 | Noveome Biotherapeutics, Inc. | New methods to modulate inflammatory and / or immune responses |
CA2677679A1 (en) | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
NZ578819A (en) * | 2007-02-12 | 2012-02-24 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US20100151025A1 (en) * | 2007-02-20 | 2010-06-17 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw |
SG179432A1 (en) * | 2007-03-01 | 2012-04-27 | Mercedes A Walton | Procurement, isolation and cryopreservation of endometrial/menstrual cells |
WO2008109816A1 (en) * | 2007-03-08 | 2008-09-12 | Hemacell Perfusion, Inc. | Method for isolation of afterbirth derived cells |
US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
EP3878949A1 (en) | 2007-04-07 | 2021-09-15 | Whitehead Institute for Biomedical Research | Reprogramming of somatic cells |
EP2139497B1 (en) * | 2007-04-13 | 2013-11-06 | Stemnion, INC. | Methods for treating nervous system injury and disease |
CN101668848B (en) | 2007-04-26 | 2014-10-22 | 雷蒙特亚特特拉维夫大学有限公司 | Pluripotent autologous stem cells from oral mucosa and methods of use |
US20100291042A1 (en) * | 2007-05-03 | 2010-11-18 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US8574567B2 (en) | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US8114668B2 (en) * | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
WO2008153685A2 (en) | 2007-05-21 | 2008-12-18 | Wake Forest University Health Sciences | Progenitor cells from urine and methods for using the same |
TWM322542U (en) * | 2007-05-23 | 2007-11-21 | Universal Scient Ind Co Ltd | Testing machine |
US20090053182A1 (en) * | 2007-05-25 | 2009-02-26 | Medistem Laboratories, Inc. | Endometrial stem cells and methods of making and using same |
EP1997457B1 (en) * | 2007-06-01 | 2010-11-10 | Allergan, Inc. | Biological tissue growth support through induced tensile stress |
US9693486B1 (en) * | 2007-06-14 | 2017-06-27 | Switch, Ltd. | Air handling unit with a canopy thereover for use with a data center and method of using the same |
US8273526B2 (en) | 2007-06-18 | 2012-09-25 | Children's Hospital & Research Center At Oakland | Method of isolating stem and progenitor cells from placenta |
US20090004271A1 (en) | 2007-06-29 | 2009-01-01 | Brown Laura J | Morselized foam for wound treatment |
US20090004253A1 (en) * | 2007-06-29 | 2009-01-01 | Brown Laura J | Composite device for the repair or regeneration of tissue |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
US9095562B2 (en) * | 2007-07-05 | 2015-08-04 | Regenerative Sciences, Inc. | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
DE102007034679A1 (en) | 2007-07-25 | 2009-01-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Material compositions containing adult stem cells derived from exocrine glandular tissue, especially for use in regenerative medicine, e.g. to restore injured or damaged myocardial tissue |
US9744043B2 (en) | 2007-07-16 | 2017-08-29 | Lifenet Health | Crafting of cartilage |
CA2693827A1 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to chondrocytes |
CA2694700C (en) | 2007-07-27 | 2015-04-14 | Humacyte, Inc. | Compositions and methods for soft tissue augmentation |
WO2009018453A1 (en) | 2007-07-31 | 2009-02-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
EP2535063A1 (en) * | 2007-08-08 | 2012-12-19 | Pervasis Therapeutics, Inc. | Materials and methods for treating skeletal system damage and promoting skeletal system repair and regeneration |
US20090062907A1 (en) * | 2007-08-31 | 2009-03-05 | Quijano Rodolfo C | Self-expanding valve for the venous system |
US20090068153A1 (en) * | 2007-09-06 | 2009-03-12 | Vitelli Francesca P | Cell composition for tissue regeneration |
WO2009033160A1 (en) | 2007-09-07 | 2009-03-12 | Surgical Biologics | Placental tissue grafts and improved methods of preparing and using the same |
KR20140107677A (en) * | 2007-09-19 | 2014-09-04 | 플루리스템 리미티드 | Adherent cells from adipose or placenta tissues and use thereof in therapy |
US20090136553A1 (en) * | 2007-09-25 | 2009-05-28 | Gerlach Jorg C | Triggerably dissolvable hollow fibers for controlled delivery |
CN101978045A (en) * | 2007-09-26 | 2011-02-16 | 细胞基因细胞疗法公司 | Angiogenic cells from human placental perfusate |
ES2530995T3 (en) | 2007-09-28 | 2015-03-09 | Anthrogenesis Corp | Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta |
EP2203186B1 (en) * | 2007-10-05 | 2014-09-24 | DePuy Synthes Products, LLC | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
WO2009052209A2 (en) * | 2007-10-16 | 2009-04-23 | University Of Kansas | Isolation of stem cells and effective control of contamination |
US20100297234A1 (en) * | 2007-10-19 | 2010-11-25 | Ilene Sugino | Method of using an extracellular matrix to enhance cell transplant survival and differentiation |
US20120219737A1 (en) | 2007-10-19 | 2012-08-30 | University Of Medicine And Dentistry Of New Jersey | Production of extracellular matrix, conditioned media and uses thereof |
NO2217329T3 (en) * | 2007-11-07 | 2018-06-09 | ||
WO2009064958A1 (en) * | 2007-11-14 | 2009-05-22 | Osteosphere, Llc | Ex-vivo production of human demineralized bone matrix |
CN101878298B (en) | 2007-11-27 | 2017-08-15 | 生命扫描有限公司 | The differentiation of human embryo stem cell |
US20090163990A1 (en) * | 2007-12-19 | 2009-06-25 | Chunlin Yang | Decellularized omentum matrix and uses thereof |
WO2009085969A2 (en) | 2007-12-19 | 2009-07-09 | Regenerative Sciences, Llc | Compositions and methods to promote implantation and engrafment of stem cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
PL2237789T3 (en) * | 2007-12-27 | 2017-07-31 | DePuy Synthes Products, Inc. | Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells |
US20100279413A1 (en) * | 2008-01-14 | 2010-11-04 | Zymes, Llc | Applications of ubiquinones and ubiquinols |
US8088163B1 (en) | 2008-02-06 | 2012-01-03 | Kleiner Jeffrey B | Tools and methods for spinal fusion |
RU2010137106A (en) | 2008-02-07 | 2012-03-20 | Байомайметик Терапьютикс, Инк. (Us) | COMPOSITIONS AND METHODS FOR DISTRACTION OF OSTEOGENESIS |
EP3095470A1 (en) * | 2008-02-07 | 2016-11-23 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
US20090209456A1 (en) * | 2008-02-19 | 2009-08-20 | Iliana Sweis | Compositions and methods for improving facial and body aesthetics |
KR101731474B1 (en) | 2008-02-21 | 2017-05-11 | 얀센 바이오테크 인코포레이티드 | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
US8318485B2 (en) * | 2008-02-25 | 2012-11-27 | Natalie Gavrilova | Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy |
US20090220995A1 (en) * | 2008-02-28 | 2009-09-03 | Sachs David H | Multiple administrations of umbilicus derived cells |
US20090232782A1 (en) * | 2008-03-14 | 2009-09-17 | Yu-Show Fu | Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells |
US20110052533A1 (en) | 2008-03-14 | 2011-03-03 | Regenerative Sciences, Llc | Compositions and Methods for Cartilage Repair |
KR20100137006A (en) | 2008-04-21 | 2010-12-29 | 티슈 리제너레이션 쎄라퓨틱스, 인코포레이티드 | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
US9480549B2 (en) | 2008-04-25 | 2016-11-01 | Allosource | Multi-layer tissue patches |
US9358320B2 (en) | 2008-04-25 | 2016-06-07 | Allosource | Multi-layer tissue patches |
US20110143429A1 (en) * | 2008-04-30 | 2011-06-16 | Iksoo Chun | Tissue engineered blood vessels |
US20090275129A1 (en) * | 2008-04-30 | 2009-11-05 | Ethicon, Inc. | Tissue engineered blood vessels |
WO2009143241A2 (en) * | 2008-05-21 | 2009-11-26 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to pancreatic cells |
US8748181B2 (en) * | 2008-05-23 | 2014-06-10 | President And Fellows Of Harvard College | Methods of generating patterned soft substrates and uses thereof |
US20090297485A1 (en) * | 2008-05-28 | 2009-12-03 | Allan Mishra | Compositions and methods for treating psychiatric and neurodegenerative disorders |
US9682173B2 (en) * | 2008-06-11 | 2017-06-20 | The Children's Mercy Hospital | Solutions for tissue engineering and methods of use |
WO2009152529A2 (en) | 2008-06-13 | 2009-12-17 | Whitehead Institute For Biomedical Research Nine Cambridge Center | Programming and reprogramming of cells |
US8197806B2 (en) * | 2008-06-26 | 2012-06-12 | Kci Licensing, Inc | Stimulation of cartilage formation using reduced pressure treatment |
WO2009157559A1 (en) * | 2008-06-27 | 2009-12-30 | 独立行政法人産業技術総合研究所 | Pancreatic cell regeneration/transplantation kit for pancreatic diseases or diabetes |
RU2011103183A (en) * | 2008-06-30 | 2012-08-10 | Сентокор Орто Байотек Инк. (Us) | DIFFERENTIATION OF PLURIPOTENT STEM CELLS |
KR101829310B1 (en) | 2008-06-30 | 2018-02-14 | 얀센 바이오테크 인코포레이티드 | Differentiation of pluripotent stem cells |
US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
DK2329012T3 (en) * | 2008-08-20 | 2020-08-24 | Celularity Inc | Treatment of stroke using isolated placental cells |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
MX339068B (en) | 2008-08-22 | 2016-05-10 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations. |
CA2735790C (en) | 2008-09-02 | 2017-02-28 | Pluristem Ltd. | Adherent cells from placenta tissue and use thereof in therapy |
EP2341951A2 (en) | 2008-09-09 | 2011-07-13 | BioMimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
US9446227B2 (en) | 2008-09-12 | 2016-09-20 | Sonescence, Inc. | Ultrasonic dispersion of compositions in tissue |
US20100069827A1 (en) * | 2008-09-12 | 2010-03-18 | Barry Neil Silberg | Pre-Surgical Prophylactic Administration of Antibiotics and Therapeutic Agents |
ES2624484T3 (en) | 2008-10-06 | 2017-07-14 | 3-D Matrix, Ltd. | Tissue plug |
WO2010048418A1 (en) * | 2008-10-22 | 2010-04-29 | The Trustees Of Columbia University In The City Of New York | Cartilage regeneration without cell transplantation |
MX349178B (en) | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage. |
JP5701765B2 (en) * | 2008-10-31 | 2015-04-15 | シンセス ゲーエムベーハー | Methods and devices for activating stem cells |
ES2634445T3 (en) * | 2008-10-31 | 2017-09-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells with pancreatic endocrine lineage |
BRPI0921494A2 (en) | 2008-11-03 | 2018-10-30 | Prad Reasearch And Development Ltd | method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation. |
NZ602455A (en) * | 2008-11-19 | 2014-03-28 | Anthrogenesis Corp | Amnion derived adherent cells |
JP5719305B2 (en) | 2008-11-20 | 2015-05-13 | ヤンセン バイオテツク,インコーポレーテツド | Methods and compositions for cell attachment and culture on a planar support |
AU2009316594B2 (en) * | 2008-11-20 | 2014-05-01 | Lifecell Corporation | Method for treatment and prevention of parastomal hernias |
MX356756B (en) | 2008-11-20 | 2018-06-11 | Centocor Ortho Biotech Inc | Pluripotent stem cell culture on micro-carriers. |
AU2009316376B2 (en) * | 2008-11-21 | 2015-08-20 | Celularity Inc. | Treatment of diseases, disorders or conditions of the lung using placental cells |
US8366748B2 (en) | 2008-12-05 | 2013-02-05 | Kleiner Jeffrey | Apparatus and method of spinal implant and fusion |
JPWO2010064702A1 (en) * | 2008-12-05 | 2012-05-10 | 国立大学法人 東京大学 | Biomarkers for predicting cancer prognosis |
WO2010065239A1 (en) * | 2008-12-05 | 2010-06-10 | Wake Forest University Health Sciences | Stem cells from urine and methods for using the same |
US20110245804A1 (en) | 2008-12-05 | 2011-10-06 | Regenerative Sciences, Llc | Methods and Compositions to Facilitate Repair of Avascular Tissue |
US20100168022A1 (en) * | 2008-12-11 | 2010-07-01 | Centeno Christopher J | Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
EP2379087B1 (en) * | 2008-12-19 | 2014-08-20 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
CA2747794C (en) * | 2008-12-19 | 2018-10-30 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of lung and pulmonary diseases and disorders |
EP2379089B1 (en) * | 2008-12-19 | 2019-04-17 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue following injury |
US20130302283A1 (en) | 2012-05-14 | 2013-11-14 | Advanced Technologies And Regenerative Medicine, Llc | hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS |
US8771677B2 (en) | 2008-12-29 | 2014-07-08 | Vladimir B Serikov | Colony-forming unit cell of human chorion and method to obtain and use thereof |
WO2010078118A2 (en) * | 2008-12-30 | 2010-07-08 | Kci Licensing, Inc. | Reduced pressure augmentation of microfracture procedures for cartilage repair |
TWI440719B (en) * | 2009-01-23 | 2014-06-11 | Univ Tokyo | Method for evaluation of cultured cells |
US9247943B1 (en) | 2009-02-06 | 2016-02-02 | Kleiner Intellectual Property, Llc | Devices and methods for preparing an intervertebral workspace |
WO2010093468A1 (en) * | 2009-02-12 | 2010-08-19 | University Of Southern California | Bioadhesive patch for sutureless closure of soft tissue |
KR101422690B1 (en) * | 2009-02-27 | 2014-07-23 | (주)차바이오앤디오스텍 | Composition for skin regeneration by using medium or secretion of embryonic stem cell derived endothelial progenitor cells and use thereof |
BRPI1013409A2 (en) | 2009-03-26 | 2018-01-16 | Advanced Tech And Regenerative Medicine Llc | human umbilical cord tissue cells as therapy for alzheimer's disease |
WO2010111522A2 (en) * | 2009-03-26 | 2010-09-30 | The Regents Of The University Of California | Mesenchymal stem cells producing inhibitory rna for disease modification |
US20120039857A1 (en) * | 2009-04-06 | 2012-02-16 | Capricor, Inc. | Systems and methods for cardiac tissue repair |
MX357440B (en) * | 2009-05-13 | 2018-07-10 | Medipost Co Ltd | Tsp-1, tsp-2, il-17br and hb-egf associated with stem cell activities and applications thereof. |
EP2432495B1 (en) * | 2009-05-20 | 2017-03-22 | Humacyte, Inc. | Elastin for soft tissue augmentation |
WO2010138782A1 (en) * | 2009-05-28 | 2010-12-02 | University Of Central Florida Research | In vitro production of oligodendrocytes from human umbilical cord stem cells |
US20150335400A1 (en) * | 2009-06-17 | 2015-11-26 | The Trustees Of Columbia University In The City Of New York | Tooth scaffolds |
US8647617B2 (en) | 2009-07-13 | 2014-02-11 | Stemnion, Inc. | Methods for modulating inflammatory and/or immune responses |
RU2540021C2 (en) * | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Differentiating human embryonic stem cells |
CN103952372B (en) * | 2009-07-20 | 2016-10-05 | 詹森生物科技公司 | The differentiation of human embryo stem cell |
AU2010276438B2 (en) | 2009-07-20 | 2015-06-11 | Janssen Biotech Inc. | Differentiation of human embryonic stem cells |
DK2456853T3 (en) * | 2009-07-21 | 2021-02-01 | Abt Holding Co | USE OF STEM CELLS TO REDUCE LEUCOCYT EXTRAVASATION |
ES2360434B1 (en) | 2009-07-21 | 2012-04-12 | Universitat Internacional De Catalunya | PLURIPOTENTIAL MOTHER CELLS OBTAINED FROM THE DENTAL PULP. |
WO2011022070A2 (en) * | 2009-08-20 | 2011-02-24 | The Regents Of The University Of California | Perivascular stem cell composition for bone |
US20110054929A1 (en) * | 2009-09-01 | 2011-03-03 | Cell Solutions Colorado Llc | Stem Cell Marketplace |
US8207651B2 (en) | 2009-09-16 | 2012-06-26 | Tyco Healthcare Group Lp | Low energy or minimum disturbance method for measuring frequency response functions of ultrasonic surgical devices in determining optimum operating point |
USD750249S1 (en) | 2014-10-20 | 2016-02-23 | Spinal Surgical Strategies, Llc | Expandable fusion cage |
US10245159B1 (en) | 2009-09-18 | 2019-04-02 | Spinal Surgical Strategies, Llc | Bone graft delivery system and method for using same |
USD723682S1 (en) | 2013-05-03 | 2015-03-03 | Spinal Surgical Strategies, Llc | Bone graft delivery tool |
US20170238984A1 (en) | 2009-09-18 | 2017-08-24 | Spinal Surgical Strategies, Llc | Bone graft delivery device with positioning handle |
US9629729B2 (en) | 2009-09-18 | 2017-04-25 | Spinal Surgical Strategies, Llc | Biological delivery system with adaptable fusion cage interface |
US9060877B2 (en) | 2009-09-18 | 2015-06-23 | Spinal Surgical Strategies, Llc | Fusion cage with combined biological delivery system |
US9186193B2 (en) | 2009-09-18 | 2015-11-17 | Spinal Surgical Strategies, Llc | Fusion cage with combined biological delivery system |
US9173694B2 (en) | 2009-09-18 | 2015-11-03 | Spinal Surgical Strategies, Llc | Fusion cage with combined biological delivery system |
US8685031B2 (en) | 2009-09-18 | 2014-04-01 | Spinal Surgical Strategies, Llc | Bone graft delivery system |
US8906028B2 (en) | 2009-09-18 | 2014-12-09 | Spinal Surgical Strategies, Llc | Bone graft delivery device and method of using the same |
US10973656B2 (en) | 2009-09-18 | 2021-04-13 | Spinal Surgical Strategies, Inc. | Bone graft delivery system and method for using same |
MX337480B (en) * | 2009-09-23 | 2016-03-08 | Davinci Biosciences Llc | Umbilical cord lining stem cells and methods and material for isolating and culturing same. |
US9109206B2 (en) | 2009-10-16 | 2015-08-18 | Rutgers, The State University Of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
AU2010319921A1 (en) * | 2009-10-29 | 2012-05-17 | Janssen Biotech Inc. | Pluripotent stem cells |
KR20120093993A (en) | 2009-10-30 | 2012-08-23 | 아벨라 파마슈티칼스, 인코포레이티드 | Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis |
US9113950B2 (en) | 2009-11-04 | 2015-08-25 | Regenerative Sciences, Llc | Therapeutic delivery device |
EP2498798A4 (en) * | 2009-11-10 | 2014-01-01 | Univ Columbia | Compositions and methods for wound treatment |
US20130129686A1 (en) * | 2009-11-19 | 2013-05-23 | Regents Of The University | Reducing Inflammation Using Cell Therapy |
US20140286911A1 (en) | 2013-03-15 | 2014-09-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
WO2011079017A2 (en) * | 2009-12-23 | 2011-06-30 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
WO2011079018A2 (en) * | 2009-12-23 | 2011-06-30 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
EP2528608B1 (en) | 2010-01-26 | 2015-12-16 | Stem Cells Spin S.A. | Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use |
US9121007B2 (en) * | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
CA2790436A1 (en) | 2010-02-18 | 2011-08-25 | Osiris Therapeutics, Inc. | Immunocompatible chorionic membrane products |
ES2811027T3 (en) * | 2010-02-19 | 2021-03-10 | Lifecell Corp | Devices for the treatment of the abdominal wall |
CN102811622A (en) | 2010-02-22 | 2012-12-05 | 生物模拟治疗公司 | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
CN102791851B (en) | 2010-03-01 | 2017-07-14 | 詹森生物科技公司 | The method of cell of the purifying derived from multipotential stem cell |
KR20190076060A (en) | 2010-04-07 | 2019-07-01 | 안트로제네시스 코포레이션 | Angiogenesis using placental stem cells |
US8562973B2 (en) | 2010-04-08 | 2013-10-22 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US8529883B2 (en) | 2010-05-07 | 2013-09-10 | Fibrocell Technologies, Inc. | Dosage unit formulations of autologous dermal fibroblasts |
EP3498825A1 (en) | 2010-05-12 | 2019-06-19 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US20130209415A1 (en) * | 2010-06-03 | 2013-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Purified compositions of cardiovascular progenitor cells |
CN105713868A (en) | 2010-07-02 | 2016-06-29 | 北卡罗来纳-查佩尔山大学 | Biomatrix scaffolds for industrial scale dispersal |
EP4245370A3 (en) | 2010-07-12 | 2023-11-29 | University of Southern California | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
US8825388B2 (en) | 2010-07-13 | 2014-09-02 | Qualcomm Incorporated | Indoor likelihood heatmap |
EP2593542B1 (en) | 2010-07-13 | 2018-01-03 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US20130203146A1 (en) * | 2010-08-03 | 2013-08-08 | Jackie Y. Ying | Microfabricated scaffold structures |
JP2012031127A (en) * | 2010-08-03 | 2012-02-16 | Nagoya Univ | Composition including umbilical cord matrix stromal cell |
IL207586A0 (en) | 2010-08-12 | 2010-12-30 | Omrix Biopharmaceuticals Ltd | A fibrin based therapeutic preparation and use thereof |
WO2012021885A1 (en) * | 2010-08-13 | 2012-02-16 | The Trustees Of Columbia University In The City Of New York | Three-dimensional tissue engineering devices and uses thereof |
WO2012030539A2 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
EP2611906B1 (en) * | 2010-08-31 | 2024-01-03 | Gallant Pet, Inc. | Systemic, allogenic stem cell therapies for treatment of diseases in cats and dogs |
MX355340B (en) | 2010-08-31 | 2018-04-16 | Janssen Biotech Inc | Differentiation of human embryonic stem cells. |
SG187947A1 (en) | 2010-08-31 | 2013-03-28 | Janssen Biotech Inc | Differentiation of pluripotent stem cells |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US8546338B2 (en) | 2010-12-08 | 2013-10-01 | Johnson & Johnson Consumer Companies, Inc. | Self-assembling hydrogels based on dicephalic peptide amphiphiles |
US8574899B2 (en) | 2010-12-22 | 2013-11-05 | Vladimir B Serikov | Methods for augmentation collection of placental hematopoietic stem cells and uses thereof |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
JP5388233B2 (en) * | 2011-01-19 | 2014-01-15 | 富士ソフト株式会社 | Method for evaluating the cartilage characteristics of regenerated cartilage |
US8945536B2 (en) * | 2011-01-26 | 2015-02-03 | The Chinese University Of Hong Kong | Stem cell sheet for tissue repair |
WO2012154301A1 (en) | 2011-03-18 | 2012-11-15 | Tornier, Inc. | Allogeneic microvascular tissue for soft tissue treatments |
WO2012127320A1 (en) | 2011-03-22 | 2012-09-27 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
CA2834496A1 (en) | 2011-04-28 | 2012-11-01 | Aquero Company, Llc | Lysine-based polymer coagulants for use in clarification of process waters |
US10478206B2 (en) | 2011-04-29 | 2019-11-19 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
EP2714111B1 (en) | 2011-05-31 | 2021-03-17 | LifeCell Corporation | Adipose tissue matrices |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
CA2837878A1 (en) | 2011-06-10 | 2012-12-13 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
AU2012275335B2 (en) | 2011-06-29 | 2017-04-20 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US20130005829A1 (en) | 2011-06-30 | 2013-01-03 | Advanced Technologies And Regenerative Medicine, Llc. | Segmented, epsilon-Caprolactone-Rich, Poly(epsilon-Caprolactone-co-p-Dioxanone) Copolymers for Medical Applications and Devices Therefrom |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
BR112014003071A2 (en) | 2011-08-10 | 2017-02-21 | Depuy Synthes Products Llc | treatment of peripheral vascular disease using umbilical cord tissue derived cells |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
MX2014007093A (en) | 2011-12-13 | 2014-10-13 | Buck Inst For Res On Aging | Methods for improving medical therapies. |
US9162011B2 (en) | 2011-12-19 | 2015-10-20 | Allosource | Flowable matrix compositions and methods |
US20130157365A1 (en) | 2011-12-20 | 2013-06-20 | Advanced Technologies And Regenerative Medicine, Llc | Induced pluripotent stem cells from human umbilical cord tissue-derived cells |
WO2013096249A1 (en) | 2011-12-20 | 2013-06-27 | Lifecell Corporation | Sheet tissue products |
ES2726105T3 (en) | 2011-12-20 | 2019-10-01 | Lifecell Corp | Fluidizable fabric products |
RU2705001C2 (en) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Differentiation of human embryonic stem cells into single-hormonal insulin-positive cells |
JP6301263B2 (en) | 2011-12-23 | 2018-03-28 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | Detection of human umbilical cord tissue-derived cells |
CA2862661C (en) | 2011-12-30 | 2021-05-25 | Amit Patel | Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses |
US9271821B2 (en) | 2012-01-24 | 2016-03-01 | Lifecell Corporation | Elongated tissue matrices |
EP2816894B1 (en) * | 2012-02-23 | 2018-01-03 | Anthrogenesis Corporation | Identification of antitumor compounds using placenta |
US8940294B2 (en) | 2012-03-02 | 2015-01-27 | Tissuetech, Inc. | Methods of isolating and culturing stem cells |
JP6383292B2 (en) | 2012-03-07 | 2018-08-29 | ヤンセン バイオテツク,インコーポレーテツド | Clear media for proliferation and maintenance of pluripotent stem cells |
US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
EP2841115B1 (en) | 2012-04-24 | 2019-07-10 | LifeCell Corporation | Functionalized tissue matrices |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
JP6469003B2 (en) | 2012-06-08 | 2019-02-13 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
EP3466964A1 (en) | 2012-07-06 | 2019-04-10 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
EP2870173B1 (en) | 2012-07-09 | 2018-10-17 | Roche Diagniostics GmbH | Recombinantly produced neutral protease originating from paenibacillus polymyxa |
US11090338B2 (en) | 2012-07-13 | 2021-08-17 | Lifecell Corporation | Methods for improved treatment of adipose tissue |
US8960674B2 (en) | 2012-07-27 | 2015-02-24 | Bally Gaming, Inc. | Batch card shuffling apparatuses including multi-card storage compartments, and related methods |
AU2013302799B2 (en) | 2012-08-13 | 2018-03-01 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US10596202B2 (en) | 2012-09-19 | 2020-03-24 | Microvascular Tissues, Inc. | Compositions and methods for treating and preventing tissue injury and disease |
US11819522B2 (en) | 2012-09-19 | 2023-11-21 | Microvascular Tissues, Inc. | Compositions and methods for treating and preventing tissue injury and disease |
ES2710921T3 (en) | 2012-09-19 | 2019-04-29 | Microvascular Tissues Inc | Compositions to treat and prevent injury and tissue disease |
US9872937B2 (en) | 2012-09-19 | 2018-01-23 | Microvascular Tissues, Inc. | Compositions and methods for treating and preventing tissue injury and disease |
AU2013323747B2 (en) | 2012-09-26 | 2017-02-02 | Lifecell Corporation | Processed adipose tissue |
KR101728808B1 (en) * | 2012-09-28 | 2017-04-20 | 한국생명공학연구원 | Pharmaceutical composition for preventing or treating muscle weakness diseases comprising Acecainide or derivatives thereof |
ITTO20120859A1 (en) * | 2012-10-02 | 2014-04-03 | Univ Degli Studi Torino | NEW THERAPEUTIC APPLICATION OF A MEANS CONDITIONED BY PLACENTARY STEM CELLS |
WO2014066649A1 (en) * | 2012-10-26 | 2014-05-01 | The Regents Of The University Of California | A strategy for engineering various 3d tissues, organoids and vasculature |
US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
US20140170748A1 (en) | 2012-12-14 | 2014-06-19 | DePuy Synthes Products, LLC | Nutrient Enriched Media for hUTC Growth |
ES2942484T3 (en) | 2012-12-31 | 2023-06-01 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators |
BR112015015714A2 (en) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | suspension and agglomeration of human pluripotent cells for differentiation into pancreatic endocrine cells |
ES2837763T3 (en) | 2012-12-31 | 2021-07-01 | Janssen Biotech Inc | Culture of human embryonic stem cells in the air-liquid interface for differentiation into pancreatic endocrine cells |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
EP2756754B1 (en) | 2013-01-17 | 2017-01-04 | Vita 34 Ag | Method for the treatment of umbilical cord tissue, in particular associated with the preservation of the tissue |
US20140212390A1 (en) * | 2013-01-30 | 2014-07-31 | NuTech Medical, Inc. | Placental Membrane Preparation and Methods of Making and Using Same |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US9867939B2 (en) | 2013-03-12 | 2018-01-16 | Allergan, Inc. | Adipose tissue combinations, devices, and uses thereof |
WO2014164900A1 (en) | 2013-03-13 | 2014-10-09 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
DK2970883T3 (en) | 2013-03-14 | 2021-08-09 | Celularity Inc | Improved placenta stem cells and use thereof |
RU2539750C2 (en) * | 2013-04-09 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Method of evaluating immunosuppressive properties of human mesenchymal stromal cells |
US20140350516A1 (en) | 2013-05-23 | 2014-11-27 | Allergan, Inc. | Mechanical syringe accessory |
CA2913074C (en) | 2013-05-30 | 2023-09-12 | Graham H. Creasey | Topical neurological stimulation |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
US10058572B2 (en) | 2013-08-15 | 2018-08-28 | The Regents Of The University Of California | Placenta-derived multipotent stem cells |
US9248384B2 (en) | 2013-10-02 | 2016-02-02 | Allergan, Inc. | Fat processing system |
US10633625B2 (en) | 2013-11-16 | 2020-04-28 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
WO2015085232A1 (en) | 2013-12-06 | 2015-06-11 | Allosource | Method of drying sheets of tissue |
US10314686B2 (en) * | 2013-12-17 | 2019-06-11 | Dtherapeutics, Llc | Devices, systems and methods for tissue engineering of luminal grafts |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
CN110623956A (en) | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
US10226379B2 (en) | 2014-02-12 | 2019-03-12 | Orbit Biomedical Limited | Method and apparatus for subretinal administration of therapeutic agent |
EP3628337A1 (en) | 2014-03-10 | 2020-04-01 | 3-D Matrix, Ltd. | Sterilization and filtration of peptide compositions |
EP3466965A1 (en) | 2014-03-10 | 2019-04-10 | 3-D Matrix Ltd. | Self-assembling peptide compositions |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
KR20160147058A (en) * | 2014-05-07 | 2016-12-21 | 오시리스 쎄라퓨틱스, 인크. | Therapeutic placental compositions, methods of making and methods of use |
EP3140417B1 (en) * | 2014-05-09 | 2021-04-21 | Reelabs Private Limited | Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders |
US10029048B2 (en) | 2014-05-13 | 2018-07-24 | Allergan, Inc. | High force injection devices |
CA2949056A1 (en) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
TW201603818A (en) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | Compositions and methods |
US9949874B2 (en) | 2014-06-06 | 2018-04-24 | Janssen Biotech, Inc. | Therapeutic agent delivery device with convergent lumen |
US9925088B2 (en) | 2014-06-06 | 2018-03-27 | Janssen Biotech, Inc. | Sub-retinal tangential needle catheter guide and introducer |
US20160000550A1 (en) * | 2014-07-05 | 2016-01-07 | Deborah Nagle | Methods for treating diseases of the colon |
CN106661552B (en) * | 2014-07-11 | 2020-07-07 | 玛土撤拉有限公司 | Cardiac cell culture material |
US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
US10322028B2 (en) | 2014-09-11 | 2019-06-18 | Orbit Biomedical Limited | Method and apparatus for sensing position between layers of an eye |
US10219936B2 (en) | 2014-09-11 | 2019-03-05 | Orbit Biomedical Limited | Therapeutic agent delivery device with advanceable cannula and needle |
US10258502B2 (en) | 2014-09-18 | 2019-04-16 | Orbit Biomedical Limited | Therapeutic agent delivery device |
US9504905B2 (en) | 2014-09-19 | 2016-11-29 | Bally Gaming, Inc. | Card shuffling device and calibration method |
KR101613478B1 (en) * | 2014-09-22 | 2016-04-19 | (주)안트로젠 | Composition comprising mesenchymal stem cell-hydrogel and preparation method thereof |
JP6830059B2 (en) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | Scheduled cell feeding |
AU2015327812B2 (en) | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
JP6871855B2 (en) | 2014-10-14 | 2021-05-19 | サムエル リンチ, | Composition for treating wounds |
US20180280447A1 (en) * | 2014-10-29 | 2018-10-04 | Sungkwang Medical Foundation | Placenta-derived cells excreting c3 or c1r complement and composition containing same |
WO2016070162A1 (en) * | 2014-10-31 | 2016-05-06 | The Administrators Of The Tulane Educational Fund | Surgical grafts for replacing the nipple and areola or damaged epidermis |
RU2750695C2 (en) | 2014-11-07 | 2021-07-01 | Экзостемтех Ко., Лтд. | Composition including exosome produced from stem cells for inducing adipogenous differentiation, regeneration of fatty tissue, skin whitening or wrinkle correction |
JP2017537702A (en) * | 2014-12-05 | 2017-12-21 | ヤンセン バイオテツク,インコーポレーテツド | Treatment of ocular symptoms using progenitor cells |
CN106471371B (en) * | 2014-12-05 | 2018-05-04 | 宣捷生物科技股份有限公司 | The method for distinguishing mescenchymal stem cell |
US20170080033A1 (en) * | 2014-12-16 | 2017-03-23 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
AU2015363088A1 (en) * | 2014-12-16 | 2017-06-15 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
CN107250349A (en) | 2014-12-19 | 2017-10-13 | 詹森生物科技公司 | The suspension culture of multipotential stem cell |
WO2016111899A1 (en) | 2015-01-05 | 2016-07-14 | Petrucci Gary M | Methods and materials for treating lung disorders |
WO2016126122A2 (en) * | 2015-02-04 | 2016-08-11 | 한양대학교 에리카산학협력단 | Composition for chondrocyte differentiation induction or cartilage tissue regeneration, containing exosomes extracted from stem cells differentiating into chondrocytes |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
WO2016138025A2 (en) | 2015-02-23 | 2016-09-01 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
BR112017019272A2 (en) | 2015-03-10 | 2018-05-02 | Allergan Pharmaceuticals Holdings Ireland Unlimited Company | multiple needle injector |
WO2016141460A1 (en) | 2015-03-11 | 2016-09-15 | The University Of British Columbia | Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) |
AU2016243612A1 (en) | 2015-03-31 | 2017-10-12 | The University Of North Carolina At Chapel Hill | Delivery vehicles for stem cells and uses thereof |
US10286009B2 (en) * | 2015-05-16 | 2019-05-14 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
CN107847526A (en) | 2015-05-20 | 2018-03-27 | 组织技术公司 | For preventing the propagation of epithelial cell and the composition and method of the conversion of epithelium mesenchyma |
WO2016187413A1 (en) | 2015-05-21 | 2016-11-24 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10335435B2 (en) | 2015-05-22 | 2019-07-02 | Marco Merida | Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US10384207B2 (en) | 2015-07-21 | 2019-08-20 | Neuro Probe Incorporated | Assay apparatus and methods |
WO2017019832A1 (en) | 2015-07-29 | 2017-02-02 | Medivation Technologies, Inc. | Methods and compositions using repair cells and cationic dyes |
WO2017019822A1 (en) * | 2015-07-29 | 2017-02-02 | Medivation Technologies, Inc. | Pellet composition containing repair cells |
US11707488B2 (en) | 2015-08-28 | 2023-07-25 | Rohto Pharmaceutical Co., Ltd. | ROR1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells |
WO2017123312A2 (en) * | 2015-09-02 | 2017-07-20 | Regeneration Worldwide Company, Inc. | Composition and methods of using umbilical cord lining stem cells |
USD797290S1 (en) | 2015-10-19 | 2017-09-12 | Spinal Surgical Strategies, Llc | Bone graft delivery tool |
WO2017087759A1 (en) | 2015-11-18 | 2017-05-26 | President And Fellows Of Harvard College | Cartridge-based system for long term culture of cell clusters |
AU2016365312A1 (en) * | 2015-12-04 | 2018-05-24 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
KR20170076484A (en) * | 2015-12-24 | 2017-07-04 | 삼성전자주식회사 | Method of isolating senescent cell with high expression of Protocadherin gene |
US10814038B2 (en) | 2016-01-06 | 2020-10-27 | 3-D Matrix, Ltd. | Combination compositions |
EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
KR102211270B1 (en) | 2016-01-14 | 2021-02-04 | 디퍼이 신테스 프로덕츠, 인코포레이티드 | Composition and method for cryopreservation of HUTC |
TW201733600A (en) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | Fetal support tissue products and methods of use |
WO2017136557A1 (en) * | 2016-02-05 | 2017-08-10 | Petrucci Gary M | Methods and materials for treating nerve injuries and neurological disorders |
US11458224B2 (en) * | 2016-03-04 | 2022-10-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Ovarian-derived hydrogels for biomedical and biotechnology applications |
US10478553B2 (en) | 2016-03-09 | 2019-11-19 | Orbit Biomedical Limited | Apparatus for subretinal administration of therapeutic agent via a curved needle |
GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
EP3223181B1 (en) * | 2016-03-24 | 2019-12-18 | Sofradim Production | System and method of generating a model and simulating an effect on a surgical repair site |
EP3436567A4 (en) | 2016-03-30 | 2019-10-30 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
AU2017246114B2 (en) | 2016-04-08 | 2022-03-17 | Allergan, Inc. | Aspiration and injection device |
MA45479A (en) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE |
JP7108537B2 (en) | 2016-04-27 | 2022-07-28 | ロート製薬株式会社 | Mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165, a method for preparing the same, and a pharmaceutical composition containing the mesenchymal stem cells and a method for preparing the same |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11000410B2 (en) | 2016-06-17 | 2021-05-11 | Gyroscope Therapeutics Limited | Guide apparatus for tangential entry into suprachoroidal space |
US10806629B2 (en) | 2016-06-17 | 2020-10-20 | Gyroscope Therapeutics Limited | Injection device for subretinal delivery of therapeutic agent |
US10646374B2 (en) | 2016-06-17 | 2020-05-12 | Orbit Biomedical Limited | Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent |
MA45502A (en) | 2016-06-21 | 2019-04-24 | Janssen Biotech Inc | GENERATION OF FUNCTIONAL BETA CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS WITH GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE |
MX2019000050A (en) * | 2016-07-05 | 2019-05-02 | Janssen Biotech Inc | Treatment of retinal vascular disease using progenitor cells. |
ES2841427T3 (en) | 2016-07-05 | 2021-07-08 | Lifecell Corp | Tissue matrices incorporating multiple tissue types |
AU2017313207A1 (en) * | 2016-08-19 | 2019-04-11 | Regentys Corporation | Extracellular matrix for tissue reconstruction of mucosal tissue |
EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
MX2019005172A (en) * | 2016-11-02 | 2019-09-26 | Axogen Corp | Amnion tissue grafts and methods of preparing and using same. |
RU2644306C1 (en) * | 2016-11-22 | 2018-02-08 | Общество с ограниченной ответственностью "ДЖИ-Групп" | Method of recovery of defects of covering tissues |
WO2018125851A1 (en) * | 2016-12-26 | 2018-07-05 | Michael Moeller | Systems and methods to isolate and expand stem cells from urine |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
US10772986B2 (en) | 2017-01-26 | 2020-09-15 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
WO2018164228A1 (en) | 2017-03-08 | 2018-09-13 | ロート製薬株式会社 | Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells |
US11076984B2 (en) | 2017-03-13 | 2021-08-03 | Gyroscope Therapeutics Limited | Method of performing subretinal drainage and agent delivery |
US11278597B2 (en) | 2017-03-17 | 2022-03-22 | Rutgers, The State University Of New Jersey | Compositions and methods for wound healing |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
WO2018184028A2 (en) | 2017-03-31 | 2018-10-04 | Terumo Bct, Inc. | Cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
KR20190141695A (en) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | Combination Cancer Immunotherapy |
EP3612191A4 (en) | 2017-04-19 | 2020-12-30 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
US10478531B2 (en) | 2017-06-22 | 2019-11-19 | Gary M. Petrucci | Methods and materials for treating blood vessels |
WO2019018545A1 (en) | 2017-07-18 | 2019-01-24 | The Research Foundation For The State University Of New York | Biomarkers for intracranial aneurysm |
US10251917B1 (en) | 2017-09-19 | 2019-04-09 | Gary M. Petrucci | Methods and materials for treating tumors |
CN111201046B (en) | 2017-10-18 | 2022-06-28 | 生命细胞公司 | Adipose tissue products and methods of production |
US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
US11826488B2 (en) | 2017-10-19 | 2023-11-28 | Lifecell Corporation | Flowable acellular tissue matrix products and methods of production |
US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
US11629318B2 (en) | 2017-10-20 | 2023-04-18 | President And Fellows Of Harvard College | Methods for producing mature adipocytes and methods of use thereof |
US20210038650A1 (en) * | 2017-10-23 | 2021-02-11 | Cell Medicine, Inc. | Mesenchymal stem cell therapy of leigh syndrome |
TW201932126A (en) * | 2017-11-03 | 2019-08-16 | 美商健生生物科技公司 | Method of inhibiting angiogenesis |
WO2019094365A1 (en) | 2017-11-07 | 2019-05-16 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
JP7391327B2 (en) | 2018-01-12 | 2023-12-05 | 国立大学法人大阪大学 | Agent for promoting normal differentiation and maturation of stratified squamous epithelial cells, therapeutic agent for epithelial diseases, and method for promoting normal differentiation and maturation of stratified squamous epithelial cells |
US20190218521A1 (en) * | 2018-01-18 | 2019-07-18 | Lorenzo Bracco | Culture medium of viruses for human vaccines have to consist of human cells from placenta and/or from umbilical cord of a fetus of the blood type 0 Rh- and of the mother of the blood type 0 Rh- (both, fetus and mother, must be of the blood type 0 Rh-) |
WO2019152483A1 (en) * | 2018-01-30 | 2019-08-08 | University Of Georgia Research Foundation, Inc. | Methods for vascular construction and products therefrom |
CN108384752A (en) * | 2018-02-13 | 2018-08-10 | 中国人民解放军第四五五医院 | Application at Cartilage culture base and its in micro- splitting technique in knee cartilage differentiation |
CA3101971A1 (en) * | 2018-05-30 | 2019-12-05 | Direct Biologics Llc | A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use |
CN108961233A (en) * | 2018-06-28 | 2018-12-07 | 华侨大学 | A kind of composite polycrystal-diamond surface defect classifying identification method |
AU2019359890A1 (en) | 2018-10-17 | 2021-06-03 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
US11603518B2 (en) | 2019-01-23 | 2023-03-14 | Asterias Biotherapeutics, Inc. | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
US11759355B1 (en) | 2019-02-26 | 2023-09-19 | Gyroscope Therapeutics Limited | Method of delivering leading blebs and agent to subretinal space |
KR102169924B1 (en) * | 2019-03-26 | 2020-10-26 | 연세대학교 산학협력단 | Composition for inducing chondrogenesis and use thereof |
KR102167257B1 (en) * | 2019-05-28 | 2020-10-19 | 부산대학교 산학협력단 | Method of promoting differentiation of stem cells into mature cardiomyocytes using tomatidine |
EP3976127A1 (en) | 2019-05-30 | 2022-04-06 | LifeCell Corporation | Biologic breast implant |
CA3144957A1 (en) | 2019-06-26 | 2020-12-30 | Neurostim Technologies Llc | Non-invasive nerve activator with adaptive circuit |
CA3152505A1 (en) * | 2019-08-29 | 2021-03-04 | Ajinomoto Co., Inc. | Method for producing mesenchymal stem cells from living body-derived cell sample containing mesenchymal stem cells |
US20220330530A1 (en) * | 2019-09-13 | 2022-10-20 | The University Of North Carolina At Chapel Hill | Method of making human mouse xenografts |
EP4041260A4 (en) * | 2019-10-07 | 2023-11-01 | University of Utah Research Foundation | Chondrogenic human mesenchymal stem cell (msc) sheets |
CN114555016A (en) | 2019-10-11 | 2022-05-27 | 陀螺仪治疗学有限公司 | Clip assembly for a syringe |
CA3152451A1 (en) | 2019-12-16 | 2021-06-24 | Michael Bernard Druke | Non-invasive nerve activator with boosted charge delivery |
CN111718410B (en) * | 2020-06-05 | 2022-10-11 | 江南大学 | Method for preparing yolk immunoglobulin |
JP6967308B1 (en) * | 2020-06-30 | 2021-11-17 | 国立大学法人高知大学 | Cranial nerve disorder therapeutic agent containing tissue cell culture supernatant derived from fetal appendages |
WO2022046954A1 (en) * | 2020-08-25 | 2022-03-03 | Celularity Inc. | Appl cells improved placental-derived adherent cells and methods of their use |
WO2022136913A1 (en) | 2020-12-22 | 2022-06-30 | Gyroscope Therapeutics Limited | Ocular cannula guide |
CA3200810A1 (en) * | 2021-01-12 | 2022-07-21 | Jaeseung Lim | Method for screening neuronal regeneration-promoting cells having neuronal regeneration activity |
CN115068438B (en) * | 2022-04-28 | 2023-09-22 | 浙江大学医学院附属邵逸夫医院 | Method for preparing cell membrane nano vesicle with osteoclast precursor homology targeting and application thereof |
CN115044542B (en) * | 2022-06-30 | 2023-09-26 | 上海市东方医院(同济大学附属东方医院) | Application of SJ000291942 in inducing mesenchymal stem cells to osteogenic differentiation |
WO2024024708A1 (en) * | 2022-07-26 | 2024-02-01 | 国立大学法人大阪大学 | Composition for cartilage repair and method for manufacturing same |
WO2024052733A1 (en) | 2022-09-06 | 2024-03-14 | Gyroscope Therapeutics Limited | Apparatus for subretinal administration of therapeutic agent via dual-curved needle |
Family Cites Families (326)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US229971A (en) | 1880-07-13 | Ttornets | ||
US2324800A (en) | 1941-08-14 | 1943-07-20 | Pfizer Charles & Co | Purification of riboflavin |
US2654735A (en) * | 1949-07-29 | 1953-10-06 | Us Vitamin Corp | Process for the production of derivatives of 9-polyhydroxyalkylisoalloxazines and products obtained |
US2864848A (en) | 1954-07-19 | 1958-12-16 | Ca Nat Research Council | Method of producing l-alpha-glycerylphosphorylcholine |
US2912332A (en) | 1958-02-27 | 1959-11-10 | Swift & Co | Stabilized thiamine composition and method of enriching food products |
US3665061A (en) * | 1969-07-16 | 1972-05-23 | United States Banknote Corp | Process for producing collagen sponges |
JPS5651747B2 (en) | 1973-05-31 | 1981-12-08 | ||
CH635748A5 (en) | 1977-08-16 | 1983-04-29 | Cellorgan Laboratoires Sa | PROCESS FOR OBTAINING PLACENTAL CELLS OF SHEEP. |
US4216144A (en) * | 1977-10-20 | 1980-08-05 | Ashmead H H | Soluble iron proteinates |
JPS6040439B2 (en) * | 1978-03-29 | 1985-09-11 | 大正製薬株式会社 | hydrocortisone derivatives |
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4393240A (en) | 1981-07-06 | 1983-07-12 | Stille John K | Optically active phosphines |
US4544516A (en) | 1982-07-28 | 1985-10-01 | Battelle Development Corporation | Collagen orientation |
US4465776A (en) * | 1982-09-27 | 1984-08-14 | Research Corporation | Monoclonal antibodies to vitamin B6 and immunoassay method |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5266480A (en) | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
US4925667A (en) * | 1986-05-27 | 1990-05-15 | Qmax Technology Group, Inc. | Substrate with particulate cosmetic |
JPS642643A (en) | 1987-06-26 | 1989-01-06 | Bio Material Yunibaasu:Kk | Artificial skin |
NZ226750A (en) | 1987-10-29 | 1990-09-26 | Amrad Corp Ltd | Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene |
US5004681B1 (en) | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5162405A (en) * | 1987-12-24 | 1992-11-10 | Elf Atochem North America, Inc. | Single-functional and mixtures of multi-functional oligomeric performance additive compositions and their uses |
GB8803697D0 (en) | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
US4963439A (en) | 1988-04-19 | 1990-10-16 | Ube Industries, Ltd. | Continuous fiber-reinforced Al-Co alloy matrix composite |
US20030032178A1 (en) * | 1988-08-04 | 2003-02-13 | Williams Robert Lindsay | In vitro propagation of embryonic stem cells |
US5618670A (en) * | 1988-08-26 | 1997-04-08 | The United States Of America As Represented By The Department Of Health & Human Services | Detection method for c-raf-1 genes |
US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US5284766A (en) | 1989-02-10 | 1994-02-08 | Kao Corporation | Bed material for cell culture |
JPH06104061B2 (en) | 1989-02-10 | 1994-12-21 | 花王株式会社 | Cell culture support material |
EP0385733B1 (en) * | 1989-02-27 | 1994-06-01 | Takasago International Corporation | Process for preparing optically active 6-t-butoxy-3,5-dihydroxyhexanoic esters |
FR2646438B1 (en) | 1989-03-20 | 2007-11-02 | Pasteur Institut | A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION |
US5437994A (en) * | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5840580A (en) | 1990-05-01 | 1998-11-24 | Becton Dickinson And Company | Phenotypic characterization of the hematopoietic stem cell |
US5145770A (en) * | 1990-06-04 | 1992-09-08 | Biosurface Technology, Inc. | Cryopreservation of cultured epithelial sheets |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5336616A (en) * | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5342761A (en) | 1990-10-01 | 1994-08-30 | Research Development Foundation | Oncofetal gene, gene product and uses therefor |
US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5140100A (en) * | 1990-12-28 | 1992-08-18 | Cedars-Sinai Medical Center | Protein that inhibits production of human choriogonadotropin |
US5286632A (en) | 1991-01-09 | 1994-02-15 | Jones Douglas H | Method for in vivo recombination and mutagenesis |
NL9100038A (en) | 1991-01-11 | 1992-08-03 | Stamicarbon | ENZYME-CATALYZED PREPARATION OF OPTICALLY ACTIVE CARBONIC ACIDS. |
KR100235782B1 (en) | 1991-05-02 | 1999-12-15 | 파울리나 벤-아미 | Compositions for the prevention and/or treatment of pathological processes |
US6399369B1 (en) | 1991-07-08 | 2002-06-04 | Neurospheres Holdings Ltd. | Multipotent neural stem cell cDNA libraries |
EP0552380A4 (en) | 1991-08-08 | 1995-01-25 | Kao Corp | Cell culture support, production thereof, and production of cell cluster using same |
EP0529751A1 (en) | 1991-08-09 | 1993-03-03 | W.R. Grace & Co.-Conn. | Cell culture substrate, test material for cell culture and preparations thereof |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
WO1993006726A1 (en) * | 1991-09-30 | 1993-04-15 | Mackenzie Walser | Methods for treatment of free-radical-mediated tissue injury |
US5308763A (en) * | 1991-10-01 | 1994-05-03 | The Johns Hopkins University | Method of making primary culture of olfactory neurons |
US5914265A (en) * | 1992-04-30 | 1999-06-22 | Baylor College Of Medicine | Keratin K1 expression vectors and methods of use |
WO1994000484A1 (en) | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
US5320962A (en) | 1992-07-22 | 1994-06-14 | Duke University | DNA encoding the human A1 adenosine receptor |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5356807A (en) * | 1992-09-08 | 1994-10-18 | Cornell Research Foundation | Cultured cell line of adult diploid cells from human brain and meningeal tissue |
US20040224409A1 (en) | 1992-09-25 | 2004-11-11 | Laurent Pradier | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) |
EP0669988B2 (en) * | 1992-10-29 | 2009-07-08 | The Australian National University | Angiogenesis inhibitory antibodies |
US5670483A (en) | 1992-12-28 | 1997-09-23 | Massachusetts Insititute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
US5955343A (en) | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
US5494899A (en) * | 1993-04-07 | 1996-02-27 | Oklahoma Medical Research Foundation | Selective regulation of B lymphocyte precursors by hormones |
WO1994025584A1 (en) | 1993-04-28 | 1994-11-10 | Johns Hopkins University School Of Medicine | Chronic endothelial cell culture under flow |
IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
JP3680114B2 (en) | 1993-09-17 | 2005-08-10 | 敏一 中村 | Cranial nerve disorder treatment |
US6686198B1 (en) * | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
US6432711B1 (en) | 1993-11-03 | 2002-08-13 | Diacrin, Inc. | Embryonic stem cells capable of differentiating into desired cell lines |
US5456835A (en) * | 1993-11-08 | 1995-10-10 | Hemasure, Inc. | Device and process for removing free hemoglobin from blood |
DE4406073A1 (en) | 1994-02-24 | 1995-08-31 | Univ Ludwigs Albert | Process for the production of human, clonogenic fibroblasts, process for gene transfection of fibroblasts and fibroblasts obtained in this way |
US5698518A (en) | 1994-03-30 | 1997-12-16 | Oklahoma Medical Research Foundation | Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US6703017B1 (en) | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
US5834308A (en) | 1994-04-28 | 1998-11-10 | University Of Florida Research Foundation, Inc. | In vitro growth of functional islets of Langerhans |
US6001647A (en) | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
ATE247933T1 (en) | 1994-06-06 | 2003-09-15 | Univ Case Western Reserve | BIOMATRIX FOR TISSUE REGENARATION |
IL114397A0 (en) | 1994-07-01 | 1995-10-31 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF-beta-family |
US5935849A (en) * | 1994-07-20 | 1999-08-10 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5660982A (en) * | 1994-10-04 | 1997-08-26 | Tryggvason; Karl | Laminin chains: diagnostic uses |
US5789147A (en) * | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5684032A (en) | 1994-12-13 | 1997-11-04 | Smithkline Beecham Corporation | Compounds |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5693332C1 (en) | 1995-08-11 | 2001-01-09 | Univ California | Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure |
US5641750A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US6200606B1 (en) | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
DE69727558T2 (en) | 1996-03-15 | 2004-12-16 | Munin Corporation, Chicago | Human CYR61, a signaling molecule of the extracellular matrix |
US6223188B1 (en) * | 1996-04-10 | 2001-04-24 | Sun Microsystems, Inc. | Presentation of link information as an aid to hypermedia navigation |
AU2808397A (en) | 1996-04-26 | 1997-11-19 | Case Western Reserve University | Skin regeneration using mesenchymal stem cells |
US6358737B1 (en) | 1996-07-31 | 2002-03-19 | Board Of Regents, The University Of Texas System | Osteocyte cell lines |
US6787355B1 (en) * | 1996-08-26 | 2004-09-07 | Mcgill University | Multipotent neural stem cells from peripheral tissues and uses thereof |
US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
WO1998031316A1 (en) | 1997-01-17 | 1998-07-23 | Celadon Science, Llc | Methods for promoting healing of corneal resurfacing wounds |
AU6144698A (en) | 1997-02-05 | 1998-08-25 | Case Western Reserve University | Stimulatory effects of bfgf and bmp-2 on osteogenic differentiation of mesenchymal stem cells |
WO1998051317A1 (en) | 1997-05-13 | 1998-11-19 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration using human mesenchymal stem cells |
JP2002513383A (en) | 1997-05-21 | 2002-05-08 | スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Methods for increasing the concentration of ascorbic acid in a patient's brain tissue |
JP4132089B2 (en) | 1997-05-30 | 2008-08-13 | オステオバイオロジックス,インコーポレイテッド | Fiber reinforced porous biodegradable implantation device |
EP1007631B2 (en) | 1997-07-14 | 2009-02-18 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6391297B1 (en) | 1997-12-02 | 2002-05-21 | Artecel Sciences, Inc. | Differentiation of adipose stromal cells into osteoblasts and uses thereof |
US6059968A (en) * | 1998-01-20 | 2000-05-09 | Baxter International Inc. | Systems for processing and storing placenta/umbilical cord blood |
US6291240B1 (en) * | 1998-01-29 | 2001-09-18 | Advanced Tissue Sciences, Inc. | Cells or tissues with increased protein factors and methods of making and using same |
DE69922933T2 (en) * | 1998-03-13 | 2005-12-29 | Osiris Therapeutics, Inc. | APPLICATIONS FOR HUMAN NON AUTOLOGOLOGY, MESENCHYMAL STEM CELLS |
EP1076563B1 (en) | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
US6179872B1 (en) * | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
EP1096941B1 (en) | 1998-05-07 | 2005-08-10 | University Of South Florida | Bone marrow cells as a source of neurons for brain and spinal cord repair |
DE69936720T2 (en) | 1998-05-29 | 2008-04-30 | Osiris Therapeutics, Inc. | HUMAN CD45 + AND / OR FIBROBLASTES + MESENCHYMAL STEM CELLS |
US6323188B1 (en) * | 1998-07-01 | 2001-11-27 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins |
DE19833340A1 (en) | 1998-07-24 | 2000-02-10 | Karlsruhe Forschzent | Worm-shaped working mechanism |
US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
CA2339326A1 (en) | 1998-08-10 | 2000-02-24 | Josephine Egan | Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
US6284245B1 (en) | 1998-08-25 | 2001-09-04 | Diacrin, Inc. | Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders |
US6444205B2 (en) | 1998-09-30 | 2002-09-03 | Diacrin, Inc. | Transplantation of neural cells for the treatment of chronic pain or spasticity |
US6610540B1 (en) | 1998-11-18 | 2003-08-26 | California Institute Of Technology | Low oxygen culturing of central nervous system progenitor cells |
US6241369B1 (en) * | 1998-11-20 | 2001-06-05 | Cooper Technologies Company | Quick mount fixture |
US6144054A (en) * | 1998-12-04 | 2000-11-07 | International Business Machines Corporation | DRAM cell having an annular signal transfer region |
DE19856428C1 (en) * | 1998-12-08 | 2000-05-04 | Heraeus Noblelight Gmbh | Discharge lamp, having spiral, inner electrode arranged at inner wall of interior tube |
ES2224726T3 (en) | 1998-12-24 | 2005-03-01 | Biosafe S.A. | BLOOD SEPARATION SYSTEM INDICATED IN PARTICULAR FOR THE CONCENTRATION OF HEMATOPOYETIC MOTHER CELLS. |
JP4932069B2 (en) | 1999-01-25 | 2012-05-16 | 株式会社セルシード | Acrylamide derivatives and polymers containing the derivatives |
IL144378A0 (en) | 1999-02-04 | 2002-05-23 | Univ Mcgill | Platform for the differentiation of cells |
JP2002538779A (en) | 1999-02-10 | 2002-11-19 | キュリス インコーポレイテッド | Pancreatic cell progenitor cells, methods and uses related thereto |
US6592623B1 (en) | 1999-08-31 | 2003-07-15 | Virginia Commonwealth University Intellectual Property Foundation | Engineered muscle |
KR100968164B1 (en) | 1999-03-10 | 2010-07-06 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Adipose-derived stem cells and lattices |
US20030007954A1 (en) | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
WO2000062630A1 (en) | 1999-04-16 | 2000-10-26 | Wm. Marsh Rice University | Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol) |
US6261600B1 (en) | 1999-04-30 | 2001-07-17 | Drugtech Corporation | Folic acid supplement |
US7371400B2 (en) | 2001-01-02 | 2008-05-13 | The General Hospital Corporation | Multilayer device for tissue engineering |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6287340B1 (en) * | 1999-05-14 | 2001-09-11 | Trustees Of Tufts College | Bioengineered anterior cruciate ligament |
WO2000073421A2 (en) | 1999-06-02 | 2000-12-07 | Lifebank Services, L.L.C. | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells |
US6329904B1 (en) * | 1999-06-11 | 2001-12-11 | Safety Through Cellular, Inc. | Apparatus and method for providing weather and other alerts |
AU5886000A (en) | 1999-06-25 | 2001-01-31 | Northwestern University | Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells |
US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6355699B1 (en) | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
EP2348104A1 (en) | 1999-08-05 | 2011-07-27 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
WO2001019379A2 (en) | 1999-09-14 | 2001-03-22 | Children's Medical Center Corporation, The | Methods for treating muscular dystrophy with bone marrow cells |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20030129745A1 (en) * | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
EP1099754A1 (en) | 1999-11-10 | 2001-05-16 | Universiteit Leiden | Mesenchymal stem cells and/or progenitor cells, their isolation and use |
IL149933A0 (en) | 1999-12-06 | 2002-11-10 | Gen Hospital Corp | Pancreatic stem cells and their use in transplantation |
US20030082155A1 (en) * | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US20020164307A1 (en) | 1999-12-06 | 2002-11-07 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
WO2001053503A1 (en) | 2000-01-18 | 2001-07-26 | Cornell Research Foundation, Inc. | Neural progenitor cells from hippocampal tissue and a method for isolating and purifying them |
US7544509B2 (en) | 2000-01-24 | 2009-06-09 | Mcgill University | Method for preparing stem cell preparations |
US6610535B1 (en) | 2000-02-10 | 2003-08-26 | Es Cell International Pte Ltd. | Progenitor cells and methods and uses related thereto |
AU2001236854B2 (en) | 2000-02-11 | 2005-04-14 | Philadelphia Health And Education Corporation | Differentiation of bone marrow cells into neuronal cells and uses therefor |
JP2003521910A (en) | 2000-02-11 | 2003-07-22 | ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド | Isolation and transplantation of retinal stem cells |
US7160724B2 (en) | 2000-03-09 | 2007-01-09 | University Of South Florida | Human cord blood as a source of neural tissue for repair of the brain and spinal cord |
AU2001245550A1 (en) * | 2000-03-09 | 2001-09-17 | Lee Walters | Applications of immune system tolerance to treatment of various diseases |
EP1264877B1 (en) | 2000-03-16 | 2013-10-02 | Cellseed Inc. | Cell cultivation-support material, method of cocultivation of cells and cocultivated cell sheet obtained therefrom |
US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
US6673606B1 (en) | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
AU2001264598B2 (en) | 2000-05-12 | 2006-07-06 | University Of Utah Research Foundation | Compositions and methods for tissue dedifferentiation and regeneration |
US8273570B2 (en) | 2000-05-16 | 2012-09-25 | Riken | Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells |
US7049072B2 (en) | 2000-06-05 | 2006-05-23 | University Of South Florida | Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state |
US6759039B2 (en) | 2000-06-30 | 2004-07-06 | Amcyte, Inc. | Culturing pancreatic stem cells having a specified, intermediate stage of development |
EP2275532B1 (en) * | 2000-07-21 | 2012-06-06 | Cellseed Inc. | Myocardium-like cell sheets and processes for producing them |
WO2002010349A1 (en) | 2000-07-21 | 2002-02-07 | Cellseed Inc. | Cultured epidermal cell sheet, laminated cultured skin sheet and process for producing the same |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
DE10038814A1 (en) * | 2000-08-09 | 2002-02-21 | Abb Research Ltd | High voltage direct current transformer |
US7211434B2 (en) | 2000-09-29 | 2007-05-01 | Van Der Kooy Derek | Primitive neural stem cells and method for differentiation of stem cells to neural cells |
US6639470B1 (en) | 2000-10-06 | 2003-10-28 | Skyworks Solutions, Inc. | Constant current biasing circuit for linear power amplifiers |
US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
WO2002036749A2 (en) | 2000-11-06 | 2002-05-10 | The Salk Institute For Biological Studies | Postmortem stem cells |
KR20080051191A (en) | 2000-11-30 | 2008-06-10 | 스템론 인크. | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
ES2522890T3 (en) | 2000-12-06 | 2014-11-19 | Anthrogenesis Corporation | Method to collect placental stem cells |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6599323B2 (en) | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
US20040121460A1 (en) | 2001-01-24 | 2004-06-24 | Lumelsky Nadya L | Differentiation of stem cells to pancreatic endocrine cells |
WO2002061053A1 (en) | 2001-01-31 | 2002-08-08 | The General Hospital Corporation | Renal stem cells and uses thereof |
WO2002062961A2 (en) | 2001-02-06 | 2002-08-15 | Massachusetts Institute Of Technology | Peptide scaffold encapsulation of tissue cells and uses thereof |
US7449180B2 (en) | 2001-02-06 | 2008-11-11 | John Kisiday | Macroscopic scaffold containing amphiphilic peptides encapsulating cells |
CA2438501C (en) | 2001-02-14 | 2014-09-16 | Leo T. Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
IL157350A0 (en) | 2001-02-14 | 2004-02-19 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
WO2002063962A1 (en) | 2001-02-14 | 2002-08-22 | Hariri Robert J | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
US20030008820A1 (en) | 2001-03-27 | 2003-01-09 | Massachusetts Institute Of Technology | Methods and products related to FGF dimerization |
US7202080B2 (en) | 2001-03-29 | 2007-04-10 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
US7838292B1 (en) | 2001-03-29 | 2010-11-23 | University Of Louisville Research Foundation, Inc. | Methods for obtaining adult human olfactory progenitor cells |
JP2004527249A (en) | 2001-04-19 | 2004-09-09 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | Method of differentiating stem cells into insulin producing cells |
KR100762261B1 (en) | 2001-04-27 | 2007-10-04 | (주)바이오니아 | Process for preparation of full-length cDNA and anchor and primer used for the same |
US20030211605A1 (en) | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
US20030022369A1 (en) | 2001-05-18 | 2003-01-30 | Helen Fillmore | Differentiation of specialized dermal and epidermal cells into neuronal cells |
CA2451838A1 (en) | 2001-05-25 | 2002-12-05 | Cythera, Inc. | Stem cell differentiation |
WO2002098365A2 (en) * | 2001-06-07 | 2002-12-12 | Skinmedica, Inc. | Conditioned cell culture media and uses thereof |
RU2183966C1 (en) | 2001-07-06 | 2002-06-27 | Общество с ограниченной ответственностью "Сибларекс" | Composition of flavonoid complex "siblareks" for biologically active supplements of medicinal and chemical-pharmaceutical articles and method of preparing bioflavonoid complex "siblareks" for biologically active supplements of medicinal and chemical-pharmaceutical articles |
US6402263B1 (en) | 2001-07-24 | 2002-06-11 | Robert Bosch Corporation | Dual actuation master cylinder |
EP1423504B1 (en) * | 2001-08-08 | 2009-09-23 | Levesque Biosciences, Inc. | Compositions and methods for isolation, propagation, and differentiation of non-embryonic human stem cells and uses thereof |
US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
AU2002313817A1 (en) | 2001-08-27 | 2003-03-10 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US20030104997A1 (en) | 2001-09-05 | 2003-06-05 | Black Ira B. | Multi-lineage directed induction of bone marrow stromal cell differentiation |
CN1195055C (en) * | 2001-09-06 | 2005-03-30 | 周胜利 | Method for establishing hematopoietic stem cells bank by extracting hematopoietic cells from placenta tissues |
US20050064587A1 (en) | 2001-09-07 | 2005-03-24 | Lawrence Rosenberg | Pancreatic small cells and uses thereof |
US9969980B2 (en) | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
EP1298201A1 (en) | 2001-09-27 | 2003-04-02 | Cardion AG | Process for the production of cells exhibiting an islet-beta-cell-like state |
US7072332B2 (en) * | 2001-09-27 | 2006-07-04 | Samsung Electronics Co., Ltd. | Soft switch using distributed firewalls for load sharing voice-over-IP traffic in an IP network |
WO2003029443A1 (en) | 2001-09-28 | 2003-04-10 | Es Cell International Pte Ltd | Methods of derivation and propagation of undifferentiated human embryonic stem (hes) cells on feeder-free matrices and human feeder layers |
US20030138951A1 (en) * | 2001-10-18 | 2003-07-24 | Li Yin | Conversion of liver stem and progenitor cells to pancreatic functional cells |
US7129034B2 (en) | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
PL374557A1 (en) | 2001-11-09 | 2005-10-31 | Artecel Sciences, Inc. | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
US7491690B2 (en) | 2001-11-14 | 2009-02-17 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
EP1442115B9 (en) | 2001-11-15 | 2009-12-16 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
JP3728750B2 (en) | 2001-11-22 | 2005-12-21 | ニプロ株式会社 | Cultured skin and method for producing the same |
CA2466478A1 (en) | 2001-11-28 | 2003-06-05 | Anges Mg, Inc. | Gene therapy agents for neurodegenerative diseases |
US6712850B2 (en) | 2001-11-30 | 2004-03-30 | Ethicon, Inc. | Porous tissue scaffolds for the repair and regeneration of dermal tissue |
ES2377099T3 (en) | 2001-12-04 | 2012-03-22 | Organogenesis Inc. | Cultured cells from pancreatic islets |
US20030109036A1 (en) * | 2001-12-06 | 2003-06-12 | The Regents Of The University Of California | Method for differentiating islet precursor cells into beta cells |
AU2002354101A1 (en) * | 2001-12-06 | 2003-06-17 | Sankyo Company, Limited | Medicinal compositions containing human amnion-origin cells |
GB2415432B (en) | 2001-12-07 | 2006-09-06 | Geron Corp | Islet cells from human embryonic stem cells |
AU2002364558A1 (en) * | 2001-12-11 | 2003-06-23 | Cytograft Tissue Engineering, Inc. | Tissue engineered cellular sheets, methods of making and use thereof |
JP3934539B2 (en) | 2001-12-12 | 2007-06-20 | 独立行政法人科学技術振興機構 | Adult or postnatal tissue progenitor cells derived from placenta |
US20030113910A1 (en) * | 2001-12-18 | 2003-06-19 | Mike Levanduski | Pluripotent stem cells derived without the use of embryos or fetal tissue |
IL162648A0 (en) * | 2001-12-21 | 2005-11-20 | Mount Sinai Hospital Corp | Cellular compositions and methods of making and using them |
US7101546B2 (en) | 2001-12-21 | 2006-09-05 | Amcyte, Inc. | In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development |
GB2398795A (en) | 2001-12-28 | 2004-09-01 | Cellartis Ab | A method for the establishment of a pluripotent human blastocyst-derived stem cell line |
EP1471918B1 (en) | 2002-01-14 | 2017-07-19 | The Board Of Trustees Of The University Of Illinois | Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
US20030158089A1 (en) | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Administrative agents via the SMVT transporter |
US20030162290A1 (en) * | 2002-01-25 | 2003-08-28 | Kazutomo Inoue | Method for inducing differentiation of embryonic stem cells into functioning cells |
WO2003066832A2 (en) | 2002-02-07 | 2003-08-14 | The Research Foundation Of The State University Of New York | Generation of new insulin cells from progenitor cells present in adult pancreatic islets |
MXPA04007732A (en) * | 2002-02-13 | 2004-10-15 | Anthrogenesis Corp | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells. |
WO2003070749A2 (en) | 2002-02-15 | 2003-08-28 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US7576065B2 (en) | 2002-02-15 | 2009-08-18 | Cornell Research Foundation, Inc. | Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein |
JP2005517441A (en) | 2002-02-19 | 2005-06-16 | メディポスト・カンパニー・リミテッド | Method for separating and culturing mesenchymal stem cells / progenitor cells derived from cord blood and method for inducing differentiation into mesenchymal tissue |
WO2003072728A2 (en) | 2002-02-22 | 2003-09-04 | University Of Florida | Cellular trans-differentiation |
US7736892B2 (en) | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
US20030161818A1 (en) | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
US7150990B2 (en) | 2002-03-06 | 2006-12-19 | Reprocell, Inc. | Self-renewing pluripotent hepatic stem cells |
JP2003259862A (en) | 2002-03-12 | 2003-09-16 | Fuji Photo Film Co Ltd | Cell-culturing carrier |
WO2003080822A1 (en) | 2002-03-27 | 2003-10-02 | Nipro Corporation | Placenta-origin mesenchymal cells and medicinal use thereof |
CA2481385A1 (en) | 2002-04-12 | 2003-10-23 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
JP4136434B2 (en) | 2002-04-17 | 2008-08-20 | 進 清野 | Induction of insulin-producing cells |
US20040161419A1 (en) | 2002-04-19 | 2004-08-19 | Strom Stephen C. | Placental stem cells and uses thereof |
JP2005523328A (en) | 2002-04-19 | 2005-08-04 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Placenta-derived stem cells and uses thereof |
CA2484223A1 (en) | 2002-04-25 | 2003-11-06 | Wisconsin Alumni Research Foundation | Use of human neural stem cells secreting gdnf for treatment of parkinson's and other neurodegenerative diseases |
US20040029269A1 (en) * | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
US20040014662A1 (en) | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
EP1507848A4 (en) | 2002-05-28 | 2005-11-23 | Becton Dickinson Co | Expansion and transdifferentiation of human acinar cells |
CN1668733A (en) | 2002-05-30 | 2005-09-14 | 细胞基因公司 | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
CA2488425A1 (en) | 2002-06-07 | 2003-12-18 | Es Cell International Pte Ltd | Methods of regulating differentiation in stem cells |
AU2003247514A1 (en) * | 2002-06-11 | 2003-12-22 | Roy Ogle | Meningeal-derived stem cells |
WO2004003561A1 (en) | 2002-06-27 | 2004-01-08 | Northwestern University | Peptide rod amphiphiles and self-assembly of same |
US7285415B2 (en) * | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
GB0216286D0 (en) | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
US7390659B2 (en) | 2002-07-16 | 2008-06-24 | The Trustees Of Columbia University In The City Of New York | Methods for inducing differentiation of embryonic stem cells and uses thereof |
EP1551955A4 (en) | 2002-07-16 | 2006-11-29 | Yissum Res Dev Co | Methods of implanting mesenchymal stem cells for tissue repair and formation |
EP1539930A4 (en) | 2002-07-29 | 2006-08-09 | Es Cell Int Pte Ltd | Multi-step method for the differentiation of insulin positive, glucose |
EP1531838A2 (en) | 2002-07-29 | 2005-05-25 | Asahi Kasei Kabushiki Kaisha | Stem cells for treating pancreatic damage |
WO2004016747A2 (en) | 2002-08-14 | 2004-02-26 | University Of Florida | Bone marrow cell differentiation |
AU2003265094A1 (en) * | 2002-08-26 | 2004-03-11 | Neuronova Ab | Method for culturing stem cells |
EP1543111A4 (en) * | 2002-08-28 | 2006-09-13 | Univ Florida | Neurogenesis from hepatic stem cells |
US7371576B2 (en) | 2002-09-06 | 2008-05-13 | Reneuron, Inc. | CD56 positive human adult pancreatic endocrine progenitor cells |
US6766863B2 (en) * | 2002-09-20 | 2004-07-27 | Hypro Corporation | Fire fighting foam injection system with auto-start feature |
US9969977B2 (en) * | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
US20040062753A1 (en) | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
JP4262465B2 (en) * | 2002-10-24 | 2009-05-13 | 富士フイルム株式会社 | Cell culture method |
AU2003287444A1 (en) | 2002-10-31 | 2004-05-25 | The General Hospital Corporation | Repairing or replacing tissues or organs |
WO2004052177A2 (en) | 2002-12-05 | 2004-06-24 | Case Western Reserve University | Cell-based therapies for ischemia |
JP4571387B2 (en) | 2003-02-07 | 2010-10-27 | 宣男 櫻川 | Human amnion-derived side population cells and uses thereof |
MXPA05008483A (en) | 2003-02-11 | 2006-03-10 | Univ Northwestern | Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon. |
JP4790592B2 (en) * | 2003-02-11 | 2011-10-12 | ダビース,ジヨン・イー | Progenitor cells from Wharton's jelly of human umbilical cord |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US20040224401A1 (en) * | 2003-03-28 | 2004-11-11 | Ludwig Tenneille E. | Physiochemical culture conditions for embryonic stem cells |
US7960166B2 (en) | 2003-05-21 | 2011-06-14 | The General Hospital Corporation | Microfabricated compositions and processes for engineering tissues containing multiple cell types |
AU2004252567B2 (en) | 2003-06-27 | 2011-10-06 | Ethicon, Incorporated | Repair and regeneration of ocular tissue using postpartum-derived cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US8790637B2 (en) * | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
CA2536909A1 (en) | 2003-08-29 | 2005-03-10 | Regents Of The University Of Minnesota | Kidney derived stem cells and methods for their isolation, differentiation and use |
US20050089513A1 (en) | 2003-10-28 | 2005-04-28 | Norio Sakuragawa | Side population cells originated from human amnion and their uses |
US7790193B2 (en) * | 2003-12-23 | 2010-09-07 | Fmc Biopolymer As | Use of alginate matrices to control cell growth |
TWI276685B (en) | 2003-12-30 | 2007-03-21 | Ind Tech Res Inst | Conditional medium for culturing Schwann cells |
US7534606B2 (en) | 2004-01-12 | 2009-05-19 | National Health Research Institutes | Placental stem cell and methods thereof |
DE102004043256B4 (en) | 2004-09-07 | 2013-09-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Scalable process for culturing undifferentiated stem cells in suspension |
US8039258B2 (en) * | 2004-09-28 | 2011-10-18 | Ethicon, Inc. | Tissue-engineering scaffolds containing self-assembled-peptide hydrogels |
WO2006050050A2 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
US7655678B2 (en) * | 2004-11-30 | 2010-02-02 | Council of Scientfic & Industrial Research | Pharmaceutical composition for the management of tumors |
WO2006083394A2 (en) | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
US20060171930A1 (en) | 2004-12-21 | 2006-08-03 | Agnieszka Seyda | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
WO2006071773A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incoporated | Treatment of osteochondral diseases using postpartum-derived cells and products thereof |
CA2589041C (en) | 2004-12-23 | 2019-08-20 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
EP1831355A2 (en) | 2004-12-23 | 2007-09-12 | Ethicon, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
JP5425399B2 (en) | 2004-12-23 | 2014-02-26 | エシコン・インコーポレイテッド | Treatment of Parkinson's disease and related disorders using postpartum-derived cells |
US7741311B2 (en) | 2005-01-03 | 2010-06-22 | Shaker Mousa | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing |
JP2008538276A (en) | 2005-01-28 | 2008-10-23 | ノヴァセラ・リミテッド | Methods for embryonic stem cell culture |
CN103356707B (en) | 2005-03-31 | 2016-07-06 | 斯丹姆涅恩有限公司 | Prepare in order to treat wound or the ulcer of diabetic neuropathy initiation, or the method for the medicine of prevention postoperative hernia formation |
US7923007B2 (en) | 2005-08-08 | 2011-04-12 | Academia Sinica | Brain tissue damage therapies |
JP5289970B2 (en) | 2005-12-16 | 2013-09-11 | エシコン・インコーポレイテッド | Compositions and methods for inhibiting reverse immune responses in histocompatible incompatible transplants |
WO2007073552A1 (en) | 2005-12-19 | 2007-06-28 | Ethicon, Inc. | In vitro expansion of postpartum derived cells in roller bottles |
US20070160588A1 (en) * | 2005-12-28 | 2007-07-12 | Ethicon, Incorporated | Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
CN103146640B (en) | 2005-12-29 | 2015-09-09 | 人类起源公司 | Placental stem cell populations |
JP5106416B2 (en) * | 2006-01-06 | 2012-12-26 | アジレント・テクノロジーズ・インク | Reaction buffer composition for nucleic acid replication comprising packed DNA polymerase |
EP2626417B1 (en) | 2006-03-23 | 2015-09-02 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
WO2007146106A2 (en) * | 2006-06-05 | 2007-12-21 | Cryo- Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
EP2078073B1 (en) | 2006-10-12 | 2013-07-24 | Ethicon, Inc. | Kidney-derived cells and methods of use in tissue repair and regeneration |
US9102915B2 (en) | 2006-11-13 | 2015-08-11 | DePuy Synthes Products, Inc. | In vitro expansion of postpartum-derived cells using microcarriers |
NZ578819A (en) * | 2007-02-12 | 2012-02-24 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US20080305148A1 (en) | 2007-03-19 | 2008-12-11 | National Yang Ming University | Treatment of spinal injuries using human umbilical mesenchymal stem cells |
EP2203186B1 (en) | 2007-10-05 | 2014-09-24 | DePuy Synthes Products, LLC | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US20090123620A1 (en) * | 2007-11-14 | 2009-05-14 | Hiti Thomas R | Automated Application of an Antimycotic Composition to Sliced Foodstuffs and an Antimycotic Application Apparatus |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
WO2009086215A2 (en) * | 2007-12-21 | 2009-07-09 | Wyeth | Pathway analysis of cell culture phenotypes and uses thereof |
PL2237789T3 (en) | 2007-12-27 | 2017-07-31 | DePuy Synthes Products, Inc. | Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells |
TWI363847B (en) * | 2008-03-28 | 2012-05-11 | Ind Tech Res Inst | Light emitting device with positioning function and assembly method thereof |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
EP2379089B1 (en) | 2008-12-19 | 2019-04-17 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue following injury |
EP2379087B1 (en) | 2008-12-19 | 2014-08-20 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
CA2747794C (en) | 2008-12-19 | 2018-10-30 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of lung and pulmonary diseases and disorders |
BRPI1013409A2 (en) | 2009-03-26 | 2018-01-16 | Advanced Tech And Regenerative Medicine Llc | human umbilical cord tissue cells as therapy for alzheimer's disease |
KR101979963B1 (en) * | 2011-01-19 | 2019-05-17 | 이 아이 듀폰 디 네모아 앤드 캄파니 | Lithium battery separator with shutdown function |
-
2004
- 2004-06-25 AU AU2004252567A patent/AU2004252567B2/en not_active Ceased
- 2004-06-25 ES ES04777286.8T patent/ES2582342T3/en active Active
- 2004-06-25 ES ES04756395.2T patent/ES2564044T3/en active Active
- 2004-06-25 JP JP2006517760A patent/JP4950661B2/en not_active Expired - Fee Related
- 2004-06-25 US US10/877,541 patent/US7413734B2/en active Active
- 2004-06-25 JP JP2006517783A patent/JP5148873B2/en not_active Expired - Fee Related
- 2004-06-25 PL PL04777231T patent/PL1641914T3/en unknown
- 2004-06-25 WO PCT/US2004/020958 patent/WO2005038012A2/en active Application Filing
- 2004-06-25 EP EP04777287.6A patent/EP1641918B1/en not_active Not-in-force
- 2004-06-25 WO PCT/US2004/020822 patent/WO2005001077A2/en active Application Filing
- 2004-06-25 PL PL04777235T patent/PL1641916T3/en unknown
- 2004-06-25 ES ES04777287.6T patent/ES2564045T3/en active Active
- 2004-06-25 CA CA2530533A patent/CA2530533C/en not_active Expired - Fee Related
- 2004-06-25 ES ES04777235.5T patent/ES2568463T3/en active Active
- 2004-06-25 EP EP10184796.0A patent/EP2336298B1/en not_active Not-in-force
- 2004-06-25 PL PL04756395T patent/PL1641913T3/en unknown
- 2004-06-25 WO PCT/US2004/020823 patent/WO2005001078A2/en active Application Filing
- 2004-06-25 ES ES04809466.8T patent/ES2565582T3/en active Active
- 2004-06-25 EP EP10183053.7A patent/EP2399990B1/en not_active Not-in-force
- 2004-06-25 CA CA2530412A patent/CA2530412C/en not_active Expired - Fee Related
- 2004-06-25 US US10/877,009 patent/US7560276B2/en active Active
- 2004-06-25 EP EP10183911.6A patent/EP2341131B1/en not_active Not-in-force
- 2004-06-25 AU AU2004252566A patent/AU2004252566B2/en not_active Ceased
- 2004-06-25 PL PL10183911T patent/PL2341131T3/en unknown
- 2004-06-25 JP JP2006517787A patent/JP4948165B2/en not_active Expired - Fee Related
- 2004-06-25 ES ES04777231.4T patent/ES2597837T3/en active Active
- 2004-06-25 EP EP04777234.8A patent/EP1641915B1/en not_active Not-in-force
- 2004-06-25 CA CA2530416A patent/CA2530416C/en not_active Expired - Fee Related
- 2004-06-25 PL PL10184796T patent/PL2336298T3/en unknown
- 2004-06-25 EP EP04756395.2A patent/EP1641913B1/en not_active Not-in-force
- 2004-06-25 WO PCT/US2004/020956 patent/WO2005001079A2/en active Application Filing
- 2004-06-25 EP EP10184306.8A patent/EP2338982B1/en not_active Not-in-force
- 2004-06-25 JP JP2006517788A patent/JP4948166B2/en not_active Expired - Fee Related
- 2004-06-25 EP EP04777235.5A patent/EP1641916B1/en not_active Not-in-force
- 2004-06-25 PL PL10184137T patent/PL2338980T3/en unknown
- 2004-06-25 EP EP04809466.8A patent/EP1649013B1/en not_active Not-in-force
- 2004-06-25 ES ES10184796.0T patent/ES2569780T3/en active Active
- 2004-06-25 PL PL04777286.8T patent/PL1641917T3/en unknown
- 2004-06-25 WO PCT/US2004/020957 patent/WO2005001080A2/en active Application Filing
- 2004-06-25 PL PL10184221T patent/PL2338981T3/en unknown
- 2004-06-25 US US10/877,012 patent/US7510873B2/en active Active
- 2004-06-25 AU AU2004252571A patent/AU2004252571C1/en not_active Ceased
- 2004-06-25 WO PCT/US2004/020931 patent/WO2005003334A2/en active Application Filing
- 2004-06-25 PL PL10183053T patent/PL2399990T3/en unknown
- 2004-06-25 CA CA2530421A patent/CA2530421C/en not_active Expired - Fee Related
- 2004-06-25 ES ES04777234.8T patent/ES2600555T3/en active Active
- 2004-06-25 JP JP2006517759A patent/JP4950660B2/en not_active Expired - Fee Related
- 2004-06-25 PL PL10184593T patent/PL2322599T3/en unknown
- 2004-06-25 US US10/877,269 patent/US7524489B2/en active Active
- 2004-06-25 ES ES10184137.7T patent/ES2542069T3/en active Active
- 2004-06-25 AU AU2004281371A patent/AU2004281371C1/en not_active Ceased
- 2004-06-25 WO PCT/US2004/020816 patent/WO2005001076A2/en active Application Filing
- 2004-06-25 ES ES10184306.8T patent/ES2554343T3/en active Active
- 2004-06-25 CA CA2530422A patent/CA2530422C/en not_active Expired - Fee Related
- 2004-06-25 CA CA2530732A patent/CA2530732C/en not_active Expired - Fee Related
- 2004-06-25 ES ES10183053.7T patent/ES2550267T3/en active Active
- 2004-06-25 AU AU2004254616A patent/AU2004254616C1/en not_active Ceased
- 2004-06-25 ES ES10183911.6T patent/ES2552226T3/en active Active
- 2004-06-25 CA CA2530255A patent/CA2530255C/en not_active Expired - Fee Related
- 2004-06-25 US US10/876,998 patent/US11191789B2/en active Active
- 2004-06-25 PL PL04777234T patent/PL1641915T3/en unknown
- 2004-06-25 JP JP2006517786A patent/JP4948164B2/en not_active Expired - Fee Related
- 2004-06-25 JP JP2006517757A patent/JP4950659B2/en not_active Expired - Fee Related
- 2004-06-25 AU AU2004252568A patent/AU2004252568B2/en not_active Expired - Fee Related
- 2004-06-25 PL PL04777287T patent/PL1641918T3/en unknown
- 2004-06-25 US US10/877,445 patent/US8703121B2/en active Active
- 2004-06-25 EP EP04777286.8A patent/EP1641917B1/en not_active Not-in-force
- 2004-06-25 EP EP04777231.4A patent/EP1641914B1/en not_active Not-in-force
- 2004-06-25 PL PL04809466T patent/PL1649013T3/en unknown
- 2004-06-25 US US10/877,446 patent/US9579351B2/en active Active
- 2004-06-25 ES ES10184221.9T patent/ES2541604T3/en active Active
- 2004-06-25 EP EP20100184137 patent/EP2338980B1/en not_active Not-in-force
- 2004-06-25 AU AU2004252570A patent/AU2004252570C1/en not_active Ceased
- 2004-06-25 PL PL10184306T patent/PL2338982T3/en unknown
- 2004-06-25 EP EP10184593.1A patent/EP2322599B1/en not_active Not-in-force
- 2004-06-25 ES ES10184593.1T patent/ES2542070T3/en active Active
- 2004-06-25 EP EP20100184221 patent/EP2338981B1/en not_active Not-in-force
-
2005
- 2005-12-22 US US11/315,969 patent/US11179422B2/en active Active
- 2005-12-22 US US11/316,104 patent/US9504719B2/en active Active
- 2005-12-23 US US11/317,574 patent/US20060234376A1/en not_active Abandoned
- 2005-12-29 US US11/321,864 patent/US20060153818A1/en not_active Abandoned
- 2005-12-29 US US11/321,863 patent/US20060153817A1/en not_active Abandoned
- 2005-12-29 US US11/322,003 patent/US20060154367A1/en not_active Abandoned
- 2005-12-30 US US11/322,372 patent/US20060188983A1/en not_active Abandoned
-
2006
- 2006-07-06 US US11/481,456 patent/US8318483B2/en active Active
- 2006-07-06 US US11/481,481 patent/US20070014771A1/en not_active Abandoned
- 2006-07-06 US US11/481,480 patent/US20070009494A1/en not_active Abandoned
-
2009
- 2009-02-19 US US12/389,305 patent/US9498501B2/en active Active
- 2009-04-24 US US12/429,849 patent/US8277796B2/en active Active
-
2012
- 2012-09-06 US US13/605,716 patent/US8658152B2/en active Active
-
2013
- 2013-09-05 US US14/018,842 patent/US9717763B2/en active Active
-
2016
- 2016-11-28 US US15/362,453 patent/US10039793B2/en active Active
-
2017
- 2017-02-27 US US15/443,733 patent/US10383898B2/en not_active Expired - Fee Related
- 2017-02-27 US US15/443,718 patent/US10195233B2/en active Active
- 2017-02-27 US US15/443,602 patent/US10220059B2/en active Active
- 2017-07-27 US US15/661,878 patent/US10500234B2/en not_active Expired - Fee Related
-
2018
- 2018-08-06 US US16/056,146 patent/US10758576B2/en active Active
-
2019
- 2019-03-04 US US16/291,784 patent/US11000554B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11000554B2 (en) | Postpartum cells derived from placental tissue, and methods of making and using the same | |
US8815587B2 (en) | Postpartum cells derived from umbilical tissue and methods of making and using the same | |
US20060166361A1 (en) | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same | |
US20060171930A1 (en) | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same | |
EP1833496A2 (en) | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220627 |